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Abstract 
Background 
Eating disorders (EDs) are serious mental disorders and associated with substantial economic 
and social burden. Anorexia Nervosa (AN) and Bulimia Nervosa (BN) account in total for 1.9 
million disability-adjusted life-years (DALYs), which equates to 0.1% of total global DALYs. 
EDs have not been explicitly considered in existing priority-setting or cost-effectiveness 
studies which have been undertaken within the Australian context.  
Objective 
This thesis comprises five studies which aim to: 
(1) investigate existing evidence of the cost-effectiveness of prevention and treatment for ED. 
(2) evaluate the effectiveness of universal, selective and indicated ED prevention. 
(3) evaluate the cost-effectiveness of evidence-based interventions for prevention and 
treatment of AN and BN within the Australian health context using methods which allow 
comparability. 
Methods  
A systematic review of cost-effectiveness studies of preventive and treatment interventions and 
a systematic review of preventive interventions were conducted in December 2015 and January 
2017, respectively. The empirical cost-effectiveness studies undertaken as part of this thesis 
adapted the technical aspects of the Assessing Cost-Effectiveness approach. Illness-death 
multi-state Markov models were developed to assess the population costs and outcomes, 
expressed as DALYs, of evidence-based interventions. The healthcare perspective was adopted 
in the primary analysis and the partial societal perspective was used in the secondary analysis. 
Results were shown as the mean incremental cost-effectiveness ratios (ICER), measured in 
2013 Australian dollars per DALY averted. Uncertainty and sensitivity analyses accompanied 
all evaluations. 
Results 
A systematic review of the existing evidence of cost-effectiveness in ED found 13 cost-
effectiveness studies with eight published since 2011. All published studies for preventive 
interventions were modelled economic evaluations whereas treatment interventions were 
mostly trial-based economic evaluations. The results of the study found that ED interventions 
were mainly cost-saving or more effective and more costly compared to comparators, however, 
some results did not reach statistical significance. 
A systematic review of preventive interventions for EDs found that only a cognitive dissonance 
intervention was found to significantly reduce both ED behaviours and symptoms. The cost-
effectiveness of this intervention (undertaken as part of this thesis) targeting high-school 
adolescents with high body-image concerns was found to be potentially cost-effective subject 
to participation rates. Further research in the dissemination and implementation of such an 
intervention is required. 
The cost-effectiveness of family-based treatment (FBT) and cognitive behavioural therapy 
(CBT) for the treatment of AN and BN, respectively, were evaluated. Both interventions were 
found to be cost-effective with 99% of uncertainty iterations falling under a value-for-money 
criterion of AUD$50,000/DALY averted. The ICERs of FBT and CBT were, AUD$5,089 
(95% uncertainty interval (UI): dominant to AUD$16,659) and $14,451 (95% UI: AUD$8,762 
to AUD$35,650) per DALYs averted, respectively. Including time and travel costs resulted in 
higher ICERs, however, that remained well below the threshold of AUD$50,000 per DALY. 
The conclusion that CBT was cost-effective changed when more than 80% patients dropped 
out of the intervention. Further research to ensure that the participation rates remain high is 
recommended.  
Conclusion 
The present thesis has demonstrated that evidence-based interventions for the treatment of AN 
and BN are cost-effective and certainly need to be considered in any mental health service. 
Prevention of EDs is potentially cost-effective subject to sufficient participant rates. In terms 
of intellectual contribution, this thesis has: i. reviewed and evaluated the existing evidence base 
of economic evaluation for EDs; ii. undertaken an updated quantitative systematic review of 
preventive interventions for EDs; iii. developed a technique to convert clinical outcomes into 
a generic health index (DALY averted); iv. built an economic model to evaluate interventions 
using comparable methods thus allowing result comparisons; and v. more than doubled the 
number of cost-utility studies for ED interventions. This thesis highlights the need for future 
research in the ED health service research.  
Keywords: Eating disorders, cost-effectiveness, economic evaluation, prevention, treatment, 
anorexia nervosa, bulimia nervosa. 
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Chapter 1: Background and context  
1.1. What are eating disorders? 
Eating disorders (EDs) are serious mental disorders affecting both male and females (but 
mostly adolescent females and young women) and are associated with significant physical and 
psychological impairment (Herpertz-Dahlmann 2009; Hudson et al. 2007). Eating disorders 
are characterized by extreme eating behaviours and distorted beliefs associated with weight, 
shape, eating and body image (American Psychiatric Association 2013). According to the 
“Diagnostic and Statistical Manual of Mental Disorders” 5th edition (DSM-5) (American 
Psychiatric Association 2013), the diagnostic category ED comprises five diagnostic sub-
categories: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorder (BED), 
other specified feeding or eating disorder (OSFED) and unspecified feeding or eating disorder 
(UFED).   
Compared to the fourth version (DSM-IV), a key revision was the broadening of diagnostic 
criteria for AN and BN and inclusion of BED as a third, formal diagnosis (American Psychiatric 
Association 2013). The DSM-5 also removed amenorrhea as a diagnostic symptom for AN due 
to insufficient empirical support for the utility of this symptom (Attia & Roberto 2009). For 
BN and BED, the specific change was a reduction in the frequency of binge eating (and for BN 
compensatory weight-control behaviours) from twice to once weekly and for BED, the duration 
of symptoms was aligned with BN to 3-months rather than 6-months (Hay, Girosi & Mond 
2015).  
The main diagnostic features of AN include persistent energy intake restriction; fear of gaining 
weight; and body image distortion. AN consists of two subtypes: restricting and binge-purge 
subtype. BN is characterized by binge eating and compensatory behaviour (e.g. fasting, 
vomiting) that occur, on average, once per week for three months and a self-concept dominated 
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by shape and weight (American Psychiatric Association 2013). There are two subtypes of BN 
including a purging subtype and a non-purging. Furthermore, BED is recognized as a main 
type of ED in DSM-5 with the frequency requirement once weekly and the duration of binge 
eating requirement three-months (American Psychiatric Association 2013). Additionally, two 
new categories, OSFED including atypical AN, sub-threshold BN, sub-threshold BED and 
UFED, replaced the former eating disorders not otherwise specified (EDNOS) category. 
Accordingly, the advent of DSM-5 has lowered the figures (e.g. incidence and prevalence) for 
the former EDNOS and increased the figures for AN, BN and BED although the magnitude of 
increase is unclear (Hay, Girosi & Mond 2015; Rosenvinge & Pettersen 2014). Most of the 
existing scientific studies (especially randomized controlled trial (RCT) based prevention and 
treatment studies) have used broader diagnostic criteria of DSM-IV to classify AN and BN 
(such as the eliminating of amenorrhea as a diagnostic symptom for AN), thus being more 
closely matched with the newer, DSM-5 criteria. 
EDs have peak risk periods of onset in early adulthood and the late-teens (Stice, Marti & Rohde 
2013). The peak age of onset is between 19-20 years for AN and 17-18 years for BN (Stice, 
Marti & Rohde 2013; Stice et al. 2009). EDs are common in the general population, however, 
prevalence studies of EDs are often undertaken in the high-risk population of young females 
(Hoek 2016). Prevalence of EDs is usually reported as the point-prevalence (i.e. defined as the 
proportion of actual cases in a population at a specific point in time) or lifetime prevalence (i.e. 
report illness during a lifetime) (Hoek 2016). The lifetime prevalence of AN, BN and BED has 
been estimated from 0.9% to 2.2%, 1.5% to 4.6% and 1% to 4.6% across countries, respectively 
(Keski-Rahkonen & Mustelin 2016; Qian et al. 2013; Rosenvinge & Pettersen 2014). Although 
point prevalence of EDs among young females was reported higher in Asia, compared to other 
areas such as Latin American, it is noteworthy that epidemiological studies of EDs in Asia 
present an important challenge due to the uncertain validity of diagnostic assessment (Hoek 
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2016). Lifetime prevalence has been reported as being three to eight times higher in females as 
opposed to males for all EDs (Preti et al. 2009). There is evidence of an increase in the 
prevalence of AN in adolescent females, and increases in other EDs since the second half of 
the twentieth century, although the prevalence of BN may have plateaued (Keski-Rahkonen & 
Mustelin 2016; Qian et al. 2013). Incidence is a better estimate to highlight the time trends 
compared to prevalence. The incidence of AN in females aged 15-19 has dramatically 
increased from 56.4 to 109.2 per 100,000 persons per year from 1988 to 2000 (Rosenvinge & 
Pettersen 2014). However, the incidence rate of BN has significantly decreased in primary care 
over a period of three decades (Keski-Rahkonen & Mustelin 2016). This may be due to the 
improved detection of EDs and/or changing diagnostic practices. All things considered, the 
overall incidence of EDs has significantly increased in both males and females over the last 10 
years (Micali et al. 2013). 
In Australia, the lifetime prevalence rates in women are 4.3% for AN and 4% to 7% for BN 
(Madden et al. 2009; Wade et al. 2006). The National Eating Disorders Collaboration (2013) 
stated that nearly 9% of the Australian population (over 2 million people) are diagnosed with 
an ED in their lifetime (NEDC 2013). The three-month point prevalence from the Health 
Omnibus Surveys was reported in 2015 at under 1% for AN and BN, whereas 1.5% for BED 
and 13.6% for other types of EDs using DSM-5 criteria (Hay, Girosi & Mond 2015; Hay et al. 
2017). Results from the Health Omnibus Surveys also found that people with EDs are generally 
younger than those without EDs especially those with AN or BN who had a mean age of under 
40 years. People with BN, and BED were more likely to be obese than those without EDs and 
other EDs (Hay et al. 2017). 
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1.2. How do eating disorders impact population health? 
The presence of an ED has a great impact on health-related quality of life (HRQoL) with the 
degree of reported impairment most likely to increase with the severity of the ED (Ágh et al. 
2016a; Jenkins et al. 2011; Winkler et al. 2014).The published evidence to date has also found 
that a variety of EDs have similar negative impacts upon HRQoL (Hay et al. 2017; Jenkins et 
al. 2011; Winkler et al. 2014). This may be because these ED types share certain 
psychopathology symptoms such as disordered attitudes, binge eating, and compensatory 
behaviours which have been found to be associated with HRQoL impairment (Ágh et al. 2016a; 
Jenkins et al. 2014). Furthermore, those with an ED had significantly lower HRQoL scores 
than those diagnosed with other mental disorders (such as mood disorders) (Jenkins et al. 
2011).  
EDs are often associated with high level of psychiatric comorbidity (Blinder, Cumella & 
Sanathara 2006). In particular, 55% and 88% adolescents with AN and BN had one or more 
comorbid psychiatric disorder(s) (Swanson et al. 2011). The level of psychiatric comorbidity 
is higher for female inpatients, of whom 97% had at least one comorbid diagnosis, and 94% 
had comorbid mood disorders particularly unipolar depression (Blinder, Cumella & Sanathara 
2006). No differences across EDs in mood or anxiety disorder were found, but alcohol 
abuse/dependence was twice as likely with BN (Blinder, Cumella & Sanathara 2006). Other 
disorders such as autistic spectrum disorders, attention-deficit hyperactivity disorders (ADHD) 
and personality disorders have been often found in people with EDs especially severe EDs 
(Brewerton & Duncan 2016; Wentz et al. 2005). Evidence suggests that the presence of high 
levels of comorbid psychiatric symptoms in those with EDs has a negative impact on HRQoL, 
especially in AN or BN (Jenkins et al. 2011). 
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There is evidence that EDs (especially AN or BN) have long-term health consequences and 
medical complications including fertility and pregnancy problems, cardiovascular 
disturbances, osteoporosis, diabetes mellitus, gastrointestinal disorder, thyroid disorders, and 
other psychiatric disorders (Donaldson & Gordon 2015; Meczekalski, Podfigurna-Stopa & 
Katulski 2013; Westmoreland, Krantz & Mehler 2016). This might be caused by the mode and 
frequency of purging (in BN), or weight loss and malnutrition (in AN) (Westmoreland, Krantz 
& Mehler 2016).  
EDs are significantly associated with increased risk of premature death (Franko et al. 2014). In 
particular, AN has the highest mortality rate of any psychiatric illness with the standardised 
mortality ratio (SMR) at 5.86 compared to a ratio of 1.6 in major depression and 2.5 in 
schizophrenia (Arcelus et al. 2011). This is partly because of medical complications and partly 
because of an increased rate of suicide (Pompili et al. 2006; Preti et al. 2011; Westmoreland, 
Krantz & Mehler 2016). The most common cause of death from AN is suicide, with 1 in 5 
deaths amongst those diagnosed with AN from suicide (Arcelus et al. 2011).  
The outcomes of an ED have long-term impacts beyond the acute phases of illness. Recovery 
rates were reported around 47% to 63% for AN and 50% to 68% for BN over 4 to 22 years 
follow up (Franko et al. 2017; Rosenvinge & Pettersen 2014). Furthermore, the mean 
improvement rates and mean chronicity rates were respectively estimated at 27% and 23% for 
BN and 33% and 20% for AN (Steinhausen, Weber & Phil 2009). In adolescents, 97.1% and 
78% of individuals with AN and BN diagnostic respectively reported role impairment in the 
past 12 months (Swanson et al. 2011). Importantly, EDs had the strongest association to social 
impairment and family relationships among adolescents, but limited impacts on daily activities 
(e.g. school or work) (Swanson et al. 2011). In contrast, most adults with BN or BED reported 
an impairment in role functioning such as work, personal life and social life in the previous 
year (Hay et al. 2017; Kessler et al. 2014; Swanson et al. 2011). 
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1.3. Economic and social burden of eating disorders 
EDs are associated with substantial economic and social burden. EDs were the 12th major 
cause of mental health hospitalisation costs within Australia1 (Mathers, Vos & Stevenson 
1999). Moreover, the cost of treatment of an episode of AN was estimated to be the 2nd most 
costly treatment after the cost of cardiac artery bypass surgery in the private hospital sector in 
Australia (Pratt & Woolfenden 2002). International evidence has indicated that AN, BN and 
BED are associated with higher healthcare costs and increased healthcare utilization (Ágh et 
al. 2016a). Recent systematic reviews found that the annual healthcare costs for AN, BN and 
BED were, respectively, estimated at €2993 to €55,270, €888 to €18,823, and €1762 to €2902 
(Ágh et al. 2016a; Stuhldreher et al. 2015). Although increasing research attention has been 
paid to the economics of EDs over the last two decades, there were only five studies which met 
the criteria for ED cost of illness in a review from Stuhldreher et al. (2012). Other studies often 
reported costs of a specific treatment or costs from a particular sector, such as hospital costs or 
out-of-pocket costs. Stuhldreher et al. (2012) found that the reported costs associated with EDs 
were likely underestimated. This is because cost of illness studies tend to identify costs through 
diagnostic codes of EDs, thus possibly failing to include costs from treatment sequelae and 
other complaints related to EDs. Furthermore, people with EDs often have psychiatric 
comorbidities, and therefore may be classified with codes related to treatment for general 
mental health conditions, comorbid psychiatric symptoms and/or weight loss rather than with 
codes specifically relating to EDs (Ágh et al. 2016a).  
The magnitude of the burden of EDs has been researched in recent years especially since AN 
and BN were included in the Global Burden of Disease (GBD) study in 2010 and updated in 
2013 (Erskine, Whiteford & Pike 2016)). GBD studies began in 1990 as a way of estimating 
                                                 
1 These estimates are the best currently available since no newer estimates including the costs of ED 
hospitalisations were found. However, it is important to note that these estimates are based on what is likely to be 
now quite outdated data. 
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the global burden of diseases as measured by disability-adjusted life years (DALY(s)). A 
DALY is a generic health metric that incorporates both mortality and morbidity and can be 
used to compare the burden of disease and injuries (Charlson et al. 2015). Findings from GBD 
2013 indicated that EDs (AN and BN) accounted for 1.9 million DALYs, which equated to 
0.1% of total global DALYs (Erskine, Whiteford & Pike 2016). It is not surprising that females 
had higher levels of burden due to EDs, where the number of DALYs were approximately four 
and a half times higher compared to males (1.51 million DALYs vs. 0.34 million DALYs) 
(Erskine, Whiteford & Pike 2016). In high-income countries, AN and BN were ranked as the 
12th leading cause of DALYs in females aged 15–19 years, which equated to 2.2% of all 
DALYs (Erskine, Whiteford & Pike 2016). In Australia, AN and BN are the 5th and 8th major 
causes of burden of disease and injuries in females aged 10 to 24 years, respectively (Global 
Burden of Disease Study 2013). It was noteworthy that Erskine, Whiteford and Pike (2016) 
highlighted the underestimation of burden of EDs in the 2013 GBD study due to lack of 
inclusion of other types of EDs (e.g. BED), insufficient data and inconsistencies within 
available data for ED epidemiology, and recent changes to ED diagnostic criteria (e.g. DSM-5 
vs. DSM-IV). 
1.4. Prevention and treatment in eating disorders 
Given that EDs have substantial health, social and economic burden, as outlined above, there 
is unsurprisingly a growing body of literature evaluating various preventive and treatment 
interventions for EDs (Bailey et al. 2014; Watson & Bulik 2013). This section will discuss and 
outline the current trends in ED prevention and treatment (for AN and BN) with a focus on 
identifying effective interventions for ED prevention and treatment from published reviews, 
systematic reviews and meta-analyses or international treatment guidelines. 
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1.4.1. Preventive interventions for eating disorders. 
Research evaluating preventive interventions for EDs boomed in the late 20th century, together 
with research on ED risk factors. Studies of preventive interventions have significantly 
increased in recent years, from 22 published RCTs in a review in 2002 to 86 controlled trials 
in the most recent review published twelve years later (Bailey et al. 2014; Pratt & Woolfenden 
2002). Early preventive interventions (i.e. the first generation preventive interventions) were 
mostly based on psycho-educational content (Fingeret et al. 2006; Stice, Becker & Yokum 
2013). These studies had poor methodology including inappropriate measures (e.g. knowledge 
about ED rather than ED risk factors), uncontrolled design and a mismatch between program 
goals and outcomes (Fingeret et al. 2006; Rosenvinge & Børresen 1999), therefore, it is 
unsurprising that efficacy results were mixed. The next generation of preventive interventions 
were didactic but targeted empirically “supposed” risk factors, such as body dissatisfaction 
(Stice, Becker & Yokum 2013). The latest generation studies have focused on participants with 
empirically “established” risk factors (such as body image, dieting). Furthermore, the features 
of these interventions were more “interactive” interventions, and the majority have used 
persuasion principles from social psychology (Stice, Becker & Yokum 2013).  
A Cochrane systematic review was conducted in 2002, which focused on preventive 
interventions targeting children and adolescents (Pratt & Woolfenden 2002). This review found 
only one statistically significant result regarding the limited effects of media literacy and 
advocacy programs in reducing thin-internalisation. In contrast, a meta-analytic review from 
Stice, Shaw and Marti (2007) found that 51% of 51 preventive programs up to 2006 were 
effective in reducing ED risk factors and 29% of these reduced current or future eating 
pathology. This review also suggested the features of successful preventive programs as 
targeting high-risk individuals (e.g. females and individuals over 15 years), more interactive, 
using multi-session formats and being delivered by health professionals. Most studies included 
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in this review for ED prevention were undertaken to determine the efficacy or effectiveness2 
of preventive interventions in general but had limited evidence regarding whether these 
interventions really prevented ED diagnosed cases. Furthermore, there has been limited 
attention with respect to the efficacy of interventions across individuals’ level of risk for EDs 
(Fingeret et al. 2006; Newton & Ciliska 2006; Yager et al. 2013).  
A framework for prevention nomenclature, that is commonly used in the mental health 
literature, classifies preventive interventions as “universal”, “selective” or “indicated” 
prevention according to the target population (Mrazek & Haggerty 1994). Universal 
interventions target whole populations, selective interventions target specific high-risk 
populations and indicated interventions target people with symptoms of disorders but not yet 
at diagnostic level. Within the Australian context, indicated prevention can sometimes be 
classified under the umbrella of “early intervention” (Rickwood 2012). 
                                                 
2 Efficacy refers to whether an intervention can work under tight experimental conditions. Effectiveness refers to 
whether an intervention can work under routine service conditions. 
 
Notes. Adapted from Mrazek and Haggerty (1994) 
Figure 1: The mental health intervention spectrum for mental disorders 
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A systematic review by Watson et al. (2010) classified the studies of preventive interventions 
as universal, selective or indicated prevention according to Mrazek and Haggerty (1994). This 
review included 72 studies (up to 2009) and found that universal prevention interventions 
(media literacy (ML)) and selective and indicative prevention interventions (including 
cognitive behavioural therapy (CBT) and cognitive dissonance (CD)) were effective in 
reducing ED risk factors or symptoms at post-test and follow-up. However, the review did not 
include a quantitative meta-analysis to determine the magnitude of the effect of these 
preventive interventions or a systematic quality appraisal to evaluate the quality of the 
evidence. This review also showed the challenges in classifying ED prevention according to 
the prevention framework from Mrazek and Haggerty (1994), especially the overlap between 
selective and indicated prevention.  
The most recent published systematic review (conducted concurrently as the first study of this 
PhD3) used the approach identified by Watson et al. (2010) but included a quantitative meta-
analysis only for selective prevention interventions (Watson et al. 2016). However, the review 
did not include obesity prevention interventions, which may be potentially effective for ED 
prevention. For selective prevention, this review found moderate to large effect sizes for CD 
and small effect sizes for CBT and healthy weight interventions on ED risk factors pathology 
outcomes (Watson et al. 2016). Findings from this review also found that ML for universal 
prevention and CBT for indicated prevention were promising preventive interventions (Watson 
et al. 2016). 
                                                 
3 Note that a more comprehensive systematic review and meta-analysis forms Chapter 6 of the current PhD thesis. 
29 
 
1.4.2. Treatment of anorexia nervosa 
Evidence-based interventions for the treatment of AN are “advancing, albeit unevenly” 
(Watson & Bulik 2013, p. 1). Watson and Bulik (2013) used a triangulated approach to update 
the evidence for AN treatment by reviewing RCTs (i.e. forty-eight RCTs were included), 
screening the existing practice guidelines (from the National Institute for Health and Clinical 
Excellence (NICE 2004) and the American Psychiatric Association (American Psychiatric 
Association 2006)) and searching for ongoing RCTs. This review found that family-based 
treatments (FBT) (also termed Maudsley family-based therapy) were the only evidence-based 
interventions for young people with AN. This recommendation was in line with other reviews 
from the literature for AN treatment (Couturier, Kimber & Szatmari 2013; Hay 2013; Lock 
2015). The overall results indicated that FBT was superior to individual therapy (known as 
adolescent-focused therapy) regarding remission outcomes at 6- to 12-month follow up (odds 
ratio (OR): 2.08 (95% confidence interval (CI): 1.07 to 4.03) (Couturier, Kimber & Szatmari 
2013). FBT has been recommended in NICE guidelines as the first-line treatment interventions 
for children and young people with AN (NICE 2017; Watson & Bulik 2013). Different formats 
of FBT (such as parent-focused FBT, short version FBT) have been found to be equally 
effective as the original form of the intervention, the Maudsley FBT (Le Grange et al. 2016; 
Lock 2015; Watson & Bulik 2013). Similarly, there was no evidence that supported other 
psychotherapies with clear superiority to the Maudsley FBT (Watson & Bulik 2013). In the 
treatment of AN in adults, there was no treatment demonstrating clear superiority, given no 
statistically significant differences across psychotherapies including: specialist supportive 
clinical management (SSCM); Maudsley Model of Anorexia Nervosa Treatment for Adults 
(MANTRA); CBT; enhanced CBT (CBT-E); or, interpersonal therapy (Galsworthy-Francis & 
Allan 2014; Hay 2013; Hay et al. 2015; Watson & Bulik 2013). It is noteworthy that these 
psychotherapies for adults with AN have also demonstrated positive improvement on weight 
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and ED symptoms. CBT, SSCM and MANTRA are the current treatments that have been 
recommended in the NICE guidelines (NICE 2017) for adults with AN. 
Pharmacotherapy has also been evaluated for AN treatment in mixed populations (i.e. young 
people and adults) and inconsistent results have been reported on body weight and 
psychological outcomes. Hormonal therapy was demonstrated to be superior to placebo with 
respect to increasing body weight (Cohen’s d = 0.42 (95% CI: 0.11 to 0.73 from 10 studies). 
However, heterogeneity was high in this meta-analysis (I2=65%), which indicated that the 
results need to be interpreted with caution. On the other hand, a meta-analysis showed that the 
pooled results from RCTs evaluating antipsychotic treatment found a non-significant 
difference in body weight (standardised mean difference (SMD) = 0.27, 95% CI: −0.01 to 0.56; 
p = 0.06, from 7 studies with a total of 195 participants) as well as other ED related outcomes 
when compared to placebo/usual care (Kishi et al. 2012). A non-significant effect on body 
weight was also found when anti-depressants were compared to placebo (de Vos et al. 2014). 
As a result, pharmacotherapy has not been recommended as the primary or sole treatment 
according to NICE or APA guidelines (NICE 2017; Watson & Bulik 2013). 
Physical therapies including aerobic and strength training, basic body awareness exercises, 
yoga and massage have also been evaluated for AN treatment (Vancampfort et al. 2014). 
Although positive impacts on eating pathology and weight status of people with AN were 
found, this finding needs to be interpreted carefully due to significant methodological issues 
including limited number studies, small sample sizes in RCTs, and significant heterogeneity in 
study designs (Vancampfort et al. 2014). 
1.4.3. Treatment of bulimia nervosa 
Psychotherapy interventions. 
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Several psychotherapy interventions have been tested for the treatment of BN, mostly for 
adults. CBT has been demonstrated as having the highest level of evidence for BN treatment, 
particularly for adults. A Cochrane systematic review found that CBT was superior to a wait-
list control and other psychotherapies in reducing binge eating (Hay et al. 2009). Notably, CBT 
was associated with a 15% reduction in cumulative binge eating abstinence (defined as 100% 
abstinence from binge eating at the end of treatment) when compared to other psychotherapies 
and 33% reduction when compared to wait-list control (Hay et al. 2009). CBT was also superior 
to wait-list control in reducing binge/bulimic symptoms and depression scores, but had similar 
effects on these outcomes in comparison with other psychotherapies. CBT delivered via group 
therapy format has also been demonstrated to be better than no treatment for remission and 
frequency of binges outcomes at the end of therapy (Polnay et al. 2014). It is unclear whether 
individual CBT was superior to group CBT for remission at the end of therapy, given that this 
result relied on only one RCT (Polnay et al. 2014).  
A refined version of original CBT is enhanced-CBT (CBT-E), including two forms: (i) broad 
CBT-E and (ii) focused CBT-E. These forms have recently been developed and tested for ED 
treatment. CBT-E is embedded within “a trans-diagnostic view of the EDs” and is, thus, 
targeted towards all EDs with some adaptations for different disorders and ages (Agras, 
Fitzsimmons-Craft & Wilfley 2017). The existing literature has found that CBT-E was 
consistently superior to waitlist control and associated with more rapid remission and 
significantly higher remission rates than IPT at end of treatment and 12-month follow up 
(Agras, Fitzsimmons-Craft & Wilfley 2017; Groff 2015). There was no statistically significant 
difference between the two forms of CBT-E, although people with more severe 
affective/interpersonal problems recovered better with the broader form of CBT (Agras, 
Fitzsimmons-Craft & Wilfley 2017). It was noteworthy that none of these research studies were 
rigorous RCTs. Instead, the majority of studies were open-trial studies with small sample sizes 
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(Agras, Fitzsimmons-Craft & Wilfley 2017; Groff 2015). Further research with improved 
methodology for CBT-E is thus required. 
Self-help interventions with or without therapist-guidance have also been examined for BN 
treatment. Self-help interventions provide information by teaching people with EDs relevant 
skills to overcome and manage their health problems (Perkins et al. 2006). A Cochrane review 
(2006) suggested that self-help interventions significantly reduced ED symptoms, psychiatric 
symptomatology and interpersonal functioning but did not differ significantly with waitlist 
control in abstinence from bingeing. Furthermore, self-help that has included direct support 
from health professionals or guided self-help had better outcomes than unguided self-help, 
especially in BN (Hay 2013). There was no evidence indicating the superiority of self-help 
interventions compared to other psychological therapies in improvement on bingeing and 
purging, other ED symptoms, level of interpersonal functioning or depression as well as 
treatment dropout (Perkins et al. 2006). However, the existing reviews to date have included 
studies which evaluated the mixed population of BN, BED or EDNOS studies. A meta-
regression has shown that guided self-help interventions were associated with an increased 
likelihood of abstinence for participants with BED compared with those with BN or mixed 
population (Traviss‐Turner, West & Hill 2017). 
Other psychotherapies have also been considered as evidence-based interventions in the 
international guidelines (American Psychiatric Association 2006; NICE 2004) include: IPT, 
which has been shown to be as effective as CBT in reducing binge eating but is associated with 
a slower rate of symptom change than CBT (Hay et al. 2009); and mindfulness-based 
interventions including acceptance and commitment therapy, dialectical behavioural therapy, 
and mindfulness-based stress reduction, which were also found to have large effects in binge 
eating reduction with high heterogeneity among studies (Hedge's g = -1.12, 95 % CI: -1.67 to 
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-0.80 from 18 studies)  (Godfrey, Gallo & Afari 2015). Unlike in AN, FBT was not considered 
a first-line treatment for BN given inconsistent findings (Schmidt et al. 2007).   
Technology-based psychological interventions (or E-mental health) have flourished in the 21st 
century in line with the rise of technology. These interventions refer to the delivery or 
enhancement of mental health services/interventions through technology, such as the internet, 
video conferencing, and mobile technology. Whilst such delivery can be associated with broad 
reach and advantages in implementation, the evidence for efficacy and effectiveness of these 
interventions is still limited (Dölemeyer et al. 2013; Hay & Claudino 2015; Schlegl et al. 2015). 
Hay and Claudino (2015) found that the majority of trials related to online interventions for 
BN had small sample sizes, mixed populations and were associated with significant variants 
around the way the interventions were delivered and the outcome measures used in the studies. 
This review therefore did not find any evidence that online interventions were more effective 
compared to placebo, sham therapy, wait-list control or no online therapy. Similarly, 
Dölemeyer et al. (2013) did not find that there was good evidence associated with the efficacy 
of internet-based interventions for adults with EDs, although internet-based guided self-help 
showed promising results in reducing ED symptoms. 
Pharmacological therapy 
Antidepressants are the most studied pharmacotherapy for BN and the only drugs which have 
been recommended for BN treatment according to guidelines in the US (American Psychiatric 
Association 2006). Antidepressants have been shown to be superior to placebo with overall 
high remission rates, a moderate reduction in binge/purge frequency and improvement in mood 
and anxiety (Bacaltchuk & Hay 2003; Flament, Bissada & Spettigue 2012; Jackson, Cates & 
Lorenz 2010; Powers & Bruty 2009). However, the pooled remission rates were generally low 
compared to those reported for psychological interventions (20% vs 39%) (Hay, Claudino & 
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Kaio 2001). Furthermore, a higher rate of dropouts were found for medication groups compared 
to placebo (except fluoxetine) (Bacaltchuk & Hay 2003). Fluoxetine, thus, is the only 
pharmacotherapy which has been approved by the U.S. Food and Drug Administration (FDA) 
for use in BN (American Psychiatric Association 2006). It is important to note that current 
evidence suggests that there are no statistically significant differences among antidepressants 
including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and 
monoamine oxidase inhibitors. Furthermore, the NICE guidelines from the United Kingdom 
(UK) have not been supported pharmacological therapy as a sole treatment for BN (NICE 
2017). 
Combination treatment: psychotherapy and pharmacotherapy. 
Results of combined psychotherapy and pharmacotherapy studies are difficult to interpret given 
significant methodological issues such as small sample sizes and low quality of evidence as 
well as high heterogeneity across studies (Hay, Claudino & Kaio 2001). Findings have 
indicated that (1) medication-alone treatments are less efficacious in terms of abstinence rates 
than single psychotherapy (e.g. CBT), and (2) dropout rates in the antidepressant arms were 
significantly higher than those in the psychotherapy arms (Hay, Claudino & Kaio 2001). 
Combinations of pharmacotherapy with psychotherapy do not show an increase in the 
remission rates compared to either single approach, but might be associated with higher 
dropout rates when compared with single psychotherapy (Hay, Claudino & Kaio 2001; NICE 
2017). 
1.4.4. Eating disorder treatment: the Australian context 
Within the Australian context, updated Australian and New Zealand clinical guidelines for the 
treatment of DSM V feeding and EDs were published in 2014 (Hay et al. 2014). The guidelines 
used the literature which were informed by the previous guidelines (dated to 2009) and updated 
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the literature with a systematic review (dated 2008 to 2013). For AN, the guidelines supported 
FBT (or an alternate family therapy) as the first-line treatment for young people. Adolescent-
focused therapy, followed by CBT was recommended for all ages in the event that FBT was 
inappropriate or not suitable. It was recommended that medication should be used cautiously 
and SSRIs are not indicated in the acute or maintenance phases of AN. In severe or chronic 
AN, harm minimisation approaches to nutrition, medical complications and weight control 
behaviours were recommended. For BN, therapist-led CBT was the first-line treatment for all 
ages. CBT adapted for internet delivery, CBT-E focused or in guided self-help form are also 
all recommended as alternative treatments for BN. In the case that CBT was not available, 
pharmacotherapy should be used whereby high dose fluoxetine (60mg per day) and other SSRIs 
are recommended. Combination of medications and psychotherapy were also specified as an 
alternative treatment if appropriate, although the evidence for this is weak. 
1.5. Australian health policy context for eating disorders 
Historically, EDs have received less attention compared to other mental disorders within the 
Australian health policy context as can be observed by the lack of formal policies specifically 
targeted to address them. A possible reason for this is the absence of a clear authority who has 
responsibility for people with EDs (NSW Government 2013). In late 2008, the Commonwealth 
Government Department of Health and Ageing initiated and funded $500,000 to establish the 
National Eating Disorder Collaboration (NEDC) led by The Butterfly Foundation 
(Commonwealth of Australia 2009; The Butterfly Foundation 2010). This initiative was also 
in line with the Australian mental health policy that emphasized the importance of prevention 
and early intervention of EDs for mental health services (Commonwealth of Australia 2009). 
The NEDC aims to bring together “ED stakeholders and experts in mental health, public health, 
health promotion, education, research, and the media”. The overall objective of NEDC is to 
develop a nationally consistent and comprehensive approach for the prevention and treatment 
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of EDs (The Butterfly Foundation 2010). Later in 2009, the National Advisory Group on Body 
Image was established to develop a new Voluntary Code of Conduct on Body Image. The 
Advisory Group also suggested a new National Strategy on Body Image that included 16 
recommendations supporting a national and strategic approach (Project Implementation 
Committee 2013). From 2010 to 2013, the NEDC received funding of $3 million by the Federal 
Government to undertake further work on developing a nationally consistent evidence-based 
approach for Australia (NEDC 2012). As a result, the first national framework for EDs was 
developed by NEDC in 2012 informing an overall guidance for the development of responses 
to the promotion, prevention and treatment of EDs in Australia (NEDC 2012). The framework 
proposed seven core principles4 of prevention and treatment of EDs for an integrated approach 
with a person centred, recovery focus together with four key principles5 for the implementation 
of the approach. Since then, several States have started a number of initiatives to prioritize the 
development of health system responses for people with EDs and their families (The Butterfly 
Foundation 2017). For example, New South Wales, South Australia, Victoria and Queensland 
have now been implementing ED service plans and are also delivering professional training 
resources developed by the NEDC (NSW Government 2013; Project Implementation 
Committee 2013).  
Very recently, the first national policy, the National Agenda for EDs that has been developed 
in parallel with the Fifth National Mental Health Plan (The Butterfly Foundation 2017). The 
                                                 
4 Seven essential practice principles include (NEDC 2012, pp. 8-9) 
- Person and family centred care that addresses the needs of individuals; 
- Prioritization of prevention, early identification and early intervention; 
- Safety and flexibility in treatment options; 
- Partnering to deliver multi-disciplinary treatment in a continuum of care;  
- Equity of access and entry; 
- Tertiary consultation is accessible at all levels of treatment; and 
- Support for families and carers as integral members of the team. 
5 Four implementation principles include: 
- Evidence informed and evidence-generating approaches; 
- A skilled workforce; 
- Communication to ensure an informed and responsive community; and 
- Systems support integration, collaboration and on-going development. 
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Agenda is based on the evidence and consensus-based, expert opinion to propose prioritisation 
of a mental health system reform that can address the needs of people with eating disorders and 
their families (The Butterfly Foundation 2017). The aim of the National Agenda is to provide 
early access to the ‘right’ treatment and enable sustainable recovery in EDs. Furthermore, the 
Australian Government has provided funding of $1.7 million into a national helpline for early 
treatment of EDs (known as ‘ED HOPE’) and a further $1.3 million to keep the NEDC 
operational.  
Importantly, there is no evidence to show that the prevention and treatment interventions are 
cost effective within the Australian context. The NEDC also highlighted these as priority ‘gaps’ 
or needs in the research in their first National Framework. Deloitte Access Economics has 
recently conducted a cost-benefit analysis of a ‘package’ including early intervention to 
treatment interventions or step-care approaches for EDs in Australia (Deloitte Access 
Economics 2014). This report has quantified benefit-to-cost as over $5 for every $1 investment. 
However, there are some considerable limitations of this work that might constrain the 
conclusion of this report. Further discussion on this report can be found in Section 4.2 of this 
thesis. Therefore, it is timely and important to develop the evidence base around cost-
effectiveness of preventive and treatment interventions for EDs within the local Australian 
context. 
1.6. Chapter summary 
This introductory chapter has highlighted that EDs are serious mental disorders that are 
associated with health, social, and economic burden. The evidence base for preventive and 
treatment interventions for EDs has substantially increased in both quantity and quality of 
evidence over the last three decades. In terms of preventive interventions, the majority of 
reviews have suggested a positive effect in terms of reducing ED risk factors or pathology, but 
few studies have investigated the effect on specific ED onset prevention. In addition, there is 
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insufficient evidence to determine whether preventive interventions have differential effects on 
different groups of the population including those with or without ED risks. In line with the 
mental health prevention literature, the efficacy and effectiveness of different strategies of ED 
prevention (i.e. universal, selective or indicated prevention) requires further research. 
Regarding treatment, several interventions have strong levels of evidence in efficacy and/or 
effectiveness as per international guidelines, including the most recent Australian and New 
Zealand guidelines for the treatment of EDs (Hay et al. 2014). Thus, implementation of 
evidence-based prevention and treatment interventions for EDs can be expected to reduce the 
burden of disease. However, evidence based interventions may not always be implemented for 
a variety of reasons such as due to lack of awareness/education in translating guidelines into 
practice. In addition, within the context of the Australian limited health budget, it is currently 
unknown whether such interventions provide value-for-money. The next chapter introduces the 
scope of the current thesis, presents the context of this research and the research questions.
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Chapter 2: Scope of thesis and research questions 
2.1. Context of research 
To reduce the burden of disease of EDs, it is desirable to develop a service system which 
reduces disorder incidence (via prevention), disease duration and severity (both via treatment) 
and premature mortality (via prevention and treatment). Resource allocation to interventions 
that might impact on these areas should ideally be informed by evidence on effectiveness and 
cost-effectiveness (Whiteford, Harris & Diminic 2013). 
The current PhD project forms part of the National Health and Medical Research Council 
(NHMRC) funded Centre of Research Excellence (CRE) in Mental Health System 
Improvement (CREMSI). One of the stated aims of the CRE is to “design a model mental 
health service system for Australia that would optimally reduce the burden of mental disorders” 
(Whiteford, Harris & Diminic 2013). This PhD project belongs to Stream 1 of the CRE, which 
has the objective of applying a high-quality priority-setting approach to examine the most 
effective, cost-effective and implementable interventions for the prevention and treatment of 
EDs. The current PhD provides information to Australian decision makers on the cost-
effectiveness of both preventive and treatment interventions for EDs using comparable 
methods. Importantly, this has never been done in an Australian (or even international) context 
before.  
The research undertaken in this thesis was conducted between September 2014 and October 
2017. Candidature was supported by a CREMSI stipend scholarship (NHRMC APP1041131) 
and Deakin University post graduate scholarship. 
2.2. Scope of thesis 
The thesis aims to evaluate the cost-effectiveness of the most effective, evidence-based 
interventions for the prevention and treatment of EDs. As the first step, an evidence-based 
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intervention was chosen if it had evidence of effectiveness from the literature and/or 
recommended by Australian practice (Hay et al. 2014) and/or other international guidelines 
(American Psychiatric Association 2006; NICE 2004). Given that there are a number of recent 
reviews as well as updated Australian and New Zealand guidelines for ED treatment, this thesis 
did not conduct a full review of treatment interventions. However, a full systematic review for 
ED prevention was conducted to address the gap in the literature of ED prevention (as noted 
above in Section 1.4., Chapter 1). 
Stream 1 of the CRE adopted the technical approach of the Assessing Cost-Effectiveness 
(ACE) methodology (Carter et al, 2008). However, the second-stage filter criteria of this 
methodology (e.g. impacts on equity, acceptability, sustainability etc) was not been used as 
these criteria are the focus of other aspects of the CRE. Therefore, the focus of this thesis is to 
economically appraise interventions for the prevention and treatment of EDs which allows 
comparability with both within EDs as well as other disorders being considered in the CRE. 
As the context of the current thesis is to inform decision-makers of effective and cost-effective 
interventions to reduce burden of disease (as measured by the most recent GBD studies as 
established by Vos et al. (2015) plus the other studies relevant to mental disorders (Vos et al. 
2005; WHO Commission on Macroeconomics and Health 2001)), the objective of this thesis 
is to evaluate whether the evidence-based interventions in prevention and treatment of AN and 
BN provide value-for-money within the Australian context. Other interventions targeted to 
BEDs or other types of EDs are out of the scope of this thesis as they are not included in the 
GBD estimates. Furthermore, the thesis aims to target the most effective interventions in the 
prevention or treatment of ED, which are currently supported by evidence in the literature or 
international guidelines but lack cost-effectiveness evidence.  
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2.3 Ethics 
The thesis collects and analyses secondary data or de-identified data that is not associated with 
individuals. The thesis is covered by the ethic approval of the CRE, which was granted by the 
Deakin University HREC (approval number 2017-295) and the Behavioural & Social Sciences 
Human Research Ethics Committee (HREC) at the University of Queensland (approval number 
2013001439). The ethics approval letters from Deakin University and the University of 
Queensland are attached in APPENDIX 1. 
2.4. Research questions 
To address the overall aim, several studies needed to be undertaken starting with an appraisal 
of the evidence for both preventive and treatment interventions, development of an economic 
model capable of assessing the cost-effectiveness of these interventions using the outcome 
metric of DALYs6. Thus, this thesis seeks to answer three overall research questions (RQs) 
that are presented in Table 1.
                                                 
6 Further details of discussion as to why the DALY was chosen as the primary outcome metric in this current work 
and contrasting this with the QALY as an outcome metric is presented in Chapter 3 (section 3.2.2.2), Chapter 5 
(section 5.2 – outcome measurement) and Chapter 10 (section 10.5) of this thesis. 
42 
 
Table 1: Research Questions of the Thesis. 
Main Research Questions Sub-Research Questions Chapters 
RQ1: What is the existing evidence 
of cost-effectiveness for preventive 
and treatment interventions for 
EDs? 
 
RQ1a. What is the existing evidence of the cost-
effectiveness of preventive interventions for EDs? 
4 
 
 
RQ1b. What is the existing evidence of the cost-
effectiveness of treatment interventions for EDs? 
4 
RQ2: What are the effectiveness 
and cost-effectiveness of preventive 
interventions for EDs including AN 
and BN? 
 
 
 
RQ2a. What is the efficacy/effectiveness of 
universal prevention interventions for EDs? 
6 
 
RQ2b. What is the efficacy/effectiveness of 
selective prevention interventions for EDs? 
6 
RQ2c. What is the efficacy/effectiveness of 
indicated prevention interventions for EDs? 
6 
RQ2d. What is the cost-effectiveness of evidence-
based interventions (i.e. cognitive dissonance 
interventions) for prevention of AN and BN? 
7 
RQ3: Are evidence-based 
interventions for the treatment of 
AN and BN cost-effective? 
 
RQ3a. What is the cost-effectiveness of the 
evidence-based interventions (i.e. family-based 
treatment and adolescent-focused treatment) for 
treatment of AN? 
8 
RQ3b. What is the cost-effectiveness of the 
evidence-based interventions (i.e. cognitive 
behavioural therapy) for treatment of BN? 
9 
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2.5. Thesis contribution 
To answer the above outlined research question, this thesis has undertaken a number of 
different approaches ranging from (systematic) literature reviews to the generation of new 
empirical evidence on cost-effectiveness of preventive and treatment interventions for EDs. In 
terms of intellectual contribution, this thesis has reviewed and evaluated the existing evidence 
base of economic evaluation for EDs. Furthermore, this thesis has also undertaken an updated 
quantitative systematic review of preventive interventions for EDs. Another contribution from 
this thesis is the development of a technique to convert clinical outcomes into a generic health 
index (DALY averted). Additionally, this thesis has built an economic model to evaluate 
interventions using comparable methods thus allowing result comparisons. Finally, the thesis 
more than doubled the number of cost-utility studies for ED interventions. Importantly, no prior 
cost-effectiveness projects to date have considered both preventive and treatment interventions 
within the one study context. 
2.6. Thesis structure 
To answer these research questions, it is important to provide a theoretical background of 
economic evaluation, and discuss why economic evaluation is important and how it can be 
applied in the health policy context as the first step. Therefore, Chapter 3 introduces the basic 
concepts of economic evaluation and considers the pros and cons of both economic evaluation 
alongside trials and modelled economic evaluation and how modelled economic evaluation is 
vital for health policy. The Chapter also includes why modelled economic evaluations can be 
an integral component of informed health policy and practice decisions. . Following that, 
Chapter 4 provides an overview of the existing evidence of the cost-effectiveness of preventive 
and treatment interventions for EDs from the literature. Chapter 5 includes a brief discussion 
of the technical aspects of the ACE approachwhich have been used to underpin the technical 
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analysis comprising the main questions answered by this thesis. This chapter is important as it 
introduces and discusses further details of the methods of economic evaluation used in Chapter 
7 to Chapter 9. The Chapter also describes how the interventions were selected for further 
empirical evaluation and rationale for Chapter 6. Chapter 6 focuses on evaluating the 
effectiveness of preventive interventions for EDs across the age spectrum in both general and 
at-risk populations. Following that, the cost-effectiveness of cognitive dissonance interventions 
(an evidence-based preventive interventions for EDs) is examined in Chapter 7. Chapter 8 and 
Chapter 9 contain economic evaluations of evidenced-based interventions as first-line 
treatment for AN and BN, respectively. Finally, Chapter 10 presents the synthesis of findings, 
discusses the significance of this thesis, the strengths and limitations and suggests further 
research directions.  
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Chapter 3: Economic evaluation – the implication for health policy 
Economic evaluations (EE(s)) have become an important tool within the priority-setting 
process whereby decision-makers allocate resources between existing and/or new healthcare 
services. Economic evaluation is defined as the comparative analysis of interventions in terms 
of both their costs and their outcomes (Drummond et al. 2015). It is noteworthy that “EEs and 
clinical evaluations are not alternative approaches to achieve the same end, but complements” 
(Drummond et al. 2015, p. 270). EE is thus considered a framework, in which the clinical 
evidence of the effects of all the alternatives on health, health care costs and other effects are 
examined (Drummond et al. 2015). 
3.1. Why is economic evaluation important? 
The ultimate goal of the health care system is to maximise the health and welfare of the 
population (Robinson 1993). Unfortunately, resources including people, time, and knowledge 
are always scarce in relation to health care needs (Drummond et al. 2015). Therefore choices 
must and will be made (Drummond et al. 2015). Economists argue that achieving greater 
efficiency from constrained resources should be a key criterion for priority setting (Palmer & 
Torgerson 1999). In broad terms, efficiency in the healthcare context refers to a way of 
measuring the utilization of healthcare resources in order to achieve the best value-for-money 
(Palmer & Torgerson 1999). Burgess (2012) uses the term ‘efficiency’ to refer to avoiding 
waste and maximizing possible outputs from constrained resource inputs. A further definition 
of ‘efficiency’ is given by Donaldson, Currie and Mitton (2002), who describe efficiency as 
the situation which occurs when benefits are maximized and opportunity costs are minimized. 
Opportunity cost is a key economic concept and basically means that the true cost of any action 
is the benefit foregone in its next best alternative use of the resources used in that action (Palmer 
& Raftery 1999). For example, the opportunity cost of allocating $100,000 to depression 
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prevention is the forgone health benefits had this amount been allocated to ED prevention. In 
other words, the opportunity cost of each choice is “the health benefits lost when the best 
alternative is not selected” (Neumann et al. 2016, p. 25).  
EE is becoming increasingly significant to assist policymakers for allocating appropriate 
resources via systematic analysis in health care over the recent years (Drummond et al. 2015). 
Australia was the first country where EEs were applied mandatorily in decisions about the 
reimbursement of pharmaceuticals (Salkeld, Davey & Arnolda 1995). The overall aim of any 
EE is to “identify, measure, value and compare the costs and consequences of the alternatives 
being considered” (Drummond et al. 2015, p. 4). EE is a tool which directly assesses the 
opportunity costs through the comparison of two or more alternatives in several types of 
economic analysis (Palmer & Raftery 1999).  
The perspective or viewpoint of an EE is an essential consideration in informing decision-
makers about their choice. Economic perspective refers to the range of costs and consequences 
which may be included in an EE (Drummond et al. 2015; Fox-Rushby & Cairns 2005). The 
broadest perspective is societal whereby all costs and consequences to whomever they accrue 
may be included (e.g. non health-care costs would be included). More limited perspectives such 
as health care perspective, only include costs and consequences attributable to the health sector 
(e.g. cost of treatment).  Thus, perspective is an important consideration to be determined early 
in the design of an EE since perspective addresses the duration of data collection, which 
resources to be used and which cost should be included (Davidoff & Powe 1996; Drummond 
et al. 2015; Neumann et al. 2016). The intervention may be cost-effective from a broader, 
societal perspective but may not be under a narrower, healthcare perspective. A hypothetical 
example from Brouwer et al. (2006) is illustrated in Table 2.  
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Table 2: Three hypothetical programs 
 Costs in budget Costs elsewhere Effects (QALYs) 
Program A 100 100 100 
Program B 10 200 100 
Program C 5 1000 100 
Notes. QALYs: quality-adjusted life-years; Source: Brouwer et al. (2006) 
The societal viewpoint favours program A (costs 2 units per quality-adjusted life year7 
(QALY)) over B (2.1 per QALY) over program C (10.05 per QALY). From a health-care 
budget perspective program, C, is the most cost-effective choice because the cost is lowest to 
the health care system (Brouwer et al. 2006). The choice of perspective in an EE largely 
depends on the aim and the scope of study (Byford & Raftery 1998; Drummond et al. 2015). 
An EE that aims to inform decisions regarding the allocation of resources across sectors should 
ideally adopt a societal viewpoint (Jönsson 2009). Alzheimer’s disease or Parkinson’s disease 
are examples where the societal perspective might be considered essential since the main 
benefits from new interventions may be associated with the reduction of productivity gains and 
costs for both community and informal care (Jönsson 2009; McIntosh 2011). However, using 
broader societal perspectives in EE usually requires greater efforts and study resources 
(Jönsson 2009). Moreover, it may increase the uncertainty about the cost and benefits of the 
interventions. In other words, it is difficult to estimate and value resources and benefits such 
as productivity gains/costs, from a societal viewpoint given approaches resolving 
methodological issues associated with the measurement of such costs have not been reached 
(Jönsson 2009). On the other hand, decision-makers of particular organisations are likely to 
                                                 
7 The concept of quality-adjusted life year is discussed in section 3.2.2.2 of Chapter 3. 
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prefer narrow perspective (usually from the organisation viewpoint) (Drummond et al. 2015). 
In Australia, the Pharmaceutical Benefits Advisory Committee recommends the adoption of a 
health care perspective as the primary analysis and a societal perspective as the supplementary 
analysis. This is in line with recommendations of Health Technology Assessment agencies in 
other high-income countries such as the UK (Claxton et al. 2010; Neumann et al. 2016).  
3.2. Types of economic evaluation  
3.2.1. Welfarist vs. extra-welfarist theoretical paradigms 
The methods associated with economic evaluations in healthcare commonly stem from two 
important theoretical economic paradigms. The first and more traditional approach, known as 
the ‘welfarist’ approach, aims to maximise social welfare from a societal perspective 
(Buchanan & Wordsworth 2015). The basic principle of this paradigm is that people as 
individuals are considered to be the best judges of their own wellbeing, and to behave in a 
utility maximising manner (Mihalopoulos 2012; Pink 2012). Under the welfarist approach, 
social welfare is the sum of the well-being of the individuals in the society as a group (Slothuus 
2000). In other words, welfare economics adhere to the principle of Pareto optimality8 in social 
welfare whereby resources are optimally allocated if it is not possible to improve one person’s 
welfare without impairing at least one other person’s welfare (Coast 2004; Slothuus 2000). 
However, this is often not a case in reality as “few policies benefit some individuals without 
affecting others” (Coast 2004, p. 1233). To deal with this, the compensation principle is used 
where a global improvement can be achieved if the individual(s) gaining from a change could 
potentially compensate those who lose from that change and still be better off (Coast 2004). 
                                                 
8 Pareto optimality refers to is a state of allocation of resources from which it is impossible to reallocate so as to 
make any one individual or preference criterion better off without making another individual worse off (Culyer 
1971). 
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The welfarist approach is consistent with orthodox market economic and helps to define how 
resources should be allocated within public provision of services (Ng 1983). 
Alternatively, the extra-welfarist approach (also known as the non-welfarist approach) 
considers health decisions as problems of constrained maximisation (Drummond et al. 2015) 
with the general aim of maximising health in a resource-constrained health system (Buchanan 
& Wordsworth 2015). The extra-welfarist approach was originally derived from Sen’s 
capabilities’ approach whereby social welfare was depended on particular ‘characteristics’ of 
individuals and not only ‘utility-maximisation’ (Birch & Donaldson 2003; Sen, Nussbaum & 
Sen 1991). The extra-welfarist approach within health economics was introduced in the 1980s 
by Culyer (1989). Extra-welfarism differs from welfarism in four following ways:  
(i) Relevant outcomes - “the extra-welfarist approach permits the use of outcomes other than 
utility” (Brouwer et al. 2008, p. 330). Extra-welfarist economics focuses primarily on a change 
of evaluative space to go beyond individual utility and to include extra measures (e.g. equity 
weights) and/or indicators of wellbeing rather than exclusively focusing on individual utility 
(Brouwer et al. 2008; Coast 2009). In extra-wefarism, the selection of relevant outcomes is 
important and dependent on the context rather than the economist’s decision (Brouwer et al. 
2008; Mihalopoulos 2012). In other words, policy makers become an important source of value 
judgements under the extra-welfarist approach (Brouwer et al. 2008). 
(ii) Source of valuation of relevant outcomes – Extra-welfarism permits the use of sources of 
valuation from any number of stakeholders other than the affected individuals (who are the 
only sources of valuation in the welfarist approach). In other words, the affected individual, or 
an expert or a representative sample of the general public or an authoritative decision maker, 
all are deemed to be appropriate sources of valuation under the extra-welfarist approach 
(Brouwer et al. 2008). 
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(iii) Weighting of relevant outcomes. Extra-welfarism permits the weighting of outcomes based 
on principles that need not be preference-based. For example, in order to weight ‘health’ certain 
characteristics can be used such as age (young vs. older) or initial level of health (poor vs. 
good). Weights within the extra-welfarist framework may be based on ethical considerations 
and can relate to variety of relevant outcomes considered important (Brouwer et al. 2008). 
Coast (2009) argued that weighting of outcomes within extra-welfarism might not be an 
‘optional extra’. Instead, it refers to fundamental importance in defining the precise ethical 
approach impacting on decision-making (Coast 2009).  
(iv) Interpersonal comparisons of relevant outcomes.  Interpersonal comparisons within the 
extra-welfarist framework refers to the ability to compare between individuals’ characteristics 
and capabilities rather than individual utilities in welfarism (Brouwer et al. 2008). This allows 
a movement beyond Pareto principle and the compensation (potential Paretian) principle in 
welfarist economics since neither of them require interpersonal comparison (Birch & 
Donaldson 2003; Brouwer et al. 2008). 
In spite of the breaks with a number of aspects of the welfarist approach, the extra-welfarist 
approach also retains many aspects of mainstream economics from a more traditional theory. 
Furthermore, the extra-welfarist approach contains a strong theoretical basis for a move away 
from the welfarism economics and still aligns with existing techniques in health economics 
(i.e. cost-effectiveness analysis) to compare across health interventions. As a result, the extra-
welfarist approach has been accepted by various governments (e.g. in the UK or Australia) as 
a mechanism for allocating health care resources (Mihalopoulos 2012).  
The next section will discuss economic evaluation that have been developed in practice under 
the welfarist and extra-welfarist theoretical approaches and have been used as tools for 
decision-making. 
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3.2.2. Economic evaluation techniques 
There are four common types of EE used in healthcare including: cost-minimisation analysis 
(CMA); cost-effectiveness analysis (CEA); cost-utility analysis (CUA); and, cost-benefit 
analysis (CBA) (Drummond et al. 2015). CMA refers to the situation where the consequences 
of two or more interventions are “broadly equivalent” and the differences between them are 
the costs of these interventions (Drummond et al. 2015). However, this is often rarely the case 
in the real world. Briggs and O'Brien (2001) have argued that it is unsuitable to conduct CMA 
based on an observed insignificant difference in either the cost or effect differences between 
options, except in a study that has been specifically designed to show the equivalence of 
alternatives (on the basis of costs or effects). Therefore, Drummond et al. (2015) do not 
consider CMA as a form of full EE. All other forms of EEs tend to measure costs in the same 
way, their distinguishing feature is how outcomes (benefits) are measured. It is noted that CEA 
and CUA fall broadly under the extra-welfarist approach, while CBA fall under the welfarist 
approach. The following section discusses the main differences between CEA, CUA and CBA. 
It is noted that CEA is commonly used as an umbrella term that includes CUA as a special case 
(Neumann et al. 2016), however the below section will discuss the two separately. Table 3 
presents a summary of the different EE techniques. 
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Notes. CEA: cost-effectiveness analysis; CUA: cost-utility analysis; CBA: cost-benefit 
analysis; BMI: body index mass; QALY: quality-adjusted life years; DALY: disability-adjusted 
life years. 
Main Strengths 
 
CEA compares costs in 
monetary term and benefits 
(or outcomes) in natural 
units such as remission, 
BMI. 
CEA 
 
CUA compares costs in 
monetary term and benefits 
(or outcomes) in generic 
measures of health gain such 
as QALYs or DALYs. 
 
CBA compares both costs 
and benefits (or outcomes) 
in monetary terms. 
 
 
CBA CUA 
Outcomes are meaningful 
to clinicians and providers. 
Allows the ability to compare 
across different conditions 
(e.g. mental disorders vs. 
obesity). 
Allow the ability to 
compare across different 
sectors (e.g. education vs. 
health). 
Main Limitations 
CEA fails to capture all the 
effects of an intervention. 
The comparability of 
interventions which may 
impact different health 
outcomes is not possible. 
The comparability between 
different sectors (e.g. 
transport vs. health) is 
impossible. 
There are several limitations 
associated with generic health 
indices and how the 
preference weights are 
derived. 
Valuing health in monetary 
can be problematic. 
Limitations of willingness-
to-pay method including 
response effect bias, being 
based on hypothetical 
scenarios, how to validate 
WTP methods and others. 
 
Table 3: Summaries of economic evaluation techniques 
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3.2.2.1. Cost-effectiveness analysis 
CEA is one of the most common forms of EE in health care. CEA compares costs in monetary 
terms and benefits (or outcomes) in natural units. The assessed outcomes in CEA vary and can 
include intermediate or surrogate outcomes9 (e.g. BMI) or clinical endpoints (e.g. remission/ 
recovery) or survival outcomes such as life-years gained. Outcomes in CEA are thus often 
meaningful to clinicians compared to outcomes used in the other types of EE. It is not surprising 
that CEAs are commonly used in EE alongside trials that measure clinical outcomes or disease-
specific HRQoL rather than generic measures of health gain (QALYs or DALYs, see below, 
section 3.2.2.2 for further discussion of these outcomes). A review of economic evaluation for 
prevention of mental health found that all CEA studies were incorporated alongside trials 
(Mihalopoulos & Chatterton 2015; Mihalopoulos et al. 2011). Furthermore, CEAs are 
frequently undertaken simply because intermediate outcomes are commonly used in many 
clinical trials.  
However, the largest limitation of CEA is that the comparability of interventions that may 
impact different health outcomes is not possible. For example, it is impossible to compare 
interventions in a given field that have different outcomes (e.g. weight reduction vs. BMI 
reduction) or the interventions in different health areas (e.g. exercise for BMI reduction vs. 
CBT for bulimia nervosa). The use of generic measures of benefit is, thus, needed to make this 
possible. The next section introduces CUA as a method to address such limitations of CEA.  
                                                 
9 Surrogate outcomes (or intermediate outcomes) are often more ‘upstream’ outcomes to final health outcomes. 
For example, blood pressure reduction is a surrogate outcome for risk of cardiovascular disease which is associated 
with mortality and morbidity. 
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3.2.2.2. Cost-utility analysis 
In CUA, outcomes are measured using a generic metric, which combines both mortality 
(quantity gains) and morbidity (quality gains) into a single unit of measurement. These single 
units of outcome have been defined as convenient measures of health where mortality and 
morbidity are conveniently combined. Thus, such generic outcome metrics can then be used 
both within and across different diseases/disorders. The most common generic metrics are 
QALYs or DALYs or the umbrella term for the family of CUA measurement: health-adjusted 
life years (Gold, Stevenson & Fryback 2002; Mihalopoulos 2012).  
The concept of QALYs was first introduced in the study of chronic renal diseases (Drummond 
et al. 2015) and this technique has become increasingly popular in health care systems 
worldwide over the last thirty years (Višnjić, Veličković & Milosavljević 2011). QALYs are 
calculated by multiplying the utility or preference score/weight associated with a health state 
by the length of life lived in that health state (Drummond et al. 2015; Neumann et al. 2016). 
Utility-weights are measured on a scale from 0 to 1, in which ‘0.00’ represents being dead and 
‘1.00’ refers to perfect health. Weights lower than ‘0’ are possible for health states deemed to 
be worse than death. The health states can be defined using direct and indirect methods. Direct 
methods refer to a number of people valuing their own health state occupied to some ideal 
while indirect methods include the use of health related quality of life measures which have an 
added utility scoring algorithm that weighs different dimensions measured on the scale. The 
most widely used direct preference elicitation techniques are the rating scale, the standard 
gamble (SG) and the time trade-off (TTO). These techniques measure directly the preferences 
of individuals for health outcomes (Drummond et al. 2015). However, these direct techniques 
are time consuming and complex tasks. To address this, multi-attribute utility instruments 
(MAUIs) are more commonly used including EQ-5D from the EuroQoL group, The 
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Assessment of Quality of Life (AQoL), the Health Utilities Index (HUI) or Short Form (SF) 
6D (Drummond et al. 2015). MAUIs use the pre-scored multi-attribute health status 
classification systems defined as health related quality of life dimensions to bypass the 
measurement task (Drummond et al. 2015). For example, EQ-5D-3L is a MAUI that includes 
five dimensions including mobility, self-care, usual activity, pain/comfort and 
anxiety/depression (Brooks & Group 1996). Each dimension in turn consists of three levels: 
no problem, some problems and major problems thus defining 243 possible health states. 
DALYs are conceptually similar to QALYs and were developed for the first time to quantify 
the burden of disease and disability in populations (Gold, Stevenson & Fryback 2002). DALYs 
are the sum of years-lived with disability (YLD) and years lost due to ill health (YLL). To 
calculate the YLD, a disability weight is multiplied by the number of prevalent cases (called 
as prevalence YLD) or number of incidence cases and the average duration of the case (or 
episode) until remission or death (called incidence YLD). The disability weight is a weight 
factor that reflects the severity of the disease on a scale from 0 (perfect health) to 1 (dead). 
DALYs have been used commonly in both Australian and international priority-setting studies 
(Hutubessy, Chisholm & Edejer 2003; Mihalopoulos 2012; Vos et al. 2010).  
It is noteworthy that there are some differences between QALYs and DALYs. Firstly, there is 
an important difference between QALY and DALY regarding the way in which quality of life 
(or utility) and disability weight/scores are derived (Sassi 2006). QALYs are based on 
preference-based quality of life elicited from populations or from groups of patients (e.g. TTO, 
SG, etc.). On the other hand, disability weights (to calculate DALY) were initially based on a 
series of weights that were derived from expert valuations (Murray & Lopez 1996). Given there 
were some arguments regarding whether the public, patients or health professionals should 
make the valuations, the disability weights reported in GBD 2013 studies have been derived 
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with preferences elicited “from a large population diverse in geography, culture, and economic 
level of development rather than from a single panel of experts” (Salomon et al. 2015). There 
is also often only a single weight for a disease or for the consequences of a disease from the 
GBD study (Salomon et al. 2015). However, in reality there are various levels of severity 
between cases and even between different stages of a disease. Thus, using disability weight 
from the GBD study cannot always capture more nuanced severity stages of disease (exceptions 
to depression and anxiety that have different weights for mild, moderate and severe). On the 
other hand, QALYs tend to rely on individual levels so different utility weights can be assigned 
to different level of severities of disease (of course it depends on the data available).  
Given that CUA uses generic measures such as QALYs and DALYs (as discussed above), 
CUA becomes useful in the context of interventions with more than one type of health outcome 
(Brazier et al. 2017). In other words, CUA is favoured over CEA when the alternatives have a 
relatively broad range of possible outcomes and there is a need for a combination of these 
outcomes. CUA is especially preferable where there is an improvement in patients’ quality of 
life but not necessarily quantity of life, for example, improvement in the management of a 
chronic disease (Franic, Bothe & Bramlett 2012). In addition, interventions with different 
outcomes can be compared against each other. In such cases, QALYs gained (or DALYs 
averted) can serve as a summary measure that is able to be used comparably across different 
interventions and disease areas (Drummond et al. 2015; Franic, Bothe & Bramlett 2012). 
Another attraction of using QALYs or DALYs in CUA is that healthcare decision-makers and 
the general public can (perhaps) understand the concepts of QALY gained or DALY averted 
as measures of health benefits (Lewis 2004). Because of the broader acceptance of such generic 
outcome measures, there is now considerable research being conducted to further evaluate how 
best to measure QALYs (or DALYs) (Fox-Rushby & Cairns 2005). 
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However, it is noted that measuring health gain in CUA can be debatable because it implies a 
“quasi-utilitarian calculus” to decide who will or will not receive treatment (Brower 2008; 
Weinstein 2008). This controversy arises largely from the principle of equity in the health care 
system. For example, there are arguments that people with more severe illness, should have 
priority over those with the less severity even if both have the same absolute rise in utility 
(Višnjić, Veličković & Milosavljević 2011). Therefore, while CUA is attractive in terms of 
achieving efficiency if indeed mortality and morbidity are what matters in terms of healthcare 
provision. If equity also matters, then CUA may be problematic if careful attention is not given 
to the implication of the technical analysis and how health gain is measured (Višnjić, 
Veličković & Milosavljević 2011). 
Whilst there are remaining philosophical and methodological issues in the literature, some of 
these issues are not unique to CUA. It remains one of the most widely accepted forms of EE in 
the healthcare area. The number of published CUAs has risen dramatically from 34 per year in 
1976-1997 to 431 per year in 2010-2012 (Neumann et al. 2016). CUA has been recommended 
as a first-choice analysis in a number of national health technology assessment guidelines (e.g. 
Australia, Ireland, New Zealand, Scotland, Sweden and the UK) and partly preferred in Canada 
and Spain (Jakubiak-Lasocka & Jakubczyk 2014). All things considered, CUA attempts to 
overcome the problems of CEA and is useful in healthcare area in comparison to other types 
of EEs.  
3.2.2.3. Cost-benefit analysis 
The definition of CBA is that both costs and outcomes are measured in monetary units 
(Drummond et al. 2015). This, however, does not mean that only financial consequences are 
included in the analysis, but other outcomes such as life-years gained, QALYs gained and 
disease-specific outcomes need to be expressed in monetary units (Drummond et al. 2015; 
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Neumann et al. 2016). Since CBA’s theoretical foundation arises from welfarist economics, it 
has considerable theoretical appeal to economists (Gafni 2006).  
CBA has an important advantage whereby a broad range of outcomes can be considered under 
a willingness to pay valuation paradigm where consumers value all attributes of goods/services 
and express their value through willingness to pay (WTP). CBA, therefore, is very useful when 
the interventions being compared have a broad scope of possible outcomes, including non-
health attributes, or if the comparison of the alternatives is not meaningful without a common 
unit of output (e.g. education versus transport) (Franic, Bothe & Bramlett 2012).  
The results of CBA could be illustrated either in the formulation of a ratio of costs and benefits 
or the net benefit of one alternative over another (Drummond et al. 2015). Therefore, CBA 
seems to be wider in scope than other techniques such as CUA. This type of analysis has been 
commonly applied to other sectors of the economy such as environment, education and 
transportation (Drummond et al. 2015; Gafni 2006). While CUA basically answers the question 
of “production efficiency” using health care outcomes, CBA is able to address the questions of 
broader societal “allocative efficiency” because it assigns relative values to health and non-
health related goals to determine which programmes are worthwhile (Drummond et al. 2015). 
However, converting health outcome data into monetary units or putting a dollar value on 
health care can be problematic (Coast 2004; Drummond et al. 2015; Franic, Bothe & Bramlett 
2012). Firstly, putting a monetary value of health can seem ‘wrong’ to some people as there is 
the perception that health cannot be valued in monetary terms. Measuring the value of human 
life or estimating the value of marginal extensions of human life can also be very difficult. 
There are different methods available to estimate the dollar value of health gain (such as human 
capital approach or WTP methods), however, they can result in different answers (Buchanan 
& Wordsworth 2015; Lewis 2004). 
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Furthermore, while the use of WTP methods have been popular in other fields of economics 
such as environmental and transport, they are only recently gaining more attention in health 
economics (Brazier et al. 2017). There are well-documented empirical and methodological 
limitations of WTP methods which are beyond the scope of the current thesis10. It is noteworthy 
that the most important concern is response effect bias whereby “responses to WTP questions 
depend on the income distribution” (i.e. ability to pay) (Gafni 2006, p. 410). This can be 
problematic in health care from an equity perspective (i.e. the allocation of healthcare resources 
could be “skewed towards the wealthy” (Coast, Smith & Lorgelly 2008, p. 1191)). It is because 
of such problems and concerns that CUA and CEA have remained the most commonly used 
techniques in health economics so far (Fox-Rushby & Cairns 2005). However, Donaldson, 
Birch and Gafni (2002) have shown that distributional issues are unavoidable in all EE of 
healthcare programs. This problem may be overcome by developing an income-free method of 
evaluation, changing the concerns in association with income distribution, and using sensitivity 
tests to show the effects of using different weights to highlight the importance of the 
distributional issue (Donaldson, Birch & Gafni 2002).  
3.3. Economic evaluation alongside trials 
While the previous section has discussed the most commonly used techniques, there are also 
two mains types of EE studies including ‘within trial’ types of evaluation and modelled 
economic evaluations. The first type is a single clinical (or effectiveness study) which is used 
as the basis or “vehicle” for economic evaluation, commonly known as trial-based EE or EE 
alongside a trial. The most common studies that include economic evaluation are randomised 
controlled trials (RCTs). RCTs are widely used to measure the efficacy or effectiveness of 
                                                 
10 Limitations of WTP studies include response effect bias being based on hypothetical scenarios and the actual 
validation of WTP methods (Mihalopoulos 2012). It is noteworthy that the method to elicit utilities also has same 
limitations, particularly as applied to the valuation of hypothetical scenarios (such as when answering a TTO) - 
participants probably do not believe they will really need to trade-off time. 
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interventions in health care. The advantage of RCTs is the minimisation of selection bias and 
high internal validity when appropriate randomization procedures are used (O'Connell et al. 
2001). Randomisation ensures that “characteristics that might affect the relationship between 
the intervention and outcome measures will be roughly equal across all arms of the study”, 
thus, minimising potential bias (Levin 2007, p. 1). Since the 1980s, EEs that have been 
incorporated alongside RCT are quite common (Drummond et al. 2015). 
The characteristics of a trial-based EE include (Drummond et al. 2015): (1) the economic 
analysis is conducted through the trial and applied to both the intervention and control arms; 
(2) resources used and economically relevant outcome data are collected within the trial; (3) 
patient-specific cost and (health) outcome data are aggregated to generate the estimates of mean 
costs and mean (health) outcomes for each arm, followed by the incremental analysis; and (4) 
the time horizon for EE is determined by the follow up period of the trial. 
There are several advantages when incorporating EEs within trials. First, as mentioned above, 
RCTs are considered the gold standard study design for efficacy/effectiveness in epidemiology 
with high internal validity. Second, an EE alongside a trial is useful as an early step to provide 
reliable estimates of cost-effectiveness at low marginal cost (Petrou & Gray 2011a). In other 
words, given that both costs and outcomes are collected in the same population, a head-to-head 
comparison is thus viable (Evers, Hiligsmann & Adarkwah 2015). Patient-specific cost and 
outcome data also allow a wide range of statistical and econometric techniques to be applied 
which can be used to investigate the impacts of heterogeneity (i.e. subgroup analysis).  
However, there are some limitations of trial-based EEs which may reduce their usefulness for 
decision-making. First, the most appropriate comparator may not be included in the study. For 
example, a study usually only includes two or three arms, typically the new intervention and 
current practice (or placebo in the case of pharmacology). Therefore, incorporating an EE in 
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the trial can result in a partial analysis, in which the relevant comparator might not be 
considered. Second, the time horizon in trial-based EE is often inadequate to capture all costs 
and outcomes relevant to the evaluated intervention (Drummond et al. 2015). This might not 
be an issue for acute conditions but might underestimate the benefit of preventive interventions 
or chronic conditions. Third, trial-based EEs have limited generalisability to different settings 
or countries (Petrou & Gray 2011a). For example, it might be problematic to transfer the results 
from a trial conducted in European countries into Asian countries given substantially different 
health service contexts. Another important consideration for trial-based EEs is the failure to 
incorporate all relevant evidence (Sculpher et al. 2006). In other words, if the trial-based EE 
does not include all relevant costs and outcomes, then, this may lead to misleading results. 
(Sculpher et al. 2006). Furthermore, Sculpher et al. (2006) argued that trial-based studies 
usually do not consider all the available evidence relating to a particular decision or problem. 
For example, estimates of treatment effects from other clinical trials of the same intervention 
which do not include an EE may not be considered and may have important results which can 
impact the efficacy/effectiveness estimates. 
To address the limitations of trial-based EE, decision analytic models that ideally use all 
available evidence may be a more appropriate framework for EE for decision making. The next 
section will briefly introduce the use of decision-analytic models for EE. 
3.4. Economic evaluation using decision-analytic modelling 
Decision-analytic models basically try to capture the state of the world, both with and without 
interventions under consideration by synthesising existing evidence from multiple sources and 
applying different mathematical techniques, usually assisted by computer software (Petrou & 
Gray 2011b; Sculpher et al. 2006). Decision-analytic modelling is a systematic approach to 
decision making in which, uncertainty is unavoidable as all models are largely abstraction from 
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reality (Siebert 2003). This section will go through the definition of decision-analytic models 
and the role this type of analysis plays in EE. Further information regarding the methods used 
in this type of analysis and how to handle uncertainty in decision analytic models follows. 
3.4.1. What is a “model” in economic evaluation? 
 “The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task 
Force on Good Research Practices– Modelling Studies” defines decision analytic model in EE 
as “an analytic methodology that accounts for events over time and across populations, that is 
based on data drawn from primary and/or secondary sources, and whose purpose is to estimate 
the effects of an intervention on valued health consequences and costs” (Weinstein et al. 2003, 
p. 10). In other words, a decision analytic “model” in EE incorporates both clinical and 
economic outcomes (from the evidence) into a single form that helps decision makers choose 
between alternatives and allocate limited resources (Roberts et al. 2012; Weinstein et al. 2003). 
Necessarily, the type of modelling discussed here differs from regression modelling or 
transmission modelling (Roberts et al. 2012). Regression modelling is a descriptive method 
that explains and predicts the relationship between inputs and outputs. It does not give 
normative direction regarding policy options but can be important to generate inputs for models 
(Roberts et al. 2012). An infectious disease transmission model is considered out of the scope 
of decision analytic modelling except in the case that it is used to evaluate what can be done to 
impact epidemics (Roberts et al. 2012). 
3.4.2. The role of decision-analytic models for economic evaluation 
Decision analytic EEs have been applied in different disease areas and different decision-
making context. It is commonly seen in EE relating to questions of whether new technologies 
(e.g. pharmaceuticals) provide value-for-money (Drummond et al. 2015). This section briefly 
outlines the advantages of decision-analytic models for EE highlighting and why decision 
analytic EE is useful or even required.  
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First, whilst trial-based economic studies can be limited by the number of alternatives 
considered, modelled EE could compare all relevant courses of action. To determine the cost-
effectiveness of anti-depressants in depression treatment, for example, a range of treatment 
arms could include ‘do nothing’, ‘current practice’, different generations of anti-depressant, or 
even psychological therapy. However, it is noteworthy that in EE, the comparator is ideally the 
sequence of alternatives available to the patient, or the treatment most likely to be replaced by 
the new treatment (i.e. newer generation versus old generation of anti-depressant) (Drummond 
et al. 2015). In some cases especially in EE of diagnostic interventions, the number of 
comparators can be very substantial (Drummond et al. 2015). For example, Colbourn et al. 
(2007) compared 1214 (i.e. 1 283 918 464 548 860) options of prenatal screening and treatment 
to prevent bacterial infections in early infancy. 
Another advantage from modelled EEs is the ability to incorporate all relevant evidence. In 
contrast to trial-based EE, modelled EEs should use all appropriate evidence including 
effectiveness evidence from different trials but also evidence associated with HRQoL, unit 
costs and resource use (Drummond et al. 2015). Furthermore, modelled EE can also try to 
consider appropriately targeted population rather than focusing on the participants who are 
convenient or inexpensively recruited in a trial-based study. However, the availability of an 
appropriate evidence-base to model the impact of interventions or different populations to those 
evaluated within clinical trials can have limitations. The fact that trial-based EEs are context 
specific applies equally well to modelled based EE. 
A substantial benefit of modelled EE is the ability to link intermediate and final outcomes. This 
is especially important for preventive interventions. Evidence from clinical trials in prevention 
usually measure risk factors as clinically meaningful outcomes, but these are not the ultimate 
measures of health which are considered in economic evaluation (e.g. disorder/disease cases or 
QALYs) (Drummond et al. 2015). The reasons of this is partly because substantial study 
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resources are required to evaluate the effect of an intervention on reducing disease cases, 
particularly for low incidence diseases such as EDs. Modelled EEs can be used to extrapolate 
over a longer time horizon compared to trial-based economic studies. This involves predicting 
what would happen (largely in terms of both costs and health outcomes) beyond what has been 
observed in the trial. Importantly, the cost-effectiveness of preventive interventions or 
treatment interventions for chronic diseases such as cardiovascular diseases might be under-
estimated if the time horizon adopted for the EE does not capture the longer terms costs and 
benefits of such interventions. The benefit associated with these types of interventions can 
often occur beyond the duration of the trial time follow up. For example, in a two-year trial, 
the ICER of cardiac resynchronization therapy via pacemaker-defibrillator that was added to 
optimal pharmacological was near $70,000 per QALY, however, when the benefits and costs 
were modelled at a seven-year time frame, the ICER was well under $50,000 per QALY 
(Feldman et al. 2005). However, extrapolating the time horizon or linking the intermediate and 
final outcomes in modelled EEs requires various reasonable assumptions which are usually 
derived from longitudinal epidemiological studies using mathematical formulas. Thus, there is 
always uncertainty from underlying assumptions in decision-analytic modelling (Buxton et al. 
1997). Siebert (2003) has argued that the formal and explicit way of exploring such uncertainty 
must be a strength and not a weakness of the decision- analytic modelling approach given the 
usual absence of long-term effectiveness or final outcome data in many trials. 
3.4.3. Structure of decision-analytic modelling 
One of most important steps in decision-analytic modelling is deciding the most appropriate 
model ‘structure’, unfortunately, there are no firm recommendations regarding the most 
appropriate model structure for any decision problem. Instead, the choice of model is based on 
the research question, the nature of the disease, the available data, how the input data are to be 
related, and how the clinical events and health states of interest are characterized (Drummond 
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et al. 2015; Roberts et al. 2012; Stahl 2008). There are different forms of modelling including 
decision trees, Markov models, and individual sampling models (including discrete event 
simulations (DES) and microsimulations) (Roberts et al. 2012). These types of models can 
handle populations in the aggregate, as a cohort or as a summary of the behaviour of individuals 
in the model. Decision trees and Markov models are two common types of model which are 
useful in an EE that considers population aggregates (Briggs, Claxton & Sculpher 2006; 
Griffiths, Legood & Pitt 2016; Siebert 2003; Stahl 2008). On the other hand, individual 
sampling models are useful when the problem requires examining behaviour at an individual 
level.  
3.4.3.1. Decision Trees 
Decision trees are the simplest and the most common form of decision-analytic models. A 
decision tree is a graphical structure representing all the alternative options and the 
consequences following each option (Briggs, Claxton & Sculpher 2006; Siebert 2003; Stahl 
2008). A decision tree (Figure 2) starts at the far left with a square decision node, indicating a 
decision point between competing strategies. Moving from left to right, each alternative option 
is followed by branches with their respective probabilities that incorporates a series of circular 
chance nodes representing the resulting specific events consequent to making a given strategic 
choice (Stahl 2008). Probabilities indicate the likelihood of a particular event at a chance node, 
that may be determined by different strategies and patient characteristics (e.g. subgroups with 
different risk factor profiles) (Siebert 2003). Each branch of a decision tree is ended at a 
“triangular terminal node, representing the cost and outcome (e.g. such as symptoms or 
QALYs) of the strategy. The expected values of each strategy are calculated as a summation 
of the pathway values of all possible outcomes (i.e. costs and clinical outcomes) weighted by 
the pathway probabilities (Briggs, Claxton & Sculpher 2006). The pathway probabilities might 
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be joint probabilities, which are calculated by multiplying probabilities along the pathways of 
subsequent events.  
 
Decision trees are useful for their simplicity and transparency in decision analytic modelling 
(Petrou & Gray 2011b). However, they are most useful in the context where events with limited 
recursion and a limited and fixed time horizon are analysed (Siebert 2003). Decision-trees can 
become quite complicated for more complicated disease areas such as chronic disease where 
numerous lengthy pathways might be required or numerous sub-groups need to be considered 
(Drummond et al. 2015). Another constraint of decision trees is that it is hard to handle time-
dependent elements of an EE since simple decision trees lack any explicit time variable 
(Drummond et al. 2015). 
 
Probability
Probability
Probability
Probability
Figure 2: A decision tree 
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3.4.3.2. Markov Model 
To overcome such limitations of simple decision trees, Markov models are often preferred 
particularly in evaluating interventions for chronic disease. In contrast to decision trees which 
represent sequences of events in terms of alternative branches, Markov models are partially 
cyclic directed graphs which allow a hypothetical cohort of patients to move through a series 
of defined “states” which can be occupied at a given time point (Figure 3) (Drummond et al. 
2015; Stahl 2008).  
Figure 3 presents a simple Markov model with three health states: well population, disease and 
death states. Patients can remain in their current state or move to another state or move to a 
death state during a discrete time period, known as cycles. ‘Death state’ is often called an 
 
Figure 3: A Markov model 
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absorbing state from which patients cannot return to other health states (Stahl 2008). The speed 
at which patients move between the Markov states is defined as transition probabilities. For 
example in figure 3, the probability of disease state  The length of these cycles varies, from a 
month (or even a week) to a year (or more), subject to the disease and interventions being 
evaluated (Drummond et al. 2015; Stahl 2008). For example, one-year cycles may be 
appropriate for a model of cancer incidence whereas monthly cycles (or even weekly cycles) 
may be more appropriate for models examining the effect of pharmacological therapy for acute 
stroke (Stahl 2008). Each health state during a cycle in a Markov model is assigned with 
relevant costs and health outcomes. Like simple decision-trees, the expected values of each 
strategy is calculated by summing the values across states and weighting by the time duration 
during which the average patient occupies the various states in the model. 
An important limitation of Markov models is that the transition probability is not dependent on 
the states a patient may have experienced before entering that state. This is referred to as the 
‘memoryless’ feature of Markov models, (called the ‘Markovian assumption’) (Briggs, Claxton 
& Sculpher 2006).  However, prior events can of course differentially influence future events 
in some instances. Therefore, one solution is to introduce time-dependency in transition 
probabilities by varying different transition probabilities for each cycle in the model (e.g. age-
dependency probability). Importantly, Markov models simulate time in discrete steps (i.e. 
cycles) and assume transitions of persons from one state to another occur at fixed intervals 
(Drummond et al. 2015). The use of discrete-time steps in such models may lead to errors when 
calculating cumulative outcomes (Sonnenberg & Beck 1993). Therefore, ISPOR guidelines 
recommend using within-cycle correction methods (the most commonly known as the ‘half-
cycle correction’) to correct for continuity of time when using discrete-time Markov models 
(Siebert et al. 2012). The half-cycle correction is to add and subtract half of the outcomes in 
each state from the first cycle and last cycle, respectively (Elbasha & Chhatwal 2016; 
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Sonnenberg & Beck 1993). Alternatively, other within-cycle correction methods, such as life 
table method, typically apply correction at each cycle, instead of at the first or final cycle 
(Barendregt 2014; Elbasha & Chhatwal 2016). Markov model can become quite complicated 
if numerous additional states are required. In this case, health economists can consider another 
modelling approach such as a combination of decision trees and Markov models (known as 
cohort models). 
3.4.3.3. Individual sampling models 
The difficulty in incorporating ‘memory’ and ‘time dependency’ are two important limitations 
of decision trees and Markov models (Siebert 2003). Individual-level modelling techniques can 
overcome these limitations. Individual sampling models are able to be undertaken as a state 
transition model with discrete cycles (retaining the concept from Markov modelling 
techniques) and are referred to first-order Monte-Carlo simulation or micro-simulation (Siebert 
et al. 2012).The micro-simulation models simulate one individual at a time instead of single 
cohorts in Markov model (which does not allow one individual from another to be 
distinguished except by state descriptions) (Siebert et al. 2012). In this type of modelling, 
individuals are simulated through particular states by transition probabilities that depend on 
their history. For example, a person with diabetes and a history of stroke could have a higher 
risk of death than a person with diabetes without a stroke (Clarke et al. 2004). Another way to 
conduct individual sampling models is that the models simulate the time to the point at which 
the next event is experienced for a given simulated patient, commonly known as DES 
(Drummond et al. 2015; Karnon et al. 2012). The way ‘time’ is handled in DES means that 
these models can advance to the next time a given simulated patient has an event (i.e. unlike 
the fixed cycle length in Markov models), thus avoiding modelling time and effort in 
unnecessary interim computations  (Karnon et al. 2012). In other words, this handling of time 
as continuous is able to improve the precision of estimates because events can occur whenever 
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appropriate, thus eliminating the need for cycle correction methods in Markov model (Caro & 
Möller 2016). As modelling at the individual level, DES has an advantage of dealing with 
heterogeneity that is rarely considered when modelling at the cohort level (Caro & Möller 
2016). DES is useful to model more complex and direct interactions between individuals (e.g., 
transmission of disease) which are known as “agent-based models”. These types of models are 
only recently gaining more attention in health areas (Chhatwal & He 2015). An important 
limitation of individual sampling models is that they require extensive evidence to populate 
given parameters associated with possible future events for a given individual depending on 
prior history. Furthermore, the simulation requirements of these models can be time-consuming 
especially when probabilistic sensitivity analysis (as discussed in the following section) is 
conducted to quantify parameter uncertainty (Drummond et al. 2015). Therefore, individual 
sampling models, such as DES, are preferred when the implementation of a defined model 
structure is not manageable as a cohort-based state transition model (Karnon & Afzali 2014). 
3.4.4. Handling variability, uncertainty, and heterogeneity in decision-analytic modelling 
The results of modelled economic evaluations are subject to the impact of variability, 
heterogeneity and uncertainty. It is noted that these issues are not unique to modelled economic 
evaluation but may also arise in relation to other types of study designs such as economic 
evaluations alongside trials.Therefore, it is important to be aware of how to handle these in 
decision analytic modelling. 
Heterogeneity refers to differences between individuals that can be partially explained by 
differences in their observed characteristics such as age, sex, disease severity or risk factor 
level. To address such heterogeneity, the target population can be separated into sub-
populations or subgroups which are predefined and justified in terms of their clinical and 
economic relevance (Drummond et al. 2015; Petrou & Gray 2011b). Variability is defined as 
the random chance that individuals with the same underlying parameters or in the same 
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subgroup experience a different outcome. It is noteworthy that heterogeneity is not the same as 
variability. Even when variables such as age and sex may be controlled (i.e. observed variables 
which may impact disease prevalence or progression), there will still be variability between 
individuals regardless as to whether or not an event (e.g. death) during the specified period of 
time will occur (Briggs, Claxton & Sculpher 2006). Both heterogeneity and variability are 
therefore not really a source of uncertainty but rather something which characterizes reality. 
The most important consideration in decision analytic modelling is to capture uncertainty, 
rather than variability or heterogeneity (Briggs, Claxton & Sculpher 2006). Characterizing the 
uncertainty provides the “correct” estimates of the expected benefits and costs (Drummond et 
al. 2015). Uncertainty in economic evaluation is also known as second-order uncertainty and 
includes two types:  structural uncertainty and parameter uncertainty (or known as uncertainty 
and sensitivity analysis). The former (known as model uncertainty) refers to the uncertainty 
surrounding the structure of the model and the assumptions inherent in the model, for example, 
the way in which the disease pathway is modelled (Drummond et al. 2015; Petrou & Gray 
2011b). This type of uncertainty can be tested by re-running the model with different structural 
assumptions. In other words, the same decision problem can be modelled in different ways. 
This type of uncertainty is not often undertaken in health economics given the requirement of 
extensive resources to re-do models and little guidance as to how to reconcile the results from 
different models (Petrou & Gray 2011b). There is also evidence that structural differences do 
not lead to substantial differences in the results of different models but rather assumptions 
around the model parameters are what causes differences in results (Karnon 2003). 
The most common uncertainty that is used in EE is parameter uncertainty which reflects the 
uncertainty in the estimation of the inputs or parameters of interest. It is important to make a 
distinction between different techniques in this type of uncertainty, called uncertainty analysis 
and sensitivity analysis. Uncertainty analysis is undertaken to explore the variation of technical 
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parameters (economic and epidemiological inputs) on the results while sensitivity analysis is 
conducted to explore whether important structural assumptions in the interventions modelling 
impacted results (e.g. psychologist versus psychiatrist for delivering the intervention) 
(Neumann et al. 2016). Both techniques are complementary as uncertainty analysis is primarily 
advocated for representing parameter uncertainty whereas sensitivity analyses are used to 
observe the consequence of changing different assumptions and scenarios (Briggs 2005; Briggs 
et al. 2012). It is noted that Drummond et al. (2015) combine both uncertainty and sensitivity 
analysis under the umbrella term of ‘sensitivity analysis’, which is undertaken to clarify the 
level of uncertainty and to examine the robustness of the results. Uncertainty and sensitivity 
analysis can be addressed through various techniques including simple one-way and multiway 
sensitivity analysis (known as deterministic sensitivity analysis or sensitivity analysis) and 
multivariable probabilistic analysis (also known as uncertainty analysis). 
In a deterministic sensitivity analysis, parameter values are varied manually to test the impact 
of specific parameters or sets of parameters on the model’s results. Deterministic sensitivity 
analysis is often called one-way sensitivity analysis if one parameter is varied at a time or multi-
way sensitivity analysis if two or more parameters are varied at a time. The process for 
deterministic sensitivity analysis, particularly one-way analysis is the most simplest and more 
flexible than probabilistic sensitivity analysis, where the model is re-run with the different 
parameters or a series of parameters to generate the output (Walker & Fox-Rushby 2001). 
Theoretically, we are able to perform n-way (two, three or more way) sensitivity analysis but 
this type of analysis is difficult to undertake and interpret as it requires the consideration of the 
joint probability of n-parameters taking values greater than the threshold values simultaneously 
(Drummond et al. 2015; Walker & Fox-Rushby 2001). Another common form of deterministic 
sensitivity analysis is “scenario analysis” – most commonly known as best and worst case 
scenarios. In this type of analysis, the parameters are set at extreme but plausible values that 
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yields the worst (highest) and the best (lowest) cost-effectiveness ratio (Drummond et al. 2015; 
Walker & Fox-Rushby 2001). 
Probabilistic analysis (or uncertainty analysis) refers to the analysis in which all variables are 
varied simultaneously using probability distributions reflecting the best available evidence to 
inform the estimates of the sample mean and sampling error of the parameters (Briggs, Claxton 
& Sculpher 2006; Drummond et al. 2015). The choice of a probability distribution is important 
and not arbitrary. The choice is based on the nature of parameters, the summary statistics 
reported and the way the parameter was estimated (Briggs, Claxton & Sculpher 2006; 
Drummond et al. 2015). It is fortunate that there are several guidelines or evidence that can 
inform which probability distributions should be used for different parameters (Briggs, Claxton 
& Sculpher 2006; Briggs et al. 2012). This type of analysis is often undertaken by using Monte 
Carlo simulation where each parameter samples at random choosing from the chosen parameter 
distributions (Briggs, Claxton & Sculpher 2006; Drummond et al. 2015). The model is re-run 
many times (often thousands of times). Each time, the parameter values are randomly varied 
across the specified distributions that generate a single estimate of the outputs (i.e. costs and 
outcomes). The probabilistic sensitivity analysis is used to present the probability (or 
proportion of times) that the intervention is cost-effective at a particular willingness to pay for 
health gains. Furthermore, it is also used to present cost-effectiveness acceptability curves, 
which show the probability of each intervention being cost-effective at an assumed maximum 
cost-effectiveness threshold (Fenwick, Claxton & Sculpher 2001; Petrou & Gray 2011b).  
Ideally, both uncertainty and sensitivity analyses are conducted within a single economic 
evaluation to reflect “true” parameter uncertainty (Briggs et al. 2012). The deterministic 
analysis is used for reporting key parameters which can impact the ICER whereas probabilistic 
analysis is used to convey overall uncertainty. Regardless of the type of uncertainty analysis, 
uncertainty and sensitivity analysis allow the analyst to examine the reliability or robustness of 
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conclusions for the context of the evaluation. Furthermore, it also helps to inform the direction 
of further research (Drummond et al. 2015; Walker & Fox-Rushby 2001). 
3.5. Chapter summary 
EE is an important tool within the decision-making process. EE is divided into three main 
types: CEA, CUA and CBA.  Each type of economic evaluation has strengths and limitations, 
but the most commonly accepted type of EE in health care decision making is CUA. CUA uses 
a generic measure of outcome (i.e. QALYs or DALYs) that most typically allow the 
comparison of interventions both within and across different health areas. CBA is a useful tool 
to compare the economic credentials of alternatives across different sectors. However, placing 
a dollar value on health and issues relating the WTP approach itself means that there is limited 
use of CBA techniques in health.  
Both EE alongside trials and modelled economic evaluation are in effect complementary and 
commonly undertaken to assist decision makers in health care resource allocation decisions. 
The use of decision analytic modelling has been increasingly used in the healthcare context. 
The reasons for this inclusion of the possibility of extrapolating the intervention at both a 
population level (i.e. beyond the setting of trials) and with longer time horizon (beyond the 
usual short time horizons of trial follow-up) and increase generalisability to different settings 
or countries. However, it is noteworthy that a well conducted EE alongside a clinical trial which 
has a sufficiently long time horizon capable of capturing all important costs and benefits and 
conducted in people who are likely to use the intervention within routine service conditions is 
in some ways a superior study for the context in which it occurs (e.g. an Australian RCT with 
a quality EE to inform Australian funding decisions). The choice of the appropriate model 
structure is usually dependent on each decision context and subject to different factors such as 
the nature of the diseases, objectives of the research, and resources available to conduct the 
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study. The most common techniques that consider populations in aggregate are decision trees 
and Markov models. An important consideration is that decision-analytic modelling is a 
systematic approach to decision making in which uncertainty is unavoidable. How to handle 
the uncertainty is, thus, an important part of modelled EEs and should be explicitly considered. 
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Chapter 4: Economic evaluation in eating disorders – what we know 
Before embarking on undertaking new EEs for ED prevention and treatment, it is important to 
know whether there are already existing studies which are fit for this purpose. As such, a 
systematic review of the EE studies for ED prevention and treatment was undertaken to answer 
the first research question (i.e what is the existing evidence of cost-effectiveness for preventive 
and treatment interventions for EDs?). While single EEs of interventions are important, 
particularly for single resource allocation decisions (such as whether a new drug should be 
listed on the Pharmaceutical Benefits Scheme in Australia) they may end up being different 
methodologically. On the other hand, priority setting adopts a broader approach informing 
resource allocation decisions more generally whereby the results of the EEs of different 
interventions can be appropriately compared. As such, a literature review of broader based 
priority setting project was also conducted. This chapter therefore comprises two section 
including: (4.1.) the published systematic review of existing cost-effectiveness studies for 
preventive and treatment interventions for EDs; and (4.2.) a discussion of the existing priority 
setting for EDs within the Australian context. 
Overall chapter conclusion: 
The existing evidence base of EEs of ED prevention and treatment as well as priority setting 
studies is insufficient to answer the research question of which ED preventive and/or treatment 
interventions are cost-effective for implementation within the Australian context. 
4.1. Review of existing economic evaluations in eating disorders 
The Authorship Statement and supplementary document of this publication is attached in 
APPENDIX 2 and APPENDIX 3, respectively. The content of this chapter is based on the 
following publication: 
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Introduction
Around 3 in every 100 Australians have a current major eat-
ing disorder (ED) with 3-month prevalence estimates of 
anorexia nervosa (AN) 0.4% (95% confidence interval 
(CI) = [0.2, 0.7]); bulimia nervosa (BN) 1.1% (95% CI = [0.7, 
1.5]) and binge-eating disorder (BED) 1.5% (95% CI = [1.1, 
2.0]; Hay et al., 2017). EDs are also associated with sub-
stantial economic and social burden (Ágh et al., 2016a; 
Deloitte Access Economics, 2012; Erskine et al., 2016; 
Stuhldreher et al., 2015) and there is evidence of an increase 
in the incidence of ED behaviours and in turn the incidence 
of the sub-threshold variants of AN, BN and BED that com-
prise the other specified feeding or eating disorder (OSFED) 
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and unspecified feeding or eating disorder (UFED) over 
the last two decades (Hay et al., 2008, 2015; Mitchison 
et al., 2014). Furthermore, evidence shows that there is an 
increasing health burden of EDs in terms of prevalence 
and quality of life impairment (Hay et al., 2017; Mitchison 
et al., 2014). Together, the two main types of EDs, AN and 
BN, account for 1.9 million disability-adjusted life years 
(DALYs) and comprise the 12th major cause of burden of 
disease and injury in young females aged 15 to 24 
(Haagsma et al., 2015). Additionally, the costs of EDs are 
substantial in terms of both direct health-care costs and 
broader societal costs including loss of productivity (Ágh 
et al., 2016a; Deloitte Access Economics, 2012; Samnaliev 
et al., 2015; Stuhldreher et al., 2015). Hospital care, com-
posed of inpatient hospital stays, treatment at day clinics 
and rehabilitation, accounted for 90% of these costs in 
people with AN (Stuhldreher et al., 2015). Furthermore, 
the cost of disability payments for AN was reported in 
Canada as being between three-quarters and 30 times 
greater than the overall cost of tertiary care treatment (Su 
and Birmingham, 2003).
There are several preventive and treatment-based inter-
ventions which have been demonstrated to be effective for 
EDs. Effective preventive interventions include cognitive-
behavioural therapy (CBT) or media literacy interventions 
(Le et al., 2017a). Effective treatment interventions include 
family-based treatment for young people with AN 
(Couturier et al., 2013) and CBT and antidepressant medi-
cations for adults with BN and BED (Hay et al., 2014). 
However, whether these interventions are cost-effective is 
uncertain.
The most recent systematic review of cost-effectiveness 
for ED interventions published in 2012 highlighted very 
few studies in this area (Stuhldreher et al., 2012). This 
review found that only two cost-effectiveness analyses 
alongside randomised controlled trials (RCT) included 
both intervention costs and costs beyond those of the spe-
cific intervention (i.e. cost offset). However, the review 
used a ‘strict’ classification of what constitutes a cost-effec-
tiveness study, in which both intervention costs and costs 
beyond the intervention were considered (Stuhldreher 
et al., 2012). In the other words, this classification excludes 
cost-effectiveness studies in which costs beyond the inter-
vention are not considered because such costs of health ser-
vices are very context specific (Mihalopoulos and 
Chatterton, 2015). However, these studies may have impor-
tant implications for decision making (Husereau et al., 
2013). Furthermore, the search only included studies pub-
lished up to January 2011.
The aim of this study was to conduct an up-to-date 
review of the evidence base for cost-effectiveness of both 
preventive and treatment interventions for EDs. This study 
also aimed to identify more recent (and therefore, most 
cost-relevant) higher quality cost-effectiveness studies and 
highlight the implication for policy makers in EDs.
Methods
The current review conformed to the evidence-based guide-
lines in the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA; Moher et al., 2009).
Search strategy
Eligible cost-effectiveness studies were identified through 
searching in MEDLINE, PsycINFO, Academic Search 
Complete, Global Health, CINAHL complete, Health 
Business Elite, Econlit, Health Policy Reference Center 
and ERIC database for articles published until March 2017. 
The search used the following search terms (eating disor-
der* OR anorexia OR bulimia OR binge*) AND (cost* OR 
economic*). Hand searching was conducted in the table of 
contents for journals that commonly publish ED studies 
(e.g. International Journal of Eating Disorders, Journal of 
Eating Disorders, Eating Disorders and European Eating 
Disorders Review) over March 2017.
Inclusion and exclusion criteria
Studies were selected for inclusion if they were compara-
tive cost-effectiveness studies of prevention or treatment of 
EDs and published in the English language. Studies were 
eligible for inclusion if they compared costs (including 
costs of interventions with or without costs beyond of the 
intervention) and outcomes of at least two interventions. 
Descriptive economic studies that reported only cost of the 
interventions without comparative outcomes or that 
reported cost and consequences of one intervention, or 
cost-of-illness studies were excluded.
Study selection and extraction
All citations were imported into an electronic database 
(Endnote® version X2) with duplicates subsequently 
removed. The first author (L.K.-D.L.) completed the lit-
erature search, screened the abstract of every record and 
reviewed the full text if appropriate for inclusion in the 
review. Decisions regarding inclusion of studies where it 
was not clear as to whether the inclusion criteria were met 
were resolved by consensus between the first and last 
authors. Included studies were classified as cost- 
effectiveness studies of prevention or treatment of EDs. 
Other information that was extracted included the type of 
cost-effectiveness study undertaken (including cost- 
effectiveness analysis [CEA, where outcomes are expressed 
in clinical units, such as clinical scales], cost-utility analysis 
[CUA, where outcomes are presented in generic units such 
as quality-adjusted life years (QALYs)] or cost-benefit anal-
ysis [CBA, where outcomes are expressed in monetary 
terms using techniques such as willingness to pay studies]); 
the perspective and time horizon; outcome measurement 
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and incremental cost-effectiveness ratio (ICER) results. To 
compare the costs or ICERs across all the studies, all costs 
were converted into 2013 US dollars. We did this by first, 
using country-specific gross domestic product inflators to 
convert the currency of the study into the 2013 equivalent. 
Second, we used purchasing power parities (PPPs) to con-
vert to US dollars for the studies which reported the costs in 
non-US dollar currencies. Finally, if the year was not 
reported, the assumption of 2 years prior to the publication 
date was made as the base year.
Quality assessment
The published Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) checklist (Husereau et al., 
2013) was used to assess the quality of included studies. 
This checklist recently consolidated and updated previous 
health economic evaluation guidelines into a single stand-
ard (Husereau et al., 2013). The checklist includes 24 items 
which are subdivided into six main categories: title and 
abstract, introduction, methods, results, discussion and 
other (Husereau et al., 2013). Quality assessment was com-
pleted for each included study by the first author (L.K.-
D.L.). A score of quality assessment was given based on the 
percentage of criteria met by each study that ranged from 
0% to 100%. A study, of which percentage of met criteria 
ranked over 50th percentile, was classified as ‘adequate’ 
quality of reporting.
Results
The literature search identified 6017 articles. After remov-
ing duplicates and screening by abstracts, 235 articles were 
retained for further consideration. Of these, 13 studies were 
identified which met inclusion criteria (Figure 1). In the 
excluded studies, there were 10 studies, which have 
reported cost outcome of interventions but did not met the 
criteria of full cost-effectiveness study. In particular, two 
studies RCTs reported costs as an outcome but did not 
examine these in relation to study outcomes and provided 
insufficient methodological information to justify their 
inclusions as full cost-effectiveness studies (Agras et al., 
2014; Schmidt et al., 2007). Two studies were excluded as 
they reported cost analysis or cost offset of the interven-
tions in which, the outcomes were not defined (Bode et al., 
2017; Kass et al., 2017). The remainder was excluded as 
they were cost-outcome descriptions of a single interven-
tion. Further information of the excluded studies is availa-
ble in Appendix S1.
Characteristics and main findings of 
included studies
Table 1 includes a comprehensive summary of included 
studies.
Preventive interventions for EDs. There were four studies that 
evaluated the cost-effectiveness of preventive interventions 
for EDs. Three studies were modelled evaluations focusing 
on adolescents aged 10–18 years, with 10-year time hori-
zons, compared with a comparator of non-intervention or 
usual care (Le et al., 2017b; Wang et al., 2011; Wright 
et al., 2014). The remaining study was a 3-year trial-based 
CEA which focused on young females (mean 
age = 21.6 years; Akers et al., 2017). Most of these studies 
adopted narrow perspectives (i.e. from organisation per-
spectives to health-care perspectives). Wang et al. (2011) 
adopted a broader societal perspective. However, this study 
did not include productivity costs and therefore may be bet-
ter characterised as a partial societal perspective. Wang 
et al. (2011) found that an obesity-prevention intervention 
for BN prevention (e.g. Planet Health Programme) was 
cost-effective with an ICER of US$18,291 per QALY 
gained when only benefits associated with ED were 
included. However, when benefits associated with both ED 
and obesity were considered the intervention became cost-
saving. Results of cost-effectiveness of preventive inter-
ventions from other studies varied substantially as a result 
of differences in how outcomes were assessed. The study 
from Wright et al. (2014) assessed a screening intervention 
for preventing all types of Diagnostic and Statistical Man-
ual of Mental Disorders (4th ed.; DSM-IV) EDs and was 
the only preventive study that included both males and 
females. This study found that the screening intervention 
reported an ICER of US$57,687 per QALY gained or 
US$9,231 per life-year with ED avoided. The studies from 
Le et al. (2017b) and Akers et al. (2017) evaluated a cogni-
tive dissonance intervention for preventing EDs in females 
with high body concerns. The results of these studies found 
that cognitive dissonance as a preventive intervention for 
ED was associated with an ICER of US$71,865 per DALY 
averted (Le et al., 2017b) and US$856 per additional at-risk 
person reducing ED symptom to a clinically meaningful 
degree (Akers et al., 2017).
Treatment interventions for EDs. There were nine studies 
that evaluated the economic credentials of ED treatments. 
For AN treatment, both studies from Egger et al. (2016) and 
Byford et al. (2007) were trial-based cost-effectiveness 
studies with time horizons of 2 years. The study by Crow 
and Nyman (2004) was a modelled evaluation with a life-
time horizon. Target populations varied between adoles-
cents aged 11–18 years (Byford et al., 2007) and female 
adults (Egger et al., 2016) and were unclear in the Crow 
and Nyman (2004) study. While the studies from Byford 
et al. (2007) and Crow and Nyman (2004) were conducted 
from a government as payer perspective, the study from 
Egger et al. (2016) used a health-care perspective in the 
base case and a broader societal perspective (i.e. included 
productivity costs) in their sensitivity analysis. Studies 
examine different outcomes: recovery (defined as having a 
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body mass index (BMI) > 17.5 kg/m2 and a score on the 
psychiatric status rating (PSR) scale of 1 or 2); QALY 
gains (based on the EuroQol – five dimensions (EQ-5D)); 
BMI changes (Egger et al., 2016); changes on the Morgan–
Russell Average Outcome Scale scores (MRAOS; Byford 
et al., 2007) and years of life saved (Crow and Nyman, 
2004). Results from the Egger et al. (2016) study indicated 
that both focal psychodynamic therapy and CBT were more 
effective at lower cost compared to optimised treatment as 
usual (TAU). Similarly, Byford et al. (2007) found that spe-
cialised outpatient treatment was more effective and less 
costly compared to psychiatric inpatient treatment or TAU. 
However, the results from both papers did not reach statisti-
cal significance. The remaining study found that imple-
menting the ‘‘adequate care’’ approach (defined as inpatient 
weight restoration to close to 100% of ideal body weight 
followed by extensive care) led to an ICER of US$30,180 
per year of life saved when compared to usual care (Crow 
Figure 1. Flow chart of economic evaluation inclusion and exclusion.
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and Nyman, 2004). However, the study did not include any 
uncertainty or sensitivity analyses, so it is unknown how 
robust the results were.
For BN treatment, all three studies were trial-based 
CEAs with 12-month follow-up and were undertaken to 
evaluate the cost-effectiveness of CBT on females aged 
16 years or over who were diagnosed with Diagnostic and 
Statistical Manual of Mental Disorders (3rd ed.; revised; 
DSM-III-R) BN within the US context (Koran et al., 1995) 
or DSM-IV BN (Crow et al., 2009, 2013). All of these stud-
ies used abstinence as the primary outcome measure. In 
terms of the economic perspective, while Crow et al. (2009, 
2013) adopted a third-party payer and societal perspective, 
Koran et al. (1995) did not state which perspective was 
used (although from the results it appears that a health-care 
perspective was adopted). Results indicated that face-to-
face CBT was not considered to be cost-effective in com-
parison with 24-week desipramine (⩽300 mg/day) or 
telemedicine CBT or a stepped care intervention. Both 
studies from Crow et al. (2009, 2013) included insufficient 
details of how the resource uses were costed while the 
remaining study used ‘projected costs’ of a treatment plan 
instead of actual costs (Koran et al., 1995).
The current review identified two studies for BED treat-
ment from Ágh et al. (2016b) and Lynch et al. (2010). The 
first study developed a population model to estimate the 
costs and benefits of lisdexamfetamine relative to placebo, 
while the second study evaluated the cost-effectiveness of 
CBT with guided self-help added to TAU. Both studies 
were conducted with a time horizon of 1 year, were within 
the US context, targeted adults with BED and clearly pre-
sented the way that resources were identified and costed. 
Lynch et al. (2010) found that adding CBT-guided self-help 
to TAU was more effective and less costly (or dominant) 
compared to TAU alone for recurrent BED treatment under 
both the societal perspective and health-care perspectives. 
Their conclusion did not change following a sensitivity 
analysis that assessed only cases with complete data (Lynch 
et al., 2010). Ágh et al. (2016b) reported an ICER of 
US$27,618 per QALY gained for lisdexamfetamine com-
pared to the placebo with an 82% probability that the inter-
vention was cost-effective at a willingness to pay threshold 
of US$50,000/QALY gained. The result of this study was 
most sensitive to the utility of the ‘non-symptomatic BED’ 
health state in the sensitivity analysis.
One remaining study evaluated the cost-effectiveness of 
an Internet-based intervention with or without clinician 
support relative to a waitlist control group. This study did 
not specify the type of ED but included adults with self-
reported ED symptoms measured by the Short Evaluation 
of EDs and the Weight Concern Scale. The study analysed 
costs from a societal perspective within a 5-month time 
horizon and measured outcomes using QALY gains based 
on the EQ-5D-3L. This study found that the active inter-
vention was more cost-effective compared to the waitlist 
control, although both cost and QALYs were not statisti-
cally significantly different across treatment arms.
Quality assessment
All the studies included in this review met over 50% of the 
CHEERs criteria checklist. The average percent of items 
reported in the studies was 71% (standard deviation: 20.8%). 
The studies that were published more recently (time cut-off 
point of 2011) achieved higher scores than the earlier stud-
ies (average scores of 77% vs 60%). Only two studies from 
Ágh et al. (2016b) and Le et al. (2017b) met 100% of the 
CHEERs criteria. Half of the studies were classified as ‘ade-
quate’ with respect to the quality of their reporting, ranking 
them in 50th percentile. A common reason why studies did 
not achieve 100% of the criteria was that the research ques-
tion did not include key elements such as the perspective, 
study population or time horizon. None of the studies under-
taken alongside RCTs met the criterion of characterising 
heterogeneity. However, it is important to note that these tri-
als were not necessarily powered to detect subgroup differ-
ences (Mihalopoulos and Chatterton, 2015). Only 3 out of 
13 studies reported any conflict of interest. Approximately 
half of studies reported costs and outcomes for every treat-
ment alternative but did not report the incremental costs and 
outcomes between the interventions. Further details of the 
quality appraisal may be found in APPENDIX S2.
Discussion
Summary of the main findings
The current review found that the number of cost-effective-
ness studies in EDs has more than doubled in the last 6 years. 
The methodological quality of studies has also improved in 
more recent studies (since 2011). Studies from Le et al. 
(2017b) and Ágh et al. (2016b) were the highest quality 
cost-effectiveness studies which met 100% CHEERs check-
list criteria. The former study highlighted that increasing the 
participation rate of the cognitive dissonance intervention 
might render the intervention to be cost-effective for AN 
and BN prevention, while the latter study supported the 
cost-effectiveness of lisdexamfetamine in BED treatment. 
Due to the variability in the types of interventions and alter-
natives evaluated and heterogeneity of targeted population, 
no conclusive recommendations can be drawn regarding the 
most cost-effective interventions for prevention and treat-
ment in EDs. Further research of cost-effectiveness with 
improved methodological rigour is needed.
Methodological limitations of included 
studies
While there have been considerable improvements in both 
quantity and quality of cost-effectiveness studies in 
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comparison to previous review by Stuhldreher et al. 
(2012), there are still some persistent methodological limi-
tations in the current studies reviewed. Many studies pro-
vided insufficient information on how resources were 
measured and costed. Furthermore, the analytical methods 
were often not clearly reported and justified. Information 
regarding the methods for dealing with skewed or missing 
data and/or how to address population heterogeneity was 
often missing. Approximately 40% of included studies did 
not report currency, reference year or conversion method-
ologies. Although three studies stated that they adopted 
societal perspectives, productivity costs were not included 
in the analyses (Byford et al., 2007; Lynch et al., 2010; 
Wang et al., 2011); instead, included societal costs 
appeared as education sector costs (Byford et al., 2007) or 
time and travel costs (Lynch et al., 2010). This is possibly 
because the target populations were adolescents who were 
not yet in the workforce (Byford et al., 2007; Wang et al., 
2011). Having said that, the cost-effectiveness of interven-
tions might be underestimated given that the societal costs 
associated with EDs are substantial (Ling et al., 2016, 
Stuhldreher et al., 2012, 2015). Another limitation is that 
conclusions regarding the long-term cost-effectiveness of 
the interventions, especially in ED treatment, cannot be 
made since only 4 out of 13 studies included time frames 
beyond two years.
Of the 13 studies, eight evaluated were cost-effective-
ness analyses alongside clinical trials. While some trials 
in EDs provided useful cost results, they did not include a 
full CFA (Agras et al., 2014; Schmidt et al., 2007). 
Importantly, the findings from these trial-based cost-
effectiveness studies should be interpreted with caution. 
The differences between costs and/or outcomes across 
treatment arms in several studies did not reach statistical 
significance (Aardoom et al., 2016; Byford et al., 2007; 
Crow et al., 2009, 2013; Egger et al., 2016; Koran et al., 
1995; Lynch et al., 2010). One reason for this may be that 
the sample sizes were too small to detect statistical sig-
nificance in use of healthcare resources and cost measures 
(Briggs, 2000). Having said that, cost-effectiveness stud-
ies with low power should ideally report the CIs along 
with the probability of being cost-effective at different 
willingness to pay threshold.
However, model-based cost-effectiveness studies are 
useful accompaniments to trial-based studies for both pre-
vention and treatment of EDs. Such research then pro-
vides important information to decision-makers as to 
whether interventions represent good value for money 
(Sculpher et al., 2006). However, there is an important 
gap for modelled cost-effectiveness studies especially for 
ED treatment, with only one out of nine studies using this 
type of analysis. A very important consideration, particu-
larly for modelled evaluations in this field, is that the syn-
thesis of clinical effectiveness data should be presented 
adequately.
Directions for future research
While the current review has demonstrated that the evi-
dence base of economic evaluations for interventions tar-
geting EDs has doubled from 2011 to 2017 (albeit with a 
small total number of studies), several evidence-based 
interventions for prevention and treatment of EDs have not 
been examined for cost-effectiveness. In particular, CBT 
has strong evidence as a treatment intervention, which has 
been found to be superior to non-intervention control in BN 
treatment (Hay et al., 2009). Family-based treatment is also 
an evidence-based intervention for the treatment of young 
people with AN and is commonly provided in many con-
texts including Australia (Couturier et al., 2013; Hughes 
et al., 2014; Watson and Bulik, 2013). Importantly, only 
two cost-effectiveness studies were identified of treatment 
for BED and there have been no cost-effectiveness studies 
of treatment for other types of Diagnostic and Statistical 
Manual of Mental Disorders (5th ed.; DSM-5) ED includ-
ing OSFED or UFED. Given that the prevalence of these 
disorders is far higher than those of AN and BN, in both 
community and clinical samples, this would appear to be a 
major shortcoming of the existing evidence base. Further 
research is needed to investigate the cost-effectiveness of 
these interventions.
Another gap in the existing evidence base is that cost-
effectiveness studies of existing interventions, both preven-
tive and treatment, have been almost exclusively confined 
to studies involving females. Findings from recent epide-
miological studies demonstrated that there are substantial 
increases in the population health burden of ED behaviour 
in males and BED is relatively common in males (Mitchison 
et al., 2014; Mitchison and Mond, 2015). Furthermore, 
there is increasing concern associated with the prevalence 
and adverse effects of ‘muscularity-oriented disordered eat-
ing’ (Murray et al., 2016). Given that, the cost-effectiveness 
of intervention involving males is an important direction 
for future research.
Finally, cost-effectiveness studies of interventions for 
ED appear to be confined, thus far, to clinical preventive 
and treatment approaches. Given that there is increasing 
awareness of the role that health promotion and early inter-
vention programmes play on the health burden of ED 
(Mond, 2016), it is important that further research is needed 
to establish the effectiveness and cost-effectiveness of these 
types of programmes.
Conclusion
In conclusion, this review found growth in terms of number 
of cost-effectiveness studies for prevention and treatment of 
EDs published in the past 6 years. This is an encouraging 
finding given that there were very few studies identified in 
the previous review (Stuhldreher et al., 2012). However, 
methodological differences between the studies have limited 
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their comparability. It is, therefore, difficult to formulate 
general conclusions on which interventions offer the best 
value for money. There is an urgent need for further research 
evaluating the cost-effectiveness credentials of evidence-
based ED interventions. Moreover, future research of cost-
effectiveness in EDs should adhere to established reporting 
standard, such as CHEERs checklist, to ensure high-quality 
reporting and conduct of cost-effectiveness studies.
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4.2. Review of existing priority-setting approaches in eating disorders 
Within the Australian mental health context, economic evaluation has been emphasized as an 
attractive solution to the problem of explicit rationing of limited healthcare resources 
(Mihalopoulos et al. 2013). However, there has been little focus on research which considers 
“how to translate from research recommendations into usable practice resources” in EDs 
(NEDC 2013, p. 119). In particular, there is a “gap” or a need for research into the cost-
effectiveness of evidence-based interventions for prevention and treatment of EDs within the 
Australian context (NEDC 2013). Although a review of cost-effectiveness study is important 
to examine what has been done in the published literature, it is also vital to examine any broader 
priority-setting and public policy studies to ensure that evidence of cost-effectiveness was not 
missed. This is because these approaches may include full economic evaluation as well as 
economic analysis (e.g. return-on-investment) that may not be published as stand-alone studies 
in the literature.  A recent review of priority setting studies undertaken in the mental health 
context (e.g. ACE-prevention, ACE-mental health, WHO generalized cost-effectiveness 
approach) did not include EDs as interest disorders (Mihalopoulos et al. 2013). Andrews and 
the TOKIEN II (2007) estimated the disease burden reduction by using a stepped care model 
to provide optimal treatment to the people in current contact with the system by reorganising 
the system. The authors found that using the current budget as that a “30% increase in budget 
could treat 50% more people and produce a 90% increase in health gains”, measured by DALYs 
averted. However, this estimation was based on ten disorders which did not include EDs 
although optimal treatment (based on expert opinion) and a costing structure of AN and BN 
were proposed (Andrews et al. 2003; Andrews & TOLKIEN II Team 2007). 
Deloitte Access Economics released a report which evaluated the economic and social impact 
of EDs in Australia (Deloitte Access Economics 2014). This report provided an economic 
rationale for investment into EDs by conducting a cost-benefit analysis to identify whether a 
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theoretical best practice system (including prevention and treatment) developed by the NEDC 
is cost effective. This report concluded that the monetary benefits of best practice care outweigh 
the costs by more than 5.38 to 1 and that most of the monetary benefits were related to 
productivity impacts. There are, however, some important limitations to this work.   
Firstly, Deloitte Access Economics assessed the outcomes of the best practice system using 
adjusted recovery rates sourced from several economic evaluation studies instead of 
randomized controlled trials or the equivalent. Moreover, as shown in the section above, these 
economic evaluation studies are all of the treatment interventions and do not include preventive 
interventions. In particular, two existing economic evaluation studies of ED prevention were 
not included in this report (Wang, Nichols & Austin 2011; Wright et al. 2014). Therefore, the 
report may have missed important interventions which have good evidence of impact but have 
not undergone economic evaluations. Furthermore, the measurement of recovery from ED from 
this report was variable and measured by: 
• abstinence in eating disordered symptoms (e.g. binge eating episodes) for BN; 
• gain in QALYs for BN;  
•  the outcomes of various validated ED assessment tools for AN; and 
•  sustained ideal body weight for AN.  
It is unclear how all these disparate results were synthesised in the common unit of outcome, 
DALYs, used in the report. Furthermore, many of the interventions evaluated did not explicitly 
include the impact on productivity in the effectiveness estimates. Therefore, given that the 
results were largely driven by productivity impacts, the evidence base upon which these 
outcomes were based is very limited and almost entirely assumption based. 
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Another limitation is that this report failed to provide a comprehensive analysis of the cost of 
the interventions (for example, prevention and treatment intervention costs were not included). 
Instead, it was assumed that the cost to implement the whole best practice system equalled total 
of the 2011-12 Australian Government budget allocated to targeting youth mental health.  
Lastly and very importantly the report placed a value of $180,000 per DALY averted. There is 
no evidence in Australia for such a high shadow price on DALYs, in fact the most commonly 
used threshold value for DALYs in the Australian context is $50,000/DALY averted (Carter et 
al. 2008) or less than three times the GDP per capita criterion (approximately $160,000 per 
DALYs) using WHO criterion (WHO Commission on Macroeconomics and Health 2001). As 
a result of these limitations, the findings from the Deloitte Access report (2014) are likely to 
be overestimated due to the highly optimistic assumptions regarding productivity impacts as 
well as the overvalued shadow price of DALYs. Given these important assumptions, it is 
unclear why the report did not undertake sensitivity analyses of these assumptions. As a 
minimum, productivity impact could have been excluded and the DALY valued at a more 
realistic Australian estimate of $50,000 to less than $160,000 (rather than $180,000).  
As is evident, there are few existing economic evaluations of interventions for EDs (section 
4.1. of this chapter) and, apart from the recent Deloitte Access report which has substantial 
methodological concerns, EDs have not been explicitly considered in the existing priority-
setting studies which have been undertaken within the Australian mental health context. It is 
difficult to know whether sufficiently adequate resources have been dedicated to EDs or even 
whether the current interventions being offered for EDs are cost-effective or whether we can 
“do better” with the existing resources being allocated to EDs. 
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Chapter 5: Methodology of cost-effectiveness studies 
This chapter introduces core methodological principles which are used across the technical 
analyses undertaken as part of this thesis to avoid duplication of specific methodological 
information in the series of publications (Chapter 7 to 9). Given that the overall methodological 
guidance based on the CRE stream 1 economic protocol mainly used the technical methods of 
the ACE approach, this chapter includes a discussion of how the ACE approach relates to the 
focus of this PhD and briefly discuss the common technical aspects of the studies.  
5.1. The implication of the Assessing Cost-Effectiveness approach 
There are a few studies which have adopted broader approaches to informing resource 
allocation decisions in mental health more generally whereby the results of the economic 
evaluations of different interventions can be appropriately compared (Andrews et al. 2004; 
Carter et al. 2008; Hutubessy, Chisholm & Edejer 2003; Mihalopoulos 2012; Vos et al. 2010; 
Vos et al. 2005). According to Mihalopoulos et al. (2013), the most useful approaches for 
healthcare decision-makers comprise both strong technical foundations as well as a process for 
incorporating the many criteria of decision-makers. An Australian developed approach which 
is both technically sound and has a process for incorporating decision-maker concerns is the 
ACE approach (Carter et al. 2008). ACE has been demonstrated to be feasible within the mental 
health context and easily adapted to local contexts (Mihalopoulos et al. 2013; Vos et al. 2010). 
Within the Australian context, the ACE-Mental Health and the ACE-Prevention studies 
identified both cost-effective and less cost-effective interventions for mental disorders in 
Australia (Mihalopoulos et al. 2013; Vos et al. 2010; Vos et al. 2005). Importantly, EDs have 
not been included in these studies to date. There are several notable key characteristics (on the 
technical side) of the ACE approach including but not limited to  
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(1) well-defined research questions that are adaptable to different contexts and settings;  
(2) standardised and documented economic evaluation methods;  
(3) succinct rationale for the selection of interventions;  
(4) using simplified assumptions based on the best available evidence, augmented by 
judgement and expert opinion;  
(5) using country-specific epidemiology data to inform economic modelling; and  
(6) reporting results as a range (around point estimates) reflecting the uncertainty of cost, 
process, outcome and value estimates (Carter et al. 2008; Haby et al. 2004; Vos et al. 2005). 
The ACE approach also includes a “second-stage filter analysis”, in which, results are placed 
within a broader decision-making framework including ‘strength of evidence’, ‘equity’, 
‘feasibility’ and ‘acceptability’ (Vos et al. 2005). These criteria are usually not captured within 
the technical cost-effectiveness results. While the ACE approach has tried to include both 
technical and non-technical components in an “ideal” priority setting process, the impact on 
policy has still been patchy (Whiteford, Harris & Diminic 2013). Prior studies have shown that 
second -stage filter analysis tends to come secondary to the technical analyses and the focus of 
the current thesis is to focus on the cost-effectiveness of ED interventions which have never 
been evaluated using the ACE approach. Therefore, the “second -stage filter analysis” is not 
formally considered in this current thesis. However, some of the issues usually discussed in the 
part of the ACE studies are included in the discussion of the technical economic evaluation of 
this thesis. 
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5.2. Technical method of economic evaluation, adapted from the ACE approach 
The ACE approach has more generally been reported elsewhere (Carter et al. 2005). Therefore, 
the general technical aspects of EEs are briefly discussed to avoid repetition. Other specific 
methods pertaining to each publication comprising this thesis such as defining the actual 
comparators, specific target populations, specific costing methods etc. are not discussed in this 
chapter to avoid duplication as they are included in the subsequent chapters. Furthermore, while 
methods developed in the ACE approach to date provide overall guidance around key 
methodological issues, specific methodological details are provided in each chapter of the 
thesis whereby the empirical studies are described. As such, the ACE approach can be viewed 
as more of a technical guide rather than overarching prescriptive methodology per se.  
Table 4 below summarises the key characteristics of the study frame and design for the 
economic evaluations which have been undertaken in this PhD. 
Table 4: Features of economic evaluation methods. 
Economic 
framework 
Cost-utility analysis 
Comparator Partial null - subject to available data 
Perspective Healthcare sector (Primary analysis) and Partial Societal (Secondary 
analysis) 
Target population Australian population in year 2013 
Study boundaries * Inclusion of health benefits for participants only (i.e. not for family 
members and carer except in a secondary analysis if data permits) 
* Inclusion of positive and harmful effects directly related to the 
intervention(s) of interest (if applicable). 
* Exclusion of the cost of treating future ‘unrelated’ disease. 
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* Exclusion of productivity gains and losses and other non-health 
sector impacts (except in a secondary analysis if data permits) 
* Modelling all interventions in ‘steady state’ operation. 
Time horizon The intervention time horizon should realistically reflect how the 
intervention would be applied in real life.  
Modelling 
approach 
Excel-based multiple-cohort Markov model adapted from Dismod II 
(Barendregt et al. 2003) 
Health outcomes Disability Adjusted Life Years. 
Unit measurement 
for costs 
Australian Dollars, 2013 reference year 
Discount rate 3% 
Sensitivity and 
Uncertainty 
analysis 
Monte-Carlo simulation for uncertainty analysis. 
One-way and two-way sensitivity analyses used on a case-by-case 
basis. 
Result presentation Incremental cost-effectiveness ratios. 
Notes. Adapted from (Carter et al. 2005) 
Economic framework: The main aims of the CRE (introduced in Chapter 2) were largely 
focused on allocative efficiency within the health sector. To inform the question of allocative 
efficiency in the health sector, comparisons across multiple interventions across all the 
disorders being considered need to be undertaken. Therefore, it is essential that the evaluations 
conducted as part of the current PhD project were as comparable as possible to the other 
evaluations being conducted within the context of the CRE. To achieve this goal, the primary 
analytic method chosen was CUA with outcomes expressed in terms of cost per DALY averted. 
The starting point of the CRE was the burden of disease as measured by the GBD study (Vos 
et al. 2015; Whiteford, Harris & Diminic 2013) using DALYs. It is noteworthy that there is a 
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fundamental difference in the construction of a DALY used in burden of disease and the 
concept of adverted DALYs in this thesis (discussed further in outcome measurement below) 
Comparator: Ultimately, all available alternatives that have some possibility of being cost-
effective should be included in EEs although this can be challenging (Drummond et al. 2015). 
The most frequently chosen comparators in the EEs are ‘current practice’ or ‘do nothing’ 
(Drummond et al. 2015). Including ‘current practice’ as a comparator to a new intervention can 
be useful because this can provide the cost-effectiveness of replacing existing practice with the 
new intervention. However, there is an issue that the result could be misleading if ‘current 
practice’ is not efficient or cost-effective compared to ‘do-nothing’. In other words, inefficient 
current practice would make the new interventions look very cost-effective. An alternative 
approach used in the ACE studies is using a ‘partial null’ comparator whereby the target 
population receives neither the active intervention nor any established intervention currently 
being operated (Carter et al. 2005). In this case, the back calculation is required to determine 
the costs and benefits of ‘current practice’ compared with ‘partial null’ comparators. And if 
there were no existing interventions that were currently implemented (i.e. ‘no intervention’ 
comparator),  no back-calculation would be required (Carter et al. 2005). Given the lack of data 
on existing prevention and treatment services for EDs, ‘no intervention’ (or equivalent 
comparators) were assumed to be indicative of this ‘partial null’ comparator.  
Perspective: As stated, since the targeted audience was healthcare decision-makers, the 
primary perspective was the health sector defined as all costs and consequences accruing to the 
Australian health sector. A full health sector perspective included the government as health 
service funder (e.g. Commonwealth and State Governments) and impacts of the interventions 
on clients and their families (e.g. out-of-pocket health care costs) (Neumann et al. 2016). This 
thesis aimed to take a full health sector perspective subject to the availability of data and 
resources as the base case of the cost-effectiveness studies. In addition, this thesis also 
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considered the informal health care resources including patients’ time and travel costs as a 
secondary analysis in each individual study. Other societal costs such as productivity might be 
considered in a secondary analysis should there be sufficient evidence upon which to base such 
analyses.  
Target population:  The aim of the CRE is to provide advice to Australian policymakers, thus, 
the target population is the Australian population. As the most recent GBD study (2015) 
includes the 2013 population, all models in this thesis are based on the actual Australian 
population in the year of 2013 as a starting point. However, the relevant target sub-population 
is varied, subject to specific interventions (type of programs), or different levels of intervention 
effectiveness. For example, universal prevention interventions are designed to reach the entire 
population or specific sub-categories of the population (adolescents/adults) without regard to 
individual risk factors while selective/indicated prevention interventions target sub-groups of 
the general population that are determined to be at risk for ED. Interventions for the treatment 
of AN or BN might target adolescents or adults if there is evidence for the effectiveness of such 
interventions in existence for these populations. 
Study boundaries: Study boundaries refer to the scopes of the study that include which 
benefits and costs are considered (Neumann et al. 2016). The first aspect of scope of EEs of 
this thesis was that the health benefits (including both the benefits and harmful side-effects if 
applicable) considered in the base-case for individuals targeted by the interventions only. 
Health benefits that might impact people other than the individuals directly affected by the 
interventions are excluded in these analyses (e.g. carers or family members). The main reason 
for the base-case focus on individuals is that the context of the study is the GBD study estimates 
which are largely based on individual disease prevalence (Vos et al. 2015). The impact on 
others who do not have the disease is, thus, not directly captured by the GBD study. Second, 
as the primary perspective is the health sector perspective, costs and outcomes accrued outside 
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this perspective (including production losses and other non-health sector outcomes and costs) 
are excluded unless there is good evidence to include such impacts in a secondary analysis. 
The costs of unrelated diseases resulting from increased life expectancy are not included 
because there is still some controversy associated with the inclusion of such costs in EE 
(Mihalopoulos 2012; Russell 2009). Finally, all studies modelled the intervention in ‘steady-
state’. This assumed that trained personnel were available to deliver the intervention and the 
appropriate infrastructure was also available. However, the specific implementation costs 
associated with each intervention such as intervention training and staff supervision during the 
intervention were explicitly considered in each evaluation, as recommended by the U.S. Second 
Panel Recommendation on cost-effectiveness in health and medicine (Neumann et al. 2016). 
Time horizon: An appropriate time horizon for tracking the associated costs should reflect a 
period for as long as costs and outcomes accrue (Neumann et al. 2016). The selection of the 
appropriate time horizon within the CRE context has to be made on a case by case basis. Prior 
priority setting studies in mental health have used short time frames (usually limited to 5 years) 
(Andrews et al. 2004; Mihalopoulos 2012; Vos et al. 2010; Vos et al. 2005). This is because 
the evidence of effectiveness associated with the longer term impact of mental health 
interventions is unclear, or long-term follow-up of interventions have shown decay in effect 
(e.g. the effectiveness of interventions reduces overtime) or lifetime epidemiology of mental 
disorders is poorly reported (Mihalopoulos 2012). Therefore, the time horizon for the current 
analyses depends on both plausible estimates of intervention impact derived from both the 
literature and input from the Technical Advisory Panel (TAP)11. The interventions evaluated 
                                                 
11 The Technical Advisory Panel included three Clinical Experts for each study who provided input into the review 
of evidence of studies, were involved in the face validity of data sources and provided expert opinion where 
empirical evidence was lacking. 
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in the current study used different time horizons. Further details are described in Chapter 7 to 
Chapter 9.  
Outcome measure: The chosen outcome for this thesis (and the CRE) is the DALY. DALYs 
are comprised of two parts; years lived with a disability (YLDs) and years of life lost (YLLs). 
The advantage of using DALY in all prior ACE studies and the current CRE is the fact that a 
consistently derived set of disability weights have been developed which aid in study 
comparability. More broadly, the choice of a generic health outcome such as a DALY is 
consistent with a health care perspective since these outcome measures are commonly accepted 
outcome metrics for health and are well regarded. In the GBD studies, disability weights are 
used to weight the YLD component and similarly in this thesis, they were used to calculate the 
amount of disability losses due to the presence of AN or BN diagnosis.  However, benefits 
(averted DALYs) in the current thesis are estimated as the difference in mortality and morbidity 
outcomes between an intervention and a comparator scenario over a defined period of time (i.e. 
the time horizon of studies). This means that the DALYs used in the current study are different 
to DALYs from GBD studies which are estimated as the difference between age at death and 
a standard life expectancy at that age for each death in a particular year (Vos et al. 2015). 
Importantly, given that effectiveness studies for prevention of ED did not tend to express 
outcomes in DALYs, another new addition of the current PhD was development of techniques 
that allowed the estimation of surrogate or clinical outcome measures used in the trials to be 
expressed as DALYs averted (further described in Chapter 7). 
Modelling Approach: Given that the aims of this thesis was to explore the optimal allocation 
of resources (but not the optimal way of getting from the current allocation to the optimal one), 
the current thesis used modelling to incorporate as much of the existing evidence-base in terms 
of efficacy/effectiveness, disease epidemiology and costs so that the research questions could 
be answered. As stated previously in Chapter 3, depending on the available evidence base of 
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the decision context, different modelling frameworks could be used. Good modelling practice 
guidelines (such as ISPOR modelling guidelines) advocates the use of transparent simple 
models which become more complicated only if required and there is an evidence-base to 
support their structure (Briggs et al. 2016; Caro et al. 2012; Roberts et al. 2012). Furthermore, 
given that there were insufficient evidence of individual heterogeneity of intervention 
outcomes, more complicated models (e.g. microsimulation) were deemed to be unsuitable. As 
such, within the current study, multiple-state-cohort-based Markov models (or known as 
illness-death models) were developed to estimate the benefits and costs of the interventions 
evaluated. Dismod II model was adapted for all models used in this thesis (Barendregt et al. 
2003). The Dismod II is a generic model for the assessment of disease epidemiology (including 
incidence, prevalence, remission and death), which has been used in a number of previous EEs 
in mental health and other diseases (Barendregt et al. 2003; Carter et al. 2009b; Gutierrez‐
Recacha et al. 2006; Lee et al. 2016). One of the advantages of Dismod II is the ability to fit 
all different epidemiological data so as to ensure internal consistency. The details regarding 
structure, components, and equations of Dismod II model were reported clearly from the 
technical publication of Barendregt et al. (2003). Each empirical individual study (Chapter 7 
to 9) is mostly reported in language which is non-technical and therefore accessible to any 
interested reader. In brief, the model basically simulated how a population cohort moved 
between three different health states including death, healthy people, and people with disease 
states. For the prevention study (Chapter 7), given that the intervention targeted to adolescent 
girls with high body image concerns, the health states from Dismod II was revised as having 
high body-concern, disease (AN/BN) and dead. For the treatment studies (Chapter 8 and 9), 
Dismod II model was adjusted for the population cohort that moved between three health states 
over time including being diagnosed with AN or BN, recovered and death. The epidemiology 
data related to EDs (i.e. incidence, prevalence, mortality and remission rates) were sourced 
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from the GBD 2015 studies that based on the actual Australian population data in 2013. A 
reason for this is to ensure that the data including epidemiology data and disability weight were 
consistently sourced from the GBD study that was chosen as the starting point of this thesis. It 
is noteworthy that all epidemiology data if used in the model were applied in ‘the partial null’ 
scenarios or in no intervention scenarios. All models were built in Excel spreadsheets and 
included two scenarios for the intervention(s) and the comparator(s). These models allowed the 
calculation of the total life years lived under each arm, whereby preventive interventions were 
associated with reductions in the current incidence of EDs and treatment interventions were 
modelled as the increase of case remission. Therefore, in the intervention arm, there were lower 
numbers of healthy people who transitioned to ED disease health states (prevention model) or 
higher number of people with AN or BN who remitted (treatment model). This led to fewer 
prevalent cases of EDs (AN and/or BN) over the modelled time horizon. This means that there 
were fewer prevalent years lived with disability and greater numbers of life-years in the 
intervention arms through a decrease in excess deaths attributable to EDs. As a result, there 
was a greater number of DALYs (averted) derived from the combination of morbidity and 
mortality impacts as described above and calculated using the following formula (Equation 1). 
DALYs = �  [ LY t × (1 − Prev t × DW) ]nt=0  (1) 
 
Where:  DALYs: Disability-Adjusted Life Years; 
  t denotes the year in the model time horizon; 
  n denotes number of total years of time horizon; 
  LYt is total number of life years lived by a population cohort at year t; 
  Prevt is the prevalence of EDs (e.g. AN and/or BN) at year t; and 
  DW is the disability weight of AN or BN taken from GBD 2013. 
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Costs: Costs included under a health perspective include all costs related to the health sector 
paid for by governments (e.g. medical, pharmaceutical, hospitalisation, etc. costs) and any out-
of-pocket expenses incurred by patients and their families. Costs which may fall into other 
sectors (e.g. welfare organisations, forensic services, etc.) and productivity costs were excluded 
in the base-case analysis. Time and travel costs (e.g. in attending the GP/specialist consultation) 
were included in the evaluations as a secondary analysis. Transaction costs which refer to the 
process of change from the provision of one intervention to another were not considered in the 
evaluation. Specific information regarding the input parameters for each of the models are 
described in each of empirical studies (Chapter 7 to 9). 
Discount rate:  Discounting refers to a positive rate of ‘time preferences’ that consider the 
impact of time on how costs and outcomes are valued. The rationale of discounting is that 
resources required for health care could have been invested elsewhere in the economy and thus 
provide a positive rate of return (Drummond et al. 2015). In other words, costs and even health 
outcomes that are incurred today are more important that those incurred in the future 
(Drummond et al. 2015). Whether health and economic consequences should be discounted at 
the same rate is controversial (Luce & Simpson 1995; Neumann et al. 2016). Most countries 
currently recommend the rate of discount between 3% and 5% with no differential discounting 
between costs and outcome. However, some countries (such as the Netherlands) use a lower 
discount rate for health outcomes compared to costs. The US Second Panel on cost-
effectiveness has recommended a discount rate of 3% for both costs and health benefits to 
increase comparability with other existing analyses (Neumann et al. 2016). A 3% discount rate 
was also used in the ACE-mental health and ACE prevention studies (Mihalopoulos et al. 
2011). Therefore, a 3% discount for both outcomes and costs was used across all interventions 
evaluated.  
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Uncertainty and sensitivity analysis: As noted in Chapter 2, both uncertainty and sensitivity 
analyses are important to test the uncertainty and robustness of results. All cost-effectiveness 
studies undertaken in the current thesis have used both these techniques. In the uncertainty 
analyses, most input parameters are varied simultaneously using probability distributions 
informed by estimates of the sample mean and sampling error from the best available evidence 
(Briggs, Claxton & Sculpher 2006). Estimates of expected outcomes (e.g. costs and DALYs) 
are obtained by re-running the model numerous times, each time varying the parameter values 
across the specified distributions and recording the estimates of expected outcomes. These 
processes are conducted by using the commercial risk-analysis Excel add-in package, called as 
‘Ersatz’, created by Jan Barendregt (Barendregt 2009). ‘Ersatz’ is an add-in software programs 
to commercial spreadsheet packages and is used to conduct Monte Carlo simulation of 
uncertainty. The probability distributions of input parameters in the uncertainty analysis were 
chosen as recommended by Briggs, Sculpher and Claxton (2006) and Barendregt (2009). As 
recommended by Briggs, Sculpher and Claxton (2006), more than 1000 iterations were 
included in the uncertainty analysis (e.g. 5000 iterations in the prevention study and AN 
treatment study (Chapter 7 and 8) and 3000 iterations in BN treatment (Chapter 9)). The 
specifics of the sensitivity analyses undertaken for each study was based on the specific 
considerations of each study (e.g. participation rate for the preventive intervention) and are 
further described in each empirical EE chapter (Chapter 7 to 9). 
Results are presented as the mean ICER along with the 95% uncertainty interval (UI). An ICER 
is calculated as the difference in total costs between the intervention and comparator divided 
by the difference in outcome (e.g. DALYs averted) between the intervention and comparator.  
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𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐼𝐼𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 − 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐼𝐼𝑐𝑐𝑖𝑖𝑐𝑐𝑐𝑐𝑐𝑐𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑖𝑖
 (2) 
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The mean ICER is calculated as the ratio of the mean of the total of the incremental costs and 
the mean of the total of incremental DALYs averted (Drummond et al. 2015). The ICER is 
examined in relation to a cost-effectiveness value-for-money threshold to determine whether 
the intervention is cost-effective. However, there are no guidelines to determine what value-
for-money should be. For example, in the UK, NICE uses a threshold of between £20,000 to 
£30,000 (equivalent to AUD$33,800 to AUD$50,700) (McCabe, Claxton & Culyer 2008) 
although there is a debate that this threshold should be decreased (Claxton et al. 2015). On the 
other hand, the WHO Commission on Macroeconomics and Health developed a rule of thumb 
criterion which stated that interventions are very cost-effective if they averted one DALY for 
less than per capita GDP for a given country and those which cost less than three times per 
capita GDP are still cost-effective (WHO Commission on Macroeconomics and Health 2001). 
All ACE studies (including mental health) have used a threshold “value-for-money” criterion 
of $50,000 per DALY averted which was somewhat arbitrary but was considered by the ACE 
stakeholders, including decision-makers, as acceptable (Mihalopoulos 2012). A study 
published by Edney et al. (2018) (published after this thesis was completed) found that the 
reference threshold of value-for-money for Australia was quite a bit lower than the usually 
cited $50,000/QALY. This study found that AUD$28,033 per QALY gained may be more 
likely for the Australian healthcare system. However, another very recent study found that the 
individual's willingness-to-pay for one QALY is approximately A$42,000-A$67,000 within 
the Australian context (Huang et al. 2018). Importantly, these studies used different approaches 
to estimate the value-for-money threshold. The former is based on a more revealed preference 
approach – known as a supply side threshold which aims to represent the opportunity cost of 
investment to the system given budget constraints - using existing expenditure (Edney et al. 
2018; Thokala et al. 2018). The latter is based on the willingness-to-pay approach – known as 
a demand side threshold that aims to reflect the value that society places on a QALY - using 
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more hypothetical scenarios (Huang et al. 2018; Thokala et al. 2018). Whether supply side 
thresholds or demand side thresholds should be used is unfortunately controversial although 
decisions based on supply side CE thresholds may be better to ensure that aggregate health is 
improved by the inclusion of new interventions (Thokala et al. 2018). Therefore, to be 
comparable with existing cost-effectiveness studies within the Australian context (Carter et al. 
2009b; Vos et al. 2010), the threshold ‘value-for-money’ of AU$50,000 per DALY averted as 
chosen as a primary threshold for the current study is probably still appropriate. A secondary 
threshold of AU$100,000 per DALY averted is also adopted since it has been used in other 
economic evaluations in EDs (Wright et al. 2014). The probability of the intervention being 
cost-effective was presented in the results, and the uncertainty iterations were plotted on the 
cost-effectiveness plane. The cost-effectiveness plane is a quadrant of cost differences plotted 
against benefit differences (Figure 4) (Drummond et al. 2015), in which compass direction is 
used to indicate the area as north, south, east and west. The area above the horizontal axis (i.e. 
north-west and north-east) indicates that the intervention is more costly while the area to the 
right of the vertical axis (i.e. north-east and south-east) indicates that the intervention is more 
effective (than the comparator). In the north-east quadrant, the intervention is cost-effective if 
the ICER falls under the specified value-for-money criterion since the intervention is more 
effective and more costly than the comparator. In the south-east quadrant, the intervention is 
less costly and more effective than the comparator (i.e. dominant), therefore the intervention is 
likely to be excellent for value-for-money. In the south-west quadrant, the intervention is less 
costly and less effective, therefore the decision to adopt the intervention may be based on 
decision-makers willingness to accept some health loss relative to cost-saving. Finally, in the 
north-west quadrant, the results show the intervention associated with greater costs but less 
health gain, therefore, not a good option to adopt. 
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5.3. Standardised method for intervention selection. 
An important step in evaluating the economic credentials for preventive and treatment 
interventions for EDs is to determine which interventions should be selected for further 
evaluation. To answer this question, a comprehensive literature review was undertaken which 
also incorporated international and national guidelines for prevention and treatment of EDs 
(including AN & BN). This work is undertaken in order to determine which interventions for 
EDs had the best evidence. Importantly, conducting systematic reviews (SRs) of the entire 
 
Notes. NW: north-west; SW: south-west; SE: south-east; NE: north-east. Adapted from figure 
2.3 - Briggs and Fenn (1998); (Hay et al. 2014). 
Figure 4: The cost-effectiveness plane 
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efficacy literature for interventions targeting EDs was beyond the scope of the current project 
and thesis due to time and resource constraints. The following steps were undertaken as a 
starting point for intervention selection for economic evaluation modelling for the current 
thesis (Figure 5) 
Step 1: 
A literature review of existing ED intervention systematic reviews/literature reviews was 
conducted as the first step. To source existing systematic reviews, systematic searches were 
undertaken from 2004 to 2014 in the electronic databases including the Cochrane Controlled 
Trial Register, MEDLINE and hand-search in Australian National Eating Disorder 
Collaboration Report and International Journal of Eating Disorders. The key words used in this 
initial search were (review or systematic review or meta-analysis or meta-analytic) and (eating 
disorder* or anorexia or bulimia). 
This initial search yielded 109 reviews after screened and de-duplication, of these, the review 
by Watson et al (2010) was used as the current starting point. The review by Watson et al. 
(2010), included both prevention and treatment in EDs and reported to the National Eating 
Disorder Collaborations. The advantage of this review is that it already included a review of 
systematic reviews and randomised controlled trials (RCTs) for both prevention and treatment 
of ED from 2004 to 2009 and categorised these interventions according to intervention strategy. 
However, it did not include a quantitative meta-analysis to pooled effects. Importantly, in order 
to ensure that I did not missed any RCTs before 2009 (cut-off point time for literature searching 
in this review), I screened other reviews to retrieve any RCTs which were not included in 
Watson et al (2010). A systematic review from Stice, Shaw and Marti (2007) provided 19 more 
RCTs for preventive interventions and systematic reviews from Hay, Claudino and Kaio 
(2001), Bacaltchuk and Hay (2003), and Hay et al. (2009) provided 41 more RCTs for treatment 
interventions. 
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Furthermore, I also screened three international and national guidelines from the US, the UK 
and Australia. The Australian guidelines were updated at the end of 2015, so was the most 
recent version available compared to other two countries. 
Step 2  
To source all relevant trials, the review published by Watson et al, (2010) was updated to 
December 2014 using the same search term strategy as reported in Watson et al. (2010) used. 
The electronic databases searched included the Cochrane Controlled Trial Register, 
MEDLINE, PsychInfo, EMBASE, and Scopus. Hand-searching was conducted in the table of 
content for journals which commonly published articles in eating disorders from 2009 to 2014 
(eg., Journal of International Eating Disorders, Journal of Eating Disorders and European 
Eating Disorders Review). The reference sections of all articles (eg. review papers, review 
chapters or review books) were also examined. The trials were selected for inclusion if they 
were randomized controlled trials (RCTs) or quasi-RCTs, published in English, and evaluated 
a prevention or treatment intervention for ED. Controlled trials, which did not state “random 
assignment”, were excluded.  
Importantly, while some of the other ACE studies have included interventions which did not 
have such stringent evidence of impact, the context of the current project is evidence-based 
interventions which require well controlled studies of impact.  
Step 3  
Each of the retrieved studies were then categorised as prevention or treatment intervention 
based on the stated purpose of the intervention (universal, selective and indicated prevention 
or acute/maintenance treatment) and type of intervention (e.g. cognitive behaviour therapy). 
The level of evidence (based on number of RCTs) and magnitude of effect (based on reported 
effect at post-test/treatment and follow up of RCTs) were then presented for each intervention 
109 
 
strategy (detailed in APPENDIX 2 TABLE S2, S3, and S4). Some results of this review are 
detailed in Chapter 1 of this thesis.  
Step 4 
A list of potential interventions from step 3 was then presented to the TAP12. The TAP then 
provided recommendations as to which interventions should be considered the most effective 
and evidence-based interventions for prevention and treatment for EDs. The two evidence-
based interventions for AN and BN treatment that were chosen to be modelled included FBT 
for adolescents and CBT (face-to-face individual/group CBT) for adults, respectively. While 
online CBT is gaining interest as an intervention treatment strategy for BN, there was 
insufficient evidence of impact to be able to model this as an alternative treatment options 
within the current thesis context. For prevention of EDs, although three interventions was 
recommended by the expert panel including media literacy (universal prevention), cognitive 
dissonance (selective prevention) and cognitive behavioural therapy (selective and indicated 
prevention), only cognitive dissonance for selective prevention was able to be modelled given 
that this is the only intervention which has demonstrated impact in reducing both ED symptoms 
and behaviours while the other interventions appeared to significantly reduce ED risk factors/ 
behaviours only. More detail of evidence in prevention of EDs was presented in the next 
Chapter (Chapter 6). 
                                                 
12 The TAP for the current thesis included Professor Phillipa Hay, Professor Susan Paxton, Professor Susan 
Sawyer, Dr Elizabeth Hughes, Professor Stephen Touyz and Professor Tracey Wade. 
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Literature review of reviews 
(limited from 2004 to 2014) 
International & National 
guidelines (focusing the US, 
the UK and Australian 
guidelines) 
Grey literature – Report from 
Australian National Eating 
Disorder Collaboration 
109 reviews retrieved Three most recent guidelines 
from the US, the UK and 
Australia 
One report that reviewed 
both prevention and 
treatment for EDs (Watson et 
al. 2010) 
List of potential interventions based on the current evidence 
TAP Judgement 
Prevention of EDs  
Cognitive Dissonance 
Cognitive behavioural therapy 
Media literacy 
AN treatment  
First line treatment: FBT for 
adolecents 
 
BN treatment  
First line treatment: CBT 
(including online version). 
May consider: FBT for 
adolescents or anti-
depressant for adults. 
Choosing cognitive 
dissonance interventions by 
conducting a systematic 
review and meta-analysis to 
update the literature until 
2015 (Chapter 6) 
Choosing FBT as the 
intervention to be modelled 
and a meta-anlysis was 
conducted to calculate 
pooled estimates. 
Choosing CBT face-to-face 
as the intervention to be 
modelled and a meta-
analysis was conducted to 
calculate pooled estimates. 
Figure 5: The intervention selection process  
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Chapter 6: Prevention of eating disorders – where we are 
Before undertaking the empirical EEs of both prevention and treatment of ED interventions, a review of 
reviews was conducted to select evidence-based interventions to model the cost-effectiveness. Some results 
of this review are detailed in Chapter 1 of this thesis. During this review of reviews in 2015 (i.e. the time when 
this PhD commenced), it was observed that the most recent published review of preventive interventions was 
by Watson et al. (2010). As such, the first empirical study for this PhD was a systematic review of studies of 
preventive interventions for EDs. This review attempted to cover all preventive interventions for EDs as well 
as to investigate the effectiveness for different at-risk populations (universal, selective and indicated 
prevention). The content of this chapter is based on the following publication: 
Le LK-D, Barendregt J, Hay P, & Mihalopoulos, C. (2017). Prevention of eating disorders: A systematic 
review and meta-analysis. Clinical Psychology Review, 53, 46–58. 
The authorship statement of this publication is attached in APPENDIX 5 
The supplementary document of this publication is attached in APPENDIX 6 
This work was also chosen as the finalist for the Peter Beaumont Young Investigator Award at the 13th annual 
conference of the Australia & New Zealand Academy for Eating Disorders, 21-22 August 2015, Gold Coast, 
Australia (Le et al. 2015). 
This publication has also received empirical comments on the Mental Health Elf website, from Sarah 
McDonald who was impressed by the quality of the systematic review 
(https://www.nationalelfservice.net/mental-health/eating-disorders/prevention-of-eating-disorders-where-do-
we-start/). 
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• Combined ED and obesity prevention interventions require further research.
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1. Introduction
1.1. Why it is important to prevent eating disorders
Eating disorders (EDs) are serious mental disorders affecting many
adolescent females and young women and are associated with signiﬁ-
cant physical and psychological impairment (Herpertz-Dahlmann,
2009; Hudson, Hiripi, Pope, & Kessler, 2007). Themostwell-known eat-
ing disorders, Anorexia Nervosa (AN) and Bulimia Nervosa (BN), are
characterized by extreme eating behaviours and overvaluation of
weight and shape. By deﬁnition, people with AN are underweight (for
age and sex) and people with BN have recurrent binge eating episodes
followed by compensatory weight-control behaviours such as self-in-
duced vomiting or fasting (American Psychiatric Association, 2013).
The thirdmain ED, binge eating disorder (BED), attained diagnostic sta-
tus in the ﬁfth revision of the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-5). It is characterized by recurrent binge eating
associated with diagnostic speciﬁers and at least moderate distress
without recurrent compensatory weight-control behaviours and with-
out the requirement for weight/shape overvaluation (American
Psychiatric Association, 2013). People with BN and BED may be normal
weight, overweight or obese. Eating disorders that do notmeet diagnos-
tic criteria for AN, BN or BED may be classiﬁed under other or unspeci-
ﬁed feeding or eating disorders (OS/UFED).
EDs are common in the general population and worldwide preva-
lence estimates are AN 0.21% (95% conﬁdence interval (CI), 0.11 to
0.38), BN 0.81% (95% CI, 0.59 to 1.09), and BED 2.22% (95% CI, 1.78 to
2.76) with increased prevalence in females compared to males (Qian
et al., 2013). There is evidence of an increase in the prevalence of AN
in adolescent females, and increases in other EDs since the second half
of the twentieth century, although the prevalence of BN may have
plateaued (Qian et al., 2013). However, it was noteworthy that the inci-
dence of EDswas stable inmental health facilities from 1970 to the 21st
century (Hoek, 2016). This suggests that perhaps there has been growth
in the incidence of ED not treated in mental health settings. The risk of
premature death is signiﬁcantly increased in individuals with EDs
(Franko et al., 2014; Preti, Rocchi, Sisti, Camboni, & Miotto, 2011). Mor-
tality is increased in all EDswith AN having the highestmortality rate of
any psychiatric illness (Arcelus, Mitchell, Wales, & Nielsen, 2011). A re-
cent reviewhighlighted that the presence of an ED impacts substantially
on health related quality of life with the degree of reported impairment
increasing with the severity of the ED (Jenkins, Hoste, Meyer, & Blissett,
2011). EDs also have high rates of psychiatric and medical comorbidity,
in particular anxiety disorder (Mehler & Brown, 2015; Mehler &
Ryhander, 2015; Swinbourne et al., 2012). This is compounded by the
current epidemic of obesity as approximately 30% to 80% of individuals
with BN, BED or OS/UFED are obese (Hay, Girosi, &Mond, 2015; Hudson
et al., 2007; Villarejo et al., 2012).
Furthermore, while the evidence base and options for treatments of
EDs have improved in the past three decades, treatment costs are high
for AN and other EDs that fail to respond to ﬁrst-line therapies. Ágh et
al. (2016) has reported yearly health care costs internationally of
€2993 to €55,270 (equivalent to US$2227 to US$41,121, converted to
US$ using purchasing power parities, found at OECD (2014)) for AN,
€888 to €18,823 (~US$661 to US$14,004) for BN and €1762 to €2902
(~US$1311 to US$2159) for BED. Although rates are higher for people
with AN (around 10%) all people with an ED are at risk of a severe and
enduring malignant form of the disorder associated with treatment re-
sistance, very high mortality and morbidity (Hay, Touyz, & Sud, 2012).
For various reasons, treatment—and especially expert, multifaceted
treatment—is not available to all, and there are unlikely to be sufﬁcient
professionals with appropriate advanced training to come close to
stemming the tide of EDs using a detect-it/treat-it approach (Cooper &
Bailey-Straebler, 2015). Therefore, it is essential to determine whether
there are successful interventions to prevent disordered eating
problems.
1.2. Aetiology of eating disorders and risk factor research
The aetiology of EDs is multi-factorial. Genetic, epigenetic and envi-
ronmental factors all play a role (Mitchison & Hay, 2014). The interplay
between temperament, formative relationships and life experiences de-
termine the development of an ED in the individual context. Twin and
adoption studies have found the estimated heritability in AN to be be-
tween28% to 74%, BN54% to 83% and BED41% to 57% indicating a strong
genetic component (Thornton, Mazzeo, & Bulik, 2010). However, to
date gene-association studies have not elucidated the genetic architec-
ture of ED disease (Brandys, de Kovel, Kas, van Elburg, & Adan, 2015).
Each ED is likely to have a complex and potentially diverse
endophenotype thatmay overlapwith other EDs. Personality character-
istics reported as increasing risks of an ED, such as perfectionism, sensi-
tivity to reward, sensitivity to punishment, and obsessionality also have
reported heritability estimates between 27% and 71% (Thornton et al.,
2010). One promising area of this research is the application of epi-ge-
netics to EDs and the identiﬁcation of developmental periods where a
genetic vulnerability is more likely to result in an ED. For example, in
an Australian longitudinal twin study Fairweather-Schmidt and Wade
(2015) reported that mid-to late adolescence may be a critical period
for increased heritable risk for disordered eating. Mid-to-late adoles-
cence represents a developmental period when non-shared
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environmental risk factors andweight-related peer teasing have greater
impacts in the young person life. Thus preventionmay bemost effective
for certain risk factors and at particular life stages.
There are a number of speciﬁc biological, social and psychological/
behavioural risk factors associated with the development of EDs
which have been identiﬁed in the literature (Brandys et al., 2015;
Bulik, Kleiman, & Yilmaz, 2016; Bulik et al., 2007). It is well documented
that age (adolescents & young adults) and sex (female) stand out as
speciﬁc risk factors (Rosenvinge & Pettersen, 2015). Although like heri-
tability, these risk factors are immutable or invariant, they may inform
where and when prevention efforts may be most relevant and effective
(Jacobi, Hayward, de Zwaan, Kraemer, & Agras, 2004). In particular, the
gender disparity is large and while the reasons for this are not fully un-
derstood, socio-cultural effects and a greater inﬂuence of the thin ideal
on women at vulnerable developmental periods of life appear likely to
be a major cause. Body dissatisfaction and dieting have, for many
years, been considered predictors for ED onset and mutable risk factors
(Rosenvinge & Pettersen, 2014). A recent epidemiological review
(2014) foundweight and shape concern, including body dissatisfaction,
to be the most studied and potent predictors for ED onset. Adolescents
engaging in dieting and disordered eating behaviours have been found
to have an increased risk for these behaviours into young adulthood
(Neumark-Sztainer, Wall, Larson, Eisenberg, & Loth, 2011). Negative af-
fect has been found to be a predictor for onset of all types of EDs includ-
ing AN, BN, BED and purging disorder since it may decrease appetite,
leading to unhealthy weight loss and increase the likelihood of un-
healthy weight control behaviours (Stice, Gau, Rohde, & Shaw, 2016).
Thin-ideal internalization, body dissatisfaction, dieting, overeating,
and mental health care have also been considered as potential predic-
tors for BN or BED onset (Rohde, Stice, & Marti, 2014; Stice, 2016a;
Stice et al., 2016b). However, limited evidence from prospective studies
has supported these risk factors for AN onset. The most strong evidence
to predict onset of threshold and subthreshold AN has been found to be
low body mass index (Stice, 2016a). Other mutable risk factors include
sexual and physical abuse and participation in aesthetic or weight-ori-
ented sports (Mitchison & Hay, 2014).
Further to shared risk factors of EDs and obesity, a personal and fa-
milial history of obesity is itself a risk for an ED and obesity is a very
common co-morbidity of both BN and BED (Campbell, Mill, Uher, &
Schmidt, 2011; Hay et al., 2015; Kessler et al., 2013). For example, re-
search has shown that the proportion of obese females with low levels
of body satisfaction was approximately doubled compared to normal-
weight females (Neumark-Sztainer, Story, Hannan, Perry, & Irving,
2002). Furthermore, body dissatisfaction and dieting have been demon-
strated to be shared risk factors for depressive symptoms, overweight
and disordered eating (Goldschmidt, Wall, Choo, Becker, & Neumark-
Sztainer, 2016). It is, therefore, vital to examine the preventive interven-
tions targeting shared risk for eating-/weight- related issues.
1.3. Overview of prevention research in EDs
Early studies evaluating interventions with largely psycho-educa-
tional content found limited effects on reducing ED risk factors and fu-
ture ED onset (Pearson, Goldklang, & Striegel-Moore, 2002;
Rosenvinge & Børresen, 1999). These studies had poor methodology in-
cluding uncontrolled designs, inappropriate measures and a mismatch
between program goals and outcomes (Rosenvinge & Børresen, 1999;
Wilksch, 2014). Studies of preventive interventions have since substan-
tially increased during the past two decades from22 published random-
ized controlled trials (RCTs) in a 2002 systematic review of preventive
interventions (Pratt & Woolfenden, 2002) to 86 controlled trials in the
most recent review (Bailey et al., 2014). In the most recent literature,
preventive interventions have been found to produce signiﬁcant effects
for ED risk factors and ED symptom reductions. Cognitive behavioural
therapy (CBT) based interventions including interactive and internet-
based approaches, (e.g. Student Bodies program) have demonstrated
reductions in ED risk factors (e.g. weight and shape concerns), the risk
of ED onset in some high-risk group and ED symptoms (e.g. frequency
of bingeing and purging) in females with subthreshold EDs (Jacobi,
Völker, Trockel, & Taylor, 2012; Taylor et al., 2006). Cognitive disso-
nance (CD) interventions which are programs designed to reduce sub-
scription to the thin-ideal (e.g. the Body Project program) have
produced a 60% statistically signiﬁcant and clinically meaningful reduc-
tion in Diagnostic and Statistical Manual of Mental Disorders IV (DSM-
IV) ED onset over a 3-year follow-up compared to an assessment only
control (Stice, Marti, Spoor, Presnell, & Shaw, 2008). However, this ef-
fect was not replicated in a follow-up high school/college effectiveness
trial (Stice, Rohde, Butryn, Shaw, & Marti, 2015; Stice, Rohde, Shaw, &
Gau, 2011). Another intervention, promoting participant-driven im-
provements to dietary intake and physical activity (e.g. HealthyWeight
program), has demonstrated a reduction of eating disorder onset by 60%
over a 2-year to 3 year follow-up compared to an assessment only or ed-
ucational brochure control (Stice, Rohde, Shaw, & Marti, 2013; Stice et
al., 2008). Given the important association between ED and obesity,
obesity prevention interventions have been recently tested in ED pre-
vention and appeared to be effective and cost-effective in preventing
disordered weight control behaviours and obesity (Austin, Field,
Wiecha, Peterson, & Gortmaker, 2005; Austin et al., 2007; Wang,
Nichols, & Austin, 2011).
Ameta-analysis by Stice, Shaw, andMarti (2007) found that in 51 ED
prevention programs, 51% of the interventions signiﬁcantly reduced at
least one established risk factor for EDs and 29% signiﬁcantly reduced
current or future EDs (Stice et al., 2007). This meta-analysis also
highlighted the programs that appeared to be most effective, were in-
teractive, utilized multi-session formats, and were targeted to high-
risk individuals (e.g. females and individuals over 15 years of age) and
delivered by professionals. Additionally, the preventive interventions
evaluated in trials using validated measures and a shorter follow up pe-
riod had larger effects in two of six risk factor outcomes but no actual
prevention of the onset of new cases were investigated. Watson,
Elphick, Dreher, Steele, and Wilksch (2010) further investigated evi-
dence-based interventions for ED prevention including a range of inter-
ventions from the commonly used prevention nomenclature of Mrazek
and Haggerty (1994). These include universal preventive strategies
targeting whole populations, selected preventive strategies targeting
speciﬁc high risk populations and indicated preventive strategies
targeting people with symptoms of disorders but not yet at diagnostic
level. This review found that universal prevention using media literacy
(ML) and selective and indicated prevention usingCBT and CD interven-
tions were effective in reducing several ED risk factors (e.g. body dissat-
isfaction, weight and shape concern, negative affect…) and symptoms
at post-intervention and follow-up. However, the quality of the evi-
dence (in terms of study design)was judged to bemoderate. Important-
ly, a quantitative meta-analysis and systematic quality appraisal of the
included studies were not undertaken in this review. The most recently
published systematic review (conducted at the same time as the current
review), has suggested that the strongest evidence is for selective pre-
ventive interventions (Watson et al., 2016). In particular, dissonance-
based interventions demonstrated moderate-large effects on several
ED risk factors and pathology outcomes (e.g. dieting, thin-ideal internal-
ization, negative affect, eating pathology) at post-intervention and
small effects at 6- to 18-month compared to waitlist or non-speciﬁc
control. CBT and the healthy weight program also showed small effects
on these outcomes compared to waitlist and non-speciﬁc control at
both post-intervention and average of 6- to 18-month follow-up.
Other interventions including ML, psychoeducation and the multicom-
ponent interventions showed small effects on examined outcomes at
post-intervention and under 12-month follow up compared to waitlist
controls. This review also stated that ML for universal prevention and
dissonance-based intervention and CBT for indicated prevention were
effective interventions, however, this conclusion was based on a narra-
tive synthesis of individual studies' results instead of a qualitativemeta-
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analysis (Watson et al., 2016). Furthermore, this review did not include
obesity prevention intervention studies which may be effective for EDs
as well as obesity. Methodologically, it used a random effect model for
meta-analysis of selective prevention outcomes whichmay substantial-
ly underestimate the statistical error (Doi, Barendregt, Khan, Thalib, &
Williams, 2015a,b; Noma, 2011).
The aim of the current study is to systematically review the recent
literature of preventive interventions for EDs across age spectrums in
both general and at-risk populations. In contrast to previous reviews,
we aim to use a quality effect model to pool the effect sizes for the
meta-analysis. This approach results in a decreased mean squared
error of the estimator while maintaining the nominal level of coverage
probability of the conﬁdence interval (Doi, Barendregt, Khan, Thalib, &
Williams, 2015c). This approachhas also been demonstrated to be supe-
rior to the random effect model in terms of handling heterogeneity
when the quality of studies is available (Doi et al., 2015c). Additionally,
in opposition to the most recently published study by Watson et al.
(2016), the current meta-analysis aims to quantitatively evaluate all in-
cluded preventive interventions (universal, selective and indicated) in
order to contribute to the growing body of literature supporting the ef-
fectiveness of preventive interventions for EDs.
2. Methods
The methods undertaken in this review adhered to the guidelines in
the Preferred Reporting Items for Systematic Reviews and Meta-analy-
ses (PRISMA) statement 2009 (Moher, Liberati, Tetzlaff, & Altman,
2009). The original method was registered on International Prospective
Register of Ongoing Systematic Reviews (PROSPERO) databases (Le,
Carter, & Mihalopoulos, 2014).
2.1. Identiﬁcation and selection of studies
A literature review of existing ED preventive intervention systemat-
ic/literature reviewswas initially conducted to extract any reviews pub-
lished between 2004 and 2014 in theCochrane Controlled Trial Register,
MEDLINE and PsychInfo. Hand-searching of the Australian National Eat-
ing Disorder Collaboration Report and International Journal of Eating
Disorderswas also undertaken. The keywords used in all these searches
included “review or systematic review ormeta-analysis ormeta-analyt-
ic” and “eating disorder* or anorexia or bulimia”.
This initial search yielded 109 reviews. After screening and removal
of duplicates, the 2010 systematic review by Watson et al. was used as
the current starting point (Watson et al., 2010). The advantage of this
review is that it was a high quality review of systematic reviews and
randomized controlled trials (RCTs) for prevention of ED from 2004 to
2009 and categorized the interventions according to intervention strat-
egy. However, a quantitative meta-analysis to pool effects was not un-
dertaken. Importantly, in order to ensure that any RCTs prior to 2009
were included in the current review (and possibly excluded from
Watson et al., 2010), other reviews were screened to retrieve any
RCTs which were not included inWatson et al. (2010). A systematic re-
view by Stice et al. (2007) provided 19 more RCTs for preventive inter-
ventions which were published prior to 2006.
To ensure all relevant studies were included for the current review,
an update of both Watson et al. (2010) and Stice et al. (2007) was un-
dertaken. The same search term strategy as reported in Watson et al.
(2010) was used. The electronic databases including the Cochrane Con-
trolled Trial Register, MEDLINE, PsychInfo, EMBASE, and Scopus were
searched until December 2015. Hand-searching was conducted in the
table of contents for journals which commonly publish eating disorders
studies (e.g. International Journal of Eating Disorders, Journal of Eating
Disorders and European Eating Disorders Review). The reference sec-
tions of all articles (e.g. review papers, review chapters or review
books) were also examined. The trials were selected for inclusion if
they were RCTs or quasi-RCTs (e.g. randomized by school), published
in English, and evaluated a preventive intervention for ED compared
to another control preventive intervention or wait list/no intervention
or minimal intervention control. Controlled trials, which did not state
“random assignment”, were excluded.
2.2. Data extraction
All citations were imported into an electronic database (Endnote®
version X2). Included RCTs were extracted by the ﬁrst author (LKDL)
and information from all studies was extracted including: recruitment
method and target group (females or males); outline of interventions
evaluated (e.g., format, duration of intervention, number of sessions);
and a description of main outcome measures. Preventive interventions
were classiﬁed into the three main types using the nomenclature of
Mrazek andHaggerty (1994). A preventive interventionwas considered
universal if it targeted a whole population (e.g. school based prevention
for females and males). Selective prevention interventions targeted a
subgroup of the population at risk of developing an eating disorder
(e.g. females with/without elevated scores on risk indicators). Indicated
prevention interventions targeted people who have some symptoms of
a disorder without meeting full diagnostic criteria (e.g. sub-threshold
EDs). The approach of each intervention program was classiﬁed into
10 sub-types by the review authors, based upon the information provid-
ed in the published studies. The subtype classiﬁcation reported in
Watson et al. (2010) was used in this classiﬁcation procedure (e.g.,
CBT) with the addition of mindfulness based interventions which ap-
plied key aspects of mindfulness and acceptance-based practice specif-
ically to body image. Interventions which contained only one session
were classiﬁed as “one-shot” interventions regardless of the length of
single session (e.g. 2-hour workshop). The data or information regard-
ing features of any of the studies, which were not included in the pub-
lished articles were obtained by contacting the ﬁrst author via e-mail.
In the Wilksch et al. (2015) study, the number of females and males in
each arm was provided by the ﬁrst author. In the series of studies eval-
uating CD and healthy weight programs, the leading author explained
the different versions of CD and healthy weight interventions used in
these studies (Stice, 2016b).
2.3. Meta-analysis methods
A quantitative meta-analysis was undertaken to pool effects across
the RCTs using an EXCEL add-in package, MetaXL (Barendregt & Doi,
2015).
2.3.1. Quality assessment
The Cochrane Collaboration criteria were used to evaluate the risk of
bias (RoB) for the included RCTs. The RoB criteria include quality ratings
related to: random sequence generation; allocation concealment;
blinding of participants; outcome assessment; incomplete outcome
data; and, selective outcome reporting (Higgins, 2011). The RoB of
each trial was assessed on each criterion and categorized as ‘low’,
‘high’, or ‘unclear’. The criterion relating to blinding of participants
was not used, as blinding is not possible in the types of interventions in-
cluded in this review. Complete outcome datawere deﬁned as ‘low risk’
when the percentage of participants lost to follow-up was low (arbi-
trarily set at values lower than 20%) and when numbers and causes of
loss to follow-up were balanced between arms. In order to observe
how the quality of RCTs impacted the effect size of interventions a qual-
ity score was determined by assigning 3 points to ‘low risk’, 2 to ‘un-
clear’, and 1 to ‘high risk’. The derived quality score of each individual
study was normalized by dividing the maximum possible quality score
(called the quality index (Qi) range: 0–1). Subsequently, Qi values
were entered in the quality effects model as described by Doi,
Barendregt, and Mozurkewich (2011) and Doi and Thalib (2008).
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2.3.2. Data analysis
An effect size was calculated to determine the difference between
the intervention group and the comparison group at post-treatment
or follow-up if available. If both intention-to-treat and per-protocol
data were presented, the former estimate was used in the meta-analy-
sis. A Hedges' g standardized mean difference (SMD) was used where
trials measured the same outcome using different scales. A weighted
mean difference (WMD) was used for trials which used the same con-
tinuous outcome measured on the same scale. For dichotomous data,
a relative risk was used to estimate the effect of the intervention. Conﬁ-
dence intervals (CIs) were obtained for all estimates. Effect sizes of
around 0.2, 0.5 and 0.8 were respectively considered small, moderate
and large (Cohen, 1988). The quality-effect (QE) model was used to
pool the data, with the random-effect (RE)model used for standardized
comparison. The advantage of the QE meta-analysis is that it allows for
redistribution of individual studies' inverse variance weights based on
assessed study deﬁciencies rather than the usual random redistribution
of weights seenwith the REmodel (Doi et al., 2011; Thalib & Doi, 2011).
Results from the quality-effect model are presented except in the case
where the random-effect model showed a different signiﬁcant trend.
In this instance both results from the random effects and the quality ef-
fects models are presented.
Statistical heterogeneity was assessed using the I2 and Cochran's Q
test. Heterogeneity was regarded as substantial when the I2 statistic
exceeded 40% and/or the Q statistic was signiﬁcant at a p b 0.10, as
per the Cochrane Collaboration recommendations (Higgins, 2011).
Pooled effect sizeswere examined to identify whether theywere driven
by outliers, deﬁned as studies in which the effect sizes and 95% CIs were
outside the 95% CIs of the pooled studies (on both sides of the CI)
(Cristea, Kok, & Cuijpers, 2015).
2.3.3. Sensitivity analysis and publication bias
To assess the robustness of themeta-analyses, threemain sensitivity
analyseswere undertaken. Firstly, the quality of studies was tested. This
sensitivity analysis evaluated the impact of study quality by removing
low quality trials (e.g. quasi-RCTs) from the meta-analysis. Secondly,
one-way sensitivity analyseswhich excluded individual studies sequen-
tially from themeta-analyses were performed.While this form of sensi-
tivity analyses is not traditionally undertaken it is a very useful as it
examines which study is the prime determinant of the pooled results
(Barendregt & Doi, 2015). The ﬁnal sensitivity analysis considered the
pooled results of selective and indicated prevention interventions
based on broader classiﬁcations of selective and indicated prevention
for EDs which have been used in previous reviews (Levine & Piran,
2004; Rodgers & Paxton, 2014; Yager, Diedrichs, Ricciardelli, &
Halliwell, 2013). For this broader classiﬁcation, we still classiﬁed pre-
ventive intervention studies as selective if they allowed participants to
self-select as having high level of ED attitudes/behaviours (e.g. high
body dissatisfaction). The main difference is that we allowed interven-
tions which have formally screened participants for both ED symptoms
and/or behaviours (but may or may not formally meet the criteria for
sub-threshold disorder) to be classiﬁed as indicated prevention. There-
fore in this sensitivity analysis there aremore interventions classiﬁed as
indicated since our inclusion criteria is less strict for this classiﬁcation.
The outcomes of themeta-analysis can be considered robust when sen-
sitivity analyses in subsets of studies show similar pooled effect sizes.
The analysis of the effect of potential unpublished studies or missed
studieswith negative resultswas undertaken to evaluate the robustness
of the meta-analysis. Funnel plots and Doi plots were used to evaluate
the presence of publication bias. Interpretation of Doi plots is similar
to the funnel plot in that a symmetrical plot suggests no or little publi-
cation bias while an asymmetrical plot suggests bias (Barendregt &
Doi, 2015). However, the Doi plot is easier to interpret than the funnel
plot. The Doi plot displays the Luis Furuya-Kanamori (LFK) index of
asymmetry, including an assessment of severity (‘No’, ‘Minor’, ‘Major’)
asymmetry (Barendregt & Doi, 2015).
3. Results
3.1. Selection and inclusion of studies
The systematic searches resulted in a total of 2187 abstracts after re-
moval of 1603 duplicates. A total of 411 papers were retrieved, of which
299 were excluded because they did not meet the inclusion criteria.
Fig. 1 presents a PRISMA ﬂowchart describing the inclusion process,
and includes an overview of the reasons for exclusion of 299 studies. A
total of 112 articles (describing 101 trials) met all inclusion criteria. Of
these, 78 articles have been reported in previous systematic reviews
(Stice et al., 2007; Watson et al., 2010).
In terms of preventive strategies, therewere 18 trials which evaluat-
ed universal prevention interventions, 79 trials which evaluated selec-
tive prevention interventions and 4 trials which evaluated indicated
prevention. The studies were carried out in the U.S., Australia, UK,
Spain, Italy, Mexico, Sweden, Norway, Canada, Israel, Germany and the
Netherlands. The smallest study had 24 participants and the largest
1451.
3.2. Study characteristics
There were seven, twelve and two types of interventions evaluated
under the umbrellas of universal, selective and indicated prevention, re-
spectively. ML was the most frequently evaluated universal prevention
intervention (ﬁve trials) followed by self-esteem enhancement, obesity
prevention and multicomponent interventions (all were evaluated in
four trials). Cognitive dissonance and CBT were the most commonly
evaluated selective prevention interventions followed by the one-shot
intervention (12 trials). Other commonly evaluated selective interven-
tions included multi-component programs (nine trials) and ML and
healthy weight program (both had seven trials). Only CBT and
psychoeducation were evaluated as indicated preventive interventions.
Most of the trials assessed preventive interventions aimed at chil-
dren, adolescents and youth (deﬁned as aged up to 24 years). In partic-
ular, universal prevention was evaluated in 18 trials which included
children or adolescents withmean ages of 11 to 14 yearswhile selective
prevention and indicated prevention mostly included participants with
mean ages of 16 to 24 years. Only two studies from selective prevention
included adult participants aged 18 up to 68 years.
Preventive interventions for ED were mainly group-based delivered
via classes, face-to-face or online. Most universal interventions where
group-based delivered in classes. For selective prevention, theML, mul-
ticomponent, one-shot, perfectionism and obesity prevention interven-
tions also used group formats delivered by school classes while the rest
were group-based delivered face-to-face or online. Themajority of con-
trol groups were waitlist or delayed treatment or non-speciﬁed control.
A small number of studies also used active interventions or minimal
treatments as control groups.
More generally, the ED preventive interventions consisted of multi-
ple sessions and interactive formats which helped participants engage
in the interventions. Notably, the intensity and content of the interven-
tions varied considerably. For universal prevention, the number of ses-
sions ranged from four sessions to many sessions spanning two-years
(the obesity prevention). Selective preventive interventions mostly
ranged from four to eight sessions. Twelve studies evaluated single ses-
sion group format interventions of CBT, CD, acceptance and commit-
ment therapy, obesity prevention and psychoeducation. These
sessions varied from 45 min to one-day workshop. CBT interventions
ranged from two sessions to sessions over a 16-week duration however
the Student Bodies program (eightweekly sessions)was themost com-
monly evaluated (9/22 trials). The Body Project program, which is a CD
interventions consisted of four 1-hour sessions or six 45-minute ses-
sions or two 2-hour sessions. Of the indicated preventive interventions,
CBT ranged from 8 to 16 sessions while psycho-education was only
three sessions.
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Further details of interventions may be found in Appendix A.1.
3.3. Risk of bias assessment
In general, most trials (58% of trials) had high risk of bias. Risk of
bias was mostly evident through lack of blinded outcome assess-
ments (in 37% of studies) and incomplete outcome data (in 30% of
trials). In particular, 83% of universal prevention trials did not in-
clude blinded outcome assessment compared to 27% of selective pre-
vention trials and 25% of indicated prevention trials. The majority of
trials (50%) did not report random sequence generation or allocation
concealment in the randomization process. Therefore, the level of
bias across studies was unclear or high risk. It is noted that some of
the trials included in this meta-analysis were effectiveness trials
which used “routine-care” type of providers and often relaxed inclu-
sion/exclusion criteria so that results are more generalizable to real
world settings. Findings are displayed in Fig. 2 and further details
can be found in Supplementary Appendix A.1.
3.4. Summary of results of meta-analysis
There were 112 pooled comparisons between the active interven-
tions versus no or minimal controls and 12 pooled comparisons
among two active interventions. Results of pooled comparison are sum-
marized in Supplementary Appendix A.2.
3.4.1. Universal prevention for eating disorders
3.4.1.1. Active interventions versus no/minimal treatment controls. There
were 38 pooled comparisons of CBT, ML, multicomponent, obesity pre-
vention, and self-esteem enhancement interventions. No pooled com-
parisons were possible for physical activity and psycho-education
interventions due to only one available study. However, the physical ac-
tivity intervention had a negative effect on drive for thinness for females
and no effect on body dissatisfaction (Zabinski, Calfas, Gehrman,
Wilﬂey, & Sallis, 2001). The psycho-education improved knowledge
about EDs butwhether this reduced ED risk factors for the target groups
was unclear (McVey, Gusella, Tweed, & Ferrari, 2008).
3.4.1.1.1. CBT interventions. Pooled comparison for ED behaviour re-
vealed no signiﬁcant differences between CBT interventions compared
with control at post-test and 6- to 12-month follow up (WMD 0.44,
95% CI:−7.00 to 7.89; I2 = 92%, p = 12.86, p = 0.00).
3.4.1.1.2. ML interventions. There were signiﬁcant reductions in
weight and shape concern of the population at post-test and at follow
up (6 to 30 months) (g for females −0.69, 95% CI: −1.17 to −0.22,
I2 = 39%, Q = 1.64, p = 0.20 and for males−0.32, 95% CI:−0.57 to
Fig. 1. Flow chart of randomized controlled trial inclusion and exclusion.
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−0.07, I2 = 0%, Q = 0.95, p = 0.33). Furthermore, pooled effects
showed signiﬁcant differences for media internalization outcomes for
males at both examined times and females at post-test (g−0.21, 95%
CI:−0.34 to−0.07). No signiﬁcant differences were found on dieting,
self-esteem, and body dissatisfaction when the studies examining ML
interventions were pooled.
3.4.1.1.3. Multicomponent interventions. Two comparisons at post-in-
tervention and at 6- to 30-month follow up of eating behaviours for fe-
males revealed signiﬁcant differences (follow up:−0.59, 95% CI:−0.77
to−0.42; I2 = 0%, Q = 0.49, p = 0.48).
Obesity prevention interventions including traditional obesity pre-
vention targets and/or modiﬁed versions plus targeting psychological
risk factors associated with healthy eating were found to signiﬁcantly
reduce the thin-ideal internalization for males at post-test (WMD
−1.75, 95% CI:−3.10 to−0.40; I2 = 0%, Q = 0.11, p = 0.74).
Self-esteem enhancement interventions did not signiﬁcantly reduce
dieting at post-test and 3- to 12-month follow up for whole population.
However, subgroup analysis revealed the signiﬁcant reductions of
dieting in females but not males at post-test and follow up
(g =−0.99, 95% CI:−1.39 to−0.58; I2 = 10%, Q = 1.12, p = 0.29).
3.4.1.2. Active interventions versus other preventive intervention controls.
Three trials evaluated ML interventions vs. other preventive interven-
tions including obesity prevention, self-esteem enhancement and mul-
ticomponent interventions (González, Penelo, Gutiérrez, & Raich, 2011;
Wade, Davidson, & O'Dea, 2003; Wilksch et al., 2015). There was a sig-
niﬁcant reduction on media internalization for male adolescents at
post-test (g = −0.35, 95% CI −0.52 to −0.18; I2 = 0%, Q = 0.20,
p = 0.65) and 12- to 30-month follow up (g =−0.20, 95% CI−0.37
to −0.03; I2 = 0%, Q = 0.19, p = 0.67). No signiﬁcant differences
among these interventions was found for other outcomes including
weight concern, shape concern and dieting.
3.4.1.3. Summary ﬁndings for universal prevention.MLwas the only inter-
vention that had small to moderate effect sizes of risk factor reductions
includingweight and shape concerns andmedia internalization for both
females and males at post-intervention and up to 30-month follow up
compared to non-intervention controls. Furthermore, this intervention
was superior to other active intervention controls in reducingmedia in-
ternalization of males at post-intervention and up to 30-month follow
up. The multicomponent intervention had moderate effect sizes on re-
duction of eating behaviours and media internalization while self-es-
teem enhancement interventions demonstrated large effect sizes on
dieting reduction. However, these effects were found only for females.
No evidence of efﬁcacy for CBT or obesity prevention interventions
were found for ED prevention.
3.4.2. Selective prevention for eating disorders
3.4.2.1. Active interventions versus no/minimal treatment control. Eighty-
three trials, reporting 12 different types of interventions of selective
prevention were retrieved. In three studies examining obesity preven-
tion interventions, no pooled comparisons were possible due to differ-
ent outcomes although some of these studies reported signiﬁcant
differences between evaluated groups. The Planet Health program re-
duced the number of females who reported purging or using diet pills
by 50% relative to a non-speciﬁed control (Austin et al., 2005) while
the low-calorie diet program reported a reduction in bulimic symptoms
(Presnell & Stice, 2003). The NewMoves program also reduced the pro-
portion of females using unhealthy weight control behaviours by 13.7%
and signiﬁcantly improved body dissatisfaction (Neumark-Sztainer et
al., 2010). Similarly, no pooled comparisons were possible for self-es-
teem enhancement and perfectionism due to only one available study.
Both interventions reported little effects on ED risk factors and these
were not maintained at follow up (Weiss & Wertheim, 2005; Wilksch,
Durbridge, & Wade, 2008).
3.4.2.1.1. CBT interventions. In the meta-analysis of 18 trials, where
data were available, signiﬁcant differences were observed between ac-
tive interventions vs. controls at both post-test and 4-week to 9-
month follow up for dieting (at follow up g =−0.40, 95% CI:−0.55
to−0.26; I2 = 0%, Q = 7.83, p = 0.45) and bulimic behaviours (at fol-
low up g = −0.20, 95% CI −0.35 to −0.05; I2 = 0%, Q = 2.71, p =
0.74). CBT interventions also reduced body dissatisfaction at up to 9-
months post-intervention (g =−0.23, 95% CI:−0.42 to−0.04; I2 =
0%, Q = 5.35, p = 0.62). No signiﬁcant differences were found for
other outcomes including shape concern, weight concern, eating con-
cern, BMI and self-esteem outcomes at both post-test and follow up.
Media literacy interventions had a signiﬁcant reduction in internali-
zation (or acceptance) of societal ideals relating to appearance with
substantial heterogeneity compared to no treatment controls at 3-
month follow up (g = −1.53, 95% CI: −2.90 to −0.15; I2 = 99%,
Q = 198.58, p = 0.00) but not at post-test (g = −1.20, 95% CI:
−2.46 to 0.06; I2 = 99%, Q = 276.40, p = 0.00). With the exclusion of
one outlier (Sharpe, Schober, Treasure, & Schmidt, 2013), the effect
size at post-test decreased to a g of−0.45 (95% CI−1.02 to 0.12) and
the heterogeneity remained signiﬁcant (I2= 90%, Q=30.50, p=0.00).
3.4.2.1.2. One-shot interventions. Four pooled comparisons of one-
session interventions on thin-ideal internalization, dieting, body dissat-
isfaction, and self-esteem outcome were possible with no signiﬁcant
differences observed between the intervention and control groups.
3.4.2.1.3. Cognitive dissonance interventions. Given the various points
of follow-up across the studies examining CD interventions, results
were pooled at post-intervention, 3- to 12-month follow-up and over
12-month follow-up. The pooled analysis indicated that there were sta-
tistically signiﬁcant differences at both post-test and 3- to 12-month fol-
low up in body dissatisfaction (g =−0.20, 95% CI−0.39 to−0.02);
dieting (g = −0.28, 95% CI −0.43 to −0.12); and negative affect
(g = −0.23, 95% CI −0.35 to −0.10). However, these effects were
not maintained at the over 12-month follow up. Furthermore, CD inter-
ventions were superior to control in reducing thin-ideal internalization
at post intervention (g =−0.71, 95% CI (−1.14 to−0.27) with sub-
stantial heterogeneity (I2 = 92%)) and at the 3-year follow up
(g = −0.16, 95% CI −0.27 to −0.05), heterogeneity was moderate
(I2 = 40%). Removal of one outlier (Serdar et al., 2014) at post-test in-
creased the effect size to g=−0.61, 95% CI (−0.77 to−0.45) and het-
erogeneity was no longer signiﬁcant. Importantly, CD interventions
signiﬁcantly reduced ED symptoms (measured by the Eating Disorder
Diagnostic Interview/Survey) at post intervention (g =−0.30, 95% CI
−0.47 to−0.13 with substantial heterogeneity I2 = 51%, Q = 16.49,
p = 0.04). However with the exclusion of one outlier (Serdar et al.,
2014), the effect size decreased to g = −0.25 (95% CI −0.37 to
−0.14) and heterogeneity became insigniﬁcant but this effect was not
Fig. 2. Risk of bias graph: review authors' judgements about each risk of bias item
presented as percentages across all included trials.
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maintained at 3- to 12-month (g =−0.06, 95% CI−0.19 to 0.06) and
over 12-month follow up (Hedges' g =−0.08, 95% CI−0.22 to 0.07).
3.4.2.1.4. Healthy weight intervention. There were four trials which
compared a healthy weight intervention versus minimal/non-treat-
ment control (Smith & Petrie, 2008; Stice, Rohde, Shaw, & Marti, 2012;
Stice, Shaw, Burton, & Wade, 2006; Stice, Trost, & Chase, 2003). At fol-
low-up, difference in dieting (g = −0.30, 95% CI −0.57 to −0.04)
and thin-ideal internalization scores (g = −0.27, 95% CI: −0.49 to
−0.05) were observed. Differences at post-test of body dissatisfaction
(Hedges' g =−0.28, 95% CI−0.45 to−0.12) were also observed. Im-
portantly, use of the RE model resulted in signiﬁcant differences in
level of the body dissatisfaction (g =−0.35, 95% CI:−0.61 to−0.08)
at follow up. In contrast, use of the QEmodel did not result in signiﬁcant
differences. Participants in the healthy weight intervention had a lower
increase in BMI compared to controls at 2- and 3-year follow up (WMD
−0.90, 95% CI−1.61 to−0.18), which indicated that this intervention
might be effective for obesity prevention as well. No signiﬁcant differ-
ences were found for other outcomemeasures including negative affect
and bulimic behaviours.
3.4.2.1.5. Psychoeducation interventions. No signiﬁcant difference be-
tween active interventions compared to controls was found for body
dissatisfaction (g = −0.25, 95% CI: −0.96 to 0.45; I2 = 79%, Q =
9.66, p = 0.01).
3.4.2.1.6. Mindfulness based interventions. Pooled comparison of stud-
ies investigating mindfulness based interventions revealed no signiﬁ-
cant differences in dieting outcome (g = 0.38, 95% CI:−0.04 to 0.80)
between active intervention and control.
3.4.2.1.7. Multicomponent interventions. Pooled comparisons of three
trials resulted in signiﬁcant Hedges' g of −0.15 (95% CI −0.28 to
−0.02) favouring the active intervention for eating behaviour out-
comes. This intervention was also superior to non-intervention control
in reducingmedia internalization at post-intervention and 6-month fol-
low up.
3.4.2.2. Active interventions versus other preventive intervention control.
There were four trials comparing ML interventions vs. other preventive
interventions including CD, multi-component and perfectionism inter-
ventions (Becker, Bull, Schaumberg, Cauble, & Franco, 2008; Becker,
Smith, & Ciao, 2006; López-Guimerà, Sánchez-Carracedo, Fauquet,
Portell, & Raich, 2011; Wilksch et al., 2008). No signiﬁcant differences
between these interventions were found for thin-ideal internalization
and dieting outcome at both post-test and at follow up.
In the meta-analysis of nine trials comparing CD interventions to
other preventive interventions including healthy weight interventions
and ML interventions. Signiﬁcant differences were found for thin-ideal
internalization at post-test (g =−0.19, 95% CI−0.32 to−0.06; I2 =
0%, Q = 6.89, p = 0.44) but this effect was not maintained at 4-week
to 3-year follow up (g =−0.05, 95% CI−0.25 to 0.15; I2 = 54%, Q =
13.15, p = 0.04). Subgroup analysis revealed no signiﬁcant difference
between CD and ML. No differences were found for other outcomes in-
cluding body dissatisfaction, dieting, and bulimic behaviours.
3.4.2.3. Summary ﬁndings for selective prevention. CD interventions dem-
onstrated small to moderate effect size with substantial heterogeneity
on a number of outcomes including dieting, thin ideal internalization,
body dissatisfaction, and negative affect at post-intervention and 12-
month follow up. The effect of CD on reducing thin ideal internalization
was maintained up to 3-year follow up. The healthy weight program
had small effect on ED risk factors at post-intervention as well as 12-
month follow up and large effect size with zero heterogeneity on BMI
at 12-month follow up. CBT was found to be effective in reducing ED
risk factors including body dissatisfaction, dieting, and bulimic symp-
toms with small to moderate effects at post-intervention and up to 9-
month follow up. The effects were small for other interventions includ-
ingmulticomponent andmedia literacy. Across active interventions, CD
was superior to healthy weight program in reducing media
internalization at post-intervention but it was not maintained at follow
up. No signiﬁcant differenceswere found between CD andMLorML and
other interventions.
3.4.3. Indicated eating disorder prevention
3.4.3.1. Active interventions versus no/minimal treatment control. Of the
four studieswhichwere classiﬁed as indicated prevention, three includ-
ing Jacobi et al. (2012), Jones et al. (2008) and Paxton,McLean, Gollings,
Faulkner, and Wertheim (2007) evaluated CBT interventions. In the
meta-analysis of these trials, where data were available, no signiﬁcant
differences of dieting, weight and shape concern, body dissatisfaction,
BMI and bulimic behaviour outcomes between active interventions
compared with controls were observed. Another study by Buddeberg-
Fischer, Klaghofer, Gnam, and Buddeberg (1998) evaluated a
psychoeducation intervention which did not demonstrate any signiﬁ-
cant differences between the intervention and non-speciﬁed control.
3.4.3.2. Active interventions versus other preventive intervention control.
No pooled comparisons were possible between the different preventive
intervention controls.
3.4.4. Sensitivity analysis
In the ﬁrst sensitivity analysis to assess the “quality of the studies”,
the effect of the multicomponent intervention in universal prevention
relied on three quasi-RCTs. Therefore, no pooled comparison were pos-
sible when these studies were removed. For the self-esteem enhance-
ment intervention (universal preventive intervention), when low
quality studieswere removed, therewere no changes to the signiﬁcance
of results and no pooled comparisons for subgroup analysis (e.g. fe-
males/males) were possible. In the meta-analysis of the ﬁve studies
which evaluated amulticomponent intervention (selective prevention),
when three quasi-RCTs were removed, the pooled effect of eating dis-
turbance became insigniﬁcant (Hedges' g =−0.14, 95% CI:−0.41 to
0.12) and no pooled comparison were possible for other examined out-
comes. When two of the four studies evaluating the ML intervention
(selective prevention)were removed, there were no changes to the sig-
niﬁcance or direction of any results.
One-way sensitivity analyses for the QEmodels were undertaken by
excluding each study in turn. For universal prevention, theML interven-
tion became insigniﬁcant for reduction of media internalization in boy
adolescents at post-test and at follow up when the trial by González et
al. (2011) or Wilksch et al. (2015) were excluded. In contrast, when
the trial byWilksch (2015) was excluded the effect size of ML interven-
tions on dieting and body dissatisfaction outcomes in males at post-test
became signiﬁcant and the heterogeneity remained insigniﬁcant. For
selective prevention, the multicomponent interventions became signif-
icant in reducing ED behaviours at post-test when the trial by McVey
and Davis (2002) was excluded but lost signiﬁcance at follow up
when the trials of López-Guimerà et al. (2011) or Franko et al. (2005)
were excluded. Excluding theWilksch et al. (2008) trial signiﬁcantly in-
creased the effect size of ML interventions in media internalization out-
come at post-test (g =−1.39 95% CI−2.75 to−0.03; I2 = 99%, Q =
227, p b 0.000) while excluding the Sharpe et al. (2013) or Neumark-
Sztainer, Sherwood, Coller, and Hannan (2000) trials led to an insignif-
icant difference in the effect size at follow up. The impact on body dis-
satisfaction of the healthy weight interventions became insigniﬁcant
when the Stice et al. (2006) trialwas excluded at post-test but this effect
at follow up became signiﬁcant and the heterogeneity was no longer in-
signiﬁcantwhen the Stice et al. (2003) trialwas excluded. The reduction
of negative affect at post-test for CD interventions became insigniﬁcant
when the Stice et al. (2006) or the Stice, Rohde, Durant, Shaw, andWade
(2013) trials were excluded. Similarly, body dissatisfaction at 1-year fol-
low up became insigniﬁcant when any trials, except the Stice et al.
(2011) or Rohde et al. (2014a) trials, were excluded; and thin-ideal in-
ternalization at 2- to 3-year follow up became insigniﬁcant when the
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Stice et al. (2011) or Stice et al. (2015) trials were excluded. CBT lost sig-
niﬁcance in reduction of bulimic behaviours at post-test in comparison
to controls when excluding any of trials by Taylor et al. (2006); Celio et
al. (2000); Jacobi et al. (2007); Bearman, Stice, and Chase (2003);
Heinicke, Paxton, McLean, and Wertheim (2007); or, Graff Low et al.
(2006). In contrast, with the exclusion of the Winzelberg et al. (1998)
or Doyle et al. (2008) studies, the effect size forweight concern at follow
up became signiﬁcant. Excluding Butters and Cash (1987) or Nicolino,
Martz, and Curtin (2002) trials resulted in signiﬁcant difference for
body dissatisfaction of CBT interventions at post-test compared to
controls.
With regard to the last sensitivity analysis (where studied were re-
classiﬁed according to broad classiﬁcation as speciﬁed above) there
were 60 studies which were classiﬁed as selective prevention and 23
studies classiﬁed as indicated prevention. No signiﬁcant changes were
observed in the results for CD, media literacy, healthy weight, and one
shot interventions regardless of how they were classiﬁed. In particular,
the Atkinson and Wade (2016) study from CD interventions, and the
Shafran, Farrell, Lee, and Fairburn (2009) study from one shot interven-
tions was categorized as indicated prevention. The psychoeducation
and mindfulness-based interventions were classiﬁed as indicated pre-
vention according to the broader classiﬁcations. Furthermore, while
only three CBT studies were classiﬁed as indicated in the primary anal-
yses, under the broader classiﬁcation 16 studies were classiﬁed as indi-
cated. This obviously then meant that few studies were classiﬁed as
selective prevention in this sensitivity analysis. The CBT interventions
classiﬁed as selective prevention signiﬁcantly reduced dieting (at follow
up g=−0.46, 95% CI:−0.73 to−0.19) and bulimic behaviours (at fol-
low up g =−0.33, 95% CI −0.56 to −0.09) at both post-test and 9-
month follow up. In contrast to the primary analyses which used the
narrower classiﬁcation, the indicated CBT interventions signiﬁcantly re-
duced ED pathology (EDE-Q global score at follow up WMD=−0.40,
95% CI −0.59 to −0.22), dieting (at follow up g = −0.38, 95% CI:
−0.54 to −0.22) and shape and weight concerns (at follow up
g =−0.34, 95% CI−0.53 to−0.15) at both post-test and 4-week to
12-month follow up.
3.4.5. Publication bias
Risk of publication bias was examined by visual inspection together
with LFK index. Most of the pooled effect results (34 of 38) of interven-
tions from the universal prevention comparisons exhibited minor and
major asymmetrical Doi plots, indicating a possibility of publication
bias. Similarly, asymmetrical Doi plots were found for 37 of 65 pooled
effect results of interventions from selective prevention and six of
seven pooled effect results of interventions from indicated prevention.
More details (e.g. LFK index) of risk of publication bias are presented
in Supplementary Appendix A.3.
4. Discussion
4.1. Main ﬁndings
In the current study, 101 RCTs were extracted from 112 articles and
described 13 types of ED preventive interventions spanning universal, se-
lective and indicated interventions. One hundred and twelve pooled com-
parisons between active interventions and no/minimal intervention
controls and twelve pooled comparisons among the active interventions
were conducted. The current review included 34more articles thanprevi-
ous reviews, which represented a 43% increase. To our knowledge, this is
the ﬁrst systematic review followed by a qualitative meta-analysis using
the updated quality effect estimator to pool the effect size for all interven-
tions including obesity prevention interventions regardless preventive
strategy. Previous meta-analysis of high quality trials (including only
RCTs) focused on only adolescents and children and did not identify pre-
vention strategies (Pratt &Woolfenden, 2002). The meta-analytic review
published by Stice et al. (2007) identiﬁed moderators for ED preventive
intervention that produced the largest intervention effects based on
RCTs and non-randomized controlled trials but it did not determine
which type of preventive interventionswere themost effective. A parallel
review fromWatson et al. (2016) didnot conduct aqualitativemeta-anal-
ysis for universal and indicated prevention.
The current review found, for universal prevention, only the ML in-
terventions, targeting adolescents, were effective for reducing ED risk
factors up to 30 months after intervention for both females and males.
This ﬁnding is consistent with previous systematic reviews (Pratt &
Woolfenden, 2002; Watson et al., 2010, 2016). It is noteworthy that
the pooled results of some examined outcomes (media internalization,
dieting, and body dissatisfaction for males) of ML intervention were
not robust after excluding one single study from the sensitivity analysis.
This may not validate the statistically signiﬁcant outcomes of the cur-
rent results. We also found that other universal preventive interven-
tions including multicomponent and self-esteem enhancement
interventions were effective in only females. However, these results
should be interpretedwith some caution because of the limited quantity
and quality of trials (e.g. 2–3 trials included in pooled comparisons)
and/or different scales to measure the same outcomes. In particular,
González et al. (2011) used EAT-40 while McVey, Tweed, and
Blackmore (2007) used EAT-children version). Similarly, the pooled
comparison for dieting outcomes related to self-esteem enhancement
interventions came from two studies in which one study used school
randomization (Martinsen et al., 2014). Given that baseline scores of
risk factors are low in universal prevention, statistically signiﬁcant re-
sults are difﬁcult to detect particularly where there is insufﬁcient
long-term follow-up (Wilksch, 2014). Amore accurate test of a “preven-
tion effect”would require larger,more representative sampleswith suf-
ﬁciently long follow up time period to detect changes in ED and their
associated risk factors (Muñoz, Beardslee, & Leykin, 2012).
For selective prevention, the CD intervention was the only interven-
tion found to be superior to controls in reducing ED behaviours and
symptoms up to 3 years post intervention and was superior to other
preventive interventions in reducing thin-ideal internalization at post-
test. It is important to note that the ED symptoms were assessed by di-
agnostic interviews and surveys which are used to reﬂect the broader
array of disordered eating andmay notmap directly onto theDSMdiag-
nostic criteria (Stice, Ng, & Shaw, 2010). Healthy weight interventions
improved both eating disorder risk factors/behaviours and body mass
index. However, these ﬁndings should be interpreted with caution be-
cause the CD and healthyweight programswere different across the tri-
als and the results of themeta-analysiswere not robust in the sensitivity
analysis. Other selective prevention interventions including CBT andML
interventions appeared to signiﬁcantly reduce ED behaviours/risk fac-
tors such as dieting, bulimic behaviours, body dissatisfaction and
media internalization at 3- to 8-month post intervention. Multicompo-
nent interventions were superior to control in reduction in ED behav-
iours at up to 1 year post intervention but this effect became
insigniﬁcant when low quality trials were removed. These results
were consistent with the results from the review conducted at the
same time as the current review by an independent team (Watson et
al., 2016). It is noted that in the sensitivity analyses where individual
studies were excluded, the pooled effects of selected examined out-
comes (i.e. ED behaviours, body dissatisfaction, bulimic symptoms) var-
ied substantially. This demonstrated a possible lack of robustness in
their data. The result of this review indicated that one-session interven-
tions were not effective in ED prevention which is consistent with the
results from Stice et al. (2007) and Watson et al. (2016). Further re-
search is required to determine the most effective versions of the selec-
tive prevention based interventions for reducing ED risk factors and
symptoms in high-risk population. As there is reasonably strong evi-
dence for selective prevention, it is important to also undertake “real-
world” effectiveness trials which will determine whether any gains
are maintained within routine settings (Shaw & Stice, 2016; Stice,
Becker, & Yokum, 2013).
54 L.K.-D. Le et al. / Clinical Psychology Review 53 (2017) 46–58
For indicated prevention, there is insufﬁcient evidence, when using
the narrower classiﬁcation system for indicated prevention, to suggest
a positive effect of CBT interventions in preventing risk factors and be-
haviours of EDs. The number of studies classiﬁed as indicated preven-
tion in the primary analyses in our review is lower compared to those
in the review by Watson et al., 2016. This is partly because our classiﬁ-
cation allowed each study to be only classiﬁed under one category
while theWatson et al., 2016 review classiﬁed some studies as both se-
lective and indicative prevention (Franko et al., 2005; Green, Scott,
Diyankova, & Gasser, 2005). It is worth noting that in the mental health
prevention intervention spectrum, theremight be a shading of selective
into indicated prevention, with the distinction between the two some-
times not clear (Levine, 2016). It is often not immediately apparent
whether interventions are selective or indicated since high risk popula-
tions (i.e. selective interventions) may also be considered as showing
early signs of illness (indicated). The sensitivity analysis demonstrated
no signiﬁcant changes were found in the results for CD, media literacy,
healthy weight, and one shot interventions regardless of how they
were classiﬁed. The most important changes in the results were ob-
served for the CBT interventions based indicated prevention. In particu-
lar, these interventions became effective in reducing ED behaviours,
dieting and shape and weight concerns at post-test and up to 12-
month follow up when the broad category was used. Therefore, it is
very important that further research examines effective indicated pre-
vention interventions in order to develop and reﬁne themby identifying
those who are at greatest risk of ED onset (Stice et al., 2010).
“Challenging the thin-ideal” is not only a part of many psychological
therapies in eating disorders (e.g., CBT) but is important in the broader
public heath arena. “Implementing prevention programs at an early age
when behaviour is more amenable to change may produce better out-
comes than treatment delivered when rigid patterns of cognition and
behaviour have already been established and are engrained” (Werner-
Seidler, Perry, Calear, Newby, & Christensen, 2017). Additionally, clini-
cians should have a good understanding of the evidence for prevention
programs as it is a part of psychoeducation and a common inquiry from
people with the lived experience, either during clinical consultations or
when the clinician is contributing to a community educational seminar
or similar. It is also important where the clinician is joining with people
with the lived experience and others in advocating for the introduction
and wider use of effective and cost-effective programs. In this instance,
with regards to eating disorders, advocacy is needed for support, ﬁscal
and otherwise, of more research into the development and implemen-
tation of prevention programs.
Therapists and education staffs have become increasingly aware of
whether there might be any harms caused by preventive interventions
for EDs (Pratt & Woolfenden, 2002). The current systematic review
found that there is insufﬁcient evidence indicating that there are any
harms associated with the existing preventive interventions for EDs.
Further research certainly is needed to verifywhether there are harmful
impacts of the evaluated interventions.
Importantly, this review provides support for the reproducibility of
ﬁndings. The reviewpresents average effect sizes for various EDpreven-
tion interventions, and thus found that preventive interventions have
produced effects that replicate.
4.2. Recommendation and future directions
The evidence to determine whether ED preventive interventions can
reduce the onset of EDs is still scarce. Only eight of 101 trials investigated
this outcome. Although some studies reported the number of participants
which met criteria for clinical ED behaviour (not diagnosed criteria for
ED), most studies focused on continuous measures of ED risk factors or
behaviours without reporting outcomes for actual cases who met ED di-
agnostic criteria (Wilksch, 2014). This is partly because very large num-
bers of subjects are needed to provide sufﬁcient statistical power in
such preventive studies (Cuijpers, 2014). This is a common problem for
preventive intervention studies for mental disordersmore generally, par-
ticularly for low prevalence disorders. Indicated preventive strategies are
therefore easier to evaluate since the target populations for these inter-
ventions are at greater risk for the development of the disorder compared
to universal or selective interventions where the risk of developing the
disorder is more diffuse (Cuijpers, 2014). Our ﬁndings also revealed that
the majority of the ED prevention interventions were classiﬁed as selec-
tive prevention (79 selective vs. 18 universal vs. 4 indicated). Future re-
search needs to evaluate true indicated prevention interventions as
these have been shown tobe effective and cost-effective in theprevention
of other mental disorders (Mihalopoulos et al., 2011).
There is insufﬁcient evidence to support the efﬁcacy of universal
prevention based interventions. Only ML interventions demonstrated
evidence of efﬁcacy in preventing ED risk factors of both females and
males. Furthermore, it is very important to improve the methodology
for universal intervention given that most of studies were quasi-RCT
with sample sizes likely to be underpowered to detect signiﬁcant differ-
ences. As noted above, further research, with longer follow-up periods,
is required to detect evidence of reduced incidence.
With regards to effects on obesity, this review found that only
healthy weight interventions signiﬁcantly reduced both eating disorder
risk factors and body mass index. The obesity prevention interventions
failed to demonstrate superiority to control interventions in preventing
ED onset. However, positive results were reported in some studies
(Austin et al., 2005, 2007) which were not examined in the meta-anal-
yses as the relevant data were unavailable. The Planet Health program
prevented over half of expected new cases of disorderedweight-control
behaviour among females (Austin et al., 2007). Future research should
evaluate potential secondary beneﬁts of ED and obesity prevention in-
terventions in a broad range of eating- and weight-related problems.
The current review also found that the majority of ED prevention
studies focused on adolescent and young females who are considered
at high-risk of developing an ED (Rohde et al., 2014b; Stice, Marti,
Shaw, & Jaconis, 2009). There is insufﬁcient evidence to support the ef-
fect of ED prevention interventions on pre-adolescent children and
adults. A recent review found that poor body image and disordered eat-
ing are quite prevalent in middle-aged women (Slevec & Tiggemann,
2011). Further research needs to examine these particular sub-groups.
Limited research has been undertaken on the implementation of ev-
idence-based preventive interventions for ED (Stice et al., 2013c). Fur-
thermore, given the lack of evidence of cost-effectiveness of these
interventions (Stuhldreher et al., 2012), research into cost-effectiveness
is needed.
4.3. Study limitations
Several limitations of this reviewneed to be considered. First, this re-
view only used published data and data was solely extracted by the ﬁrst
author, although there was substantial discussions of the studies and
classiﬁcation systems with all the co-authors. Second, a full search of
studies published post 2009 was undertaken for the current study,
with reliance on existing high quality reviews for studies published
prior to 2009. Theremay be unpublished studies that were inadvertent-
ly not included. Third, we used endpoint data rather than change scores
which is more sensitive to baseline imbalance. This may have impacted
the accuracy of the results (Higgins, 2011). Fourth, the outcomes con-
sidered in most studies are only risk factors and not ﬁnal outcomes of
actual cases of averted disorders. Relatedly, the outcome instruments
employed in the studies did not, in most instances, map directly onto
DSM diagnoses although elements of the diagnosis are included in
most measures (e.g. heavy preoccupation with eating).
5. Conclusion
The public health burden of eating disorders is well documented,
and the considerable progress that has been made in the prevention of
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eating disorders over the past several decades (Austin, 2016; Levine,
2016). This systematic review andmeta-analysis found that for selective
prevention, CD interventions were effective for late adolescent and
young adult females in reducing risk factors and symptoms of ED. Re-
search is, however, needed into use of this intervention in younger ad-
olescents (15 years and under) and whether it can be used by non-
professionals (e.g with Becker and Stice's “train the trainers” approach
(Kilpela et al., 2014)). Healthy weight programs were promising in re-
ducing both ED risk factors and obesity onset risks but this result re-
quires further research. Other selective prevention based interventions
including CBT andML are effective in preventing risk factors and behav-
iours of ED. The universal prevention intervention for which there was
the best evidence of efﬁcacy in preventing ED risk factors was ML, but
future research is also required to conﬁrm this result. Although some
positive ﬁndings were identiﬁed, the value of other preventive inter-
ventions should be viewed as uncertain. Further research, with im-
proved methodologies, is necessary to determine deﬁnitively whether
such interventions reduce the onset of clinical EDs. Furthermore re-
search regarding how to improve uptake of such interventions is re-
quired. Such research will help to better establish the effectiveness
and cost-effectiveness of preventive interventions in EDs and thus pro-
vide vital information to decision-makers, including clinicians and
funders of health services, as to which interventions are worth
delivering.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cpr.2017.02.001.
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Chapter 7: The cost-effectiveness of cognitive dissonance interventions 
for prevention of anorexia nervosa and bulimia nervosa 
As noted in Chapter 6, the intervention with the best effectiveness credential for the prevention 
of AN and BN is cognitive dissonance. This chapter evaluates the cost-effectiveness of 
cognitive dissonance for prevention of AN and BN. As noted in the previous chapter, this 
intervention has been demonstrated to reduce ED symptoms as measured by the Eating 
Disorder Diagnostic Scale or Eating Disorder Diagnostic Interview. However, how such 
outcomes can then be converted into DALYs averted becomes an important empirical question. 
As such, the first part of this Chapter (section 7.1.) describes a novel method which has been 
developed to estimate a relative risk effect size from continuous data collected using ED 
symptom scales. This method was derived from a publication in which I am the second author. 
In this publication (APPENDIX 8), I have contributed to the development of the formula for 
the method, collected data to validate the method in ED and contributed to the manuscript (the 
authorship statement is attached in the APPENDIX 7). To avoid duplication, section 7.1 briefly 
outlines the background and context to the development of this method, introduces the 
mathematical formula as well as a validation of this method in ED. All works presented in this 
section were completed by me as part of the works undertaken for this PhD. The second part 
of this Chapter presents the full cost-effectiveness analysis of the cognitive dissonance 
intervention for prevention of AN and BN in adolescent girls. The economic evaluation study 
in this section has used the methods described in Chapter 5. Specific input details as well as 
model structure were addressed in the actual publication and are not described in Chapter 5. 
This cost-effectiveness study was published in the International Journal of Eating Disorders, 
therefore, a full publication is presented in this section.
126 
 
7.1. The estimation of a relative risk effect size when using continuous outcomes 
data in eating disorders  
7.1.1. Background and rationale 
Guidelines for modelled economic evaluations of interventions advise that all literature should 
be considered and the final health outcomes be considered  where possible (e.g. morbidity 
and/or mortality impacts or even disease/disorder impacts) (Caro et al. 2012). The relationship 
between surrogate outcomes to final outcomes is very important and often unclear (Caro et al. 
2012). The pathway from the multiple outcomes presently assessed in the ED intervention 
literature to disorder impacts (e.g. whether the interventions impacts cases of new (incidence) 
or existing disorder (prevalence impacts) is particularly uncertain. In fact, most 
selective/indicated prevention trials have focused on continuous measures of disordered eating 
behaviours without reporting outcomes for actual diagnosed cases, while universal trials have 
generally evaluated risk factor outcomes without directly assessing ED behaviours (Wilksch 
2014). This imprecise specification between surrogates to final outcomes is problematic in the 
context of our current study which aims to evaluate the impact of various interventions on the 
burden of disease estimates as measured by the most recent GBD studies. Mathematical 
modelling techniques provide a way forward to cost-effectiveness analysis in ED and the 
translation of such surrogate outcomes to final outcomes (Buxton et al. 1997). The following 
sections outline methods used to calculate a RR effect size from continuous data collected using 
ED symptom scales. The theory behind calculating RR effect size estimates from continuous 
outcomes data is briefly presented. Following that the validation of the conversion method is 
reported.  
7.1.2. Methods to calculate an ‘relative risk’ effect size using continuous data 
Mean scores on a disorder-specific rating scale can be combined in a meta-analysis under one 
of two scenarios: (1) the raw mean difference (RMD) scenario – when different studies in a 
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meta-analysis use an identical scale; and (2) the standardised mean difference (SMD) scenario 
– when different studies use an assortment of scales to measure a common construct (Egger, 
Smith & Altman 2008). RMD and SMD are continuous measures of effect size, and in order 
to calculate the impact of the effect size on incidence, a continuous relative risk function is 
needed (Barendregt & Veerman 2010). An efficient way to model such a continuous relative 
risk function is to estimate a ‘per unit’ relative risk, expressed as a relative risk per unit increase 
in the measurement scale. This implies an exponential relative risk function. 
Equation (1) can be used in the RMD scenario to calculate an RR effect size based on the mean 
scores observed between two groups in a trial: 
𝐼𝐼𝐼𝐼𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝 = (𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝)(𝑐𝑐1−𝑐𝑐2) (1) 
where: 
𝐼𝐼𝐼𝐼𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝 is the predicted RR effect size based on continuous outcomes data. 
𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝 is the RR per unit for ED symptom scale. 
m1: mean response in the intervention group. 
m2: mean response in control group. 
Equation (2): can be used in the SMD scenario to calculate an RR effect size based on the mean 
scores between two groups in a trial: 
𝑔𝑔 = 𝑚𝑚1 −𝑚𝑚2
𝐼𝐼
 × �1 − 3(4(𝑛𝑛1 + 𝑛𝑛2) − 9)� = �(𝑚𝑚1 −𝑚𝑚2)𝐼𝐼  × 𝐼𝐼� 
(𝑚𝑚1 −𝑚𝑚2) = 𝑔𝑔 × 𝐼𝐼
𝐼𝐼
 
𝐼𝐼𝐼𝐼𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝 = (𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝)(𝑔𝑔×𝑠𝑠𝐶𝐶 ) (2) 
Where 
𝐼𝐼𝐼𝐼𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝𝑖𝑖𝑐𝑐𝑖𝑖𝑖𝑖𝑝𝑝 is the predicted RR effect size based on continuous outcomes data. 
𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝 is the RR per unit for ED symptom scale. 
g: Hedges standardised mean difference in the meta-analysis 
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s: pooled standard deviation of the two groups. 
C: Hedges correction factor  
n1: number of participants in intervention group and  
n2: number of participants in the control group. 
In both situations, the 𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝 of the scale is required. Details of the methods to determine RR 
per unit of the measurement scale are presented in the full-paper which is attached in 
APENDIX 6. In brief, the 𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝 parameter for a scale can be estimated by solving two 
simultaneous equations to convert: (1) a categorical risk factor estimate – indicating the RR of 
a mental disorder when scoring above a cut-off on a rating scale; into (2) a continuous risk 
factor estimate – indicating the RR of a mental disorder per unit score on the scale. These two 
equations are based on comparative risk assessment methods used in GBD studies (Barendregt 
& Veerman 2010; Ezzati et al. 2004; Murray et al. 2003). 
To calculate 𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝, data from studies examining the diagnostic utility (i.e., sensitivity and 
specificity) of a disorder-specific rating scale in a population-representative sample are 
required. These studies must provide data of the cut-off score of the scales and data of the 
number of cases vs. non-cases estimated by the scale, and, the mean and SD of the target 
population. The intervention that had the best evidence in prevention of EDs is cognitive 
dissonance. This intervention has significantly reduced ED symptoms that were measured by 
two measurement scales (EDDS and EDDI). The EDDS is a 22-item self-report measure that 
assesses DSM-IV eating disorder symptoms. According to a population study, the EDDS 
ranges from 0 – 122 with the total cut-off score of 16.5 which distinguished clinical patients 
from healthy controls (e.g. the number of cases vs. non-cases estimated by the scale) 
(Krabbenborg et al. 2012). The integral function was used to calculate categorical RR of risk 
factor that was undertaken in Microsoft Excel. Unfortunately, such information is not available 
for the EDDI scale. However, the EDDS is a brief self-report screening measure that assessed 
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DSM-IV eating disorder symptoms adapted from EDDI questions (Stice et al. 2013b)  so per 
unit RR based on EDDI responses was imputed as follows: 
𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝(𝐼𝐼𝐷𝐷𝐷𝐷𝐼𝐼) =  1 + ��𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝(𝐼𝐼𝐷𝐷𝐷𝐷𝐸𝐸) − 1� × 𝑟𝑟𝑎𝑎𝑛𝑛𝑔𝑔𝑎𝑎(𝐼𝐼𝐷𝐷𝐷𝐷𝐸𝐸)𝑟𝑟𝑎𝑎𝑛𝑛𝑔𝑔𝑎𝑎(𝐼𝐼𝐷𝐷𝐷𝐷𝐼𝐼)�  (3) 
Where  
𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝(EDDI) and 𝐼𝐼𝐼𝐼𝑐𝑐𝑝𝑝(EDDS) is per unit RR of EDDI and EDDS scale. 
range (EDDI) and range (EDDS) is the range of EDDI and EDDS scale.  RRpu estimates were calculated for each study by (1) using EpigearXL (available at 
http://www.epigear.com/Products/EpigearXL/epigearxl.html) to numerically compute 
integrals within each equation and (2) using Excel Solver to apply the optimisation algorithm. 
7.1.3. Validation of the conversion method for eating disorders 
To validate the proposed conversion method, RCTs involving preventive interventions for EDs 
were identified by previous systematic reviews which have examined the efficacy or 
effectiveness of interventions for the prevention of eating disorders in young women (Le et al. 
2017a; Watson et al. 2016). The inclusion criteria for RCTs comprised studies that 
simultaneously: (1) presented data on the mean and standard deviation of scores for a given 
rating scale in both intervention and control groups; and (2) calculated a RR effect size estimate 
from dichotomous diagnostic outcomes identified using DSM/ICD diagnostic criteria via 
structured clinical interviews.  
Data on the actual RR effect size reported by each study and the mean/standard deviation of 
rating scale scores for both intervention and control groups were extracted for each follow-up 
point and used to calculate predicted RR effect sizes. The predicted and actual RR effect sizes 
were compared on a scatterplot, where: predicted RR estimates were plotted on the x-axis, and 
actual RR estimates were plotted on the y-axis (Piñeiro et al. 2008). The Pearson's correlation 
coefficient (𝑟𝑟) was used to measure the strength of the linear relationship between both sets of 
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estimates, which was defined as: ‘weak’ if |𝑟𝑟| was 0.00 to 0.33; ‘moderate if |𝑟𝑟| was 0.34 to 
0.66; and ‘strong’ if |𝑟𝑟| was 0.67 to 1.00 (Mason, Lind & Marchal 1998; Weber & Lamb 1970). 
In addition, a simple linear regression was conducted to regress observed RR values (on the y-
axis) against predicted RR values (on the x-axis). We compared the slope and intercept values 
of the fitted line against the 1:1 line (a.k.a. the line of equality) by conducting t-tests to examine 
the null hypothesis that 𝐼𝐼𝑠𝑠𝐶𝐶𝑠𝑠𝑎𝑎 = 1 and 𝑖𝑖𝑛𝑛𝑡𝑡𝑎𝑎𝑟𝑟𝑖𝑖𝑎𝑎𝑠𝑠𝑡𝑡 = 0 (Piñeiro et al. 2008). 
7.1.4. Results 
Per unit relative risk of Eating Disorder Symptom Scale 
The RR per unit of EDDS is calculated as 1.06 (95% CI: 1.04 to 1.08). 
The RR per unit of EDDI is calculated as 1.08 (95% CI: 1.06 to 1.11). 
Pooled relative risk of CD interventions. 
In general, the pooled relative risk (RR) of CD interventions compared to control related to ED 
onset was calculated as 0.85 (95% CI: 0.79 to 0.92) by this method. This means that the effect 
of CD interventions on ED symptoms at post-intervention reduced the incidence of ED by 15% 
compared to the control condition. For 1-year follow up, compared to control related to ED 
onset, the pooled RR of CD interventions was calculated as 0.94 (95% CI 0.86 to 1.03). This 
means that the intervention reduced 6% of ED cases compared to control at 1-year follow up 
although this effect size was not statistically significant. 
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Validation of the conversion method for EDs. 
Given the paucity of RCTs that examined the ED onset cases (Le et al. 2017a; Watson et al. 
2016), three RCTs were included in the validation step (Stice et al. 2015; Stice et al. 2011; 
Stice et al. 2013c). A crude visual inspection of scatterplots revealed predicted RR estimates 
were slightly higher than actual estimates among RCTs involving EDs in young women (see 
Figure 6). Regarding Pearson's correlation coefficient, there was a strong correlation was 
observed between predicted and actual RR effect sizes (r=0.90). Furthermore, there is 
insufficient evidence to reject null hypotheses that slope=1 and intercept=0. However, it was 
noteworthy that it is unlikely that the point estimates for these coefficients were nowhere near 
their desired outcomes. This might suggest the paucity of in-scope RCTs for EDs preclude the 
power to detect meaningful differences in this analysis. Further research with better and more 
recent ED data is required to confirm the validation. 
 
Notes. RR: relative risk; RCTs: randomized controlled trials. 
 
 
Figure 6: Scatterplot of predicted RR effect size versus actual RR effect sizes 
among RCTs for young women with eating disorders. 
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7.2. The Cost-Effectiveness of cognitive dissonance interventions for prevention of 
anorexia nervosa and bulimia nervosa 
This section presents the cost-effectiveness study evaluating the modelled population cost-
effectiveness analysis of the cognitive dissonance intervention compared to no intervention for 
the prevention of Anorexia Nervosa and Bulimia Nervosa within the Australian context. The 
cognitive dissonance intervention was chosen given that this is the only preventive intervention 
demonstrating an impact on both ED symptoms and behaviours. The economic evaluation was 
conducted in adolescent girls aged 15 to 18 year old to estimate the cost per DALY averted 
over 10 years. The study was conducted using a health care perspective plus including time 
and travel costs of parents in the sensitivity analysis. Results showed that the cognitive 
dissonance intervention was more effective and more costly compared to no intervention in 
prevention of AN and BN. The base case ICER was $103,980 (95% UI: $62,273 to $168,814) 
per DALY averted with none of uncertainty iterations falling below the value-for-money 
threshold of $50,000 per DALY averted. Sensitivity analysis showed that if the effect of the 
intervention remained up to five years, the intervention would have 84% chance of being cost-
effective. Importantly, the study found that participant rates in terms of taking up the 
intervention was a key parameter that impacted on the ICER with higher aprticipation rates 
associated with more favourable results. In fact, if up to 90% of girls at school who were 
eligible for intervention decided to access it, the intervention would be cost-effective. Results 
from this study have considerable implications for current practice for prevention of EDs given 
that there is a general low level of policy interest in preventive programs for ED. This is 
highlighted by the fact that few policy documents mention prevention of EDs as an important 
policy imperative. Further research in this field should not only focus on ways to enhance the 
effectiveness of the intervention but also need to consider techniques which may be used to try 
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and encourage more eligible people to participate in this intervention. This section is based on 
the following publication: 
Le LK-D, Barendregt JJ, Hay P, Sawyer SM, Paxton, SJ, & Mihalopoulos C. The Modelled 
Cost‐Effectiveness of Cognitive Dissonance for the Prevention of Anorexia Nervosa and 
Bulimia Nervosa in Adolescent Girls in Australia. International Journal of Eating Disorders. 
2017; 50: 834-841. 
The authorship statement of this publication is attached in APPENDIX 9. 
The supplementary data of this publication are attached in APPENDIX 10.
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Abstract
Background: Eating disorders (EDs), including anorexia nervosa (AN) and bulimia nervosa (BN), are
prevalent disorders that carry substantial economic and social burden. The aim of the current
study was to evaluate the modelled population cost-effectiveness of cognitive dissonance (CD), a
school-based preventive intervention for EDs, in the Australian health care context.
Method: A population-based Markov model was developed to estimate the cost per disability
adjusted life-year (DALY) averted by CD relative to no intervention. We modelled the cases of AN
and BN that could be prevented over a 10-year time horizon in each study arm and the subse-
quent reduction in DALYs associated with this. The target population was 15-18 year old
secondary school girls with high body-image concerns. This study only considered costs of the
health sector providing services and not costs to individuals. Multivariate probabilistic and one-
way sensitivity analyses were conducted to test model assumptions.
Results: Findings showed that the mean incremental cost-effectiveness ratio at base-case for the
intervention was $103,980 per DALY averted with none of the uncertainty iterations falling below
the threshold of AUD$50,000 per DALY averted. The evaluation was most sensitive to estimates
of participant rates with higher rates associated with more favourable results. The intervention
would become cost-effective (84% chance) if the effect of the intervention lasted up to 5 years.
Conclusion: As modelled, school-based CD intervention is not a cost-effective preventive inter-
vention for AN and BN. Given the burden of EDs, understanding how to improve participation
rates is an important opportunity for future research.
K E YWORD S
anorexia nervosa, bulimia nervosa, cost-effectiveness, eating disorders, economic evaluation
1 | INTRODUCTION
Eating disorders (EDs), including anorexia nervosa (AN) and bulimia
nervosa (BN), are common and are associated with significant impair-
ment of health related quality of life (HRQoL) (Agh et al., 2016; Jenkins
et al., 2011). EDs are also associated with substantial economic and
social burden (Agh et al., 2016). The global burden of disease study
(GBD) (2013) estimated that BN and AN respectively are the 5th and
8th major causes of disease burden in Australian females aged 10 to 24
years, calculated in disability-adjusted life years (DALYs) (Erskine et al.,
2016; Vos et al., 2015). EDs were the 12th major cause of mental health
hospitalisation costs within Australia (Mathers et al., 1999). Moreover,
the annual costs of AN treatment in Australia (based on a broader soci-
etal perspective) were estimated to be up to $20,000, of which health
care costs accounted for 10–15% (Deloitte Access Economics, 2012). In
the private hospital sector, the cost of treatment of an episode of AN
was estimated to be the second most costly treatment after the cost of
cardiac artery bypass surgery (Pratt andWoolfenden, 2002).
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A number of risk factors (e.g., dieting, body dissatisfaction) are
associated with the development of EDs including AN and BN (Rohde
et al., 2014). Of note, recent research studies have highlighted that
adolescents engaging in dieting and disordered eating behaviours con-
tinue to have an increased risk for these behaviors into young adult-
hood (Neumark-Sztainer et al., 2011 ). A number of interventions have
been developed to try and prevent the development of disordered eat-
ing problems (Jacobi et al., 2012; Le et al., 2017; McVey et al., 2008;
Stice et al., 2009; Watson et al., 2016; Wilksch, 2014). Amongst these
interventions, two recent systematic reviews found that a cognitive
dissonance (CD) based intervention known as The Body Project is the
only intervention with strong evidence of reducing ED risk factors as
well as ED diagnostic symptoms as measured by the Eating Disorder
Diagnostic Survey/Interview (EDDS/EDDI) (Le et al., 2017; Watson
et al., 2016). This intervention has been broadly implemented in high
schools, colleges, and universities in the United States (US), Iceland,
and Mexico (Shaw and Stice, 2016)
To our knowledge, economic evaluations of preventive interven-
tions targeting EDs are relatively rare in the academic literature. How-
ever, such evaluations are an important tool to aid decision-makers in
determining which interventions are value-for-money (Mihalopoulos
and Chatterton, 2015). There have been two modelled cost-utility anal-
yses (CUAs) of preventive interventions for ED (Wang et al., 2011;
Wright et al., 2014). In one of these studies, Wang and colleagues
(2011) evaluated the cost-effectiveness of “Planet Health”, an obesity
preventive intervention targeting the prevention of BN, while in the
other study, Wright and colleagues (2014) evaluated the cost-
effectiveness of annual screening interventions for EDs. Wang and col-
leagues (2011) estimated that averting one case of BN would result in
an estimated cost-saving of US$33,999 and a gain of 0.7 quality-
adjusted life years (QALYs) at an intervention cost of US$46,803.
Wright and colleagues (2014) found that the evaluated screening pro-
gram was 41% likely to be cost-effective at the commonly accepted
(Neumann et al., 2014) willingness-to-pay threshold of US$50,000 per
QALY.
The goal of the current study was to evaluate the modelled popu-
lation cost-effectiveness analysis of a cognitive dissonance intervention
relative to no intervention to answer the question of whether CD pro-
vides value-for-money within the Australian health care system.
2 | METHODS
The current study was conducted within the context of a larger study.
This larger study has the overall aim of using economic evidence to
inform mental health interventions and service delivery within the Aus-
tralian context. A standardised economic evaluation protocol has been
developed to ensure that the methods across the different evaluations
are as similar as possible in order to improve the comparability of cost-
effectiveness of different interventions across different mental disor-
ders (Carter et al., 2008; Mihalopoulos, Carter, Pirkis, & Vos, 2013;
Whiteford, Harris, & Diminic, 2013). As a first step, the effectiveness
and characteristics of preventive interventions of ED were retrieved
from the published literature. The intervention was chosen based on
the strength of evidence of effectiveness as well as generalisability of
the setting/population to the Australian context. The effect size of the
chosen interventions were based on a meta-analysis of multiple rando-
mised controlled trial studies of that intervention (Le et al., 2017). The
decision-analytic model was then developed to estimate the costs and
benefits of implementing the chosen intervention among adolescent
girls in the Australian context.
The current study employed a cost-utility analysis framework,
expressing outcomes as DALYs. As the context of the study is the
global burden of disease estimates for Australia, the disability weights
of AN and BN was sourced from the GBD 2013 (Murray et al., 2013).
A health sector perspective was adopted that focussed on costs and
benefits accruing to students, health care providers, school staff and
third-party payers. All costs and cost offsets were measured in Austra-
lian dollars and expressed in 2013 dollar values (using published health
price deflators from the Australian Institute of Health and Welfare
(AIHW), if appropriate) (Australian Institue of Health and Welfare,
2015). Students’ time and travel costs were not included since the
intervention occurs in school settings. The costs of unrelated diseases
resulting from increased life expectancy were also excluded. A discount
rate of 3% per annum was applied to all costs and benefits. Results
(with and without cost-offsets) are reported as the incremental cost-
effectiveness ratio (ICER) (an ICER is calculated as the difference in
total costs between the intervention and comparator divided by the
difference in DALYs averted between the intervention and compara-
tor). The ICER was examined in relation to a cost-effectiveness value-
for-money threshold of AU$50,000 per DALY averted (primary thresh-
old) or AU$100,000 per DALY averted (secondary threshold) which
have been used in previous Australian economic evaluation studies
(Carter et al., 2008; Vos et al., 2010). This study adheres to the guide-
lines in Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) (Husereau et al., 2013).
2.1 | Intervention description
The CD intervention is characterised as a psychological intervention
based on interactive verbal, written and behavioural exercises that
guide participants toward taking a stance against the thin-ideal. The
intervention is delivered in group format (six to ten participants) (Stice
et al., 2009), with session numbers and duration ranging from six ses-
sions of 45 minutes to four sessions of 60 minutes (Shaw and Stice,
2016; Stice et al., 2009). If a participant misses a session, brief (10–15
minute) individual make-up sessions are conducted to review missed
material when possible (Stice et al., 2009). For the current modelled
evaluation, we assumed the intervention was delivered by school
counsellors.
2.2 | Eligible population for the intervention
Wemodelled the intervention pathway based on how studies of preven-
tive CD interventions were undertaken. The technical advisory panel
constituted for this study suggested that this was likely to be realistic of
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routine roll-out. All females aged 15–18 years enrolled in Australian sec-
ondary schools are recruited using emails, flyers, and leaflets inviting
females with body image concerns to participate in the CD intervention.
The proportion of participants who respond to these recruitment materi-
als is 9.2% (sourced from clinical trials) (Stice et al., 2009). Students who
verbally affirm that they have high body image concerns through phone
screening with staffs are offered the intervention. The proportion of Aus-
tralian female students who self-identify as having high body image con-
cern (68.9%) was sourced from the 2013 Mission Australia Youth Survey
of young women (Perrens et al., 2013). Data from RCT studies (n512)
indicate that 83% (range: 64 – 95%) of students agree to participate in
the intervention after such initial screening. We assumed a much lower
participation rate of 30% in the real world setting given that financial
incentives would not be provided to participants and the staging of these
interventions during the later years of secondary school coincides with a
heavy student assessment load (Atkinson andWade, 2013).
2.3 | Effectiveness of intervention
Based on a meta-analysis undertaken in 2016 (Le et al., 2017), CD inter-
ventions were effective in reducing ED symptoms (measured by EDDS/
EDDI) compared to waitlist control at post-test (Hedges’ g520.30, 95%
confidence interval [CI] 20.47 to 20.13) with substantial heterogeneity
(I2551%, Q516.49, P50.04). The exclusion of one outlier (Serdar
et al., 2014) decreased the effect size to g520.25 (95% CI 20.37 to
20.14) and the heterogeneity became insignificant. Therefore, this effect
size (after removal of the outlier) was chosen as the estimate of interven-
tion effectiveness for use in the economic evaluation. Although the
effect on ED symptoms at 1-year follow up still favoured CD interven-
tions compared to control, this effect size became non-significant
(Hedges’ g520.06, 95% CI 20.19 to 0.06, I250%, Q54.76, 0.45) (Le
et al.). Therefore, statistically significant effect sizes (i.e., post-interven-
tion) have been modelled in the baseline cost-effectiveness models.
A new method has been developed by the research team which re-
weights Hedges’ g formulation to transform the effect size on ED symp-
toms to reduced ED incidence (Le et al., submitted). The ED incidence
outcome is important as the burden of disease studies only included diag-
nosed prevalent cases (including new incident and existing cases) of men-
tal disorders in the estimates. Applying this method, we estimated that
the intervention can reduce 15% of the incidence of ED post-
intervention (relative risk (RR)50.85, 95% CI: 0.79 to 0.92). A 50%
decay rate of benefit was modelled for interventions from 1-year to 4-
year follow up and by year 5 the intervention effect reduces to almost
zero. This decay effect is consistent with the results of the meta-analysis
of preventive interventions for mental health (e.g., depression) which
found that intervention effects reduce over time (Cuijpers et al., 2007).
2.4 | Costs
Cost of the intervention includes the cost of recruitment and screening,
cost of training intervention for school-counsellors and the cost of
school counsellors who deliver the CD sessions. We assumed that these
will all be publicly provided services. The unit cost of school-counsellors
was sourced from The Australian Psychologist and Counsellors in
School Association’s Report 2013 (The Australian Psychologist and
Concellors in School Association, 2013). The cost of training school
counsellors was sourced from the Body Project expert training website
(Body Project Collaborative Training Costs, 2015). We assumed that
the intervention is in “steady state” operation, i.e., trained staff and nec-
essary infrastructure are available to scale up the interventions, which is
assumed to be working in accordance with their efficacy potential (Car-
ter et al., 2009, 2008; Vos et al., 2010). The cost offsets (that is, averted
treatment costs) were the mean cost of treating each ED case (weighted
by AN & BN prevalence) valued at $788 (sourced from AIHW for the
year 2008–2009, and inflated to 2013 prices) (Deloitte Access Econom-
ics, 2012). Cost offset included hospital costs, out-of-hospital costs
TABLE 1 Assumption and cost items for the CD intervention
Parameters Assumption/unit cost Sourced
Screening staﬀ A school counsellor spent 10 mins to deliver ﬂyers to
25 students (equivalent to one secondary-school class size)
Expert opinion
Screening process A school counsellor spent 10 mins (5 mins preparation15 mins
of a phone call) to do a phone screening per student. At least
three phone calls were undertaken.
Expert opinion
Training Each school receives formal training for one school counsellor
from Body Project experts plus 15 minutes of technical support.
Expert opinion
School counselors (average
salary of school counselors)
$80,467 per year The Australian Psychologist and
Counsellors in School Association, 2013
$41.3 per hour
Training cost Body Project Training Team & Estimation.
Converted to AUD$ using purchasing
power parties of 1.48 in 2013.
Onsite training $1850 per training (16 participants)
Trainer travel expense $1480 per training (16 participants)
Technical assistance (4 hours) $185 per hour (4 participants)
Oncosts 30% Expert opinion
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(including GP services, imaging, pathology, psychologists and medical
specialists) and medication costs. Key assumptions which have been
made in costing the intervention pathway are detailed in Table 1.
2.5 | Modelling health outcomes
A decision-analytic multiple cohort Markov model developed in Micro-
soft Excel 2010 was designed using a 10-year time horizon to estimate
the cost effectiveness of CD interventions compared to no interven-
tion controls. The DisMod-II model was adapted to simulate how a
population cohort moves between three health states over time having
body image concerns, having a specified ED (AN and/or BN) and being
dead (Figure 1). More complicated models (e.g., microsimulations) were
not appropriate to the current context as we have no evidence of indi-
vidual heterogeneity of intervention outcomes.
Transitions between health states were governed by epidemiologi-
cal data (from the GBD 2013 study) including adjusted ED incidence,
remission rates, and adjusted mortality rates (Vos et al., 2015). The inci-
dence of ED was the sum of the incidence of AN and BN with the
assumption that comorbid cases are assigned to one of each (e.g.,
female adolescent who developed AN could never develop BN). The
ED remission rate and mortality rate was, respectively the average of
remission rate and mortality rate of AN & BN, weighted by AN and BN
prevalence. The ED incidence rate from GBD 2013 was adjusted for
age and body dissatisfaction risk factors in the model. According to
Rohde et al. (2014), elevated body dissatisfaction is associated with an
elevated odds ratio of 1.51 and 1.67 at age 15 and 16 of developing an
ED (these odds were converted to relative risks of 1.44 and 1.57,
respectively) (Barendregt, 2012). The assumption was made that the
relative risk of 1.57 would be applied to adjust the incidence of ED
for age 17 and so on. The mortality was adjusted by standardized mor-
tality ratios of (SMRs) of 5.86 for AN and 1.93 for BN (Arcelus et al.,
2011).
2.6 | Uncertainty and sensitivity analysis
To test how robust the results are to the assumptions made in the
analysis, a probabilistic multivariate uncertainty analysis was under-
taken using Monte Carlo simulation methods. For the Monte Carlo sim-
ulation, probability distributions related to natural history parameters,
relative risks, disability weighs, and costs were incorporated into the
analysis. Estimates of incremental costs and DALYs were obtained by
re-running the model which draws values from the distribution parame-
ters in 5000 replications. Details of the parameters varied in the uncer-
tainty analysis are presented in Table 2.
The uncertainty simulations are presented on a cost-effectiveness
plane. A cost-effectiveness plane is a quadrant of cost differences plot-
ted against benefit differences. The area above the horizontal axis indi-
cates that the intervention is more costly while the area to the right of
the vertical axis indicates that the intervention is more effective (than
the comparator).
In addition to multivariate probabilistic uncertainty analysis
described above, we also employed a series of one-way sensitivity
analyses to explore how different assumptions and parameters, such as
incidence and participation rate, affect the results. The following sce-
narios were modelled:
 Scenario 1: Decay rates range from 0% (full benefit lasts for the
entire 5 years) to 100% (one year benefit)
 Scenario 2: Incidence rates range from normal incidence without
adjusting for body dissatisfaction to double normal incidence with
adjusting for body dissatisfaction.
 Scenario 3: Time horizon of model ranges from 5 years to 15 years.
 Scenario 4: Proportion of participants who respond to recruitment
material ranges from 5% to 30%.
 Scenario 5: Proportion of participants who have high body-image
concerns ranges from 46.8% to 84%.
 Scenario 6: Participant rates of receiving the intervention ranges
from 10% to 90%.
 Scenario 7: Cost offsets range from $0 (no cost offset) to $5841.
3 | RESULTS
Table 3 contains a detailed breakdown of the economic evaluation
results of the CD intervention. The mean of total intervention costs
was $1,565,676 (without cost off-sets) (95% CI: $1,336,190 to
$1,803,168) or $1,509,932 (with cost off-sets) (95% CI: $1,278,657 to
$1,748,913). The mean of total DALYs averted by the intervention was
16 (95% CI: 9 to 24). In the cost-effectiveness plane, the uncertainty
iterations fell in the north-east corner which means that the interven-
tion was more effective and more costly than no intervention (Figure
2). Without cost-offsets, the mean ICER for this intervention was
$103,980 per DALY averted (95% CI: $62,273 to $168,814) and none
of the iterations fell below the willingness-to-pay (WTP) threshold of
AUD$50,000 per DALY. In relation to a secondary WTP threshold of
AU$100,000 per DALY averted, the ICER without cost-offset was still
FIGURE 1 State transition diagram used to estimate health
benefit of cognitive dissonance intervention for eating disorder
prevention [Color figure can be viewed at wileyonlinelibrary.com]
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slightly higher but 50% of the iterations fell below this threshold.
Including cost-offsets (i.e., $788 per case per year) made very little dif-
ference to both primary and secondary results.
3.1 | Sensitivity analysis
Generally, the evaluation was most sensitive to intervention effect
decay rate (scenario 1), ED incidence rate (scenario 2) and the propor-
tion of participants who receive the intervention (scenario 6). In sce-
nario 1, the ICER was $40,033 (95% CI: $24,136 to $65,771) per
DALY if there was no decay of intervention effect. The intervention
was also 84% likely to be cost-effective at WTP threshold of $50,000
per DALY. In scenario 2, doubling the incidence rates of EDs led to a
lower ICER ($53,865, 95% CI: $32,220 to $88,536) but this ICER was
still slightly higher than the WTP threshold of $50,000 per DALY. Vari-
ation in time horizon in scenario 3 did not significantly alter the ICER
except a shorter time horizon led to an increase in the ICER. In scenario
4, the ICER was $92,114 (95% CI: $56,041 to $148,831) per DALY
and the intervention was not cost-effective at the examined threshold
when 30% participants who responded to recruitment materials was
used. Scenario 5 indicated an ICER of $87,879 (95% CI: $52,540 to
$143,631) per DALY when a high proportion of participants who have
high-body image concerns was employed. Regarding the proportion
who would take up the intervention (scenario 6), the ICER decreased
to $46,427 (95% CI: $27,568 to $75,904) per DALY and the interven-
tion was 68% likely to be cost effective at WTP threshold of $50,000
per DALY when a tripled participation rate was considered. The sensi-
tivity analysis that refers to the higher cost-offset (scenario 7) led to a
decrease of the ICER to $76,724 (95% CI: $41,487 to $132,538) with
nine percent of iterations falling under the WTP threshold of $50,000 per
DALY. Further details of sensitivity analysis were presented at Figure 3.
4 | DISCUSSION
In this study, a population-based Markov model was developed to esti-
mate the cost-effectiveness of a CD intervention relative to no inter-
vention for the prevention of EDs. To our knowledge, this is the first
study to assess the cost-effectiveness of an evidence-based selective
TABLE 2 Input parameters and uncertainty ranges used in the simulation analysis
Parameters Values
Uncertainty
distributions Source
Eﬃcacy (RR of developing ED) – post test 0.85 (0.79, 0.92) Lognormal From nine RCTs comprising meta-analysis
(Le, Barendregt, Hay, & Mihalopoulos, 2017)
Body dissatisfaction adjusted for incidence (RR) Lognormal Rohde, Stice, and Marti (2014)
Age 15 1.44 (1.00, 2.05)
Age 16 to 30 1.58 (1.17, 2.13)
Standardized mortality ratios Lognormal Arcelus, Mitchell, Wales, and Nielsen (2011)
Anorexia nervosa 5.86 (4.17, 8.26)
Bulimia nervosa 1.93 (1.44, 2.59)
Disability weight of ED (Average AN & BN
disability weight, weighted by AN & BN prevalence)
0.22 (0.15, 0.31) Beta GBD 2013 study (Salomon et al., 2015)
Private costs (including unit costs of school
counsellors, screening materials and training costs)
620% Pert Own assumption
Number of sessions 4 Discrete From eight RCTs
Make-up session duration (hour) 0.2 (0.15, 0.25) Pert From eight RCTs
Note. RR, relative risk; RCTs, randomized controlled trials; ED, eating disorder; AN, anorexia nervosa; BN, bulimia nervosa.
TABLE 3 Results of cost-effectiveness analysis for cognitive dissonance intervention
Mean 95% CI
Probability to be
cost-eﬀective at $50,000
per DALY averted
Probability to be
cost-eﬀective at $100,000
per DALY averted
DALYs averted 16 9 to 24
Cost (exclude cost-oﬀsets) 1,565,676 $1,336,190–$1,803,168
Cost (include cost oﬀsets) 1,509,932 $1,278,657–$1,748,913
ICER (exclude cost oﬀsets) –
per DALY averted
$103,980 $62,273–$168,814 0% 50%
ICER (include cost oﬀsets) –
per DALY averted
$100,363 $59,417–$164,021 0% 56%
Note. DALY, Disability averted life year; ICER, incremental cost effectiveness ratio.
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preventive intervention of ED from a population cost-effectiveness
perspective. This study demonstrated that CD is likely to result in very
few DALYs averted, although the costs of the intervention are also not
prohibitive. The cost-effectiveness ratio was above commonly
accepted value-for-money thresholds of $50,000 per DALY in an Aus-
tralian setting. Although such thresholds are somewhat arbitrary,
$50,000 per DALY appears an acceptable threshold to Australian
decision-makers and has been used in a number of previous health
economic evaluations, including mental health interventions (Carter
et al., 2008; Mihalopoulos et al., 2013). Having said that, the sensitivity
analysis demonstrated that variations in some of the modelling parame-
ters could change this conclusion.
The largest component of the intervention costs was the screening
costs which accounted for 50% of the total costs. With a low participa-
tion rate for the actual CD intervention (which is what reduces the bur-
den) it is therefore unsurprising that the results of the current analysis
were not favourable. Our resultant ICER was higher than that observed
in previous studies. Previous US research by Wright et al. (2014), which
evaluated a screening intervention, found an ICER of AUD$87,010 per
QALY (convert to AUD$ using purchasing power parities of 1.54 in
2012 [OECD-Stats, 2012]) while Wang et al. (2011) evaluated the
cost-effectiveness of an obesity–ED prevention program and reported
an ICER of AUD$27,437 per QALY (self-calculated and converted to
AUD$ using purchasing power parties of 1.50 in 2010 [OECD-Stats,
2010]). The differences between these results and our results is likely
to be because of the low participant rates and the screening costs (e.g.,
recruitment cost) that were included in this study.
The strength of the current study is the use of plausible assump-
tions based on the latest available literature to develop the economic
model. However, it is important to note that many of these have their
own limitations. For example, while we used health-sector related cost-
offsets from the AIHW, it is known that EDs are associated with higher
costs, ones that often lie outside the health sector (Stuhldreher et al.,
2012, 2015). For example, Stuhldreher and colleagues found that up to
40% of the costs associated with EDs are attributable to indirect (or
productivity costs) (Stuhldreher et al., 2015). We may therefore have
underestimated the potential cost-savings associated even with a delay
in ED onset, particularly as the intervention girls enter adulthood
(Stuhldreher et al., 2015). Future intervention-based research needs to
consider adding economic dimensions so that a more accurate estima-
tions of any costs, cost-offsets as well as health impacts from various
interventions can be obtained.
Another strength (that is also a limitation) of the current study is
the background context of the burden of disease studies for Australia.
Any health benefits associated with interventions for ED have to
impact either the prevalence or incidence of existing disease since the
health benefit was based on a single disability weight. This does not
include sub-syndromal disease, which is common in ED (Stice et al.,
2010) or even disease severity (Whiteford et al., 2016). It must there-
fore be appreciated that the current health burden averted by such
interventions has been conservatively estimated in this study. The epi-
demiological data from the GBD 2013 study pooled all data available
for a given disorder into a weighted average, while simultaneously
adjusting for known sources of variability in estimates reported across
studies (Whiteford et al., 2016). The current simulation model, as with
all similar simulation models, used many assumptions that limit
FIGURE 3 One-way sensitivity analyses of the potential cost-effectiveness of cognitive dissonance intervention [Color figure can be
viewed at wileyonlinelibrary.com]
FIGURE 2 Cost-effectiveness plane of base case analysis with
willingness to pay threshold of $50,000 and $100,000 per DALY
[Color figure can be viewed at wileyonlinelibrary.com]
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conclusions. However, our approach in the use of both uncertainty
analysis and sensitivity analysis helped to ascertain which variables had
the largest impact on the conclusions. For example, the current study
used the assumption that a female adolescent with AN could never
develop BN given that the transition between AN & BN is difficult to
address in the current model. While the cross-over rates might impact
on the incidence rates, the sensitivity analysis of lower or higher inci-
dence rate of EDs (i.e., scenario 2) showed that the overall study con-
clusion was unchanged although the ICER was substantially altered.
One issue highlighted by the sensitivity analysis as being signifi-
cantly important is the low participation rate for actual engagement
with the CD intervention. This study estimated that only 30% of female
adolescents with high-body image concerns (equivalent to 2% of the
female population in this age range) agreed to participate in the inter-
vention under non-financial incentive circumstances. The sensitivity
analysis demonstrated that if this participant rate was doubled or tripled,
the ICER would reduce to AUD$58,642 or $44,716 per DALY averted
and the intervention would be between 27% and 68% likely to be cost-
effective at willingness-to-pay threshold of AUD$50,000 per DALY
averted, respectively. Enhancing dissemination of a preventive interven-
tion for EDs is an important challenge since individuals have been found
to have a low interest in ED prevention (Becker et al., 2008), especially
teenagers, where “there is not always an easy avenue for mandatory
participation as for school programmes” (Atkinson and Wade, 2013). It
is important that future research considers how such interventions can
appropriately engage more people who are most likely to benefit from
the interventions, including the role of financial drivers.
Lastly, the current study was developed to assess the cost-
effectiveness of screening and treatment interventions from an Austra-
lian perspective. The proportion of female adolescents who have high-
body image concerns and the proportion of those who receive the
intervention may differ across countries. Therefore, extrapolation of
the results to different contexts needs to be undertaken with caution.
In particular, even though the CD intervention has been found to be
effective for female undergraduate or college students in the US, this
would require a different screening pathway which was not evaluated
in this study and may incur different costs in Australia.
5 | CONCLUSION
This analysis suggests that the CD intervention delivered to Australian
female adolescents with high body dissatisfaction to prevent diagnos-
able case of ED is more effective and more costly relative to the “no
intervention” control, with the ICER falling above commonly accepted
value-for-money thresholds in Australia. However, extensive sensitivity
analysis around this result suggested that important model assumptions
impacted the ICER. Approaches that increase the participation rate of
the CD intervention might render the intervention to be cost-effective
at such thresholds. Future research needs to consider the economic
credentials of such interventions along with their ability to reliably
impact cases of ED.
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Chapter 8: The cost-effectiveness of family-based treatment and adolescent-based 
treatment of anorexia nervosa 
As described in Chapter 1, the best available evidence for AN treatment is FBT which is most frequently 
compared to AFT in adolescence. As further highlighted in Chapter 4, there was no existing evidence 
evaluating the cost-effectiveness of FBT and AFT. Therefore, the aim of the current chapter is to evaluate the 
cost-effectiveness of FBT and AFT compared to no intervention. An economic evaluation was undertaken to 
estimate costs and outcomes (measured by DALYs averted) of FBT compared to an active intervention, 
namely individual therapy and no intervention control over six year. The study targeted adolescents aged 11 
to 18 with AN of relatively short duration (under three year). The study showed that FBT was more effective 
and less costly than individual therapy. However, FBT was more effective and more costly compared to no 
intervention, with an ICER of $5,089 (95% UI: dominant to $16,659) per DALY averted. The most important 
parameter which impacted the result of study is the cost offsets (i.e. hospitalisation costs). Although excluding 
this cost-offset led to an increase in the ICER, the conclusion that FBT was cost-effective did not change. This 
study is the first study to evaluate economic analysis of an evidence-based therapy (FBT) for treatment of AN. 
This study has important implications for the Australian current practice for AN treatment given that only half 
of the recommended course of treatment would potentially receive publicly subsidised funding from Medicare. 
With now strong evidence of cost-effectiveness, FBT, despite being more costly to deliver compared to other 
form of psychological therapy, it should be strongly considered for appropriate financing and implementation 
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Abstract
Background: Anorexia nervosa (AN) is a prevalent, serious mental disorder. We aimed to evaluate
the cost-effectiveness of family-based treatment (FBT) compared to adolescent-focused individual
therapy (AFT) or no intervention within the Australian healthcare system.
Method: A Markov model was developed to estimate the cost and disability-adjusted life-year
(DALY) averted of FBT relative to comparators over 6 years from the health system perspective.
The target population was 11–18 year olds with AN of relatively short duration. Uncertainty and
sensitivity analyses were conducted to test model assumptions. Results are reported as incremen-
tal cost-effectiveness ratios (ICER) in 2013 Australian dollars per DALY averted.
Results: FBT was less costly than AFT. Relative to no intervention, the mean ICER of FBT and
AFT was $5,089 (95% uncertainty interval (UI): dominant to $16,659) and $51,897 ($21,591 to
$1,712,491) per DALY averted. FBT and AFT are 100% and 45% likely to be cost-effective,
respectively, at a threshold of AUD$50,000 per DALY averted. Sensitivity analyses indicated that
excluding hospital costs led to increases in the ICERs but the conclusion of the study did not
change.
Conclusion: FBT is the most cost-effective among treatment arms, whereas AFT was not cost-
effective compared to no intervention. Further research is required to verify this result.
K E YWORD S
adolescent-focused treatment, anorexia nervosa, eating disorder, family-based therapy, health
economics
1 | INTRODUCTION
Anorexia nervosa (AN) is a serious mental disorder with substantial
impairment in health-related-quality of life, medical morbidity, and the
highest mortality of any psychiatric disorder (Arcelus, Mitchell, Wales,
& Nielsen, 2011; Jenkins, Hoste, Meyer, & Blissett, 2011; Zipfel, Giel,
Bulik, Hay, & Schmidt, 2015). In comparison to other types of eating
disorders (EDs), patients with AN have significantly elevated healthcare
utilization and higher healthcare costs (Agh et al., 2016), primarily due
to the extent that individuals with AN require hospitalization (Agras
et al., 2014; Madden et al., 2015; Striegel-Moore, Leslie, Petrill, Garvin,
& Rosenheck, 2000).
Family-based treatment (FBT) is the most evidence-based treat-
ment for adolescents with AN (Watson & Bulik, 2013) supported by
national treatment guidelines in the USA, UK, and Australia (Hay et al.,
2014; Watson & Bulik, 2013). The most recent meta-analysis found†Deceased 04 June 2017.
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that FBT was superior to individual treatment in achieving remission at
6–12 months follow-up (Couturier, Kimber, & Szatmari, 2013), with
individual treatment consisting of adolescent-focused treatment (AFT).
Although FBT has been compared to other forms of family interven-
tions (Agras et al., 2014; Eisler et al., 2000; Le Grange et al., 2016), and
different durations of FBT have been compared (Lock, Agras, Bryson, &
Kraemer, 2005), it is noteworthy that no significant differences in out-
comes have been found. Importantly, there is limited evidence regard-
ing direct head-to-head comparisons between other types or versions
of FBT and individual treatment (Couturier et al., 2013).
Whether FBT or AFT is cost-effective when it is implemented at a
population level is of relevance to decision-makers including health
providers and their funders. To our knowledge, such information is
rarely reported, although some studies have undertaken economic eval-
uations of psychotherapy for AN alongside clinical trials. In particular, a
recent study from Agras et al. (2014) suggested that the average cost
of FBT treatment plus hospitalization at the end of treatment per indi-
vidual was US$10,000 less than systemic family therapy. Byford et al.
(2007) demonstrated that specialist out-patient treatment was more
effective and less costly than both psychiatric inpatient and treatment
as usual (TAU) for AN treatment. However, both studies’ results did
not reach statistical significance.
The objective of this study was to represent the modeled popula-
tion cost-effectiveness analysis of FBT for adolescents with AN relative
to individual treatment (in this case, AFT) or no intervention within the
Australian healthcare system. This study aims to provide a comprehen-
sive economic evaluation to address whether FBT provides value-for-
money when implemented at the population level.
2 | METHOD
The analytical methods used in this study are based on a standardized
technical methods developed as part of the assessing cost-
effectiveness approach that has been developed to help improve the
comparability of cost-effectiveness of different interventions across
different mental disorders in Australia (Carter et al., 2008; Mihalopou-
los, Carter, Pirkis, & Vos, 2013; Whiteford, Harris, & Diminic, 2013).
This study also adheres to the guidelines reported in the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) (Husereau
et al., 2013). The main objective of this study was to evaluate the cost-
effectiveness of different interventions that could be used to reduce
the burden of mental disorders as measured by the most recent burden
of disease studies (Whiteford, Ferrari, & Degenhardt, 2016). Thus, a
cost-utility analysis framework was used, expressing outcomes as
disability-adjusted life-years (DALYs). DALY is a measure reflecting bur-
den of disease that captures the impact of premature deaths and years
of healthy life lost due to ill-health or disability (Vos et al., 2015). In the
other words, total DALYs averted were estimated as the difference
between total DALYs within each arm, which accounts for the years of
life lived with a disability (YLDs) and number of life years lived via a
reduction in excess deaths attributable to AN. To calculate the preva-
lent YLD, the prevalence rate was multiplied by the most recent Global
Burden of Disease (GBD) disability weight (Salomon et al., 2015).
This study adopted the perspective of the health system, and
included costs and benefits accruing to individual patients, health care
providers, and third-party payers. Productivity costs (i.e., costs of
decreased productivity at the workplace) were excluded as they fall
beyond the health system and there is also limited evidence regarding
how these costs are incurred by patients and families of adolescents
with AN. The costs of unrelated diseases resulting from increased life
expectancy were also excluded. Parents’ time and travel costs to attend
treatment sessions were excluded in the base case but reported as a
secondary analysis. To adjust the time preference for the costs and
benefits of a decision, by providing present value, all costs and benefits
were discounted at 3% per annum, as recommended by Husereau et al.
(2013). All costs were measured in Australian dollars and expressed in
2013 dollar values using published health price deflators from the Aus-
tralian Institute of Health and Welfare when appropriate (Australian
Institute of Health & Welfare, 2015).
Results of this study were presented as incremental cost-
effectiveness ratios (ICERs), which are calculated as the difference in
total costs between alternative interventions divided by the difference in
DALYs averted. In the other words, the ICER refers to the cost to gener-
ate an additional averted DALY by the intervention relative to the com-
parator. To determine whether the ICER is acceptable, it is compared to
a cost-effectiveness willingness-to-pay threshold that represents the
highest acceptable cost per additional averted DALY. This study used a
cost-effectiveness willingness-to-pay threshold of AU$50,000 per DALY
averted, which has been used in previous Australian economic evaluation
studies (Carter et al., 2008; Vos et al., 2010).
2.1 | Intervention descriptions
FBT was chosen for this economic evaluation given the strongest evi-
dence of efficacy and effectiveness for adolescents with AN (Couturier
et al., 2013). Included within the evaluation were family therapies that
utilized the FBT manual (Lock & Le Grange, 2013), and those that
adhered to the same core principles (i.e., Maudsley family therapy
[Eisler, 2005] or behavioral family system therapy [Robin et al., 1999]).
Hereafter, these are collectively referred to as FBT. In brief, the inter-
vention promotes parental control of weight restoration while enhanc-
ing family functioning as it relates to adolescent development (Lock
et al., 2010). The intervention is delivered by a psychologist in a face-
to-face format, with 24 sessions of 60 min (Lock et al., 2010; Russell,
Szmukler, Dare, & Eisler, 1987). Parents are required to attend all
sessions together with their adolescent.
AFT is the most frequently comparator to FBT in the literature.
Briefly, this is a psychodynamically informed individual psychotherapy
focusing on enhancing autonomy, self-efficacy, individuation, and
assertiveness while also including collateral parent meetings to support
individual treatment (Lock et al., 2010; Robin et al., 1999; Russell et al.,
1987). In this study, AFT included individual therapies that followed
the same core principles, referred to as ego-orientated individual
therapy (Robin et al., 1999). Similar to FBT, this intervention is also
delivered by a psychologist, in a face-to-face format but with 32
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sessions of 45 min. Parents are required to attend separately with
adolescents in 8 sessions (Lock et al., 2010).
Another comparator arm included in this study was no interven-
tion. We defined no intervention as adolescents with AN who did not
receive any treatment except hospitalization if needed.
2.2 | Eligible population for the intervention
The target population for the interventions in the model was the 2013
Australian population of adolescents aged 11–18 years and diagnosed
with AN. According to the literature, FBT is most effective in adolescents
with less than three-year duration of disease (Couturier et al., 2013).
Approximately 71% of adolescents diagnosed with AN were assumed to
meet this criteria. This proportion was sourced from the literature (Mor-
gan, Purgold, & Welbourne, 1983; Morgan & Russell, 1975). Given that
individuals with diagnosable ED have low levels of help seeking for an
ED-specific treatment, 50% of those were assumed to receive the inter-
ventions (Hart, Granillo, Jorm, & Paxton, 2011; Kirk et al., 2017).
2.3 | Outcome of interventions
We updated the most recent meta-analysis of FBT for AN treatment
(Couturier et al., 2013). Although a number of randomized controlled
trials related to FBT were found from 2010 (the cutoff year of the pre-
vious review), these were all trials which compared different types of
FBT (Dimitropoulos, Farquhar, Freeman, Colton, & Olmsted, 2015; Le
Grange et al., 2016), compared FBT to systemic family therapy (Agras
et al., 2014) or different duration of inpatient stays prior to FBT (Mad-
den et al., 2015). Therefore, only three trials from the previous meta-
analysis were used to calculate the effect-size of efficacy of FBT versus
AFT.
Recovery was chosen for this economic evaluation since this study
sought to model burden reduction which required health outcome data
to be expressed as a change in the discrete number of prevalent AN
cases. It is noteworthy that there is significant inconsistency in how
recovery is defined across studies (Couturier & Lock, 2006; Lock, Cou-
turier, & Agras, 2008). Effect sizes for this outcome (expressed as a rel-
ative risk) for FBT versus AFT were calculated post-treatment and at
one-year follow-up using available data. Given the lack of intervention
effect size beyond one-year follow up, it was assumed that interven-
tion effects are reduced by 50% annually for the next 4 years (Mihalo-
poulos, Vos, Pirkis, & Carter, 2011). After that, the efficacy of FBT was
assumed to be equal to AFT. This assumption was tested in the sensi-
tivity analysis in which the decay rate was varied.
2.4 | Costing analysis
In the base case, the interventions were assumed to operate in a
“steady state,” meaning that trained staff and the necessary infrastruc-
ture are available to implement the interventions (Carter, Vos,
Barendregt, Doran, & Lopez, 2005). However, the specific training
costs for FBT and AFT were added to the intervention costs. The inter-
ventions’ costs also included the cost of Psychologist sessions (sourced
from the Medicare Benefits Schedule (Australian Government
Department of Health & Aging, 2013)) and Psychologist supervision.
The time costs for psychologists to attend training and weekly supervi-
sion were sourced from Payscale (2015).
Costs of clinical investigations were included for both FBT and
AFT interventions. Dual energy X-ray absorptiometry for bone density
was assumed to be undertaken twice: at the beginning of treatment
and one year later. Other routine investigation costs were assumed to
be conducted at the beginning of treatment. We also included the cost
of an initial GP visits to examine the adolescent and refer them to a
psychologist as the first step toward specialist treatment, and assumed
three GP visits (one 40-min visit plus two 20-min or less visits) for FBT
or AFT. In addition to the specialist service, GP visits (at least 40 min
per visit) were assumed to occur monthly during the treatment dura-
tion for active interventions.
Hospitalization costs were also included. The assumption that 36%
of adolescents requiring hospitalization in the treatment phase (early
hospitalization), was made regardless of treatment arm (Lock et al.,
2010; Madden et al., 2015). However, the length of stay was assumed
to vary across treatment arms (Hughes et al., 2014). In particular, we
assumed that each adolescent who received FBT had an average of 30
days hospitalization per year compared to 40 days per year for each
adolescent who received AFT or no intervention. These data were
retrieved from an Australian FBT implementation study which showed
that the average annual bed days per person declined by 10 days when
comparing two time points: 2 years prior to the introduction of FBT
and 2 years after the introduction of FBT (Hughes et al., 2014). The
hospitalization costs were estimated based on National Activity Based
Funding (The Independent Hospital Pricing Authority, 2014) using
Australian Refined Diagnosis Related Groups for EDs.
Parents’ time and travel costs were also included in the current
analysis. For FBT, we allocated one and a half hours of parent time to
attend a psychologist visit with their child. For AFT, only one hour was
allocated of the parent’s time to attend a psychologist visit. Regardless
of intervention type, parents were assumed to incur one hour of travel.
Travel costs were based on a standardized weighted average cost of a
trip to a health professional, similar to that reported in other mental
health economic evaluations (Lee et al., 2016; Vos et al., 2010).
The key assumptions that were made in costing the intervention
pathway are detailed in Table 1.
2.5 | Modeling health outcomes
A decision-analytic multiple-cohort Markov model (known as illness-
death model) was developed in Microsoft Excel to estimate the bene-
fits and costs across the included interventions. A time horizon of 6
years was chosen as that was the length of follow-up in the studies
evaluating the efficacy of FBT (Eisler et al., 1997; Eisler, Simic, Russell,
& Dare, 2007). The revised DisMod-II model was used to simulate how
a population cohort moves between three health states over time
(being diagnosed with AN, recovered and dead) (Supporting Informa-
tion, Figure S1) (Barendregt, Van Oortmarssen, Vos, & Murray, 2003;
Le et al., 2017). As there is limited evidence of individual heterogeneity
of intervention outcomes, more complicated models (e.g., microsimula-
tions) were considered unsuitable (Le et al., 2017). Transitions between
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health states were governed by remission rates, relapse rates, and
adjusted mortality rates.
Recovery for FBT was calculated from eight studies. Recovery for
no intervention was calculated from five natural disease or controlled
studies published from 2000 (i.e., this cutoff was selected as more
recent studies would represent more recent disease epidemiology). The
linear regression function in Excel was used to impute the remission
values if these were not available from the literature. Recovery for AFT
was calculated by dividing the recovery rates of FBT by the effect size
of FBT versus AFT as listed in Table 2. Further details are presented in
Supporting Information, Tables S2 and S3.
Relapse rates were also retrieved from the literature. Given limited
evidence about the relapse of AN in adolescents, the pooled relapse
probabilities post-treatment (42%, 95% CI: 30%–57%) and at one-year
follow up (33%, 95% CI: 24%–41%) were calculated from natural his-
tory of disease or controlled studies published from 2000 (Supporting
Information, Table S4). Relapse rates for the following year were
assumed to be equal to relapse rates at one-year follow-up.
TABLE 1 Assumptions and cost items for the interventions
Parameters Unit cost (range, if applicable) Sourced/assumption
General practitioner
visit (adolescent)
$39 per visit MBS items 3, 23, 36 (weighted average annual costs of combined services
by age group) for 20-min or less visit (Australian Government Department
of Health and Aging, 2013)
$104 per visit MBS item 44 for 40-min or more visit (Australian Government Department
of Health and Aging, 2013)
Psychologist visit (adolescent) $120 per visit MBS items 80010 and 80110 (weighted average annual costs of combined
services by age group) (Australian Government Department of Health and
Aging, 2013).
Psychologist salary $37.6 ($25.9 to $62.4) per hour Clinician Psychologist average salary from PayScale 2015
Investigation costs
DEXA bone density $102.40 MBS—item 12306, 12309, 12312, 12315 (Australian Government
Department of Health and Aging, 2013)
Electrocardiography $31.25 MBS—item 11700 (Australian Government Department of Health and Aging,
2013)
Full Blood Test $16.95 MBS—item 65070 (Australian Government Department of Health and Aging,
2013)
Liver Function Tests, Urea and
Electrolytes including Creatinine,
Calcium, Magnesium, Potassium,
Acid Phosphate, Phosphate
$17.70 MBS—item 66500 (Australian Government Department of Health and Aging,
2013)
B12 & Folate $23.60 MBS—item 66599, 66602 (Australian Government Department of Health
and Aging, 2013)
Thyroid function tests $34.80 MBS—item 66719 (Australian Government Department of Health and Aging,
2013)
Training costs
Workshop costs $888 Training Institute for Child and Adolescent Eating Disorders (Training
Institute for Child and Adolescent Eating Disorders, 2016) (using
purchasing power parity to convert USD to AUD) (OECD, 2013)
Duration of workshop 2 days equivalent to 15
working hours of psychologists
Training Institute for Child and Adolescent Eating Disorders (Training
Institute for Child and Adolescent Eating Disorders, 2016)
Supervision costs
Senior psychologist salary $75.9 ($28.4–$312.2) per hour Assumption that a senior psychologist's salary is 1.1 to 5.0 times a
psychologist's salary.
Duration of session 75 (60–90) min Expert opinion
Number of sessions 24 sessions for FBT Expert opinion
32 sessions for AFT
Parent costs
Time $23.49 per hour Mihalopoulos et al. (2015)
Travel $8.9 per trip Mihalopoulos et al. (2015)
Note. MBS5Medicare Benefit Schedule; DEXA5dual energy X-ray absorptiometry.
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Mortality rates were retrieved from the GBD 2013 study (Vos
et al., 2015). These were adjusted by the standardized mortality ratio
of 5.86 as reported in the previous meta-analysis of AN mortality rates
(Arcelus et al., 2011).
2.6 | Uncertainty and sensitivity analysis
To test the robustness of the results to the assumptions made in the
analysis, a probabilistic multivariate uncertainty analysis was under-
taken using Monte Carlo simulation. For the Monte Carlo simulation,
probability distributions related to all input parameters (e.g., remission
rates, relapse rates), disability weight and costs were incorporated into
the analysis. The incremental costs and DALYs were estimated by
rerunning the model 5000 times, whereby each time a different
draw was undertaken from the prespecified distributions. Results of
uncertainty simulations are presented on a cost-effectiveness plane
that is a quadrant of cost differences plotted against benefit differen-
ces (Briggs, 1999), in which compass direction is used to indicate the
area as north, south, east, and west. The area above the horizontal axis
(i.e., north west and north east) indicates that the intervention is more
costly while the area to the right of the vertical axis (i.e., north east and
south east) indicates that the intervention is more effective (than the
comparator). The proportion of iterations of the ICER under the
willingness-to-pay threshold of $50,000 per DALY averted was
deemed as the probability of the intervention being cost-effective. The
details of the parameters that were varied within the uncertainty analy-
sis are shown in Table 2.
Further to multivariate probabilistic uncertainty analysis, a series of
one-way sensitivity analyses were conducted to explore how different
input parameters (e.g., hospitalization and participant rates) impacted
the analysis. Two-way sensitivity analyses were also conducted to test
the impact of two parameters varying at the same time. These analyses
included equivalent effect of AFT versus no intervention combined with
population remission rates from GBD 2013 study or equivalent effect
of AFT versus no intervention with decay rate on the results. (Further
details of different sensitivity analyses are reported in Table 3.)
TABLE 2 Input parameters and uncertainty ranges used in the simulation analysis
Parameters Values Statistical distributionsb Source
Efficacy (FBT vs. AFT) RRs
Postintervention
One-year follow-up
Two-year follow-up
Three-year follow-up
Four year follow-up
1.69 (1.02, 2.80)
1.75 (1.13, 2.70)
1.37 (1.06, 1.85)
1.19 (1.03, 1.42)
1.09 (1.01, 1.21)
Lognormal Own meta-analysis of three RCTs (Lock et al.,
2010; Robin et al., 1999; Russell et al., 1987).
AN remission for FBT
Postintervention
One-year follow-up
Two-year follow-up
Three-year follow-up
Four year follow-up
Five-year follow-up
0.49 (0.36, 0.66)
0.28 (0.19, 0.41)
0.27 (0.16, 0.38)a
0.26 (0.14, 0.38)a
0.26 (0.13, 0.43)a
0.28 (0.20, 0.66)
Gamma Own meta-analysis of nine studies. Nonavailable
data were imputed by linear regression.
AN remission for no intervention
Postintervention
One-year follow-up
Two-year follow-up
Three-year follow-up
Four-year follow-up
Five-year follow-up
0.09 (0.04, 0.22)
0.15 (0.10, 0.24)a
0.17 (0.11, 0.25)
0.20 (0.11, 0.29)a
0.23 (0.12, 0.32)
0.28 (0.12, 0.66)
Gamma Own meta-analysis of four studies. Nonavailable
data were imputed by linear regression.
AN relapse
Postintervention
Follow-up
0.55 (0.36, 0.84)
0.20 (0.14, 0.26)
Gamma Own meta-analysis of five studies (post-intervention)
and one study (follow-up)
Standardized mortality ratios
Anorexia nervosa 5.86 (4.17, 8.26)
Lognormal Arcelus et al. (2011)
Disability weight of AN 0.22 (0.15, 0.31) Beta GBD 2013 study (Salomon et al., 2015)
Number of FBT/AFT sessions 24 (16.0, 46.8) Pert From 5 RCTs
Proportion of attended sessions 88% (53%, 98%) Pert From 5 RCTs
Psychologist salary $37.6 ($25.9, $62.4) Pert Payscale 2015
Senior psychologist salary $75.9 ($28.4, $312.2) Pert Expert opinion
Private costs 620% Pert Own assumption
Note. FBT5 family-based treatment; AFT5 adolescent-focused treatment; RR5 relative risk; RCTs5 randomized controlled trials; AN5 anorexia
nervosa; GBD5Global Burden of Disease.
aImputed value by linear regression.
bThe statistical distribution was chosen based on guidance from Briggs and Gray (1999) and Barendregt (2009).
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3 | RESULTS
Table 4 contains a detailed breakdown of the baseline cost-
effectiveness results. In the primary analysis in which patients’ time and
travel costs were excluded, the largest total costs were $13,383,861
(95% uncertainty interval [UI]: $11,225,374–$15,700,089) for AFT, fol-
lowed by $10,600,559 (95% UI: $8,798,924–$12,527,236) for FBT and
$9,878,893 (95% UI: $8,481,095–$11,293,603) for no intervention. In
terms of DALYs averted, relative to no intervention, FBT and AFT
accounted for 142 (95% UI: 74–225) and 65 (95% UI: 2–146) DALYs
averted, respectively. FBT averted 74 (95% UI: 26–130) DALYs com-
pared to AFT.
Base case analysis indicated that FBT was dominant (i.e., more
effective and less costly) compared to AFT with none of the uncer-
tainty iterations above the threshold of $50,000 per DALY averted. As
opposed to no intervention, FBT and AFT were more effective and
more costly in both primary and secondary analysis. The ICER of FBT
and AFT relative to no intervention were, respectively, $5,089 (95%
UI: dominant to $16,659) and $51,897 (95% UI: $21,591–$1,712,491)
per DALY averted. With a willingness-to-pay threshold of $50,000 per
DALY, FBT is 100% cost-effective, whereas AFT had a 45% chance of
being cost effective compared to no intervention. Figure 1 shows that
the uncertainty iterations mainly fell in the north-east corner of the
cost-effectiveness plane, which represents health gain at a cost for
both active interventions in the primary analysis.
In the secondary analysis, the inclusion of patients’ time and travel
costs did not change the conclusion of cost-effectiveness of FBT com-
pared to no intervention (i.e., 99% uncertainty iteration of ICER fell well
below threshold of $50,000 per DALY averted) but led to AFT having
lower probability (i.e., 21%) of being cost-effective (Table 4).
3.1 | Sensitivity analyses
The results of the sensitivity analyses are presented in Figure 2. In
brief, the sensitivity analyses demonstrated some changes in the ICER
results; however, the overall conclusion still remained that FBT was a
cost-effective choice when compared to AFT or no intervention and
that AFT was not likely to be cost effective as opposed to no interven-
tion when the willingness-to-pay threshold of $50,000 per DALY
averted was considered.
One-way sensitivity analyses found that the current evaluation
was most sensitive to hospitalization costs (scenarios 1a, 1 b, or 1c). In
Scenario 1a, in which hospitalization costs were excluded or deemed
similar across treatment arms, the ICER of FBT versus no intervention
increased to $24,829 per DALY averted yet remained well below the
willingness-to-pay threshold of $50,000 per DALY averted. Similarly,
TABLE 3 Details of sensitivity analysis
Scenarios Values (range)
1a. The hospitalization costs were excluded or they were similar across arms
1b. Hospitalization rates 0%–90%
1c. FBT had fewer days in hospital than those treated with AFT and no treatment 1–20 days
2. The effect of AFT and no treatment on remission rate were assumed to be equivalent.
3. The time horizon of the model. 2–10 years
4. The proportion of participants who had AN for <3 years 50%–100%
5. The participant rates of receiving the intervention 10%–90%
6. The remission rates were imputed by exponential regression.
For effect size between FBT versus AFT, two scenarios were proposed:
7. The decay rate. 0%–100%
8. Excluding the Russell et al.’s (1987) study in the effect size calculation since this study used less stringent
criteria for remission and the version of FBT and AFT were somewhat different compared to those in the
Robin et al.’s (1999) and Lock et al.’s (2010) studies.
Two-way sensitivity analysis included
9. The effect of AFT and no intervention on remission rate was assumed to be equivalent and the remission
rate from GBD 2013 study was used.
(Vos et al., 2015)
10. The effect of AFT and no intervention on remission rate was assumed to be equivalent and the decay
rate of effect size varied from 0% to 100%.
11. The effect of AFT and no intervention on remission rate was assumed to be equivalent and the
hospitalization costs were excluded.
12. Hospitalization rates and length of hospital stay were sourced from Lock et al. (2010) FBT: 15% versus AFT5no treatment: 37%
10 days of hospital stay were applied
for all treatment arms.
Note. FBT5 family-based treatment; AFT5 adolescence-focused treatment, GBD5Global Burden of Disease.
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the ICER of FBT versus no intervention was increased to $23,108 per
DALY averted and half of uncertainty iteration fell below the threshold
of $50,000 per DALY averted when the differences in number of hos-
pitalized days per year per person varied to one day. Other sensitivity
analyses including similar effect on remission between AFT and no
intervention (Scenario 2), variation in time horizon (Scenario 3), changes
in the proportion of adolescents who were diagnosed with AN within
3 years (Scenario 4), the proportion who agreed to receive the
interventions (Scenario 5), and use of an alternative method to predict
remission rates (Scenario 6) did not or only slightly altered the results
of the ICER of FBT versus no intervention (Figure 2). Similarly, changes
in the decay rate of the effect size or estimated effect size after exclud-
ing the Russell et al.’s (1987) study did not change the conclusion that
FBT was less costly than AFT.
Two-way analysis indicated that the ICER of FBT versus no interven-
tion was significantly increased to $47,168 per DALY averted with 56%
TABLE 4 Results of cost-effectiveness at primary and secondary analysis
Without patients’ time and travel costs
Primary analysis
With patients’ time and travel costs
Secondary analysis
Mean 95% Uncertainty interval Mean 95% Uncertainty interval
Total costs
FBT $10,600,559 $8,798,924–$12,527,236 $12,209,523 $9,849,833–$14,876,457
AFT $13,383,861 $11,225,374–$15,700,089 $14,816,404 $12,238,856–$17,740,492
No intervention $9,878,893 $8,481,095–$11,293,603 $9,878,893 $8,481,095–$11,293,603
DALYs averted
FBT versus AFT 74 26–130
FBT versus no intervention 142 74–225
AFT versus no intervention 65 2–146
Incremental cost-effectiveness ratio
FBT versus AFT Dominanta Dominant–Dominant Dominant Dominant–Dominant
FBT versus no intervention 5,089 Dominant to $16,659 $16,436 5,374–$40,452
AFT versus no intervention $51,897 21,591–$1,712,491 $73,109 $29,907–2,418,113
Probability of being cost-effective at $50,000 per DALY averted
FBT versus AFT 100% 100%
FBT versus no intervention 100% 99%
AFT versus no intervention 45% 21%
Note. FBT5 family-based therapy; AFT5 adolescent-focused therapy; DALYs5 disability-adjusted life years.
aDominant means the FBT was “cost-saving” or “more effective and less costly” than the comparators.
FIGURE 1 Cost-effectiveness plane of primary analysis with a willingness to pay threshold of $50,000 per DALY averted.
DALYs5disability adjusted life years; FBT5family-based therapy; AFT5adolescent-focused based therapy; WTP5willingness-to-pay [Color
figure can be viewed at wileyonlinelibrary.com]
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uncertainty iterations under the stated threshold willingness-to-pay in
the worst case Scenario 11, suggesting that FBT was still cost-effective
(Figure 2). In Scenario 12 where FBT reduced hospitalization rates but
not length of hospital stay (sourced from Lock et al., 2010) compared to
no intervention, the ICER was increased to $17,669, with 99% of itera-
tions of ICER falling below the threshold of $50,000 per DALY averted.
Other two-way analysis did not change the conclusion of the study.
4 | DISCUSSION
In this study, FBT was shown to be more effective at a lower cost than
AFT. On the other hand, FBT and AFT was found to be more costly than
no intervention and 100% and 45% of uncertainty iterations fell below
the value-for-money threshold of $50,000 per DALY, respectively. While
this threshold is somewhat arbitrary, it appears to be an acceptable
threshold for Australian decision-makers that has been used in a number
of previous health economic evaluations, including mental health inter-
ventions (Carter et al., 2008; Le et al., 2017; Mihalopoulos et al., 2011).
Importantly, the conclusion that FBT was cost-effective is robust in the
sensitivity analyses, even with three worst case scenarios: (a) when the
cost offsets (i.e., hospitalization costs) were excluded; (b) when people
who did not receive intervention achieved similar recovery-rates to AFT,
with or without a decay of the effect-size beyond the first year; and (c)
when a short-term effect (i.e., 2-year time horizon) was adopted. Fur-
thermore, regardless of the benefit of FBT on reduction of hospital rates
or length of stay, the conclusion that FBT remained cost-effective com-
pared to AFT or no intervention remained. Compared to AFT, in only
one scenario (excluding cost offsets), FBT had an ICER of $31 per DALY
averted or $2,370 per DALY averted (when including time and travel
costs); otherwise, FBT was the more effective and less costly choice.
Findings from this study are difficult to compare with other eco-
nomic evaluations for AN as to our knowledge, this is the first cost-
effectiveness analysis of FBT relative to AFT or no intervention using a
population-based model. Three economic evaluations have investigated
the cost-effectiveness of psychotherapy for AN. Byford et al. (2007)
used the Morgan-Russell Average Outcome Scale score as a primary
outcome and found that specialized outpatient treatment for adoles-
cents with AN (not limited to <3 years duration) including individual
cognitive behavioural therapy (CBT) and parental counselling was more
effective and less costly than inpatient treatment and TAU. Similarly,
Egger et al. (2016) showed that outpatient psychotherapies for adults
with AN, including focal psychodynamic therapy and enhanced CBT,
were found to be less costly than optimized TAU in all outcomes exam-
ined (i.e., recovery, quality-adjusted life years, BMI) from a societal eco-
nomic perspective. It is noteworthy that both of these studies were
economic evaluations conducted alongside clinical trials and that while
the results supported the cost-effectiveness of the active interventions,
the differences between groups on both costs and outcomes were not
statistically significant. Another modeled evaluation from Crow and
Nyman (2004) which examined adequate care (treatment approach
involving inpatient weight restoration to close 100% of ideal body
weight) compared to usual care, indicated that adequate care yielded
an incremental cost of US$30,180 per year of life saved. All things con-
sidered, our study compares favorably to other studies in terms of sup-
porting the cost-effectiveness of psychotherapies for AN treatment.
This study has several strengths. First, we used plausible assump-
tions which were sourced from the latest available literature, aug-
mented by expert opinion. This study also made an effort to design an
intervention pathway which was as similar as possible to routine care.
Using both uncertainty and (one-way and two-way) sensitivity analyses
helped to ascertain which variables had the largest impact on the con-
clusions. Despite the Australian context, the methods and results of
this study can be applied internationally. For instance, the intervention
pathway, intervention effect size and program training information was
based on data from high income settings such as the United States,
Europe, and Australia.
However, this study also has some limitations. First, only health-
sector related costs were included in the primary evaluation. Given
that there is insufficient evidence to model any incremental differences
relating to productivity impacts between the different interventions,
FIGURE 2 One-way and two-way sensitivity analyses of the potential cost-effectiveness of FBT intervention compared to no intervention
ICER5incremental cost-effectiveness ratio; DALY5disability-adjusted life-year; AFT5adolescent-focused treatment; No.I5no intervention
[Color figure can be viewed at wileyonlinelibrary.com]
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the partial societal perspective that included parents’ time and travel
costs was examined in the secondary analysis. It was noteworthy that
including productivity costs (should there be any such impacts) is likely
to make FBT even more cost-effective. Second, the definition of recov-
ery (and relapse) was not equivalent across studies, and recovery rates
were retrieved from individual studies instead of from head-to-head
comparison studies. This led to uncertainty in the effect size of FBT or
AFT compared to no intervention. However, in the very conservative
scenario that “no intervention” had a similar effect to AFT, the ICER of
FBT remained well below the threshold of $50,000 per DALYs averted.
It is appropriate for future research to directly test the effectiveness
and cost-effectiveness of FBT versus either AFT or no intervention.
Third, our study might overestimate that all therapists required training
for FBT and AFT. However, if the training costs are reduced in the real
world (i.e., less therapists receiving intervention training), the impact
of this would be to make FBT even more cost-effective. Finally, as
with similar simulation models, the current model used many
assumptions that might limit conclusions. For example, although this
study took into account the additional health services of GPs during
the treatment phase, other costs associated with psychiatrist visits
and/or medication usage were not captured in the model. However,
including medication costs is unlikely to change the conclusion of
this study given that these costs accounted for a very small
proportion (e.g., 3%) of total treatment costs for AN (Lock et al.,
2008). Future effectiveness studies that include an economic dimen-
sion are needed to more accurately determine an estimation of cost-
effectiveness in the treatment of AN.
5 | CONCLUSION
The economic evaluation suggests that FBT is a cost-effective treat-
ment for adolescents with AN of relatively short duration compared to
either AFT or no intervention in Australia. These results therefore sup-
port the implementation of FBT as a very cost-effective first-line family
therapy for adolescents with AN.
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Chapter 9: The cost-effectiveness of cognitive-behavioural therapy for 
bulimia nervosa   
Following on from the evaluation of the main evidence-based intervention for the treatment of 
AN, this chapter evaluates the cost-effectiveness of CBT for the treatment of BN. CBT was 
chosen as the main intervention since the most recent review and ED guidelines highlight this 
form of therapy as being the most evidence-based intervention. This cost-utility analysis was 
conducted for adults with BN who accessed CBT treatment within the Australian context. The 
study, for the first time, demonstrated CBT to be an effective and cost-effective treatment 
interventions for adults with BN with the ICER of $14,451 (95% UI: $8,762 to $35,650) per 
DALY averted. Including time and travel costs did not alter the conclusion of the study. 
However, the sensitivity analysis indicated that the intervention was not cost-effective if over 
80% of people discontinued the treatment. Similarly to FBT for AN, these results have 
important policy and practice implications regarding the current policy of publicly funding up 
to 10 psychological therapy sessions under Medicare. This chapter’s content is based on the 
following publication: 
Le LK-D, Hay P, Wade T, Touyz S, Mihalopoulos C. The cost‐effectiveness of cognitive 
behavioural therapy for treatment of bulimia nervosa in Australia. International Journal of 
Eating Disorders. 2017; 50: 1367-1377. 
The authorship statement of this publication is attached in APPENDIX 13. 
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Abstract
Objective: This study was to model the cost-effectiveness of specialist-delivered cognitive behav-
ioral therapy for bulimia nervosa (CBT-BN) compared to no intervention within the Australian
context.
Method: An illness-death model was developed to estimate the cost per disability-adjusted life-
year (DALY) averted of CBT-BN over 2 years from the healthcare perspective. Target population
was adults aged 18–65 years with BN. Results are reported as incremental cost-effectiveness
ratios (ICER) in 2013 Australian dollars per DALY averted. Uncertainty and sensitivity analyses
were conducted to test the robustness of results.
Results: Primary analysis indicated that CBT-BN was associated with greater DALY averted (0.10
DALY per person) and higher costs ($1,435 per person) than no intervention, resulting the mean
ICER of $14,451 per DALY averted (95% uncertainty interval [UI]: $8,762 to $35,650). Uncertainty
analysis indicated CBT-BN is 99% likely to be cost-effective at a threshold of $50,000 per DALY
averted. Including the patients’ time and travel costs resulted in the mean ICER of $18,858 per
DALY averted (95% UI: $11,235 to $46,026). Sensitivity analysis indicated the intervention was
not cost-effective if over 80% people discontinued treatment. Other analyses including a reduced
time horizon, increased remission rates, and 4-month effect size of CBT-BN increases the ICERs
but these ICERs remained well below under a threshold of $50,000 per DALY averted.
Conclusion: This study has demonstrated that CBT-BN for adults with BN is a cost-effective treat-
ment intervention. Further research is required to investigate the practicability of CBT-ED and the
cost-effectiveness of other formats of CBT-BN delivery.
K E YWORD S
bulimia nervosa, cognitive behavioral therapy, cost effectiveness, economic evaluation, health
economics
1 | INTRODUCTION
Cognitive behavioral therapy is currently the frontline treatment recom-
mended for people with bulimia nervosa (known as CBT-BN) (Hay,
Bacaltchuk, Stefano, & Kashyap, 2009; Polnay et al., 2014) as indicated
by treatment guidelines (APA, 2006; Hay et al., 2014; NICE 2017). CBT-
BN is superior to waitlist as well as other psychotherapies with greater
remission at post-treatment (Hay et al., 2009; Polnay et al., 2014), and
may be associated with greater improvements in quality of life compared
to other comparison interventions (Linardon & Brennan, 2017). CBT-BN
has been examined in a variety of formats, including individual, group,
guided and pure self-help, and delivery through online platforms such as
the Internet, videoconferencing, and mobile technology (Hay & Claudino,
2009). Individual therapy may be superior to group therapy with respect
to remission at the end of therapy (Polnay et al., 2014), and internet-
based CBT has only been categorized as a promising intervention sup-
ported by very low quality of evidence (D€olemeyer, Tietjen, Kersting, &
Wagner, 2013; Hay & Claudino, 2009).
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To our knowledge, there have been four published economic eval-
uations, in which three were trial-based analyses and one was modeled
evaluation examining the primary outcome as the incremental cost per
abstinent case. Koran et al. (1995) found that pharmacological treat-
ment (despiramine over 24 weeks) was less costly than CBT-BN.
Across different types of CBT-BN delivery, Crow et al. (2009) sug-
gested that the CBT intervention that was delivered by telemedicine
was less costly and had similar efficacy compared to face-to-face CBT.
Compared to stepped care, CBT-BN was less effective and more costly
(Crow, Agras, Fairburn, Mitchell, & Nyman, 2013). However, these
studies all have an important limitation in that trial conditions may not
represent intervention delivery in real-world settings, such as existing
health systems. The fourth economic study is the most recent one
from the NICE guidelines and found that the guided self-help interven-
tion was more cost-effective in comparison to CBT or no intervention
within the UK context (NICE 2017). However, this modeled evaluation
used a very conservative assumption of four month-effect of CBT-BN.
The objective of the current study was to model the population-
based cost-effectiveness of CBT-BN (face-to-face version) for adults
with BN relative to no intervention within the Australian healthcare
system. This study aims to evaluate a cost-effectiveness of CBT-BN
using the cost-utility framework to determine whether such interven-
tion provides value-for-money when implemented at the population
level in Australia.
2 | METHOD
2.1 | Analytical methods
The current study used the analytical methods which are based on
standardized technical economic modeling methods developed as part
of the Assessing Cost-Effectiveness (ACE) approach to enhance the
comparability of cost-effectiveness of different interventions across
different mental disorders in Australia (Mihalopoulos, Vos, Pirkis, & Car-
ter, 2011). The ACE technical approach is a commonly used method in
mental health economic evaluation in Australia (Carter et al., 2008; Le
et al., 2017; Mihalopoulos, Carter, Pirkis, & Vos, 2013; Whiteford, Har-
ris, & Diminic, 2013). This study also adheres to the guidelines in Con-
solidated Health Economic Evaluation Reporting Standards (CHEERS)
(Husereau et al., 2013).
We utilized a cost–utility analysis framework, expressing outcomes
as disability-adjusted life-years (DALYs), which account for the years of
life lived with a disability (YLDs) and number of life years lived via a
reduction in excess deaths attributable to BN. To calculate the preva-
lent YLD, the prevalence rate was multiplied by the most recent Global
Burden of Disease (GBD) disability weight for BN (Salomon et al.,
2015). The DALYs averted were calculated as the difference between
total DALYs within each arm (i.e., being treated with CBT-BN versus
not being treated). This study adopted a healthcare perspective that
included costs and benefits accruing to individual patients, health care
providers, and third-party payers. Other costs including productivity
costs (i.e., costs of decreased productivity at the workplace) were
excluded. Costs of unrelated diseases resulting from increased life
expectancy were also not considered in this study. While patient time
and travel costs to attend treatment sessions were not included in the
primary analysis, these were reported as a secondary analysis. As per
standard economic evaluation methodology to adjust for time prefer-
ence for the costs and benefits of a decision by providing present values,
all costs and benefits accruing beyond one year were discounted using a
3% discount rate in the base cases (Husereau et al., 2013). All costs
were measured in Australian dollars and expressed in 2013 dollar values
using published health price deflators from the Australian Institute of
Health and Welfare when appropriate (Australian Institute of Health and
Welfare, 2015). Similar to other economic evaluations (Carter et al.,
2009; Le et al., 2017), the current study assumed that the interventions
operate in a “steady state”, meaning that trained staff and the necessary
infrastructure are available to implement the interventions.
Results were presented as incremental cost-effectiveness ratios
(ICERs) which are calculated as the difference in total costs between
the two states of the world being evaluated (which in the current
instance is CBT-BN vs. no intervention) divided by the difference in
DALYs. The ICER was evaluated in relation to a cost-effectiveness will-
ingness-to-pay threshold of AU$50,000 per DALY averted which has
been used in previous Australian cost-effectiveness studies (Le et al.,
2017b; Mihalopoulos et al., 2011).
2.2 | Intervention descriptions
CBT-BN is the first-line treatment for BN recommended by international
guidelines. CBT-BN in this study was defined as being informed by a
manual which was developed by Fairburn (1993), as well as those
approaches that adhered to the same core approaches of CBT-BN, deliv-
ered as either individual or group sessions (6–10 individuals), with varied
sessions (i.e., 10–20 sessions) of 60 min (individual CBT-BN) to 90–
120 min (group CBT-BN). In Australia, CBT-BN is most usually delivered
by a Clinical Psychologist. The comparator to CBT-BN evaluated in this
study was no intervention since it was used as a wait-list comparator to
CBT in the randomized controlled trials (RCTs). The nonintervention con-
trol did not receive any contact during the period of the study. In many
respects, this comparator can be likened to a “partial null” comparator
used in the generalized cost-effectiveness framework which is part of
the ACE technical methods. This is because CBT-BN is the main inter-
vention shown to be effective for BN in high quality trials.
2.3 | Eligible population
The target population in the model was the 2013 Australian population
of adults aged 18–65 years and diagnosed with BN. The proportion of
BN patients receiving CBT-BN was assumed at 23.2% (95% confidence
interval (CI): 16.6% to 31.4%) as per Hart, Granillo, Jorm, and Paxton
(2011). The assumption was made that those who receive the treat-
ment were medically stable as assessed by general practitioners (GPs).
In those people, the assumption that 70% receive CBT-BN individual
therapy and 30% receive CBT-BN group therapy was made of by clini-
cal expert authors. The drop-out rate of 22% (range from 0 to 47%) as
reported in Hay et al. (2009) was applied and conservative assumption
1368 | LE ET AL.
that these people did not derive any health benefits, incurred some
costs related to the intervention was made. In particular, the assump-
tion that those who dropped out of the intervention received half the
number of sessions compared to those who completed the treatment
was made. Treatment completion was defined as attendance at least
75% number of sessions (based on literature (Zerwas et al., 2017) plus
clinical expert opinion in this study). Figure 1 presents the intervention
pathway.
2.4 | Effectiveness of interventions
Given the aim of this study was to model burden reduction which
required health outcome data to be expressed as a change in the dis-
crete number of prevalent BN cases, remission was chosen as the pri-
mary outcome. The Cochrane systematic review (Hay et al., 2009) was
updated to retrieve trials which evaluated CBT-BN compared to no
intervention (or waitlist) control for adults aged 18–65 years, diagnosed
with BN, and reported outcome as remission or recovery published
since 2007. Searches were conducted on PubMed and PsychINFO, and
hand searches of reference lists in included trials, review publications,
and clinical guideline practices. No trial met the inclusion criteria from
2007 to 2016, therefore, the seven trials included to calculate the
effect size for remission outcome were sourced from the Cochrane sys-
tematic review (Hay et al., 2009). It was noteworthy that there was sig-
nificant inconsistency in how remission was defined across these
studies (Williams, Watts, & Wade, 2012). In particular, remission was
defined as abstinence of binging (Griffiths, Hadzi-Pavlovic, & Channon-
Little, 1994; Lee & Rush, 1986; Telch, Agras, Rossiter, Wilfley, &
Kenardy, 1990; Wilfley et al., 1993), abstinence from purging (Agras,
Schneider, Bruce, Raeburn, & Telch, 1989), abstinence from vomiting
(Leitenberg, Rosen, Gross, Nudelman, & Vara, 1988), or not meeting
DSM-IV criteria for BN or any other eating disorder (Sundgot-Borgen,
Rosenvinge, Bahr, & Schneider, 2002). A relative risk (RR) was used to
estimate remission outcome (i.e., number of people who showed remis-
sion) between CBT-BN and WL control at post-treatment and at up to
18-month follow-up (if data were available).
Quality of the included trials was assessed through risk of bias based
on the Cochrane Collaboration criteria (Higgins & Green, 2011). The
quality-effect (QE) model was used to pool the available data since it
allows for redistribution of individual studies’ inverse variance weights
based on assessed study deficiencies (Doi, Barendregt, Khan, Thalib, &
Williams, 2015). The pooled RR of remission outcome at post treatment
was 10.05 (95% CI 2.47–40.82) for CBT-BN individual (Agras et al.,
1989; Griffiths et al., 1994) or 7.83 (95% CI 2.13–28.80) for CBT-BN
FIGURE 1 Intervention pathway: eligible population for cost-effectiveness model. *Treatment completion is defined as 75% session attend-
ance. BN 5 bulimia nervosa; CBT 5 cognitive behavioral therapy
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group (Lee & Rush, 1986; Leitenberg et al., 1988; Telch et al., 1990;Wilf-
ley et al., 1993) and at 18-month follow-up was 8.19 (95% CI: 1.56–
42.88) for combined individual and group CBT-BN (Lee & Rush, 1986;
Leitenberg et al., 1988; Sundgot-Borgen et al., 2002). Given that insuffi-
cient evidence supported the long-term ongoing effectiveness of CBT-
BN, the intervention was modeled within a 2-year time horizon. The
time horizon of 1–5 years was examined in the sensitivity analysis.
2.5 | Modeling health outcomes
A decision-analytic multiple-state Markov model was developed in
Microsoft Excel to estimate the benefits and costs of the CBT-BN inter-
ventions. The economic model adapted the revised DisMod-II model as
a simple remission-illness-death model. The model simulates the annual
transitions between three health states (being diagnosed with BN, recov-
ered and dead) for each age-sex cohort over a 2-year time horizon (Bare-
ndregt, Van Oortmarssen, Vos, & Murray, 2003). Given the insufficient
evidence of individual heterogeneity of intervention outcomes, more
complicated models (e.g., microsimulations) were considered unsuitable
(Le et al., 2017). Furthermore, this model has been used in other mental
health cost-effectiveness studies (Le, Barendregt, Hay, Sawyer, Elizabeth,
et al., 2017; Le, Barendregt, Hay, Sawyer, Paxton, et al., 2017; Lee, Y.
et al., 2016). Annual transitions between health states were governed by
epidemiological data including remission rates, adjusted mortality rates
and relapse rates. The first two parameters were sourced from the most
current GBD study 2013 (Vos et al., 2015), in which mortality rates were
adjusted by the standardized mortality ratio of 1.93 as reported in the
previous meta-analysis (Arcelus, Mitchell, Wales, & Nielsen, 2011). The
relapse rates at 2-year follow-up for BN were retrieved from Olmsted,
Kaplan, and Rockert (2005) study, which reported the relapse probability
at 19 months was 37% (ranging from 21% to 55%) subject to the defini-
tion of remission and relapse applied. The relapse rate was tested in the
sensitivity analysis in which it varied from 10% to 90%.
2.6 | Costing analysis
In the primary analysis, costs related to intervention were based on the
component activities which were identified in the pathway analysis.
These included costs of treatment such as general practitioner (GP) vis-
its or examination blood tests, the cost to deliver CBT-BN sessions
such as training costs, Psychologist’s session costs, and costs of Psy-
chologists to attend monthly supervision. The assumption was made
that those who would receive CBT-BN need to have two GP visits and
a basic examination (e.g., full blood tests, liver and urea tests). Further-
more, these patients would require a Mental Health Plan from their GP
before they are referred to Psychologists and these costs were taken
from the average cost in the 2013 of three Medicare Benefits Schedule
(MBS) item numbers (2700, 2701, and 2712). CBT-BN training costs
(2-day workshop) were sourced from the Oxford University training
centre in 2016 (converted to Australian dollars and inflated to the ref-
erence year). Costs of Psychologist sessions were sourced from the
MBS 2013 (Australian Government Department of Health and Aging,
2013). The time costs for psychologists to attend training workshop
and monthly supervision during treatment were sourced from the psy-
chologist salary from PayScale (2015).
In the secondary analysis, patients’ time and travel costs were also
included. For attending the intervention, one-hour of session and one-
hour of travel were allocated to attend a visit. Patients’ time and travel
costs were based on a standardized weighted average cost of a trip to
a health professional which is reported in other mental health eco-
nomic evaluations (Le et al., 2017,b). The key assumptions that were
made in costing the intervention pathway are detailed in Table 1.
2.7 | Uncertainty and sensitivity analysis
The uncertainty and sensitivity analysis was undertaken to investigate
the robustness of the results to the assumptions made in the primary
analysis. For the uncertainty analysis, a probabilistic multivariate analy-
sis was undertaken using Monte Carlo simulation, in which, probability
distributions related to all input parameters (e.g., remission rates,
relapse rates), disability weight and costs were incorporated into the
analysis (Table 2). To perform the Monte Carlo simulation, Ersatz soft-
ware (version 1.31, Sunrise Beach, Australia; http://www.epigear.com/)
was used to re-run the model 3000 times whereby each time a differ-
ent draw was undertaken from the pre-specified distributions. Results
of uncertainty simulations are presented on a cost-effectiveness plane
that plotted cost differences against benefit differences (Briggs, 1999;
Briggs & Fenn, 1998).
In addition to uncertainty analysis, a series of one-way sensitivity
analyses were to evaluate the impact of different input parameters
(e.g., participant rates, relapse rates) on the primary analysis results.
One-way sensitivity analysis included a variety of scenarios, summar-
ized in Table 3.
3 | RESULTS
3.1 | Cost effectiveness
Table 4 contains a detailed breakdown of the baseline cost-
effectiveness results. In the primary analysis, the total costs of CBT-BN
were $22,555,613 (95% uncertainty interval (UI): $16,357,399 to
$30,197,610). In consideration of patients’ time and travel costs, the
total costs of CBT-BN were $29,435,311 (95% UI: $20,283,349 to
$41,149,962). The intervention averted 1,561 DALYs (95% UI: 607 to
2609) compared to no intervention. Primary analysis indicated that
CBT-BN is a cost-effective intervention for adults with BN at $14,451
per DALY saved (95% UI $8,762 to $35,650) with 99% of the uncer-
tainty iterations under the threshold of $50,000 per DALY averted.
Inclusion of the patients’ time and travel costs resulted in the ICER of
$18,858 per DALY averted (95% UI: $11,235 to $46,026) and the
intervention is 98% likely to be cost-effective under the threshold of
$50,000 per DALY averted (Figure 2).
3.2 | Sensitivity analysis
The results of the sensitivity analysis are detailed in Figure 3. In brief,
the one-way sensitivity analyses demonstrated some changes in the
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TABLE 1 Assumptions and cost items for the interventions
Parameters Unit cost (range, if applicable) Sourced/assumption
General Practitioner visit (adults) $40.35 per visit MBS items 3, 23, 36 (weighted average annual costs of
combined services by age group) for 20-min or less visit
(Australian Government Department of Health and
Aging, 2013)
Mental Health Plan—GP $76.12 per visit MBS item 2700, 2701, and 2712 for a visit (weighted
average annual costs of combined services by age
group) (Australian Government Department of Health
and Aging, 2013)
Psychologist visit—Public funded
(adults)
Individual
Group
$120 per visit (45–75 min)
$30.33 per person per visit
(over 1 h)
MBS items 80010 and 80110 for individual and items
80120 and 80020 for group (weighted average
annual costs of combined services by age group).
(Australian Government Department of Health and
Aging, 2013)
Psychiatrist visit—public funded
Individual
Group
$178.01 per visit (45–75 min)
$57.46 per person per visit
(over 1 h)
MBS items 306, 316, and 319 for individual session and
342, 344, and 346 for group session (weighted average
annual costs of combined services by age group).
(Australian Government Department of Health and
Aging, 2013)
Psychologist visit—private funded
Individual
Group
$235 per visit (46–60 min)
$88 per person per visit
(91–120 min)
Recommended fees from Australian Psychology Society
(2015)
Psychiatrist visit—private funded
Individual
Group
$270 per visit (45–75 min)
$88 per person per visit
Psychiatrist — individual cost per visit was the average
psychiatrist fees in 2014–2015 (Royal Australian and
New Zealand College of Psychiatrists, 2017). Psychia-
trist—group cost was assumed to be equivalent cost of
private psychologist group.
Psychologist salary $37.6 ($25.9 to $62.4) per hour Clinician Psychologist Salary (PayScale, 2015)
Investigation costs
Electrocardiography $31.25 per test MBS—item 11700 (Australian Government Department of
Health and Aging, 2013)
Full blood test $16.95 per test MBS—item 65070 (Australian Government Department of
Health and Aging, 2013)
Liver function tests, urea and electro-
lytes including creatinine, calcium,
magnesium, potassium, acid phos-
phate, phosphate
$17.70 per test MBS—item 66500 (Australian Government Department of
Health and Aging, 2013)
Training costs
Workshop costs $546 per person Oxford Cognitive Therapy Center (2016) (using purchasing
power parity to convert GBP to AUD) (OECD, 2013)
Duration of workshop 2 days equivalent to 15 working-
hours of a therapist
Oxford Cognitive Therapy Center (2016)
Training book $60 (Book Depository, 2017)
Supervision costs
Senior psychologist salary $75.9 ($28.4 to $312.2) per hour Assumption that senior psychologist has 1.1 to 5.0 times
psychologist salary.
Duration of session 75 (60–90) min per supervision
group (which include 2–4 psy-
chologist).
Expert opinion
Number of sessions 4–6 sessions Expert opinion
Time and travel costs
Time $23.49 per hour Mihalopoulos et al. (2015)
Travel $8.9 per trip Mihalopoulos et al. (2015)
Note. MBS 5 Medicare Benefit Schedule; min 5 minutes; GBP 5 British Pound; AUD 5 Australian Dollar.
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ICER results, however, the overall conclusion still remained that CBT
was a cost-effective choice when it is implemented at the population
level. The current evaluation was most sensitive to the completion rate
of the treatment group. The ICER increased to above the threshold of
50,000 per DALY averted when over 80% participant did not adhere
to the treatment. Other sensitivity analyses including one-year time
horizon, increase remission rates triple times, and 4-month effect size
of CBT-BN altered the results to increase significantly the ICER of
CBT-BN (i.e., $41,138 to $43,593) but these ICERs remained well
below under threshold of 50,000 per DALY averted (i.e., over 90% of
uncertainty iterations under the threshold of $50,000 per DALY
averted). Delivering CBT-BN by Psychologists in a private setting or
Psychiatrist in a public or private setting increased the ICER range from
$28,640 to $34,521, but the probability of CBT-BN being cost-
effective remained over 90%.
4 | DISCUSSION
In an Australian health care context, CBT has previously been found to
be a cost-effective treatment of choice for several mental disorders,
e.g., major depression, generalized anxiety disorder and panic disorder
(Haby, Tonge, Littlefield, Carter, & Vos, 2004; Heuzenroeder et al.,
2004; Vos, Corry, Haby, Carter, & Andrews, 2005). This study, to our
knowledge, is the first study that supports the cost-effectiveness of
CBT for adults with BN when it is implemented at a population level in
Australia. Compared to the most common willingness to pay threshold
of $50,000 per DALY averted in Australia, CBT-BN was 99% likely to
be cost-effective. Although this threshold is somewhat arbitrary, it
appears to be an acceptable threshold for Australian decision-makers
that has been used in a number of previous health economic evalua-
tions, including mental health interventions (Le et al., 2017; Mihalopou-
los et al., 2011; Vos et al., 2010). Having said that, the probability of
CBT-BN to be cost effective remains over 90% unless the threshold
under $25,000 per DALY averted is used. Regardless of whether CBT-
BN was delivered by a Psychologist or Psychiatrist, it was demon-
strated to be cost-effective, with the lowest costs when delivered by a
public Psychologist. Delivering CBT-BN by Psychiatrists publicly or pri-
vately was found to be more cost-effective than by private Psycholo-
gists because there were no supervision costs for Psychiatrists
(Psychology Board, 2009). Sensitivity analysis supported the robustness
of the results except that the intervention became not cost-effective if
over 80% patients discontinued the treatment. This implies that retain-
ing patients in treatment is an important factor impacting the cost-
effectiveness of CBT-BN. Outcomes in the real world setting may be
TABLE 2 Input parameters and uncertainty ranges used in the simulation analysis
Parameters Values Statistical distributionsa Source
Efficacy (RRs)
– Post intervention
1 Individual CBT
1 Group CBT
– 18-month follow up
10.05 (2.47, 40.82)
7.83 (2.13, 28.80)
8.19 (1.56, 42.88)
Lognormal Own meta-analysis of seven RCTs
(Agras et al., 1989; Griffiths et al.,
1994; Lee & Rush, 1986; Leitenberg
et al., 1988; Sundgot-Borgen et al.,
2002; Telch et al., 1990; Wilfley
et al., 1993)
AN relapse 0.23 (0.12, 0.40) Gamma Olmsted et al. (2005)
Standardized mortality ratios
– Anorexia nervosa 1.93 (1.44, 2.59)
Lognormal Arcelus et al. (2011)
Disability weight of BN 0.22 (0.15, 0.31) Beta GBD 2013 study (Salomon et al.,
2015)
Number of CBT sessions
1 Individual
1 Group
15 (10, 20)
14.8 (10, 20)
Pert From seven RCTs and expert opinion
Proportion of attended session
1 Individual
1 Group
88.3% (75–100%)
88.3% (75–100%)
Pert From seven RCTs, listed above.
Proportion of taking up CBT 23.2% (16.6%, 31.4%) Pert Hart et al. (2011)
Proportion of drop out 22% (0%, 47%) Pert Expert opinion
Number of supervision 5 (4, 6) Pert Expert opinion
Number of psychologist per super-
vision group
3 (2, 4) Pert Expert opinion
Psychologist salary $37.6 ($25.9, $62.4) Pert Payscale 2016
Senior psychologist salary $75.9 ($28.4, $312.2) Pert Expert opinion
Private costs 620% Pert Own assumption
Note. CBT 5 cognitive behavioral therapy; RR 5 relative risk; RCTs 5 randomized controlled trials; BN 5 bulimia nervosa; GBD 5 global burden of
disease.
aThe statistical distribution was chosen based on guidance from Briggs, A. H. and Gray (1999) and Barendregt (2009).
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compromised as the Australian Medicare system only funds up to 10
psychotherapy treatment sessions with a psychologist annually despite
the manualized CBT-BN recommending 15–20 sessions. Preliminary
research indicates the practicability of the current form of CBT-BN in
real world settings (Banasiak, Paxton, & Hay, 2005; Byrne, Fursland,
Allen, & Watson, 2011), including the use of shorter interventions such
as guided self-help interventions (NICE 2017).
Findings from this study were in line with other results to support
the cost-effectiveness of CBT-BN for other mental disorders in Aus-
tralia (e.g., depression and anxiety) although our ICER is higher than
those reported in these studies (Haby et al., 2004; Heuzenroeder et al.,
2004; Vos et al., 2005). This might be because this study conservatively
included training costs and supervision costs associated with CBT-BN,
plus the disability weights used for the various diseases varied substan-
tially. It is difficult to compare our results in the base-case with other
cost-effectiveness studies of CBT-BN given different contexts and set-
tings, different examined outcomes, different comparators and differ-
ent assumptions in the model (Crow et al., 2009, 2013; Koran et al.,
1995; NICE 2017). However, our conclusion that CBT-BN is a cost-
effective intervention is contrary to the conclusion of the published
economic model from the NICE guidelines (NICE 2017). There are sev-
eral reasons for this difference. First, seven trials were included to esti-
mate the between group effect size of CBT compared to waitlist
control, but only two of these studies (Lee & Rush, 1986; Leitenberg
et al., 1988) were included in the NICE network meta-analysis (i.e.,
study from Sundgot-Borgen et al. (2002) was excluded due to “no criti-
cal outcomes” whereas other four studies (Agras et al., 1989; Griffiths
et al., 1994; Telch et al., 1990; Wilfley et al., 1993) were not mentioned
in the guidelines) (NICE 2017). Second, the NICE economic model used
a four-month effect size with one-year time horizon versus the 18-
month effect size with two-year time horizon in our model. Third, NICE
assumed the use of booster therapy for those who remitted at the end
of treatment but relapsed within one-year follow up. Fourth, NICE
used QALY as an outcome versus DALY in our study. However, in the
worst case scenario, when modeling a time horizon of one year with
only an end of treatment impact (i.e., four months), our study reached
the same conclusion as the NICE guidelines (result was not shown).
Given that CBT has been demonstrated to maintain a long-term effect
until 18-month follow-up (Sundgot-Borgen et al., 2002), and indeed
TABLE 3 Details of scenarios in the sensitivity analysis
Scenarios Values (range)
1. Participant rates of receiving
the intervention
10–90%
2. Proportion of participants who
receive individual CBT.
0–100%
3. Drop-out rates 0–90%
4. Relapse probability annually
for BN
10–90%
5. The CBT intervention was
delivered by psychiatrist
publicly funded.
Individual CBT-BN
Group CBT-BN
$178.01 per visit (45–75 min)
Group: $57.46 per person per
visit (over 1 h)
[sourced from the Medicare
Benefit Schedule (2013)]
6. The CBT intervention was
delivered by Psychologist
privately funded.
Individual CBT-BN
Group CBT-BN
$235 per visit (46–60 min)
$88 per person per visit
(91–120 min)
[sourced from the Australian
Psychology Society
(2015)]
7. The CBT intervention was
delivered by Psychiatrist
privately funded.
Individual CBT-BN
Group CBT-BN
$270 per visit (45–75 min)
$88 per person per visit
(sourced from Royal Australian
and New Zealand College of
Psychiatrists (2017))
8. Time horizon 2–5 years
9. Remission rates Decrease/increase triple times
Note. CBT 5 cognitive behavioral therapy; BN 5 bulimia nervosa.
TABLE 4 Results of cost-effectiveness at primary and secondary analysis
Primary analysis
without patients’ time and travel costs
Secondary analysis
with patients’ time and travel costs
Mean 95% Uncertainty interval Mean 95% Uncertainty interval
Total costs
CBT $22,555,613 $16,357,399 to $30,197,610 $29,435,311 $20,283,349 to $41,149,962
DALYs averted
CBT versus No-I 1,561 607 to 2,609 1,561 607 to 2,609
Incremental cost-effectiveness ratio ($per DALY averted)
CBT versus No-I $14,451 $8,762 to $35,650 $18,858 $11,235 to $46,026
Probability of being cost-effective at $50,000 per DALY averted
CBT versus No-I 98.9% 98.0%
Note. CBT 5 cognitive behavioral therapy; No-I 5 no intervention; DALYs 5 disability adjusted life years.
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some studies showed a five-year impact (Fairburn, Jones, Peveler,
Hope, & O’Connor, 1993; McIntosh, Carter, Bulik, Frampton, & Joyce,
2011), assumption of four-month effect might be very conservative.
The current study adds to the existing economic evaluations of CBT
for BN treatment. The sensitivity analysis indicated CBT-BN might be
more cost-effective if it is delivered via a group therapy modality. How-
ever, this result should be interpreted with some caution given that the
drop-out rates between group and individual CBT-BN were assumed to
be equivalent, and there are fewer studies examining group format. The
current study, unfortunately, is limited to the examination of the “original”
CBT-BN compared to no intervention. Other versions or formats of CBT
were not evaluated, including the enhanced version (CBT-E), which has
been demonstrated to be a promising intervention for BN (Agras,
Fitzsimmons-Craft, & Wilfley, 2017; Groff, 2015). However, CBT-E also
involves additional modules, training and is also delivered over 20 ses-
sions, which might incur more out-of-pocket costs to the patients given
the reimbursement of 10 psychotherapies session annually from Medi-
care. As a result, it might reduce the adherence of the intervention.
Technology-based CBT might be a cost-effective alternative for BN treat-
ment especially where access to specialist therapists is precluded by dis-
tance and/or cost (Hay & Claudino, 2009). Further research is needed to
examine the effectiveness and cost-effectiveness of such interventions.
The study’s model had a number of limitations or assumptions.
First, our analysis used DALYs as an outcome to enhance the compara-
bility of the interventions across mental disorders in Australia. Any
health benefits associated with interventions for ED have to impact the
prevalence of existing disease since there is no scope to model altera-
tions in severity of illness using the GBD DALY weights (there is only
one weight for BN as compared to severity weights for other mental
disorders such as anxiety and depression) (Whiteford, Ferrari, & Degen-
hardt, 2016). It must therefore be appreciated that the current study is
likely to underestimate the health burden averted by such interventions
FIGURE 2 Cost-effectiveness plane of primary and secondary analysis of CBT versus no intervention within the Australian context with a
willingness to pay threshold of $50,000 per DALY averted. DALYs 5 disability adjusted life years; CBT 5 cognitive behavioral therapy;
WTP 5 willingness-to-pay [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 One-way sensitivity analyses of the cost-effectiveness of CBT intervention. *Base case ICER as $14,451 per DALY averted.
DALYs 5 disability adjusted life years; CBT 5 cognitive behavioral therapy; ICER 5 incremental cost-effective ratio. [Color figure can be
viewed at wileyonlinelibrary.com]
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by not accounting for changes in illness severity (Le et al., 2017). This
study also used the epidemiological data from the GBD 2013 study
which pooled all data available for a given disorder into a weighted
average, while simultaneously adjusting for known sources of variability
in estimates reported across studies (Whiteford et al., 2016). However,
sensitivity analysis indicated that varied remission rates, for example,
did not alter the conclusion of the study. Furthermore, since the cur-
rent study used a meta-analysis of trials, in which remission is not con-
sistently defined there is unknown with the impact of this
inconsistency on the effect size of CBT (Williams et al., 2012). Given
that more recent studies no longer use a waiting list control, the pooled
effect-size was based on the early controlled trials that might not
reflect accurately current treatment approaches. Finally, our study
assumed the intervention to be in steady state and therefore did not
include any infrastructure costs in the analysis. It is noteworthy that
such costs in the public sector can be quite high, as they tend to not be
included in therapist costs, and also differ from such costs in the pri-
vate sector where costs are factored into fees charged.
This study also has several limitations of generalizability. First, a
limited healthcare perspective was adopted, as opposed to a more
comprehensive societal perspective (i.e., including productivity costs).
Given insufficient evidence to model any incremental differences relat-
ing to productivity impacts between the different interventions, this
study applied a partial societal perspective in the secondary analysis in
which patients’ time and travel costs were included. However, taking
into account productivity costs would likely make CBT-BN even more
cost-effective given significant associations of binge eating and dimin-
ished work productivity (Striegel, Bedrosian, & Wang, 2012). Second,
the generalizability of this finding to other high-income countries is
probably reasonable although it would depend on what the cost of
delivering the intervention in in other settings since the epidemiology
of EDs between countries is not likely to be substantially different.
5 | CONCLUSION
In the current study, CBT-BN was demonstrated to be a cost-effective
intervention for adults with BN. This finding therefore further supports
CBT-BN as a first-line treatment. The results of this study may be used
to inform future policy in ED health services in Australia and elsewhere.
Findings indicated adherence to CBT-BN is an important factor which
impacts cost-effectiveness thus ensuring people with BN remain in
treatment is vital to ensuring the intervention achieves cost-
effectiveness in routine health service conditions. Given that research
is growing for other types or formats of CBT, further research on the
cost-effectiveness of these is required. Long-term effectiveness of
CBT-BN also warrants more evaluation, as well as the effectiveness of
shorter CBT-BN interventions.
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Chapter 10: Discussion and conclusion 
10.1. Introduction 
The overall objective of this thesis is to examine the cost-effectiveness of evidence-based 
interventions for the prevention and treatment of EDs to inform decision-makers about whether 
such interventions provide value-for-money within the Australian context. This body of work 
began with a literature review to determine which interventions are effective and cost-effective 
for the prevention and treatment of EDs. Following that, a systematic review of EEs of 
preventive and treatment interventions of EDs was undertaken (Chapter 4). Given that there 
was a need for updating the literature for ED preventive interventions, a systematic review and 
meta-analysis was undertaken for all types of preventive interventions for EDs by categorizing 
the interventions based on the strategies of the target population as universal, selective or 
indicated prevention (Chapter 6). A series of cost-effectiveness studies for the prevention and 
treatment of EDs (i.e. AN and BN) were subsequently undertaken, in which, high-quality and 
standardised EE techniques were applied. 
This chapter summarizes the main findings of this empirical work in the next section (section 
10.2), followed by the discussion about the significance of the thesis contribution and 
implications of the thesis findings for decision-makers (section 10.3). Limitations and strengths 
of the thesis (section 10.4) and directions for future research (section 10.5) are also discussed. 
Finally, the thesis conclusions are presented (section 10.6). 
10.2. Main findings 
10.2.1. RQ1: What is the existing evidence of cost-effectiveness for preventive and 
treatment interventions for eating disorders? 
Findings from the systematic review of the cost-effectiveness of the preventive and treatment 
interventions for ED found a growth of cost-effectiveness studies for ED prevention and 
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treatment compared to the previous review (Stuhldreher et al. 2012). Even though there was a 
doubling of studies identified in this new review conducted as part of the current thesis, there 
were still a limited number of studies. Thirteen cost-effectiveness studies (including one study 
from Chapter 7) were identified. Four studies focused on ED prevention whereas the remaining 
studies examined the treatment of ED (Le, Hay & Mihalopoulos 2017). Importantly, at the 
onset of this PhD, limited studies exploring the cost-effectiveness of evidence-based 
interventions for EDs (for example, CD for prevention, FBT for AN treatment, CBT for BN 
treatment) existed. Furthermore, the existing evidence was largely comprised of trial-based 
economic evaluations. This indicates a significant gap in the existing evidence of cost-
effectiveness. Consequently, there is little and insufficient information on which to base 
policymakers’ decisions about allocation of resources in this important area (Weissman & 
Rosselli 2017).  
Whilst the majority of studies indicated that preventive and treatment interventions for ED 
were cost-effective, there was no consistent recommendation as to which interventions offered 
value-for-money. Comparability of results between existing studies was also limited, given the 
variability in study quality. Despite increasing in the number of published studies examining 
cost-effectiveness of ED interventions, the existing body of literature suffers from some 
methodological issues. Particularly, there is insufficient information regarding the 
measurement of resources in the existing studies. Furthermore, there was little justification of 
analytical methods used in the EEs. 
Another important finding was that few modelled EEs for treatment of EDs exist. All of cost-
effectiveness studies of preventive interventions were modelled EEs whereas only two out of 
nine studies of treatment interventions used modelling techniques (Ágh et al. 2016b; Crow & 
Nyman 2004). This may be because modelled EEs are most appropriate for preventive 
interventions due to the requirement of extrapolation of interventions’ benefits and costs over 
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a longer time horizon. Modelled EEs are useful for treatment interventions where the full 
relevant evidence-base (e.g. pooled effect size) needs to be considered. It is noteworthy that 
synthesis of clinical effectiveness data (in both prevention and treatment) should be presented 
adequately in the modelled cost-effectiveness studies and that the existing studies did not 
appear to do this. 
10.2.2. RQ2: What are the effectiveness and cost-effectiveness of preventive interventions 
for eating disorders? 
10.2.2.1. The effectiveness of preventive interventions for EDs 
Research for ED prevention started early in the 20th century and has grown significantly over 
the past two decades. There was a significant need for an updated review and meta-analysis of 
preventive interventions given the gap in the existing evidence base (Chapter 6). At the same 
time as the systematic review of this thesis was being conducted, another independent research 
team published a very similar review (Watson et al. 2016). However, the review of this thesis 
had a broader scope and approach compared to all other reviews so far (including the Watson 
et al. 2016 review). Firstly, the current review undertaken as a part of this thesis included all 
types of preventive interventions, including the obesity-prevention interventions which might 
be effective in the prevention of EDs and obesity (Austin et al. 2007). Secondly, the review in 
this thesis included a meta-analysis for all universal, selective and indicated prevention using 
the most updated quality effect estimator to pool the effect size. Finally, the review also 
examined the impacts of different perspectives in the categorisation of preventive interventions 
as universal, selective or indicated prevention on the results.  
Findings of this review (Chapter 6) suggest that several interventions (CD, CBT or Healthy 
Weight interventions) which were delivered as selective prevention were found to effectively 
reduce ED risk factors/behaviours and/or symptoms. CD interventions were most effective in 
selective prevention, with small to moderate effect on a number of risk factor outcomes 
169 
 
including dieting, thin-ideal internalization, body dissatisfaction and negative affect. 
Furthermore, the effect of these interventions on thin-ideal internalization was maintained at 
up to three-year follow-up. Importantly, CD interventions were the only interventions which 
significantly reduced ED symptoms (measured by diagnostic interview or questionnaire 
reflecting the broader array of disordered eating). Healthy weight interventions were found to 
significantly reduce ED risk factors with small effect sizes (e.g. dieting and thin-ideal 
internalization) and BMI with large effect sizes. This indicated a potential “dual-effect” of 
these interventions for prevention of EDs and obesity. CBT effectively reduced dieting, body 
dissatisfaction and bulimic symptoms with small to moderate effect sizes. 
This review found that universal preventive interventions had small to moderate effect sizes in 
the reduction of ED risk factors. ML interventions were most promising with positive 
improvement in ED risk factors for both male and female adolescents. There was no evidence 
for indicated prevention given the limited quantity of studies. However, when using a less strict 
classification of indicated prevention where participants were screened for ED symptoms 
and/or behaviours, CBT might be a choice for indicated prevention (Chapter 6). 
One noticeable finding was that the majority of clinical data of ED prevention interventions 
did not explicitly measure whether preventive interventions actually lower ED onset (Chapter 
6). This is a considerable gap in the existing evidence base for ED prevention. Having said that, 
a challenge in ED prevention (especially universal prevention) requires very large and more 
representative samples with an appropriately long follow-up to provide sufficient statistical 
power regarding the onset of new cases (Cuijpers, Smit & Van Straten 2007). Focusing on ED 
risk factors and behaviours is reasonable for a preventive program, however many people with 
ED risk factors or behaviours never progress to developing an ED. For example, many people 
experience body dissatisfaction without progression to development of an ED (Wilksch 2017). 
The lack of evidence on whether preventive interventions are effective in reducing the onset of 
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new ED cases therefore raises the question of where ED prevention is best targeted and to 
whom (Le et al. 2017a; Watson et al. 2016; Wilksch 2014).  
Table 5 contains a summary of the economic evaluation results for the prevention and treatment 
of ED interventions evaluated in this thesis which is related to the next three sections.
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Table 5: Summary of cost-Effectiveness results of empirical economic evaluation studies undertaken as part of this thesis (costs and health benefits 
discounted at 3%) 
Alternatives Total costs Total cost-
offsets 
Total 
DALYs 
averted^ 
ICER Probability to be cost-effective at 
threshold of $50,000 per DALYs 
Important 
factors 
Mean Lower 
limit* 
Higher 
limit* 
Primary 
analysis# 
Secondary 
analysis# 
 
CD 
Prevention of AN 
& BN 
$1,565,676 -$55,744 16 $100,363 $59,417 $164,021 0% N/A % receiving the 
intervention 
FBT 
Treatment of AN 
$10,600,559 -$9,878,893 142 $5,089 Dominant $16,659 100% 99% Hospitalisation 
costs 
AFT 
Treatment of AN 
$13,383,861 -$9,878,893 65 $51,897 $21,591 $1,712,491 45% 21% Hospitalisation 
costs 
CBT 
Treatment of BN 
$22,555,613 0 1,561 $14,451 $8,762  $35,650 99% 98% % adherence to 
the treatment 
Notes. DALYs: Disability-adjusted life years; ICER: Incremental cost-effectiveness ratio; CD: Cognitive dissonance interventions; FBT: Family-based treatments; 
AFT: Adolescent-focused treatments; CBT: Cognitive Behavioural Therapy. 
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^ DALY averted compared to no intervention.  
* Uncertainty intervals are based on 5000 uncertainty iterations (for prevention of AN & BN or treatment of AN) and 3000 uncertainty iterations (for treatment of 
BN).  
# Primary analysis: no inclusion of time and travel costs; Secondary analysis: inclusion of time and travel costs. 
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10.2.2.2. The cost-effectiveness of cognitive dissonance interventions for the prevention of AN 
and BN 
The aim of the study was to evaluate the cost-effectiveness of the most evidence supported CD 
interventions within the Australian context (Le et al. 2017c). This study, for the first time, used 
decision modelling analytic to examine the cost-effectiveness of an evidence-based 
intervention in ED prevention. Previous studies examined screening or obesity-prevention 
interventions that might not be supported by the most rigorous evidence of the literature (Le et 
al. 2017a; Watson et al. 2016). This study found that CD averted very few DALYs (i.e. 16 
(95% CI: 9 to 24) for he total intervention costs of AU$1,565,676 (95% CI: AU$1,336,190 to 
AU$1,803,168) within the period of 10 years resulting in an ICER of AU$103,980 per DALY 
averted. Under the Australian context, the intervention was not considered to be cost-effective 
at a willingness-to-pay threshold of either AUD$50,000 or AUD$100,000 per DALY averted. 
The ICER in this cost-effectiveness study is higher than those in other studies (Wang, Nichols 
& Austin 2011; Wright et al. 2014). A possible reason for this was the inclusion of screening 
costs (due to selective prevention) and the low participant rates engaging in the active 
intervention. Findings from the thesis are different to that of Akers et al. (2017) (published at 
the same time with our study) who found CD intervention to be potentially cost-effective with 
the reported ICER of US$838 per at-risk person reducing eating disorder symptomology to a 
clinically meaningful degree13. It is unclear whether this finding represents value for money 
given that the study frame is a cost-effectiveness study whereby there is no inherent value-for-
money threshold for such a clinical outcome. Secondly, this economic evaluation failed to 
incorporate all relevant evidence, but rather used data from one clinical trial (Stice et al. 2013a). 
                                                 
13 Participants attained a clinically meaningful reduction in eating disorder symptoms when the difference in their 
eating disorder symptom scores (measured by Eating Disorder Diagnostic Interview) before and after study is at 
least twice the standard error difference (1.96) in the desired direction. This is based on the Reliable Change Index 
(Akers et al. 2017). 
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Thirdly, although the study included screening costs, it was unclear whether these costs were 
also applied to those who did not receive the intervention but participated in the screening. 
Finally, given that the study only included one-way sensitivity analysis, it is unlikely that is 
has captured the uncertainty surrounding parameter estimates since lack of bootstrapping or 
probabilistic analysis was included (Briggs et al. 2012; Drummond et al. 2015). 
The most important clinically relevant finding was that one of the key drivers for cost-
effectiveness was the participation rate for the actual engagement with the preventive 
intervention. The uncertainty and sensitivity analysis indicated that the ICER of the study fell 
below the common threshold of $50,000 per DALY if the participation rate was tripled, or 
equivalent to 90% of those who were eligible for CD intervention. However, engaging a large 
number of participants in a preventive intervention for ED may be associated with substantial 
challenges (Becker, Ciao & Smith 2008; Lipson et al. 2017). For example, there may be lack 
of adequate interest of adolescents and youths in ED prevention. Lipson et al. (2017) found 
that undergraduate and graduate students tend not to seek treatment “because they do not think 
they need it” (Lipson et al. 2017, p. 5). Therefore, further research should focus on increasing 
the perceived need and students’ interest in engaging in ED prevention (Lipson et al. 2017). 
Recently, there has been increasing interest in the investigation of the effectiveness and cost-
effectiveness of dissemination approaches and how to increase participation rates in ED 
prevention (Moessner et al. 2016; Perez, Ohrt & Bruening 2016). More intense, expensive 
strategies (with personal contact, peer networks or partnership with student organizations) have 
been demonstrated to be effective and cost-effective approaches.    
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10.2.3. RQ3: Are evidence-based interventions for the treatment of anorexia nervosa and 
bulimia nervosa cost-effective? 
Both EEs in the treatment of AN and BN demonstrated that FBT and CBT are cost-effective, 
interventions. The results (Table 5) of these analyses showed that such intervention was 
comparable in terms of cost-effectiveness to other treatments for mental disorders such as 
depression and anxiety as assessed by the ACE-Mental Health study (Vos et al. 2005).  
FBT has been the most evaluated evidence-based treatment for adolescents and youth with AN 
(Hay et al. 2014; Watson & Bulik 2013). In addition the treatment costs of FBT in AN have 
also been considered to be substantial (Lock, Couturier & Agras 2008). This thesis provides 
new and important information on the cost-effectiveness of FBT treatment for adolescents with 
AN (Le et al. 2017b). Findings indicated that FBT is the most cost-effective choice compared 
to either AFT or no intervention control. FBT was found to be dominant or cost-saving 
compared to the AFT and more effective and more costly than no intervention. The ICER of 
FBT vs. no intervention was $5,089 (95% UI: dominant to $16,659) from a health care 
perspective or $16,436 (95% UI: 5,374 to $40,452) from a (partial) societal perspective. It is 
not surprising that the key driver of the cost-effectiveness of FBT was hospitalisation costs. In 
other words, the more hospitalisation costs are reduced, the more cost-effective FBT became. 
The conclusion of this study was robust with respect to the majority of uncertainty and 
sensitivity analysis, even when excluding hospitalisation costs. This thesis thus supports the 
widespread dissemination of FBT as the first-line treatment for adolescents and youths with 
AN. 
CBT was also found to be cost-effective compared to no intervention for adults with BN (Le 
et al. 2017d). The ICER of CBT was $14,451 per DALY averted (95% UI: $8,762 to $35,650), 
with 99% of iterations of the ICER below the value-for-money threshold of $50,000 per DALY 
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averted in the uncertainty analysis (Chapter 9). The most important finding to emerge from the 
analysis is that the cost-effectiveness of CBT was sensitive to the adherence to treatment. The 
ICER could increase to above the threshold of $50,000 per DALY averted if treatment drop-
out becomes over 80 percent. 
This thesis also answers the important question of how much burden from ED could be avoided 
through the prevention or treatment of EDs and at what cost are required for delivering these 
interventions (Musgrove & Fox-Rushby 2006; Whiteford & Weissman 2017). The package of 
treatment interventions (FBT and CBT) for AN and BN that are cost-effective could avert 1,703 
DALYs with the upfront costs of interventions of $33,161,172. However, this would result in 
a reduction of $9,878,893 on health care costs (mostly from hospitalisation costs). The ICER 
of evidence-based interventions is approximately $13,688 per DALY averted. Prevention of 
AN and BN is only cost-effective if participation rates increase to 90%. If this can be assured, 
then the total package of prevention and treatment for AN and BN could avert 1,751 DALYs 
with $35,252,612 as the total costs of interventions. However, the total package of prevention 
and treatment of AN and BN would save $10,046,700 of health care costs. This would thus 
result in an ICER of $14,395 per DALY averted.   
10.3. Thesis contributions and implications 
This thesis comprises a series of publications that have comprehensively examined the 
important role of preventive interventions for EDs and evaluated the cost-effectiveness of the 
prevention and treatment of AN and BN. To my knowledge, no prior cost-effectiveness projects 
to date have considered both preventive and treatment interventions within the one study 
context. The present study, for the first time, adopted a standardised economic evaluation 
method and adhered to the best practice guidelines for reporting on economic evaluations 
(Husereau et al. 2013). This enhances the comparability of the studies’ results for healthcare 
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priority-setting within local and international contexts. Figure 7 presents a summary of the 
thesis contributions and implications.
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Figure 7: Summary of Thesis Contributions and Implications. 
● Extending the knowledge of cost-
effectiveness and resource allocation of 
preventive and treatment interventions for 
EDs 
● Contributing to cost-effectiveness research, 
which is an important consideration for 
dissemination or implementation of evidence-
based interventions 
● The importance of the coverage level in the 
prevention of EDs or the adherence to 
treatment on the cost- effectiveness was 
highlighted as a substantial consideration in 
cost-effectiveness studies. 
 
 
● A systematic review with broader scope than the 
existing literature and a quantitative meta-analysis 
for all preventive strategies including universal, 
selective and indicated prevention. 
● Reviewed and evaluated the existing evidence 
base of economic evaluation for EDs; 
● Extended knowledge of prevention by 
investigating the ‘dual-effect’ prevention of 
obesity and ED. 
● Increasing the number of CUA studies in the 
literature by 50% and doubling the number of 
modelled CUA for the treatment of EDs. 
 
● A novel method incorporating surrogate 
outcomes to final outcomes in mental 
health economic research. 
● An application and validity of this 
method for economic evaluation in ED 
prevention. 
● Development of a cohort-model that is 
capable of evaluating both preventive and 
treatment interventions. 
 
 Literature Methodology 
Empirical Studies 
Notes. ED(s): eating disorder(s); CUA: cost-utility analysis 
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The most valuable contribution of this research is extending the knowledge of cost-
effectiveness and resource allocation of preventive and treatment interventions for EDs. So far, 
very few cost-effectiveness studies and even fewer CUA studies for ED are available. 
Therefore, this thesis has greatly increased the number of robust cost-effectiveness studies for 
EDs by 50% and doubled the number of modelled cost-effectiveness studies for the treatment 
of EDs, making up the equivalent of one-fourth of the total number of cost-effectiveness studies 
in ED literature (three versus twelve studies). More importantly, the present thesis, for the first 
time, adheres to the CHEERS checklist in terms of high-quality cost-effectiveness reporting. 
In fact, only one cost-effectiveness study from the ED literature has achieved 100% criteria 
from the CHEERS checklist (Le, Hay & Mihalopoulos 2017). 
Another noteworthy contribution is that the thesis has provided a new tool which is able to 
incorporate surrogate outcomes to final outcomes in mental health research, particularly in the 
ED area. It is common for clinical trials in prevention to assess effectiveness in terms of 
reduction of disease symptom outcomes that are clinically relevant but might not be appropriate 
for use in an economic evaluation (Buxton et al. 1997). Therefore, converting changes in 
symptom outcomes to the reduction of disease incidence allows for a more interpretable and 
incremental cost-effectiveness ratio (Buxton et al. 1997). The methods developed as part of the 
work in this thesis are pioneering in developing mathematical techniques that can be used to 
determine the impact of preventive intervention on the incidence rate of ED based on a 
difference in means for psychological variables (e.g. ED symptom outcomes). This important 
method has a broader application (such as depression) in economic evaluation within other 
healthcare contexts. 
Research in terms of cost-effectiveness was scarce in the literature (Weissman & Rosselli 
2017). Findings of this thesis have provided evidence in cost-effectiveness research that can be 
an important consideration for dissemination or implementation of evidence-based 
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interventions. EDs are associated with high mortality and morbidity, however, if there is no 
evidence supporting the cost-effectiveness of these interventions, government funding may be 
allocated to other disorders causing similar (or even less) burden for which evidence of cost-
effective interventions are available (Whiteford & Weissman 2017). Informing the evidence of 
cost-effectiveness is one of the important factors that can influence government policies and 
decision making (Whiteford & Weissman 2017). 
The empirical findings of this thesis provide a better understanding of the importance of the 
coverage level in the prevention of EDs and the adherence to treatment in terms of the impact 
on cost-effectiveness. There are considerable needs in the establishment and improvement of 
the available services for EDs across the spectrum of interventions from prevention to treatment 
(NEDC 2013). This is certainly true in the case of prevention and early intervention programs 
that appear to be implemented on an ad-hoc basis and dependent on the funding and priorities 
of individual schools or local communities (Eating Disorders Policy Paper Writing Group 
2016; NEDC 2013). The Australian Government has improved the access to mental health 
services by establishing the Access to Allied Psychological Services (ATAPS) program in 2001 
that provides low cost or no cost services for those experiencing the economic barriers (e.g. 
homeless, living in rural and remote areas, or from culturally diverse backgrounds) and Better 
Access to Psychiatrists, Psychologists and GPs through the MBS in 2006 that covers ten 
individual sessions per calendar year (Eating Disorders Policy Paper Writing Group 2016; 
Harrison, Britt & Charles 2012). Unfortunately, none of these programs reaches the level of 
treatment necessary for any of the interventions evaluated in the current thesis. Twenty 20 
sessions for BN and BED or up to 30 sessions for AN are required to be effective and cost-
effective. A key policy priority should therefore be increased provision of publicly funded 
health care for EDs to effectively find and treat more people with EDs using evidence-based 
and cost-effective treatments. While it is currently unknown how many people with EDs are 
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actually receiving evidence-based interventions, research in other areas of mental health (such 
as affective and anxiety disorders) suggest that the proportions are worryingly low (Harris et 
al. 2015). 
The research on the effectiveness of preventive interventions for ED is an essential foundation 
for future studies (Chapter 6). This is the first study that had such a broad scope of intervention 
inclusion and also conducted a quantitative meta-analysis for all preventive strategies including 
universal, selective and indicated prevention. This review may also be considered as 
comprising a series of mini-reviews of preventive interventions. The review made an effort to 
use the most sensible classification approach to categorize the preventive interventions by 
preventive strategies. The review also used different perspectives of the classification approach 
to not only test the robustness of the results but also highlight an important gap in this field. 
The review found that there is little research into the defining features of factors that identify 
individuals who are at an elevated risk for future onset of EDs and prodromal eating pathology 
that are also indicative of the onset of EDs (Stice, Ng & Shaw 2010).  
The integrated approach for prevention and treatment of obesity and ED have been called as a 
“rising tide” in the early 20th century (Battle & Brownell 1996, p. 755). This thesis, for the first 
time, contributed to the existing knowledge of prevention by investigating the ‘dual-effect’ of 
the prevention of obesity and ED with the inclusion of studies that evaluated obesity-prevention 
interventions for ED. Unfortunately, findings indicated insufficient evidence to support the 
effectiveness of obesity-prevention interventions for EDs. This finding highlighted the 
considerable challenges in bridging the fields of obesity and EDs of which, the goals for 
prevention, are somewhat contradictory (Irving & Neumark-Sztainer 2002; Neumark‐Sztainer 
2005). The meta-analysis of the ‘healthy weight program’ that “promotes participant-driven 
lasting healthy improvements to dietary intake and physical activity” has indicated the potential 
for the ‘dual-effect’ of obesity and ED although further research is needed to confirm this (Le 
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et al. 2017a; Stice et al. 2008, p. 335). This suggests preventive interventions for obesity and 
ED may need to target a range of weight-related disorders or the risk factors that are shared 
between these two health conditions (Haines & Neumark-Sztainer 2006; Neumark‐Sztainer 
2005). Prevention of obesity and EDs are required to provide a consistent, complementary, but 
not contradictory, public health key message(s) (Schwartz & Henderson 2009).  
10.4. Strengths and limitations 
This thesis has several strengths. First, the current thesis used a standardised and well-validated 
economic evaluation methodology based on the ACE-approach that allows the comparability 
between the interventions evaluated in this thesis and other interventions evaluated not only 
within the CRE but also within the Australian healthcare context that have used a similar 
approach. However, while the ACE approach provides a guide to cost-effectiveness studies, 
several new and important contributions had to be made in terms of the application of the 
approach to the new area of EDs. Second, a series of economic evaluations were undertaken 
and reported using the most recent reporting standards for health economic research, the 
CHEERS checklist (Haddad & McLawhorn 2016). Finally, methodologically, the use of well-
validated epidemiological data from the Global Burden of Disease to inform the analytic 
modelling in the cost-effectiveness studies is a strength of the work (although does have some 
limitations, see below).  Figure 8 summarises the strengths and limitations of the current thesis.
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Figure 8: Summaries of Strengths and Limitations of this thesis.
 Development of novel techniques allowing 
the adoption of a standardised and well-
validated economic evaluation methodology 
of the ACE-approach. 
 Adhering to the most recent standards for 
economic evaluation reporting, the CHEERS 
checklist 
 Using strong and well-validated 
epidemiological data from the Global 
Burden of Disease studies. 
 Using Technical Advisory Groups who are 
Clinical Experts to provide advice on the 
selection of interventions, the modelling 
methods, interpretation of the results, 
formulation of policy-relevant 
recommendations and a dissemination 
 
 Lack of modelling other types of EDs such 
as BEDs. 
 Underestimating the health burden averted 
by such interventions by not accounting for 
changes in illness severity. 
 Lack of national databases for EDs in 
Australia to inform the health service 
information in economic analyses. 
 Not using a ‘true’ societal perspective, but 
rather a healthcare perspective and a ‘partial’ 
societal perspective was used.  
 Using assumptions that might have 
influenced the interpretation of the findings 
(i.e. limitations of modelled economic 
evaluation, more generally). 
STRENGTHS LIMITATIONS 
Notes. ACE: Assessing Cost-Effectiveness; CHEERS: Consolidated Health Economic Evaluation Reporting 
Standards; EDs: Eating disorders; BED: Binge Eating Disorders. 
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Choosing the background context of GBD studies had two important limitations. First, the 
disability weight from GBD studies only captures the disability associated with short- and long-
term health loss in the individuals with EDs but does not reflect other impacts such as on the 
family, social, and economic consequences (Whiteford, Ferrari & Degenhardt 2016). For 
example, the impact of the disorders on people’s ability to conduct meaningful relationships is 
not adequately captured in the GBD weight. In addition, given that GBD 2013 only included 
AN and BN, it was not possible to model the benefits of interventions for other types of EDs 
such as BED. More importantly, given that there is only a single weight for AN or BN, it is not 
possible to model alterations in disease severity (e.g. a movement from severe to moderate) as 
it is for other mental disorders (e.g. depression and anxiety) (Mihalopoulos 2012). As such, the 
health benefits may have been underestimated in the cost-effectiveness studies. Second, data 
from the 2013 GBD studies were also susceptible to literature gaps and the availability of 
country-level data. If the data were not available for a given country, the solution was to 
produce an imputed estimate for each epidemiological parameter which was based on data 
available from surrounding countries (Whiteford, Ferrari & Degenhardt 2016). In doing so, the 
GBD studies “pooled all data available for a given disorder into a weighted average, while 
simultaneously adjusting for known sources of variability in estimates reported across studies” 
(Whiteford, Ferrari & Degenhardt 2016, p. 1116). 
Other important limitations to the current body of work was the absence of national databases 
for EDs in Australia to inform health service information of economic analyses. For example, 
other CRE projects and prior ACE studies have used the 2007 National Mental Health and 
Wellbeing survey (NMHWB) of high prevalence disorders for depression and anxiety (Slade, 
Teesson & Burgess 2009), the 2010 National Survey of High Impact Psychosis (SHIP) 
(Morgan et al. 2012) and the 2014 Child and Adolescent Survey of Mental Health and 
Wellbeing for ADHD, conduct disorders and childhood depression and anxiety disorders 
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(Lawrence et al. 2015). Such surveys are useful because they are locally representative of the 
disorder, include good diagnostic criteria and also include locally detailed data regarding 
service use and health outcomes. Unfortunately, no equivalent surveys for EDs is available 
although some surveys of ED services have been conducted in Australia (Deloitte Access 
Economics 2014; Hay, Marley & Lemar 1998; Hay, Loukas & Philpott 2005; Mond et al. 2009; 
Mond et al. 2006; Mond et al. 2007). However, these surveys are not community-based studies 
and are considerably smaller than the prior mentioned national surveys. This means that the 
assumptions used in the modelling studies comprising this thesis were sometimes not evidence-
based, but relied on expert opinion in this field. For example, the assumption regarding the 
number of school counsellors participating in the preventive intervention or the proportion of 
people receiving the intervention were all based on expert opinion (Le et al. 2017b). 
The main weakness of this study was the paucity of the information of the relevant comparators 
such as ‘treatment-as-usual’ or ‘current practice’ for cost-effectiveness analyses. As noted 
above, there has been lack of evidence regarding the current service use of people with EDs in 
Australia. Therefore, the actual constituents of TAU within the Australian context are currently 
not defined in detail. This thesis, thus, considered ‘no intervention’ as the best comparators to 
the active intervention.  
The scope of this thesis was somewhat limited in terms of not using a true societal perspective. 
Previous evidence has shown that EDs are associated with considerable impairment in 
functioning and work productivity (Krauth, Buser & Vogel 2002; Ling, Rascati & Pawaskar 
2017; Mond & Hay 2007; Pawaskar et al. 2017) as well as associated with substantial 
impairment in social and occupational functioning (e.g. close relationships or social leisure 
(Tchanturia et al. 2013; Turner, Bryant-Waugh & Peveler 2010). This means that considerable 
costs outside the health sectors are associated with EDs (Deloitte Access Economics 2014; 
Ling, Rascati & Pawaskar 2017; Stuhldreher et al. 2015). However, there is a lack of a credible 
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evidence base to model any incremental differences relating to productivity impacts or even 
impact in other sectors between the different interventions. Such costs were not therefore 
included in the cost-effectiveness analysis of this thesis. Therefore, the current studies may 
provide an under-estimate of cost-offsets in prevention and treatment of EDs using a broader 
societal perspective. However, this thesis did conduct evaluations using a partial societal 
perspective that captured the patients’ time and travel costs. The inclusion of such broader 
societal costs (should there be any such impacts) would make the interventions even more cost-
effective. 
Another limitation of this thesis is a general limitation of modelled EEs which use many 
assumptions that might influence the interpretation of the findings. For example, there were 
large variabilities in defining remission across the limited trials in the treatment of AN and BN. 
The effect size of FBT compared to no intervention was retrieved from the natural disease 
history studies rather than head-to-head trials. However, the current research made an effort to 
use plausible assumptions which were sourced from the synthesis of the latest available 
evidence and augmented by expert opinion. In addition, both uncertainty and sensitivity 
analysis were included to test the robustness of the results. These approaches also helped to 
ascertain which variables had the largest impact on the conclusions.  
10.5. Directions for future research 
More broadly, research is needed to determine the effectiveness and cost-effectiveness of 
prevention and treatment of other types of EDs such as BEDs. This is important since the 
prevalence of BED in Australia is three times higher than that of AN or BN (Hay, Girosi & 
Mond 2015). In addition, there is good evidence suggesting that both pharmacological (e.g. 
lisdexamfetamine and second-generation antidepressants) and psychological (e.g. CBT) 
interventions are effective in the treatment of BED (Brownley et al. 2016). 
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Further research should be conducted to capture the severity of EDs as well as other types of 
EDs using more nuanced disability weights or using an alternative common outcome metric 
such as QALYs (as noted in Chapter 3). QALYs are more commonly used in cost-utility 
analyses compared to DALYs (e.g. most health technology assessment agencies such as NICE 
and PBAC recommend QALYs rather than DALYs). However, to undertake such comparative 
cost-effectiveness studies, where multiple interventions are simultaneously compared, a 
consistently derived set of utility weighs needs to be available. While such weighs are now 
available within the Australian context for high prevalence disorders (for example, the AQoL-
4D, a generic MAUI was included in the 2007 NMHWB and SHIP surveys), this is not 
available for EDs. Different generic outcome (such as DALYs or QALYs) may or may not 
impact on the conclusion of the study. Nevertheless, it may have some important implications 
with regards to different priorities (Gold, Stevenson & Fryback 2002; Mihalopoulos et al. 
2015). Further research on different outcomes is required to enhance the cost-effectiveness of 
prevention and treatment of EDs. 
The current thesis provides additional evidence with respect to different ways that the 
prevention of ED can be categorised into universal, selective and indicated prevention as 
commonly used in the mental health prevention literature. The concepts of universal, selective 
and indicated prevention are familiar to decision-makers and commonly used for decision-
making in prevention. Therefore, to be consistent with other mental health research in 
prevention, extending knowledge of prevention categorisation is important.  
Given the increasing prevalence of obesity with comorbid binge eating or other ED behaviours 
(da Luz et al. 2017), more research is also required to determine the efficacy and effectiveness 
of prevention (and treatment) for EDs and obesity. For example, a recent study has shown that 
healthy weight program is promising in preventing obesity and EDs (Stice et al. 2017). 
Furthermore, another revised version of healthy weight program which added dissonance-
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induction activities, called “Project Health” program, targeting both obesity and eating 
disorders showed to be promising in reducing increases in measured BMI compared to healthy 
weight program (Stice et al. 2017). It is also important to assess the cost-effectiveness of these 
promising interventions targeting shared risk for eating-/weight-related issues. 
Research on cost-effectiveness is important in this field. However, simply providing a list of 
cost-effective interventions which should be implemented may be insufficient to influence 
government policies and decision making (Whiteford & Weissman 2017). More broadly, 
further studies regarding the implementation and dissemination of the cost-effective 
interventions to improve health services in EDs are required. This requires national health 
surveys or equivalent surveys involving EDs as one of interest disorders so that the extent of 
which interventions are currently being used by people with EDs can be determined. 
10.6. Conclusion 
The findings of this research provide important insights for the empirical cost-effectiveness of 
prevention and treatment interventions for EDs. Taken together, these results suggest that 
treatment of EDs are cost-effective and comparable to other interventions for the treatment of 
mental disorders. Unfortunately, such interventions are not properly financed in the Australian 
healthcare system, thus are probably not routinely provided in the community setting. 
Therefore, there is an urgent need to address this issue in terms of publicly funded availability 
of evidence based interventions particularly for the treatment of AN and BN. Whilst evidence 
regarding the benefit of prevention of ED is inconclusive, preventive interventions are 
potentially cost-effective if the participation rates are of higher level than what is realistically 
anticipated. An implication of this is the possibility of considering how such interventions can 
appropriately engage more people who are most likely to benefit from the interventions. Given 
the increasing prevalence of EDs especially for BEDs and other types of EDs, it is important 
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for further research to also assess the effectiveness and cost-effectiveness of interventions 
targeting these type of EDs. In this regards, it is important that national health surveys or 
equivalent surveys on health services consider ED as an important mental health disorder. 
Overall, further work needs to be done to establish and enhance the translation of the evidence 
determined in this body of work into effective health practice and health policy in ED. 
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APPENDIX 3: Supplementary data of publication 1 
Title of publication: A Systematic Review of Cost-Effectiveness Studies of Prevention and Treatment for Eating Disorders. 
APPENDIX S1: Studies reported cost outcomes of intervention but did not met inclusion criteria. 
Authors and 
Years 
Targeted 
Population 
Interventions  Evaluation 
types 
Perspective 
Time horizon 
Country  
Year of pricing 
Costs Outcomes/ Results Reason for excluded 
Schmidt et al. 
(2007) 
Girls aged 13 to 
20 years 
diagnosed with 
DSM-IV BN or 
EDNOS  
(1) Family-based 
treatment 
(2) CBT Guided 
self-care 
RCT Unclear 
10 months 
US 
Unclear 
 
Intervention costs, 
health care utilisation 
costs, lost 
productivity, families 
and patients’ out-of-
pocket costs. 
Abstinence cases, 
BMI. 
Costs were reported as an 
outcome but did not 
examine these costs in 
relation to the study 
outcomes and there was 
insufficient 
methodological 
information to justify the 
study as a full economic 
evaluation 
Agras et al. 
(2014) 
Boys & Girls 
aged 12 to 18 
years. 
(1) Family-based 
treatment 
(2) Systemic family 
therapy 
RCTs Unclear 
88 weeks 
US 
Unclear 
Intervention costs, 
health care utilisation 
costs. 
% IBW, Remission. Costs were reported as an 
outcome but did not 
examine these costs in 
relation to the study 
outcomes and there was 
insufficient 
methodological 
information to justify the 
study as a full economic 
evaluation 
Kass et al. 
(2017) 
Unclear 
College students 
(1) online GSH  
(2) online 
preventive 
(3) step-care model 
(combined (1)+(2)) 
(4) Usual care 
Modelled cost 
analysis 
Payer 
2 years 
US 
2016 
Intervention costs, 
health care utilisation 
costs 
Unclear - the 
number of 
individuals who 
would avoid 
in-person 
psychotherapy 
Cost-analysis study – 
outcome was not defined. 
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APPENDIX S1: Studies reported cost outcomes of intervention but did not met inclusion criteria. 
Authors and 
Years 
Targeted 
Population 
Interventions  Evaluation 
types 
Perspective 
Time horizon 
Country  
Year of pricing 
Costs Outcomes/ Results Reason for excluded 
Bode et al. 
(2017) 
Unclear - 
patients who 
might be willing 
to undergo 
treatment within 
the year 
(1) FBT for AN, 
CBT for AN & BN 
(2) Untreated  
Modelled cost-
offset at 
population level 
Unclear  
1 year 
Germany 
Unclear - varied 
Intervention costs, 
health care utilisation 
costs, productivity 
costs. 
Unclear. QALY + 
mortality rates 
converted to 
monetary term. 
Cost-offset analysis 
compared between 
treated and untreated 
treatment. 
Pohjolainen et 
al. (2017) 
Females (mean 
age of 22) 
diagnosed with 
ICD-10 AN 
Hospital routine 
including 
psychoeducation, 
cognitive-
behavioural 
therapy, nutritional 
counselling and 
medications. 
Pre-post study Unclear 
2 years 
Finland 
2002-2005 
Health care utilisation 
costs 
QALYs Cost-outcome descriptive 
study. No comparator 
was included. 
Pohjolainen et 
al. (2010) 
Females (mean 
age of 25) 
diagnosed with 
ICD-10 BN 
Step-care model Pre-post study Unclear 
2 year 
Finland 
Unclear 
Health care utilisation 
costs 
QALYs Cost-outcome descriptive 
study. No comparator 
was included. 
Guarda et al. 
(2017) 
Adults (mean 
age of 32.5) 
diagnosed with 
DSM-IV-TR 
AN 
Hospital-based 
inpatient - partial 
hospitalization EDs 
program 
Retrospective 
study 
Third party 
12 years 
US 
2015 
 
Health care 
utilisations 
Weight gain Cost-outcome descriptive 
study. No comparator 
was included. 
Williamson, 
Thaw and 
Varnado-
Sullivan 
(2001) 
People 
diagnosed with 
ED (both 
subthreshold 
and threshold) 
Hospital-based 
cognitive- 
behavioral 
treatment program 
initiating with 
inpatient or partial 
day hospital. 
Retrospective 
cohort study 
Unclear 
2 years 
US 
1999 
 
Health care 
utilisations 
BMI, MAEDS Cost-outcome descriptive 
study. This study did not 
evaluate purely inpatient 
or partial day hospital 
programs. 
Lock, 
Couturier and 
Agras (2008) 
Adolescents 
aged 12 to 18, 
Hospital and 
psychiatric services 
Prospective 
cohort study 
Unclear 
1 year 
US 
Health care utilisation Recovery/ 
remission 
Cost-outcome descriptive 
study. No comparator 
was included. 
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APPENDIX S1: Studies reported cost outcomes of intervention but did not met inclusion criteria. 
Authors and 
Years 
Targeted 
Population 
Interventions  Evaluation 
types 
Perspective 
Time horizon 
Country  
Year of pricing 
Costs Outcomes/ Results Reason for excluded 
diagnosed with 
DSM-IV AN 
2004 
Birchall et al. 
(2002) 
Unclear 
People 
diagnosed with 
severe AN 
Intensive day 
programme 
treatment 
Pre-post cohort 
study 
Unclear 
Varied (1.45 to 4.2 
years) 
US 
Unclear 
Health care 
utilisations 
BMI Cost-outcome 
descriptive.  
FBT: family-based therapy; RCT: randomized controlled trial; GSH: guided self-help; QALY(s): quality-adjusted life year(s); AN: anorexia nervosa; BN: bulimia nervosa; ED: 
eating disorder; CBT: cognitive behavioural therapy; IBW: ideal body weight; BMI: body mass index; ICD-10: 10th revision of the International Statistical Classification of 
Diseases and Related Health Problems; DSM-IV: the 4th version of the Diagnostic and Statistical Manual of Mental Disorders. 
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APPENDIX S2: Quality assessment of included economic evaluation studies using CHEERS checklist. 
  Prevention of Eating Disorders Anorexia Nervosa Treatment Bulimia Nervosa treatment Binge Eating 
Disorder treatment 
Other 
types of 
EDs 
% meet 
criterion 
Criteria/Author Item 
No. 
Wang, 
Nichol
s and 
Austin 
(2011) 
Wright 
et al. 
(2014) 
Akers et 
al. 
(2017) 
(Le et al. 
2017c) 
Byford et 
al. (2007) 
Egger et 
al. 
(2016) 
Crow 
and 
Nyman 
(2004) 
Koran et 
al. (1995) 
Crow et 
al. (2009) 
Crow et 
al. (2013) 
Lynch 
et al. 
(2010) 
Ágh et 
al. 
(2016b) 
Aardoo
m et al. 
(2016) 
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19         ○   ○ ○   ○     ○ 55% 
Characterizing 
uncertainty 
20a 
20b 
n.a. 
  
n.a. 
  
  
n.a 
n.a 
  
  
n.a. 
  
n.a. 
n.a. 
○ 
○ 
n.a. 
  
n.a. 
  
n.a. 
  
n.a. 
n.a. 
  
  
n.a. 
86% 
75% 
Characterizing 
heterogeneity 
21 n.a. n.a. ○   ○ ○ n.a. ○ ○ ○ ○ n.a. ○ 0% 
Discussion 
Study findings, 
limitations,  
generalizability, 
and current 
knowledge 
22         ○   ○             82% 
Other 
Source of 
funding 
23             ○     ○       82% 
Conflict of 
interest 
24   ○ o    ○   ○ ○ ○ ○ ○   ○ 27% 
% meet 
criterion 
 68% 82% 67% 100% 76% 86% 41% 40% 60% 45% 90% 100% 71%  
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APPENDIX 4: Intervention Selection. 
Table S1. Overview and comparison of preventive interventions for EDs* 
 Approaches Level of 
evidence  
(I & II) 
Magnitude of 
effect 
Meta-analysis Program example 
Universal 
prevention 
Cognitive-behavioural therapy Some Low N/A - 
Media literacy Moderate Substantial ++ Media Smart 
Multicomponent Strong None N/A Healthy Schools Healthy 
Kids 
Obesity prevention Moderate Low-Moderate N/A Planet Health 
Psychoeducation (teachers) Some Low N/A The Student Body: 
Promoting Health At 
Any Size 
Self-esteem enhancement Moderate Low N/A Everybody’s Different 
Physical Activity Some None N/A Fitness for Life 
Selective 
prevention 
Cognitive-behavioural therapy Strong Moderate -
Substantial 
++ Student Bodies 
Cognitive dissonance Strong Moderate - 
Substantial 
?* Stice version 
Media literacy Strong Moderate + - 
Multicomponent Strong Moderate ?** Everybody is Somebody 
Obesity prevention Moderate Low-Moderate N/A Planet Health 
One-shot Moderate None N/A - 
Perfectionism Some Low N/A - 
Psychoeducation Some Low N/A - 
Self-esteem enhancement Some Low N/A Everybody’s Different 
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Indicated 
Prevention 
Cognitive-behavioural therapy  Strong Substantial  +++ My Body, My Life; 
Student Bodies 
Cognitive dissonance  Strong Substantial  +++ Stice version 
Healthy weight  Strong Moderate - 
Substantial 
++ Stice version 
Media literacy  Some  None-Low  N/A - 
Mental health literacy  Some None-Low N/A - 
Multicomponent Moderate  Low-Moderate N/A Everybody is a 
Somebody 
One-shot  Moderate  Moderate  - Stice version Healthy 
Weight Intervention/ 
Cognitive Dissonance 
(condensed to 1 
session) 
Perfectionism  Some  Low N/A - 
Psychoeducation  Moderate Low N/A - 
Yoga and meditation Some None N/A - 
*Updated evidence overview from the National Eating Disorders Collaboration in 2010 
Level of evidence: None = no RCT studies; Some = 1 to 2 RCT studies; Moderate = 3-4 RCT studies; Strong: >= 5 RCT. 
Magnitude of effect at follow-up for eating disorder risk variables: None = no beneficial effect at post-tx; Low = slight beneficial effect (have 
effect at post-tx but no at follow up); Moderate = moderate beneficial effect; Substantial = substantial and persistent effect. 
Meta-analysis effect: +: significant effect on = 1 measurement scale at post-tx or follow up; ++ significant effect on >=2 measurement scale post-
tx or follow up; +++ significant effect on >= 2 measurement scale at post-tx and follow up 
* Non-significant effect vs. media literacy selective prevention. 
** Meta-analysis cannot be done due to different measurement scale 
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Table S2: Evidence-based interventions for treatment of Anorexia Nervosa.* 
 Approaches Level of 
evidences 
Magnitude of effect Outcome measures 
(Clinical outcome) 
Young 
people 
Ego-oriented therapy/ Adolescence 
focused therapy 
Strong Moderate % pt remission, BMI, % pt achieve target BMI 
Family-based treatment  Strong Substantial % pt remission; BMI, % pt achieve target BMI 
Inpatient psychiatric treatment Moderate Low-Moderate - Morgan-Russell Average Outcome Scale -% Full remission 
Specialised outpatient treatment (1) Moderate Low -Moderate - Morgan-Russell Average Outcome Scale -% Full remission 
Pharmacotherapy Low None BMI, Weight, ED symptoms, ED attitudes. 
Resistance training Low None Weight/BMI; Muscular strength; Functional Mobility; Quality of life 
Adults Antidepressant medication Strong Unclear - None Weight change; severity of eating disorder, depression and anxiety symptoms. 
Antipsychotic medication 
Strong Unclear - None 
Weight change (increase BMI); ED symptoms. 
ED attitudes including body dissatisfaction & 
drive for thinnes. 
Behavioural therapy Low None Weight change, menstrual status, Morgan and Russell Scales. 
Cognitive analytic therapy Low None  Morgan-Russell Average Outcome Scale; Weight gain. 
Cognitive-behavioural therapy Strong Low - Moderate BMI, ED symptoms, broader psychopathology. 
Family-based treatment (Maudsley 
therapy) Strong Unclear - Low 
Weight change, menstrual status, Morgan 
and Russell Scales. 
Focal psychoanalytic therapy Low Unclear - Low Weight change, menstrual status, Morgan and Russell Scales. 
Hormone replacement therapy Moderate None - Low Weight, BMI, EDE, EDI 
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Interpersonal psychotherapy Moderate 
 Unclear - Low 
Global anorexia nervosa measure, BMI, 
Weight. EDI, EDE. 
Nutritional supplement Low Low Weight gain, rate BMI gain/day. 
Refeeding Low Low- Moderate Weight gain, gain in fat free mass and excess energy. Relapse-free period. 
Specialist supportive clinical 
management Strong Low-Moderate 
Global anorexia nervosa measure: Good to 
poor outcome. BMI, EDE, EDI. 
Nutritional rehabilitation + CBT 
Low Unclear - Low 
BMI, global Eating, Disorder 
psychopathology, and eating-related 
obsessiveness. ED attitudes. 
Acupuncture Low Low BMI, EDQoL, EDI-3, EDE. 
Cognitive Remediation Therapy 
Low None 
Reaction times in shift run of the cued task-
switching paradigm. Basic Cognitive 
Functions 
*Updated evidence overview from the National Eating Disorders Collaboration in 2010 
Level of evidence: None = no RCT studies; Some = 1 to 2 RCT studies; Moderate = 3-4 RCT studies; Strong: >= 5 RCT. 
Magnitude of effect at post-tx and follow-up for eating disorder variables: None = no beneficial effect at post-tx; Low = slight beneficial effect 
(have effect at post-tx but no at follow up); Moderate = moderate beneficial effect; Substantial = substantial and persistent effect. 
(1) No significant effect between specialised outpatient treatment but it is more cost-effective than inpatient treatment due to high 
adherence of treatment. 
 
Table S3: Evidence-based interventions for treatment of Bulimia Nervosa. 
 Approaches Level of 
evidences 
Magnitude of 
effect 
Outcome measures 
(Clinical outcome) 
Adolescence
s 
Family-based 
treatment  
Moderate Moderate Abstinence and remission rate, ED attitudes. 
CBT guided self help Low Moderate Abstinence and remission rate, ED attitudes. 
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Adults Antidepressant 
medication 
Strong Moderate Binge eating, purging, depression. ED related psychotherapy. Remission rate. 
Anticonvulsant 
medication Strong 
Low - 
moderate 
Binge episodes per week, binge day per week. 
Androgen receptor 
antagonist medication 
Low Unclear  
Serotonin antagonist Low Moderate Binge eating and vomiting frequency. Time spent engaging bulimic behaviour. Body weight. 
Cognitive-behavioural 
therapy Strong Substantial 
Abstinence rate (100% binge free); bulimic symptoms, 
depression. BMI. Binge eating frequency, vomiting. 
CBT Guided Self-help Strong Moderate to substantial 
Abstinence rate (100% binge free); bulimic symptoms, 
depression. BMI. Binge eating frequency, vomiting. 
CBT Pure Self-help Strong Low Abstinence rate (100% binge free); bulimic symptoms, depression. BMI. Binge eating frequency, vomiting. 
CBT + antidepressant 
medication Moderate Moderate 
Remission rate. Dropout rate. ED attitudes. 
CBT + Interpersonal 
psychotherapy 
Strong 
 
Unclear - 
Moderate 
Remission rate. Dropout rate. ED attitudes. 
CBT + ERP Strong Low Remission rate. Dropout rate. ED attitudes 
Enhanced CBT Moderate Moderate - 
substantial 
Frequency of binge eating episodes and compensatory 
behaviors measured by the EDE. Depression. Anxiety. 
Interpersonal 
psychotherapy Moderate 
Low - 
Moderate 
Remission rate. Dropout rate. ED attitudes. 
Crisis Intervention Low None  
Dialectical behaviour 
therapy Moderate Unclear 
ED behaviors and other forms of psychopathology. 
Guided imagery Low Moderate ED attitudes. Binge eating and purging frequency. 
Healthy Weight 
Program Low Moderate 
BMI reduction. Bulimic symptoms. Remission rate. 
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Integrative Cognitive 
affective therapy Low Moderate 
- Frequency of binge eating episodes and compensatory 
behaviors measured by the EDE. Depression. Anxiety. 
Nutritional 
management 
Moderate Moderate Binge eating, vomiting, body dissatisfaction, depression, and other psychopathology. 
Active light Low 
Moderate 
Binge frequency, binge eating episodes. Purging frequency, 
weekly meal. Depression & eating-related obsessions and 
compulsions 
Stress management Low Moderate Binge eating, vomiting, body dissatisfaction, depression, and other psychopathology. 
Multimodal day 
program 
Low Moderate Bulimic attitudes and behaviours, binge eating frequency, vomiting, and general psychopathology. Relapse. 
Multimodal inpatient 
program 
Low Moderate Bulimic attitudes and behaviours, binge eating frequency, vomiting, and general psychopathology. Relapse. 
Repetitive transcranial 
magnetic stimulation 
Low 
None 
Depression symptoms, obsessive-compulsive symptoms, 
binge episodes per day, or vomiting frequency, binge eating 
frequency. 
*based on evidence overview from the National Eating Disorders Collaboration in 2010 
Level of evidence: None = no RCT studies; Some = 1 to 2 RCT studies; Moderate = 3-4 RCT studies; Strong: >= 5 RCT. 
Magnitude of effect at post-tx and follow-up for eating disorder variables: None = no beneficial effect at post-tx; Low = slight beneficial 
effect (have effect at post-tx but no at follow up); Moderate = moderate beneficial effect; Substantial = substantial and persistent effect. 
 
 
 


APPENDIX A.1: TRIAL SUMMARIES FOR EATING DISORDER PREVENTION AND RISK OF BIAS RESULTS 
Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Universal Prevention (18) 
Cognitive-
behavioural 
therapy (2) 
Grave, 
Luca, and 
Campello 
(2001) 
61 females 
45 males 
Age 11-15 
Italy 
1. CBT (Garner &
Bemis, 1982)
2. Usual school
curriculum.
6 sessions + 2 
booster 
session (after 
6 mths) 
Classroom 
delivered 
ITT Risk factors 12 months High 
de León, 
Díaz, and 
Ruiz (2008) 
61 females 
59 males 
Age: 9.93 (0.44) 
Mexico 
1. SCT - informative
format
2. SCT - didactic
format
3. Control (not
specified)
8 sessions Classroom 
delivered 
ITT Risk factors 
% clinically 
significant 
changes 
6 months High 
Media literacy 
(5) 
Wade, 
Davidson, 
and O'Dea 
(2003) 
33 females 
53 males 
Age 13.42 (0.39) 
Australia 
1. ‘Go Girls’ program
2. Everybody’s
different
3. Usual school
curriculum.
5 sessions Class-room 
delivered 
Unclear Risk factors 3 months High 
Wilksch 
and Wade 
(2009) 
273 females 
267 males 
Age 13.62 (0.37) 
Australia 
1. Media Smart
2. Classes as usual.
8 sessions Class-room 
delivered 
ITT Risk factors 
% clinically 
significant 
changes 
30 months High 
Wilksch 
(2013) 
27 females 
24 males 
Age 12.43 (0.61) 
Australia 
1. Media Smart
2. Class as usual
8 sessions Class-room 
delivered 
ITT Risk factors 6 months High 
APPENDIX 6: Supplementary data of publication 2 
Title of publication: Prevention of Eating Disorders: A Systematic Review and Meta-analysis 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Wilksch et 
al. (2014) 
840 females 
475 males 
Age 13.21 (0.68) 
Australia 
1. Media Smart
2. Life Smart
3. Helping,
Encouraging,
Listening &
Protecting Peers
4. Class as usual
8 sessions Class-room 
delivered 
ITT Risk factors 
% met 
clinical shape 
and weight 
concern and 
BMI 
12 months High 
González, 
Penelo, 
Gutiérrez, 
and Raich 
(2011) 
254 females 
189 males 
Age 13.5 (0.4) 
Spain 
1. ML
2. ML + Nutrition
awareness
3. Class as usual
4 sessions 
5 sessions 
5 sessions 
Classroom 
delivered 
COM Risk factors 
Value 
changes 
30 months High 
Multi-
component (4) 
González et 
al. (2011) 
254 females 
189 males 
Age 13.5 (0.4) 
Spain 
1. ML
2. ML + Nutrition
awareness
3. Class as usual
4 sessions 
5 sessions 
5 sessions 
Classroom 
delivered 
COM 30 months High 
Mccabe, 
Ricciardelli, 
and Salmon 
(2006) 
173 females 
195 males 
Age 8-13 
Australia 
1. Active Children and
Self-Esteem Study
(ACE-Kids)
2. Usual school
curriculum
8 sessions Unclear Risk factors None High 
McVey, 
Tweed, and 
Blackmore 
(2007) 
355 females 
332 males 
91 teachers 
Age 11.27 (0.67) 
Canada 
1. Healthy Schools-
Healthy Kids.
2. Control.
8 months Class-room 
delivered 
COM Risk factors. 
% change in 
weight loss 
and muscle-
gaining 
behaviours 
6 months High 
Mora et al. 
(2015) 
100 females 
100 males 
1. ML + Nutrition
2. “Theatre Live”
10 sessions Classroom 
delivered 
COM Risk factors 13 months High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Age 13.4 (0.5) 
Spain 
3. Class as usual
Obesity 
prevention (4) 
Huang, 
Norman, 
Zabinski, 
Calfas, and 
Patrick 
(2007) 
434 females 
385 males 
Age 13 
USA 
1. Patient Centred
Assessment and
Counselling for
Exercise Plus
Nutrition Project
(PACE)
2. Sunsmart Control.
12 months Computer-
based; face-
to-face & 
telephone 
counselling 
COM Risk factors None High 
Austin et al. 
(2007) 
749 females 
702 males 
Age n.s. (grade 
6&7) 
USA 
1. 5-2-1 Go! (Planet
Health program +
School Health Index.)
2. Control: Module 1
SHI
2 years School-
based 
intervention 
COM No. of 
prevented 
cases of 
disordered 
weight-
control 
behaviors 
None High 
Wilksch 
and Wade 
(2013) 
51 females 
63 males 
Age 12.71 (0.41) 
Australia 
1. Life Smart
2. Class as usual
8 sessions Class-room 
delivered 
COM Risk factors None High 
Wilksch et 
al. (2014) 
840 females 
475 males 
Age 13.21 (0.68) 
Australia 
1. Media Smart
2. Life Smart
3. Helping,
Encouraging,
Listening &
Protecting Peers
4. Class as usual
8 sessions Class-room 
delivered 
ITT Risk factors 
% met 
clinical shape 
and weight 
concern and 
BMI 
12 months High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Psycho-
education 
(teachers) (1) 
(McVey, 
Gusella, 
Tweed, & 
Ferrari, 
2008) 
167 teachers & 
health practice 
professionals. 
Canada 
1. The Student Body:
Promoting Health At
Any Size.
2. Wait-list control.
n.s (60 days) Computer-
based 
program 
COM Risk factors None High 
Self-esteem 
enhancement (4) 
Wade et al. 
(2003) 
33 females 
53 males 
Age 13.42 (0.39) 
Australia 
1. ‘Go Girls’ program
2. Everybody’s
different
3. Usual school
curriculum.
5 sessions Class-room 
delivered 
Unclear Risk factors 3 months High 
O'Dea and 
Abraham 
(2000) 
297 females 
173 males 
Age 11-14 years 
Australia 
1. Everybody’s
Different
2. Control: scheduled
personal development
and health class
9 sessions Classroom 
delivered 
COM Risk factors 
% trying to 
lose weight 
12 months Unclear 
Ghaderi, 
Mårtensson, 
and Schwan 
(2005) 
87 females 
77 males 
Age 11 (??) 
Sweden 
1. Everybody’s
Different
2. Control: scheduled
personal development
and health class
9 sessions Classroom 
delivered 
COM Risk factors None High 
Martinsen 
et al. (2014) 
384 females 
193 males 
Age 16.5 (0.3) 
Norway 
1. Self-esteem
intervention.
2. Control
1 year Classroom 
delivered 
COM Risk factors. 
No. of case 
met DSM-IV 
ED 
9 months High 
Physical Activity 
(1) 
Zabinski, 
Calfas, 
Gehrman, 
Wilfley, and 
184 females 
154 males 
Age 24 (1.95) 
USA 
1. Fitness for Life
2. Control: Health
topics lecture
15 weeks Classroom 
delivered 
COM Risk factors None Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Sallis 
(2001) 
Selective prevention (83) 
Cognitive 
behaviour 
therapy (22) 
Graff Low 
et al. (2006) 
72 female 
Age n.s 
USA 
1. Student Bodies
program (with a
clinically moderated
discussion group)
2. Student Bodies
program (with an
unmoderated
discussion group)
3. Student Bodies
program (with no
discussion group)
4. Control – n.s
8 sessions 
plus 1 
follow-up 
session 
Computer-
based 
ITT + 
COM 
Risk factors 8-9
months
High 
Doyle et al. 
(2008) 
50 females 
30 males 
Overweight >=85th 
percentile 
Age 14.5 (1.7) 
USA 
1. Student Bodies 2
2. Control: usual care
16 weeks Computer 
based 
ITT Risk factors 4 months Low 
Winzelberg 
et al. (2000) 
60 females 
Age 20 (2.8) 
USA 
1. Student Bodies
2. Waitlist control
8 weeks Computer 
based 
COM + 
ITT 
Risk factors 3 months High 
Winzelberg 
et al. (1998) 
57 females 
Age 19.7 (n.s.) 
USA 
1. Student Bodies
2. Waitlist control
8 weeks Computer 
based 
COM Risk factors 3 months High 
Nicolino, 
Martz, and 
85 females 
Age 18.9 (2.5) 
1. Thompson (1996)
version
5 sessions Group 
based 
ITT Risk factors None High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Curtin 
(2002) 
USA 2. Brief educational
session
Bearman, 
Stice, and 
Chase 
(2003) 
73 females 
Age 18.9 
USA 
Include: women 
w/ body image 
concern. 
1. CBT – Cash and
Rosen version (1987;
Rosen, Cado, Silberg,
Srebnik, & Wendt,
1990).
2. Waitlist control
4 sessions Group 
based 
ITT Risk factors 6 months Unclear 
Celio et al. 
(2000) 
76 females 
Age 19.6 (2.2) 
USA  
Include: females 
had high BD 
measure by BSQ 
1. Student Bodies
(SB)
2. Body Trap (BT)
3. Waitlist control
8 sessions Computer 
based (SB) 
Classroom 
delivered 
(BT) 
COM + 
ITT 
(effect 
report 
only) 
Risk factors None High 
Jacobi et al. 
(2007) 
100 female 
Age 22.5 (2.7) 
Germany 
Include: Female 
want to improve 
their body image. 
1. Student Bodies
program – German
version.
2. Wait-list control.
8 sessions Computer-
based 
COM Risk factors 3 month Unclear 
Heinicke, 
Paxton, 
McLean, 
and 
Wertheim 
(2007) 
73 females 
Age 14.4 (1.53) 
Australia 
Include: Female 
self-identified 
as having body 
image or eating 
problems 
1. My Body, My Life
2. Delayed-treatment
control
6 sessions Group 
based 
COM 6 months High 
239 
Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Luethcke, 
McDaniel, 
and Becker 
(2011) 
168 females  
Age 18.45 (0.78) 
USA 
1. Mindfulness based
mirror exposure.
2. Nonjudgmental
based mirror
exposure.
3. CD based mirror
exposure.
2 sessions Group 
based 
ITT Risk factors/ 
ED 
symptoms 
1 month High 
Zabinski, 
Wilfley, 
Calfas, 
Winzelberg, 
and Taylor 
(2004) 
60 females. 
Age 18.9 (2.4) 
USA 
Include: Female 
with mean score 
≥57 on the WCS. 
1. CBT (Fairburn,
Marcus, & Wilson,
1993).
2. Wait list control.
8 sessions Computer 
based 
ITT Risk factors 10 weeks Unclear 
Rosen, 
Saltzberg, 
and Srebnik 
(1989) 
23 females. 
Age 19 (1.15) 
USA 
Include: Female 
with mean score 
≥109 on the BSQ. 
1. CBT
2. Minimal treatment
control
6 sessions Group 
based 
Unclear Risk factors 2 months Unclear 
Delinsky 
and Wilson 
(2006) 
45 females 
Age 20.5 (2.7) 
USA 
Include: Female 
with score ≥ 4 on 2 
of 4 EDE-Q 
1. Mirror exposure
treatment
2. Control: non-
directive therapy
3 sessions Group 
based 
COM Risk factors 4 weeks Unclear 
Taylor et al. 
(2006) 
480 female 
Age 20.8 (2.6) 
USA 
1. Student Bodies
program.
2. Wait-list control.
8 sessions Computer 
based 
COM Risk factors 
No. of case 
met DSMIV 
ED 
3 years Low 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Include: Female 
with mean score 
≥50 on the WCS 
(subgroup 
analysis) 
Gollings 
and Paxton 
(2006) 
40 women 
Age 21.1 (2.9) 
AUS 
Include: Female 
with mean score 
>81.5 on BSQ
Set Your Body Free 
1. Computer based.
2. Face-to-face.
8 sessions Group 
based. 
Face-to-face 
and 
computer 
delivered 
COM Risk factors 2 months High 
McLean, 
Paxton, and 
Wertheim 
(2011) 
61 women 
Age 43.92 (8.22) 
Australia 
Include:  
Female with body 
dissatisfaction with 
a mean score> 90 
BSQ or >3.5 on the 
combined WSC 
subscales of the 
EDE-Q 
1. CBT based program
2. Control: delayed
treatment
8 sessions Group 
based 
COM Risk factors 3 months High 
Butter et 
Cash 1987 
32 females 
Age 21.3 (5.0) 
Include: 
<25th percentile of 
the BSRQ 
Appearance 
Evaluation 
subscale norms for 
college women. 
1. CBT based program
2. Waitlist control
6 sessions Individual COM Risk factors 7 weeks High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
T scores < 70 on 
both the 
Psychoticism & 
Paranoid Ideation 
scales of the SCL-
90-R.
Weight ≤ 25%
above or below the
median desirable
weight
Dworkin 
and Kerr 
(1987) 
79 females  
Age n.s. 
USA 
Include: women 
had moderate & 
severe body image 
problems & weight 
falling within 
±20% of the 
normal weight 
ranges. 
1. Cognitive therapy
2. CBT
3. Reflective therapy
4. Waitlist control
3 sessions Classroom 
delivered 
COM Risk factors None Unclear 
Kass et al. 
(2014) 
151 females 
Age 21 (2.0) 
USA 
Include: women 
with high weight 
and shape concerns 
(>47 on WSC 
scale). 
1. Student Bodies with
guided self-help
2. Student Bodies
without guided self-
help
8 sessions Internet 
based 
ITT Risk factors None Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Cognitive 
dissonance (CD) 
(24) 
Wiseman, 
Sunday, 
Bortolotti, 
and Halmi 
(2004) 
188 females 
Age 18.9 (2.4) 
USA & Italy 
1. Cognitive
dissonance
2. Attention control
5 sessions (6 
weeks) 
Classroom 
delivered 
Unclear Risk factors None High 
Becker, 
Smith, and 
Ciao (2005) 
149 females 
Age 19.95 (0.9) 
USA 
1. CD (Stice version)
2. Psychoeducation
content of CD
3. Wait-list Control
2 sessions Group 
based (F2F) 
ITT Risk factors 1 months High 
Green, 
Scott, 
Diyankova, 
and Gasser 
(2005) 
155 females 
Age 18.95 (1.01) 
USA 
1. CD low level
2. CD high level
3. No treatment
control
2 sessions Individual 
(F2F) 
COM Risk factors 4 weeks High 
Serdar et al. 
(2014) 
333 females 
Age 18-25 
USA 
1. Face-to-face CD
Stice version
2. Online CD – Stice
version
3. Assessment only
control
3 sessions Group/com
puter based 
Revised 
ITT 
Risk factors None High 
Mitchell, 
Mazzeo, 
Rausch, and 
Cooke 
(2007) 
93 females 
Age 19.56 (4.12) 
USA 
1. Mindfulness
meditation & Yoga
2. CD – Stice vers.
3. Control
6 sessions Group 
based 
ITT Risk factors None High 
Smith and 
Petrie 
(2008) 
29 females 
Age 19.32 (0.94) 
USA 
1. CD – Stice version
2. Healthy weight –
Stice version
3 sessions Group 
based 
ITT Risk factors None Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Include: athletes 
with score on body 
dissatisfaction < 
median 
3. Waitlist control
Stice, Trost, 
and Chase 
(2003) 
148 females 
Age 17.4 
USA 
Include: self-
reported body 
image concern. 
1. CD – Stice version
2. Healthy weight –
Stice version
3. Waitlist control
3 sessions Group 
based 
ITT Risk factors 6 months Unclear 
Stice, Marti, 
Spoor, 
Presnell, 
and Shaw 
(2008); 
Stice, Shaw, 
Burton, and 
Wade 
(2006) 
481 females 
Age 17.4 
USA 
Include: self-
reported body 
image concern. 
1. CD – Stice version
2. Healthy weight –
Stice version
3. Expressive writing
4. Waitlist control
3 sessions Group 
based 
COM Risk factors. 
No. of case 
met DSM-IV 
ED 
3 years Low 
Stice, 
Rohde, 
Gau, and 
Shaw 
(2009); 
Stice, 
Rohde, 
Shaw, and 
Gau (2011) 
306 females 
Age 15.7 (1.1) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. CD – Stice version
2. Educational
brochure control
3 sessions Group 
based 
ITT Risk factors. 
No. of case 
met DSM-IV 
ED 
3 years Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
McMillan, 
Stice, and 
Rohde 
(2011) 
124 females 
Age 20.9 (3.9) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. High Dissonance
program
2. Low Dissonance
program
3. Wait-list control
4 sessions Group 
based 
ITT Risk factors 3 months Unclear 
Stice, 
Durant, 
Rohde, and 
Shaw 
(2014); 
Stice, 
Rohde, 
Durant, and 
Shaw 
(2012) 
107 females 
Age 21.6 (6.6) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. eBody Project
2. Body Project
3. An educational
videos
4. An educational
brochure.
6 sessions 
4 sessions 
Internet/Gro
up based 
ITT Risk factors. 
No. of case 
met DSM-IV 
ED 
3 year Low 
Stice, 
Butryn, 
Rohde, 
Shaw, and 
Marti 
(2013); 
Stice, 
Rohde, 
Butryn, 
Shaw, and 
408 females 
Age 21.6 (5.64) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. Enhanced Body
Project
2. Educational
brochure control
4 sessions Group 
based 
ITT Risk factors. 
No. of case 
met DSM-IV 
ED 
3 year Low 
245 
Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Marti 
(2015) 
Stice, 
Rohde, 
Durant, 
Shaw, and 
Wade 
(2013) 
Study 1 
171 females 
Age 20.9 (4.0) 
US 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. Body Project peer-
led
2. Body Project
clinical-led
3. Educational
brochure control
4 sessions Group 
based 
ITT Risk factors 1 year Low 
Stice, 
Rohde, 
Durant, et 
al. (2013) 
Study 2 
148 females 
Age 21.0 (4.1) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. Intermediate peer-
led Body Project
2. Waitlist control
4 sessions Group 
based 
ITT Risk factors None Low 
Rohde et al. 
(2014) 
Study 1 
81 females 
Age 12.1 (0.9) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. Body Project for
middle school
2. Educational
brochure control
6 sessions Group 
based 
ITT Risk factors None Low 
Rohde et al. 
(2014) 
52 females 
Age 12.5 (0.8) 
1. Enhanced Body
Project
6 sessions Group 
based 
ITT Risk factors 3 months Low 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Study 2 USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
2. Educational
brochure control
Atkinson 
and Wade 
(2014) 
50 females 
Age 20.57 (3.22) 
Australia 
Include: Female 
with body image 
concern with score 
of ≥50 of WCS; at 
least moderately 
afraid of gaining 1 
kg; rating weight as 
the most important 
thing in their lives. 
1. Mindfulness based
intervention
2. The Body Project
3. Control
3 sessions Group 
based 
COM Risk factors 6 months High 
Stice, 
Chase, 
Stormer, 
and Appel 
(2001) 
87 females 
Age 19 (?) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. Body Project
2. Healthy weight
progam
3 sessions Group 
based 
ITT Risk factors 3 months High 
Becker, 
Smith, and 
Ciao (2006) 
80 females 
Age 18.66 (6.2) 
USA 
1. CD (modified Stice
version)
2. Media literacy
2 sessions Group 
based (F2F) 
ITT Risk factors 8 months Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Becker, 
Bull, 
Schaumberg
, Cauble, 
and Franco 
(2008) 
188 females 
Age 18.64 (0.63) 
USA 
1. CD (modified Stice
version)
2. Media literacy
2 sessions Group 
based (F2F) 
ITT Risk factors 8 months Unclear 
Becker, 
McDaniel, 
Bull, 
Powell, and 
McIntyre 
(2012) 
157 females, 
athletes 
Age 18.94 (1.04) 
USA 
1. Athletes modified
CD
2. Athletes healthy
weight
3 sessions Peer led 
group based 
COM Risk factors 1 year High 
Becker et 
al. (2010) 
102 females 
Age 18.73 (0.72) 
USA 
1. Modified Healthy
Weight
2. CD (Stice version)
2 sessions Peer led 
group based 
ITT Risk factors 14 months High 
Healthy Weight 
(7) 
Stice, 
Rohde, 
Shaw, and 
Marti 
(2012, 
2013) 
398 females 
Age 18.4 (0.6) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. Healthy Weight 2
intervention
2. Psyco-educational
brochure control
4 sessions Group 
based 
ITT Risk factors. 
No. of case 
met DSM-IV 
ED 
2 year Low 
Smith and 
Petrie 
(2008) 
29 females 
Age 19.32 (0.94) 
USA 
Include: athletes 
with score on body 
1. CD – Stice version
2. Healthy weight –
Stice version
3. Waitlist control
3 sessions Group 
based 
ITT Risk factors None Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
dissatisfaction < 
median 
Stice et al. 
(2003) 
148 females 
Age 17.4 
USA 
Include: self-
reported body 
image concern. 
1. CD – Stice version
2. Healthy weight –
Stice version
3. Waitlist control
3 sessions Group 
based 
ITT Risk factors 6 months Unclear 
Stice et al. 
(2008); 
Stice et al. 
(2006) 
148 females 
Age 17.4 
USA 
Include: self-
reported body 
image concern. 
1. CD – Stice version
2. Healthy weight –
Stice version
3. Waitlist control
3 sessions Group 
based 
COM Risk factors. 
No. of case 
met DSM-IV 
ED 
3 years Low 
Stice et al. 
(2001) 
87 females 
Age 19 (?) 
USA 
Include: Female at 
high school with 
body image 
concern (verbal 
affirmation). 
1. Body Project
2. Healthy weight
progam
3 sessions Group 
based 
ITT Risk factors 3 months High 
Becker et 
al. (2012) 
157 females, 
athletes 
Age 18.94 (1.04) 
USA 
1. Athletes modified
CD
2. Athletes healthy
weight
3 sessions Peer led 
group based 
COM Risk factors 1 year High 
Becker et 
al. (2010) 
102 females 
Age 18.73 (0.72) 
USA 
1. Modified Healthy
Weight
2. CD (Stice version)
2 sessions Peer led 
group based 
ITT Risk factors 14 months High 
249 
Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Multimedia 
Literacy (7) 
Kusel et al. 
1999 
172 females 
Age 10.8 (0.86) 
USA 
1. Media literacy
2. Control: Video
2 sessions Classroom 
delivered 
COM Risk factors 3 months High 
Neumark-
Sztainer, 
Sherwood, 
Coller, and 
Hannan 
(2000) 
226 females 
Age 10.6 (0.7) 
USA 
1. “Free to be me”
programs
2. Control: stress
management
6 sessions Classroom 
delivered 
COM Risk factors 3 months High 
Sharpe, 
Schober, 
Treasure, 
and 
Schmidt 
(2013) 
448 girls 
Age 13.06 (0.59) 
UK  
1. “Me, You & Us”
program: combine
“Happy Being Me”
and “Media Smart”
2. Usual curriculum
control.
6 sessions Classroom 
delivered 
COM Risk factors 
% clinically 
significant 
change 
3 months High 
López-
Guimerà, 
Sánchez-
Carracedo, 
Fauquet, 
Portell, and 
Raich 
(2011) 
263 females 
Age 13.41 (0.38) 
Spain 
1. Media Literacy
program
2. ML + Nutrition
awareness
3. Class as usual.
4 sessions 
5 sessions 
4 sessions 
Classroom 
delivered 
COM Risk factors 6 months High 
Wilksch, 
Durbridge, 
and Wade 
(2008) 
138 females 
Age 15.0 (0.4) 
Australia 
1. ML
2. Perfectionism
3. Class as usual
8 sessions Classroom 
delivered 
COM Risk factors 
% clinically 
significant 
change 
3 months High 
Becker et 
al. (2006) 
80 females 
Age 18.66 (6.2) 
1. CD (modified Stice
version)
2 sessions Group 
based (F2F) 
ITT Risk factors 8 months Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
USA 2. Media literacy
Becker et 
al. (2008) 
188 females 
Age 18.64 (0.63) 
USA 
1. CD (modified Stice
version)
2. Media literacy
2 sessions Group 
based (F2F) 
ITT Risk factors 8 months Unlcear 
Multicomponent 
(9) 
McVey, 
Davis, 
Tweed, and 
Shaw 
(2004) 
258 females 
Age 11.18 (0.38) 
Canada 
1. “Everybody is
Somebody”
2. Usual school
curriculum
6 sessions Classroom 
delivered 
Unclear Risk factors 12 months High 
Killen et al. 
(1993) 
931 females 
Age 12.4 (0.72) 
USA 
1. Psycho-education +
Healthy eating +
Physical activity +
others
2. Classes as usual
18 sessions Classroom 
delivered 
COM Risk factors 24 months High 
Canetti, 
Bachar, 
Gur, and 
Stein (2009) 
290 females 
Age n.s. (12 yrs) 
Israel 
- Multi-component
- Control group
6 sessions  + 
booster 
sessions 
Classroom 
delivered 
COM Risk factors 1 year Unclear 
McVey and 
Davis 
(2002) 
263 females 
Age 10.88 (0.43) 
Canada 
1. “Everybody is
Somebody”
2. No intervention
control
6 sessions Classroom 
delivered 
ITT Risk factors 12 months High 
Franko et 
al. (2005) 
240 females 
Age 18.2 (0.41) 
USA 
1. “Food, Mood,
Attitude”
2. Attention Control
2 sessions Computer 
based 
COM Risk factors 3 months Unclear 
Favaro, 
Zanetti, 
Huon, and 
141 females 
Age 17 (1.1) 
Italy 
1. Psycho-education +
ML
5 sessions Classroom 
delivered 
ITT Risk factors 1 year Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Santonastas
o (2005)
2. Control (not
specified)
No. of case 
met DSM-IV 
ED 
Elliot et al. 
(2006) & 
Elliot et al. 
(2004) 
928 females 
Age 15.4 (1.2) 
USA 
1. ATHENA program
2. Treatment as usual
8 sessions Group 
based 
COM Risk factors None Unclear 
Raich et al. 
(2008) 
323 females 
Age 13.11 (0.48) 
Spain 
1. Criticism of the
Feminine
Aesthetic-Beauty
Model (AMC) + ML
2. AMC + ML +
Nutrition counselling
3. No intervention
control
2 sessions Classroom 
delivered 
COM Risk factors 6 months High 
López-
Guimerà et 
al. (2011) 
263 females 
Age 13.41 (0.38) 
Spain 
1. Media Literacy
program
2. ML + Nutrition
awareness
3. Class as usual.
4 sessions 
5 sessions 
4 sessions 
Classroom 
delivered 
COM Risk factors 6 months High 
Obesity 
prevention (3) 
Austin, 
Field, 
Wiecha, 
Peterson, 
and 
Gortmaker 
(2005) 
480 females 
Age 11.5 (0.7) 
USA  
1. Planet Health.
2. Control (n.s.)
2 years Class-room 
delivered 
COM Reduced risk 
of using self-
induced 
vomiting/ 
laxatives or 
diet pills to 
control 
weight in the 
past 30 days. 
21 months High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Neumark-
Sztainer et 
al. (2010) 
356 females 
Age 15.8 (1.2) 
USA 
1. New Moves
2. Control: Physical
education class
16 weeks Classroom 
delivered 
ITT Risk factors 
% unhealthy 
weight 
control 
behaviors 
9 months High 
Presnell and 
Stice (2003) 
82 females 
Age 18-28 
USA 
1. Low calorie diet –
LEARN program.
2. Waitlist control
3 sessions 
(6 weeks) 
Classroom 
delivered 
COM + 
ITT 
Risk factors None High 
One-shot (12) Roehrig et 
al. 
2008 
139 females 
Age 20.63 (2.51) 
USA 
1. Obesity prevention
‘prodieting’
messaging
2. ED prevention
“anti-dieting”
messaging
3. Control: Flu
prevention
1 session Group –
Classroom 
delivered 
COM Risk factors 2 weeks High 
Irving and 
Berel 
(2001) 
110 female 
Age 18.93 (2.07) 
USA 
1. External Oriented
ML – Slim Hopes
2. Internal Oriented
ML – Slim Hopes
3. Video only
intervention
4. No intervention
control
1 session Classroom 
delivered 
Unclear Risk factors None High 
Martz and 
Bazzini 
(1999) 
Study 1 
114 females 
Age n.s. 
USA 
1. Peer educator
presentation
2. Control (n.s.)
1 session Group/class
room 
delivered 
COM Risk factors None 
(post-test 
collected 
after 1 
month) 
High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Martz and 
Bazzini 
(1999) 
Study 2 
77 females 
Age n.s. 
USA 
1. Peer educator
presentation w/ guided
imagery exercise.
2. Control n.s.
1 session Group/class
room 
delivered 
COM Risk factors None High 
Dohnt and 
Tiggemann 
(2008) 
84 females 
Age 6.56 (0.77) 
Australia 
1. Shapesville
program
2. Stop, Elephant,
Stop Book (attention
control)
1  session Classroom 
delivered 
Unclear Risk factors 6 weeks Unclear 
Ridolfi and 
Vander Wal 
(2008) 
81 females 
Age 19.16 (1.46) 
USA 
1. Body image session
2. Attention control:
stress management
session.
1 session Classroom 
delivered 
COM Risk factors 4 weeks High 
Buchholz et 
al. 
2008 
62 gymnast female 
Age 13.4 (1.45) 
Canada 
1. Body Sense
2. Wait-list control
1 session Group 
based 
ITT Risk factors None High 
Boivin, 
Polivy, and 
Herman 
(2008) 
63 females 
Age 19.9 (3.1) 
Canada 
1. CD – negative
thinness expectancy
(63)
2. CD – positive
thinness expectancy
3. Measurement only
control
1 session Group 
based 
Unclear Risk factors 4 weeks Unclear 
Mutterperl 
and 
Sanderson 
(2002) 
107 females 
Age 18.08 (0.57) 
USA 
1. Norm
misperception
brochure –
intervention.
2. Healthy behaviour
brochure – control
1 session Group/class
room 
delivered 
COM Risk factors 3 months Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
 Matusek, 
Wendt, and 
Wiseman 
(2004) 
84 females 
Age ?? 
USA 
Inclusion criteria: 
Female with high 
body 
dissatisfaction 
(verbal affirmation) 
1. CD - Stice version
2. Healthy Weight
Intervention
3. Waitlist control
1 sessions Group 
based 
COM Risk factors 4 weeks Unlcear 
Shafran, 
Farrell, Lee, 
and 
Fairburn 
(2009) 
50 females 
Age 18-45 
UK 
Inclusion criteria:  
Female with 
17.5<BMI<35 and 
score one SD or 
more above the 
mean on shape 
concern subscale of 
EDE-Q or a score 
above the mean 
together with a 
score of five or six 
on the ‘Shape 
dissatisfaction’ 
item.  
1. CBT
2. Applied relaxation
(AR)
3. Delayed CBT
4. Delayed AR
1 session 2-hour
workshop
COM Risk factors 12 weeks Low 
Pearson, 
Follette, and 
Hayes 
(2012) 
73 females 
Age 43.4 (14.7) 
Australia 
1. Acceptance and
Commitment Therapy
2. Wait-list control
1 session 1 day 
workshop 
COM Risk factors 2 weeks Unclear 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Inclusion criteria: 
Female with high 
body 
dissatisfaction 
(verbal affirmation) 
Perfectionism (1) Wilksch et 
al. (2008) 
138 females 
Age 15 (0.4) 
Australia 
1. ML
2. Perfectionism
3. Attention control
8 sessions Classroom 
delivered 
COM Risk factors 
% clinically 
significant 
change 
3 months High 
Psycho-
education (6) 
Neumark-
Sztainer, 
Butler, and 
Palti (1995) 
269 girls 
Age 15.3 (0.4) 
Israel 
1. The Weight to Eat
2. Control (n.s.)
10 sessions Classroom 
delivered 
COM Risk factors 
% unhealthy 
dieting and 
bingeing 
behaviors 
2 years High 
Santonastas
o et al.
(1999)
308 females 
Age 16.1 (0.8) 
Italy 
1. Psycho-education
2. Treatment as usual
4 sessions Group 
based 
COM Risk factors 1 year Unclear 
Kaminski 
and 
McNamara 
(1996) 
29 females 
Age 18.3 
USA 
Inclusion criteria: 
Female with a 
score in the top 
50th percentile on 
the EDBQ + at 
least 
2 of 5 
requirements: 
1. Psycho-education
2. Control (n.s.)
8 sessions Group 
based 
COM Risk factors 5 weeks High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
(a) score > the 66th
percentile EDI-
perfectionism
subscale
(b) score < the 33rd
percentile on the
RSE scale
(c) score > the 66th
percentile on the
BAAQ
(d) score > the 66th
percentile on the
FNE scale
(e) score < the 33rd
percentile on the
BES
Olmsted, 
Daneman, 
Rydall, 
Lawson, 
and Rodin 
(2002) 
85 females 
Age 16.0 (2.0) 
Canada 
Inclusion criteria: 
Female with 
diabetes type 1 
have at least: 
- Score ≥9 EDI-DT
- Score ≥5 EDI-B
- Score ≥15 EDI-
BD
- Current or past
binge eating,
1. Psycho-education
2. Control
6 sessions Group 
based 
ITT Risk factors 6 months High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
induced vomiting, 
laxative, or diuretic 
use, dieting, insulin 
omission for weigh 
loss on Modified 
Diagnostic Survey 
of ED 
O'Brien and 
LeBow 
(2007) 
24 females 
Age 22.2 
Canada 
Females with score 
on Revised 
Restrained scale 
≥16 
1. Psycho-education
2. Self-monitoring
control
8 sessions Group 
based 
COM Risk factors 6 months Unclear 
Self-esteem 
enhancement (1) 
Weiss and 
Wertheim 
(2005) 
173 females 
Age 14-16.9 
Australia 
1. “Making Choices”
program
2. No treatment
control
4 sessions Group 
based 
COM Risk factors 3 months High 
Mindfulness 
Meditation & 
Yoga (3) 
Mitchell et 
al. (2007) 
93 females 
Age 19.56 (4.12) 
USA 
1. Mindfulness
meditation & Yoga
2. CD – Stice vers.
3. Control
6 sessions Group 
based 
ITT Risk factors None High 
Atkinson 
and Wade 
(2014) 
50 females 
Age 20.57 (3.22) 
Australia 
Include: Female 
with body image 
concern with score 
of ≥50 of WCS; at 
1. Mindfulness based
intervention
2. The Body Project
3. Control
3 sessions Group 
based 
COM Risk factors 6 months High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
least moderately 
afraid of gaining 1 
kg; rating weight as 
the most important 
thing in their lives. 
Alberts, 
Thewissen, 
and Raes 
(2012) 
26 females 
Age 48.5 (7.90) 
Netherland 
Include: Female 
with experienced 
one or more of the 
following types of 
problematic eating: 
emotional eating, 
stress related 
eating, eating 
without awareness 
and/or overeating 
1. Mindfulness based
intervention
2. Waitlist control
8 sessions Group 
based 
Unclear Risk factors None Unclear 
Interpersonal 
Psychotherapy 
(1) 
Tanofsky-
Kraff et al. 
(2014) 
116 females 
Age 14.5 (1.7) 
USA 
Include: at risk of 
excess weight gain 
because of 
BMI between 75th 
and 97th 
percentiles & at 
least one episode of 
loss of control 
1. Interpersonal
psychotherapy
2. Health education
program
12 sessions Group 
based 
COM Risk factors 12 month Low 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
eating in the past 1 
month 
Indicated prevention 
Cognitive 
Behavioural 
Therapy 
Jones et al. 
(2008) 
105 males and 
females 
Age 15.0 (1.0) 
USA 
Include: 
overweight 
adolescents with 
binge eating 
behavior 
1. Studies Bodies 2-
BED
2. Wait-list control
16 sessions Computer 
based 
COM Risk factors 9 months High 
Jacobi, 
Völker, 
Trockel, 
and Taylor 
(2012) 
126 females 
Age 22.3 
Germany 
Include: women 
with high weight 
and shape concerns 
(>42 on WSC 
scale) and below 
threshold bingeing, 
purging, chronic 
dieting or several 
of these symptoms 
1. Student Bodies
2. Wait-list control
8 sessions Group 
based 
COM % of 
abstinent 
from all 
symptoms of 
disordered 
eating 
Risk factors 
6 months Low 
Paxton, 
McLean, 
Gollings, 
Faulkner, 
and 
116 women 
Age 25.61 (5.83) 
Australia 
Include: Female 
with mean score 
1. “Set Your Body
Free”-
Computer Based
8 sessions Group 
based. 
Face-to-face 
and 
COM + 
ITT 
Risk factors 6 months High 
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Approaches/ 
Intervention (no. 
of trials) 
Study Sample 
Age mean or 
range (SD) 
Study arm Treatment 
durations 
Format Analysis 
method 
Risk factor 
vs. onset 
cases 
Follow up Risk of 
bias 
Wertheim 
(2007) 
≥100 on BSQ or 
BULIT-R score > 
104 + BSQ = 90–
99. 
2. “Set Your Body
Free”- Face to face
(42)
3. Wait-list Control
computer 
delivered 
Psycho-
education 
Buddeberg‐
Fischer, 
Klaghofer, 
Gnam, and 
Buddeberg 
(1998) 
314 females 
Age 16.1 (1.8) 
USA 
Inclusion criteria: 
Female with EAT 
total score ≥ 10 
1. Psycho-education
2. Control (n.s.)
3 sessions Class 
delivered 
COM Risk factors 3 months Unclear 
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APPENDIX A.2.: Summary of pooled effect results of the preventive interventions of eating disorders. 
Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Universal prevention : Media Literacy vs. control 
Shape & Weight Concern (Girls) 2 (2) 300 (300) SMD (Hedges’g, QE, 95% CI) -0.74 [-0.99, -0.49] -0.69 [-1.17, -0.22] EDE-Q WSC 
Shape & Weight Concern (Boys) 2 (2) 291 (291) SMD (Hedges’g, QE, 95% CI) -0.29 [-0.54, -0.04] -0.32 [-0.57, -0.07] EDE-Q WSC 
Dieting (Girls) 4 (4) 783 (783) SMD (Hedges’g, QE, 95% CI) -0.13 [-0.28, 0.02] -0.01 [-0.16, 0.14] DEBQ-Restraint + 
EDE-Q Dieting 
Dieting (Boys) 4 (4) 593 (593) SMD (Hedges’g, QE, 95% CI) -0.16 [-0.33, 0.01] -0.00 [-0.17, 0.17] DEBQ-Restraint + 
EDE-Q Dieting 
Body Dissatisfaction (Girls) 3 (3) 767 (767) SMD (Hedges’g, QE, 95% CI) -0.08 [-0.23, 0.07] -0.05 [-0.20, 0.10] EDI-BD 
Body dissatisfaction (Boys) 
Excluding outliers 
Wilksch 2015 (post-tx) 
3 (3) 
2 
566 (566) 
542 
SMD (Hedges’g, QE, 95% CI) -0.18 [-0.37, 0.00]
-0.24 [-0.41, -0.06]
-0.03 [-0.21, 0.14] EDI-BD 
Media Internalization (Girls) 4 (4) 968 (968) SMD (Hedges’g, QE, 95% CI) -0.21 [-0.34, -0.07] -0.09 [-0.23, 0.05] SATAQ-3 + 
CIMEC 
Media Internalization (Boys) 
Excluding outliers 
4 (4) 968 (968) SMD (Hedges’g, QE, 95% CI) -0.49 [-0.87, -0.11] -0.26 [-0.49, -0.03] SATAQ-3 + 
CIMEC 
270 
Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Wilksch & Wade 2009 (post-tx) 3 442 -0.68 [-0.89, -0.47]
Self-Esteem (Girls) 2 300 SMD (Hedges’g, QE, 95% CI) 0.22 [-0.03, 0.46] 0.18 [-0.40, 0.75] RSE 
Self-Esteem (Boys) 2 291 SMD (Hedges’g, QE, 95% CI) 0.20 [-0.05, 0.44] 0.08 [-0.17, 0.33] RSE 
Universal Prevention: Media Literacy vs. other active interventions (obesity prevention, self-esteem and multicomponent). 
Dieting (Girls) 2 (2) 442 (442) SMD (Hedges’g, QE, 95% CI) -0.04 [-0.23, 0.15] -0.09 [-0.46, 0.28] DEBQ-Restraint + 
EDE-Q dieting 
Dieting (Boys) 2 (2) 242 (242) SMD (Hedges’g, QE, 95% CI) -0.31 [-0.69, 0.07] -0.13 [-0.54, 0.29] DEBQ-Restraint + 
EDE-Q dieting 
Media Internalization (Girls) 2 (2) 542 (542) SMD (Hedges’g, QE, 95% CI) -0.02 [-0.63, 0.59] 0.02 [-0.51, 0.54] SATAQ-3 + 
CIMEC 
Media Internalization (Boys) 2 (2) 316 (316) SMD (Hedges’g, QE, 95% CI) -0.44 [-0.67, -0.21] -0.26 [-0.49, -0.04] SATAQ-3 + 
CIMEC 
Weight concern (Girls) 2 (2) 442 (442) SMD (Hedges’g, QE, 95% CI) -0.08 [-0.50, 0.01] -0.27 [-0.58, 0.04] EDE-Q Weight 
concern subscale 
Weight concern (Boys) 2 (2) 242 (242) SMD (Hedges’g, QE, 95% CI) -0.25 [-0.50, 0.01] -0.14 [-0.40, 0.11] EDE-Q Weight 
concern subscale 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Shape concern (Girls) 2 (2) 442 (442) SMD (Hedges’g, QE, 95% CI) -0.01 [-0.20, 0.17] -0.26 [-0.67, 0.15] EDE-Q Shape 
concern subscale 
Shape concern (Boys) 2 (2) 242 (242) SMD (Hedges’g, QE, 95% CI) -0.10 [-0.35, 0.16] -0.13 [-0.39, 0.12] EDE-Q Shape 
concern subscale 
Universal Prevention: CBT intervention 
ED behaviours 2 (2) 186 (186) WMD (WMD, QE, 95% CI) -1.51 [-5.51, 2.50] 0.44 [-7.00, 7.89] ChEAT-26 
Universal prevention: self-esteem enhancement. 
Dieting 4 (3) 1271 (1118) SMD (Hedges’g, QE, 95% CI) -0.04 [-0.46, 0.38] -0.05 [-0.45, 0.35] EDI-dieting, 
ChEAT-diet, EDE-
Q-restraint 
Dieting (Girls) 2 (2) 215 (215) SMD (Hedges’g, QE, 95% CI) -0.90 [-1.19, -0.61] -0.99 [-1.39, -0.58] EDI-dieting, EDE-
Q-restraint 
Dieting (Boys) 2 (2) 423 (423) SMD (Hedges’g, QE, 95% CI) 0.04 [-0.21, 0.29] 0.08 [-0.32, 0.47] EDI-dieting, EDE-
Q-restraint 
Universal prevention: obesity prevention interventions 
Body dissatisfaction (Girls) 
Excluding outlier 
3 1013 SMD (Hedges’g, QE, 95% CI) -0.05 [-0.30, 0.20] EDI-BD 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Wilksch et al. 2013 2 967 -0.01 [-0.19, 0.16]
Body dissatisfaction (Boys) 3 726 SMD (Hedges’g, QE, 95% CI) -0.10 [-0.33, 0.13] EDI-BD 
Thin-ideal internalization (Girls) 2 575 WMD (WMD, QE, 95% CI) -0.94 [-4.88, 2.99] SATAQ-3 
Thin-ideal internalization (Boys) 2 345 WMD (WMD, QE, 95% CI) -1.75 [-3.10, -0.40] SATAQ-3 
Dieting (Girls) 2 575 WMD (WMD, QE, 95% CI) -1.00 [-2.30, 0.29] DEBQ-restraint 
Dieting (Boys) 2 345 WMD (WMD, QE, 95% CI) 0.25 [-1.23, 1.72] DEBQ-restraint 
Universal prevention: multicomponent 
ED behaviours (whole population) 2 (2) 447 (447) SMD (Hedges’g, QE, 95% CI) -0.21 [-0.61, 0.18] -0.37 [-1.07, 0.32] EAT-40 + EAT-26 
ED behaviours (Girls) 2 (2) 534 (534) SMD (Hedges’g, QE, 95% CI) -0.74 [-1.16, -0.31] -0.59 [-0.77, -0.42] EAT-40 + ChEAT-
26 
Thin Ideal Internalization (Whole 
population) 
Excluding outlier 
Gonzalez et al. 2011 (post-tx and 
follow up) 
3 (3) 
2 (2) 
1134 (1134) 
834 (834) 
SMD (Hedges’g, QE, 95% CI) -0.14 [-0.73, 0.45]
-0.01 [-0.55, 0.53]
-0.41 [-0.68, -0.13]
-0.33 [-0.47, -0.19]
SATAQ + 
SATAQ3 + CIMEC 
Thin Ideal Internalization (Girls) 2 (2) 534 (534) SMD (Hedges’g, QE, 95% CI) -0.12 [-0.86, 0.63] -0.52 [-0.77, -0.27] SATAQ + CIMEC 
Thin Ideal Internalization (Boys) 2 (2) 453 (453) SMD (Hedges’g, QE, 95% CI) -0.07 [-0.87, 0.72] -0.26 [-0.74, 0.23] SATAQ + CIMEC 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Body Dissatisfaction (Whole 
population) 
2 (2) 834 (834) SMD (Hedges’g, QE, 95% CI) 0.04 [-0.10, 0.17] 0.01 [-0.13, 0.15] BSS + CDRS 
Selective prevention: Cognitive Behavioural Therapy 
Weight concern 5(5) 354 (354) SMD (Hedges’g, QE, 95% CI) -0.18 [-0.39, 0.03] -0.12 [-0.33, 0.09] EDE-Q Weight 
Concern subscale 
Shape concern 
Excluding outliers:  
Winzelberg et al. (1998) (post-tx ) 
5 (5) 
4 
354 (354) 
297 
SMD (Hedges’g, QE, 95% CI) -0.09 [-0.30, 0.12]
-0.14 [-0.37, 0.09]
-0.06 [-0.27, 0.15] EDE-Q Shape 
Concern subscale 
Eating concern 5 (5) 354 (354) SMD (Hedges’g, QE, 95% CI) -0.20 [-0.44, 0.03] -0.18 [-0.60, 0.25] EDE-Q Eating 
Concern subscale 
Body dissatisfaction 
Excluding outliers:  
Butter et Cash (1987), Nicolon et al. 
(2001) & Rosen et al. (1989) (post-
tx) 
12 (8) 
9 
717 (467) 
578 
SMD (Hedges’g, QE, 95% CI) -0.24 [-0.67, 0.18]
-0.40 [-0.65, -0.14]
-0.23 [-0.42, -0.04] BSQ + EDI-BD + 
BDBPS 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Dieting 
Excluding outliers: 
Winzelberg et al. (1998) & Nicolon 
et al. (2001) (post-tx) 
Winzelberg et al. (1998) (follow up) 
12 (9) 
10 
(8) 
1144 (925) 
1002 
(868) 
SMD (Hedges’g, QE, 95% CI) -0.44 [-0.67, -0.20]
-0.51 [-0.68, -0.35]
-0.40 [-0.55, -0.26]
-0.44 [-0.59, -0.29]
EDI – Drive for 
thinness + DRES + 
EDE- restraint 
Bulimia symptoms 7 (6) 796 (723) SMD (Hedges’g, QE, 95% CI) -0.27 [-0.41, -0.13] -0.20 [-0.35, -0.05] EDI-Bulimia + 
BULIT-R 
BMI at post tx 7 (6) 849 (776) WMD (WMD, QE, 95% CI) -0.02 [-0.46, 0.43] 0.07 [-0.63, 0.78] 
Self-Esteem 2 (2) 105 (105) WMD (WMD,QE, 95% CI) 0.06 [-3.74, 3.86] 0.28 [-3.18, 3.74] RSE 
Thin ideal internalisation 2 134 SMD (Hedges’g, QE, 95% CI) -0.58 [-0.98, -0.18] SATAQ-3 
Selective Prevention: Cognitive Dissonance vs. control 
Thin-ideal internalization 
Excluding outliers:  
Serdar et al. 2014 (post-tx) 
12 (9) 
(4)* 
11 
1905 (1455) 
(994)* 
1684 
SMD (Hedges’g, QE, 95% CI) -0.71 [-1.14, -0.27]
-0.61 [-0.77, -0.45]
-0.32 [-0.47, -0.17]
-0.16 [-0.27, -0.05]*
IBSS, SATAQ-3 
Dieting 12 (9) 1706 (1455) SMD (Hedges’g, QE, 95% CI) -0.39 [-0.59, -0.19] -0.28 [-0.43, -0.12] DRES 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
(3)* (773)* -0.04 [-0.19, 0.11]*
Body Dissatisfaction 12 (9) 
(4)* 
1706 (1455) 
(1014)* 
SMD (Hedges’g, QE, 95% CI) -0.42 [-0.61, -0.24] -0.20 [-0.39, -0.02]
-0.10 [-0.40, 0.21]*
BDBPS +BPSS-R 
Negative Affect 
Excluding outliers 
Stice et al. 2003 and Rohde et al. 
2014 (post-tx) 
10 (8) 
(2)* 
8 
1307 (1172) 
(649)* 
1142 
SMD (Hedges’g, QE, 95% CI) -0.31 [-0.56, -0.06]
-0.40 [-0.52, -0.27]
-0.23 [-0.35, -0.10]
-0.10 [-0.26, 0.05]*
PANAS-X + 
PANAS-Ch + BDI 
Eating disorder symptoms 
Excluding outliers 
Serdar et al. 2014 and Green et al. 
2006 (post-tx) 
10 (7) 
(3)* 
7 
1550 (1100) 
(773)* 
1185 
SMD (Hedges’g, QE, 95% CI) -0.32 [-0.52, -0.13]
-0.25 [-0.37, -0.14]
-0.09 [-0.27, 0.09]
-0.08 [-0.22, 0.07]*
EDDI + EDDS + 
EDE-Q 
Selective prevention: Cognitive dissonance interventions vs. other interventions (Media literacy and healthy weight interventions). 
Body Dissatisfaction 
Excluding outliers 
7 (6) 792 (773) SMD (Hedges’g, QE, 95% CI) -0.08 [-0.30, 0.14] -0.07 [-0.23, 0.09] BDBPS +BPSS-R 
+ BDS
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Stice et al. 2001 (post-tx) 6 705 -0.03 [-0.18, 0.12]
Dieting 8 (7) 949 (930) SMD (Hedges’g, QE, 95% CI) -0.09 [-0.22, 0.04] -0.03 [-0.16, 0.10] DRES 
Thin Ideal Internalization 
Excluding outliers 
Stice et al. 2001 (follow up) 
8 (7) 
(6) 
949 (930) 
(843) 
SMD (Hedges’g, QE, 95% CI) -0.19 [-0.32, -0.06] -0.05 [-0.25, 0.15]
0.01 [-0.13, 0.14] 
IBSS-R, SATAQ-3 
Bulimic behaviours 8 (7) 949 (930) SMD (Hedges’g, QE, 95% CI) -0.01 [-0.17, 0.14] 0.03 [-0.12, 0.18] EDEQ-B, BULIT-R 
Selective prevention: Healthy Weight vs. control 
Body Dissatisfaction 
Excluding outlier 
Stice et al. 2003 (follow up) 
4 (3) 
(2) 
745 (728) 
(641) 
SMD (Hedges’g, QE, 95% CI) -0.28 [-0.45, -0.12] -0.28 [-0.56, 0.01]
-0.23 [-0.38, -0.07]
BDBPS +BPSS-R 
+ BDS
Thin Ideal Internalization 2 (2) 330 (330) SMD (Hedges’g, QE, 95% CI) -0.45 [-1.16, 0.27] -0.27 [-0.49, -0.05] IBSS-R 
Dieting 
Excluding outlier 
Stice et al. 2003 (post-tx & follow 
up) 
4 (3) 
3 (2) 
745 (728) 
658 (641) 
SMD (Hedges’g, QE, 95% CI) -0.23 [-0.55, 0.09]
-0.17 [-0.33, -0.02]
-0.30 [-0.57, -0.04]
-0.25 [-0.41, -0.10]
DRES 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Negative Affect 
Excluding outlier 
Stice et al. 2006 (post-tx) 
Stice et al. 2003 (follow up) 
4 (3) 
3 
(2) 
745 (728) 
502 
(641) 
SMD (Hedges’g, QE, 95% CI) -0.02 [-0.43, 0.39]
0.16 [-0.02, 0.34] 
0.00 [-0.35, 0.35] 
0.05 [-0.18, 0.29] 
PANAS-X 
Bulimia 2 (2) 330 (330) SMD (Hedges’g, QE, 95% CI) -0.30 [-1.21, 0.60] -0.33 [-0.94, 0.29] EDE-Q Bulimia 
BMI 2 641 WMD (WMD, QE, 95% CI) -0.89 [-1.60, -0.17]
Selective prevention: Media literacy interventions vs. control 
Media/Thin Internalization 
Excluding outliers 
Sharpe et al. 2013 (post-tx) 
5 (5) 
4 
1060 (1060) 
612 
SMD (Hedges’g, QE, 95% CI) -1.20 [-2.46, 0.06]
-0.45 [-1.02, 0.12]
-1.53 [-2.90, -0.15] SATAQ, SATAQ-3 
and CIMEC 
Selective prevention: Media literacy interventions vs. other interventions (Cognitive Dissonance, Multicomponent and Perfectionism interventions.) 
Media/Thin Internalization 4 (4) 482 (482) SMD (Hedges’g, QE, 95% CI) 0.11 [-0.07, 0.29] 0.09 [-0.18, 0.36] SATAQ, SATAQ-3 
and CIMEC 
Dieting 4 (4) 482 (482) SMD (Hedges’g, QE, 95% CI) 0.06 [-0.12, 0.24] 0.08 [-0.09, 0.27] DEBQ-R (DRES), 
EDE-Q-R, EAT-D 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Selective prevention: Multicomponent interventions 
ED behaviours 3 (5) 677 (1046) SMD (Hedges’g, QE, 95% CI) -0.15 [-0.31, 0.01] -0.15 [-0.28, -0.02] EAT-40, ChEAT-
26 
Media Internalization 2 (2) 414 (414) WMD (WMD, QE, 95% CI) -0.27 [-0.48, -0.05] -0.31 [-0.60, -0.03] CIMEC 
Selective prevention: One-shot interventions 
Media/thin Internalization 6 515 SMD (Hedges’g, QE, 95% CI) 0.01 [-0.22, 0.24] SATAQ, SATAQ-3 
Dieting 5 434 SMD (Hedges’g, QE, 95% CI) -0.12 [-0.31, 0.07] CBDS, Self-
efficacy over 
Dieting, EDI-DT 
Body dissatisfaction 
Excluding outlier 
Matusek et al. 2004 
3 
2 
218 
158 
SMD (Hedges’g, QE, 95% CI) -0.04 [-0.31, 0.22]
0.07 [-0.24, 0.38] 
BSQ-R, EDI-BD 
Self-esteem 
Excluding outlier 
Buchholz et al. 2008 
4 
3 
357 
251 
SMD (Hedges’g, QE, 95% CI) 0.09 [-0.12, 0.31] 
0.00 [-0.26, 0.25] 
BES, RSE 
Selective prevention: Psychoeducation interventions 
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Body dissatisfaction 
Outliers excluding  
Kaminski & McNamara (1999) 
2 (3) 
(2) 
114 (378) 
(349) 
SMD (Hedges’g, QE, 95% CI) -0.73 [-2.32, 0.87] -0.25 [-0.96, 0.45]
-0.15 [-0.37, 0.06]
EDI-BD 
ED behaviours (2) (578) SMD (Hedges’g, QE, 95% CI) -0.09 [-0.25, 0.07] EAT-20 & EAT-40 
Selective prevention: Mindfulness-based interventions 
Dieting 2 53 WMD (WMD, QE, 95% CI) 0.38 [-0.04, 0.80] EDI-BD 
Indicated Prevention: Cognitive Behavioral Therapy 
Shape and weight concern 2 (2) 208 (208) SMD (Hedges’g, QE, 95% CI) -0.13 [-0.41, 0.14] -0.14 [-0.41, 0.14] EBI, WSC 
Body dissatisfaction 2 182 SMD (Hedges’g, QE, 95% CI) -0.39 [-1.20, 0.41] BSQ, EDI-BD 
Dieting 2 182 SMD (Hedges’g, QE, 95% CI) -0.31 [-0.74, 0.11] EDE-restraint, 
DEBQ 
Bulimic behaviour 2 182 SMD (Hedges’g, QE, 95% CI) 0.06 [-0.46, 0.58] EDI-Bulimia, 
BULIT-R 
BMI 3 (2) 287 (208) WMD (WMD, QE, 95% CI) -0.52 [-1.42, 0.39] -0.78 [-1.76, 0.20]
SMD: Standardized Mean Difference; WMD: Weighted Mean Difference; EDE-Q: Eating Disorder Examination – Questionnaire; WSC: Weight and Shape Concern; DEBQ: 
Dutch Eating Behavior Questionnaire. EDI-BD: Eating Disorder Inventory – Body Dissatisfaction scale; EDI-DT: Eating Disorder Inventory- Drive for Thinness. SATAQ: 
Sociocultural Attitudes Towards Appearance Questionnaire; CIMEC: Questionnaire on influences of aesthetic body ideal; BES: Body Esteem Scale;  RSE: Rosenberg Self-
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Outcome or Subgroup Title No. of 
studies 
at post-
test (at 
follow 
up) 
No. of 
participants 
at post-test 
(at follow 
up) 
Statistical method Pooled effect at 
post-test [95% CI] 
Pooled effect at 
follow up [95% CI] 
Measure Scale 
Esteem; ChEAT: Eating Attitudes Test – Children version; BSQ: Body Satisfaction Questionnaire; IBSS: The Ideal-Body Stereotype Scale; EDDS: The Eating Disorder 
Diagnostic Survey; EDDI: The Eating Disorder Diagnostic Interview; EBI: Eating Behaviors Inventory; BULIT-R: Bulimia Test Revised; BDBPS: the Satisfaction and 
Dissatisfaction With Body Parts Scale; PANAS-X: the Positive Affect and Negative Affect Scale-Revised; BDI: Beck Depression Inventory; DRES: The Dutch Restrained 
Eating Scale; BMI: Body Mass Index, BSS: Body Dissatisfaction Scale, CDRS: Contour Drawing Rating Scale, CBDS: Cognitive Behaviour Dieting Scale. 
*At second follow up: 2- to 3- year follow up.
Figures in parentheses are at follow up. 
APPENDIX A.2: RISK OF PUBLICATION BIAS: RESULTS OF LFK INDEX1 
Outcome or 
Subgroup Title 
LFK index at 
post test 
Risk of 
publication bias 
LFK index at 
follow up 
Risk of 
publication 
bias 
Universal prevention : Media Literacy vs. control 
Shape & Weight 
Concern (Girls) 
4.30 Major 4.27 Major 
Shape & Weight 
Concern (Boys) 
-4.40 Major 4.33 Major 
Dieting (Girls) -3.84 Major 2.42 Major 
Dieting (Boys) 0.23 No 3.62 Major 
Body Dissatisfaction 
(Girls) 
-2.16 Major 2.05 Major 
Body dissatisfaction 
(Boys) 
3.66 Major -0.04 No 
Media 
Internalization 
(Girls) 
-2.87 Major -0.04 No 
Media 
Internalization 
(Boys) 
-2.44 Major 1.93 Minor 
Self-Esteem (Girls) 4.38 Major 4.41 Major 
Self-Esteem (Boys) -4.37 Major 4.36 Major 
Universal Prevention: CBT intervention 
Eating pathology -3.23 Major -2.89 Major 
Universal prevention: self-esteem enhancement. 
Dieting 3.05 Major 3.00 Major 
Dieting (Girls) 4.34 Major -4.59 Major 
Dieting (Boys) 4.32 Major 4.31 Major 
Universal prevention: obesity prevention interventions 
Body dissatisfaction 
(Girls) 
-2.66 Major 
Body dissatisfaction 
(Boys) 
-0.30 No 
Thin-ideal 
internalization 
(Girls) 
-4.64 Major 
Thin-ideal 
internalization 
(Boys) 
4.79 Major 
Dieting (Girls) -3.83 Major 
Dieting (Boys) 2.95 Major 
Universal prevention: multicomponent 
Eating pathology 2.31 Major 2.27 Major 
1 LFK index of asymmetry which was developed by Luis Furuya-Kanamori assess the 
severity (‘No if LFK index within ±1’, ‘Minor if LFK index exceeds ±1 but within ±2’, and 
‘Major’ if LFK index exceeds ±2) of risk of publication bias. 
Outcome or 
Subgroup Title 
LFK index at 
post test 
Risk of 
publication bias 
LFK index at 
follow up 
Risk of 
publication 
bias 
(whole population) 
Eating pathology 
(Girls) 
2.51 Major -2.63 Major 
Thin Ideal 
Internalization 
(Whole population) 
-3.34 Major -2.65 Major 
Thin Ideal 
Internalization 
(Girls) 
-2.66 Major -2.64 Major 
Thin Ideal 
Internalization 
(Boys) 
-2.91 Major -2.9 Major 
Body Dissatisfaction 
(Whole population) 
-3.43 Major -3.43 Major 
Selective prevention: Cognitive Behavioural Therapy vs. control 
Weight concern 0.81 No 0.57 No 
Shape concern 1.24 Minor 0.45 No 
Eating concern -1.34 Minor -2.41 Major 
Body dissatisfaction -0.64 No -2.73 Major 
Dieting 1.81 Minor -0.12 No 
Bulimia symptoms -1.50 Minor -3.18 Major 
BMI -0.46 No 0.31 No 
Self-esteem 7.32 Major 
Media internalisation -1.95 Minor 
Selective Prevention: Cognitive Dissonance vs. control 
Thin-ideal 
internalization 
-0.46 No -0.12 No 
At 2-3 year follow up 1.54 Minor 
Dieting 0.00 No -0.45 No 
At 2-3 year follow up -2.91 Major 
Body Dissatisfaction 1.24 Minor -1.54 Minor 
At 2-3 year follow up -0.46 No 
Eating 
Pathology/symptoms 
-0.54 No -0.39 No 
At 2-3 year follow up -0.19 No 
Negative affect 2.84 Major 0.36 No 
Selective Prevention: Cognitive Dissonance vs. other interventions 
Body Dissatisfaction 1.31 Minor -1.80 Minor 
Thin Ideal 
Internalization 
0.74 No -1.28 Minor 
Dieting 3.90 Major -1.16 Minor 
Bulimic behaviours 0.49 No -0.67 No 
Selective prevention: Healthy Weight vs. control 
Body Dissatisfaction -1.81 Minor -3.66 Major 
Thin Ideal 
Internalization 
-2.95 Major 2.81 Major 
Dieting -2.20 Major -3.11 Major 
Negative Affect  1.87 Minor -1.82 Minor 
Outcome or 
Subgroup Title 
LFK index at 
post test 
Risk of 
publication bias 
LFK index at 
follow up 
Risk of 
publication 
bias 
Bulimia -2.96 Major -2.92 Major 
BMI -2.24 Major 
Selective prevention: Media literacy interventions vs. control 
Media/thin 
Internalization 
-0.33 No -1.66 Minor 
Selective prevention: Media literacy interventions vs. other interventions 
Media/thin 
Internalization 
-2.48 Major 2.50 Major 
Dieting -0.26 No 0.07 No 
Selective prevention: multicomponent interventions 
ED 
pathology/symptoms 
-0.46 No 0.35 No 
Media 
Internalization 
2.20 Major -2.52 Major 
Selective prevention: One-shot interventions 
Media/thin 
Internalization 
0.16 No 
Dieting -0.66 No 
Body dissatisfaction -1.78 Minor 
Self-esteem 0.68 No 
Selective prevention: Psycho-education 
Body Dissatisfaction -3.22 Major 
Eating Pathology 
Selective prevention: Mindfullness based intervention 
Dieting 1.74 Minor 
Indicated Prevention: Cognitive Dissonance Therapy 
Shape and weight 
concern 
-1.69 Minor -1.72 Minor 
Body dissatisfaction -2.08 Major 
Dieting -2.02 Major 
Bulimia symptoms -1.97 Minor 
BMI 0.25 No -3.33 Major 
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Estimation of a Relative Risk Effect Size
When Using Continuous Outcomes Data:
An Application of Methods in the Prevention
of Major Depression and Eating Disorders
Yong Yi Lee , Long Khanh-Dao Le, Emily A. Stockings, Phillipa Hay,
Harvey A. Whiteford, Jan J. Barendregty, and Cathrine Mihalopoulos
Abstract
Introduction. The raw mean difference (RMD) and standardized mean difference (SMD) are continuous effect size
measures that are not readily usable in decision-analytic models of health care interventions. This study compared
the predictive performance of 3 methods by which continuous outcomes data collected using psychiatric rating scales
can be used to calculate a relative risk (RR) effect size. Methods. Three methods to calculate RR effect sizes from
continuous outcomes data are described: the RMD, SMD, and Cochrane conversion methods. Each conversion
method was validated using data from randomized controlled trials (RCTs) examining the efficacy of interventions
for the prevention of depression in youth (aged  17 years) and adults (aged 18 years) and the prevention of eating
disorders in young women (aged  21 years). Validation analyses compared predicted RR effect sizes to actual RR
effect sizes using scatterplots, correlation coefficients (r), and simple linear regression. An applied analysis was also
conducted to examine the impact of using each conversion method in a cost-effectiveness model. Results. The predic-
tive performances of the RMD and Cochrane conversion methods were strong relative to the SMD conversion
method when analyzing RCTs involving depression in adults (RMD: r = 0.89–0.90; Cochrane: r = 0.73; SMD: r =
0.41–0.67) and eating disorders in young women (RMD: r = 0.89; Cochrane: r = 0.96). Moderate predictive
performances were observed across the 3 methods when analyzing RCTs involving depression in youth (RMD: r =
0.50; Cochrane: r = 0.47; SMD: r = 0.46–0.46). Negligible differences were observed between the 3 methods when
applied to a cost-effectiveness model. Conclusion. The RMD and Cochrane conversion methods are both valid meth-
ods for predicting RR effect sizes from continuous outcomes data. However, further validation and refinement are
required before being applied more broadly.
Keywords
methods, meta-analysis, outcome measures, major depressive disorder, eating disorders, prevention
Date received: September 26, 2017; accepted: July 11, 2018
Structured clinical interviews are the gold standard for
measuring the efficacy of interventions for the treatment
or prevention of mental disorders.1,2 Even so, these inter-
vention trials often measure outcomes using continuous
scores on a psychiatric rating scale.3,4 Examples of psy-
chiatric rating scales include the Beck Depression
Inventory (BDI) for major depression5,6 and the Eating
Disorder Diagnostic Scale (EDDS) for eating disorders.7
Using psychiatric rating scales to measure changes in
the diagnosis and/or symptomatology of mental disor-
ders can be less resource intensive than conducting
yDeceased 4 June 2017.
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comprehensive diagnostic interviews.4,8 Despite these
advantages, the clinical interpretation of rating scale out-
comes is often reliant on subjective rules of thumb.3,4
For example, cutoff scores are typically used to differ-
entiate the boundary between mental health and mental
illness (e.g., an EDDS score 16.5 indicates a possible
diagnosis for an eating disorder).3,9
Two methods are commonly used when meta-
analyzing randomized controlled trials (RCTs) to calcu-
late a pooled effect size based on continuous data from
psychiatric rating scales.10,11 The first is the raw mean
difference (RMD), which measures the absolute differ-
ence between the mean scores of intervention and control
groups in an intervention RCT.10,11 The RMD measure
is simple to interpret as outcomes are scaled to the origi-
nal units of analysis. However, this method is only appli-
cable when all RCTs in the analysis measure intervention
outcomes using an identical rating scale—a scenario that
rarely occurs in practice.11–13 By contrast, the standar-
dized mean difference (SMD) is used when the RCTs in
a meta-analysis evaluate conceptually similar outcomes
(e.g., the severity of depressive symptoms) using different
psychiatric rating scales.10,11 Heterogeneous scale out-
comes are translated into a standardized metric by
expressing the intervention effect in terms of the variabil-
ity observed in the RCT.10 Cohen’s d is a well-known
SMD measure that calculates the difference in means
between 2 groups (intervention v. control) divided by the
pooled within-group standard deviation.10,14 However,
due to a slight bias in Cohen’s d, it is common to apply a
correction factor (J) to calculate Hedges’ g.10,14 The
effect sizes d and g are expressed in standard deviation
units, which makes them difficult to interpret without
appropriate interpretative benchmarks.10,11,15 For exam-
ple, it is common to classify SMD effect sizes as ‘‘small’’
when d = 0.2, ‘‘moderate’’ when d = 0.5, and ‘‘large’’
when d= 0.8.16
Problems arise when incorporating RMD or SMD
effect sizes in decision-analytic models of health
care interventions. Modeling intervention effects often
involves calculating the change in disease-related inci-
dence and/or remission following an intervention.17–19
The most common parameter type used to incorporate
intervention effects into such models is the relative risk
(RR), an effect size measure calculated using dichoto-
mous outcomes data.17,20 Applying this effect size mea-
sure involves multiplying the RR by the disease-related
parameter of interest.17,18 Unlike the RR effect size, it is
unclear how a continuous RMD or SMD effect size can
be used to calculate changes in disease-related incidence
or remission. A method described in the Cochrane hand-
book, hereafter referred to as the ‘‘Cochrane conversion
method,’’ can be used to convert an SMD effect size into
an RR effect size.10,14,21,22 Briefly, this involves calculat-
ing an odds ratio (OR) by assuming that continuous out-
comes across the intervention and control groups have
certain mathematical properties.21,22 The resulting OR is
then transformed into an RR effect size using an esti-
mate of the assumed control risk.10 Despite being
straightforward to implement, the Cochrane conversion
method can potentially lead to a loss of continuous
information due to the dichotomization of continuous
data obtained from psychiatric rating scales.
This study will propose novel methods by which con-
tinuous outcomes data collected using a psychiatric rat-
ing scale can be used to calculate an RR effect size while
simultaneously preserving the continuous information
inherent to the scale. Validation analyses will be con-
ducted to compare the predictive performance of these
‘‘continuous’’ conversion methods to the ‘‘dichotomous’’
Cochrane conversion method by applying them to psy-
chiatric rating scales for 2 mental disorders—major
depression and eating disorders.
Methods
Overview
The methods for this study are outlined over several sec-
tions. The first section describes methods by which to
calculate RR effect sizes from continuous outcomes
data. Continuous conversion methods are outlined for
both the RMD and SMD scenarios, hereafter referred to
as the ‘‘RMD conversion method’’ and the ‘‘SMD con-
version method.’’ This is followed by a description of the
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dichotomous Cochrane conversion method. The second
section describes methods used to estimate a central
parameter required to implement the RMD/SMD con-
version methods (i.e., the RR per unit parameter). The
sections after this outline validation analyses that were
conducted to evaluate the predictive performance of the
RMD, SMD, and Cochrane conversion methods by
using empirical data from intervention RCTs. The final
section describes an analysis conducted to examine the
relative impact of applying each conversion method in a
cost-effectiveness model.
Methods to Calculate an RR Effect Size Using
Continuous Data
A meta-analysis of continuous outcomes data can be
conducted under 1) the RMD scenario when the RCTs
in a meta-analysis use an identical scale and 2) the SMD
scenario when the RCTs use an assortment of scales to
measure a common construct. Equation (1) can be used
in the RMD scenario to calculate an RR effect size based
on the mean scores observed between 2 groups in an
RCT:
RRpredicted =RRpu
mimcð Þ; ð1Þ
where RRpredicted is the predicted RR effect size based on
continuous outcomes data, RRpu is the RR per unit for a
particular rating scale, mi is the mean score of the inter-
vention group, and mc is the mean score of the control
group. The RRpu parameter denotes the risk of having a
mental disorder for each additional unit score on a psy-
chiatric rating scale. In this case, the psychiatric rating
scale is representative of a risk factor exposure with an
underlying distribution of scores in the population.23
This is akin to other physical health risk factors such as
body mass index (BMI) and systolic blood pressure,
which are causally linked to chronic diseases like heart
disease and diabetes.24 Just as an additional BMI unit is
associated with an increased risk of diabetes, so too is an
additional unit on a psychiatric rating scale associated
with an increased risk of having a mental disorder.
Equation (1) calculates the absolute difference in mean
scores between the intervention and control groups (the
RMD effect size) and then translates this difference into
a corresponding RR effect size by exponentiating it with
the RRpu associated with the relevant scale.
Equation (2) can be used in the SMD scenario to cal-
culate an RR effect size based on the mean scores
between 2 groups in an RCT:
RRpredicted =RRpu
g:swithin
Jð Þ; ð2Þ
where g is an estimate of Hedges’ g, swithin is the pooled
within-group standard deviation, and J is the Hedges’ g
correction factor. Equation (2) follows a similar process
as equation (1). However, the exponent of equation (2)
now estimates the absolute difference in mean scores
between the intervention and control groups by inverting
the formula used to calculate Hedges’ g (the SMD effect
size). Further description of the 2 equations is provided
in Supplemental Text S1.
The Cochrane conversion method is a dichotomous
alternative to the continuous RMD/SMD conversion
methods and encompasses 2 steps. The first step trans-
forms an SMD effect size to a (log) odds ratio using
equation (3):
ln ORð Þ= pﬃﬃﬃ
3
p
 
:SMD; ð3Þ
where ln ORð Þ is the log odds ratio, and SMD is the stan-
dardized mean difference. This equation is based on the
assumption that the mean scores for the intervention and
control groups follow a logistic distribution and have
standard deviations that are equal across both
groups.21,22 The second step transforms the OR estimate
to a corresponding RR effect size using equation (4):
RR=
OR
1 ACR3 1 ORð Þ ; ð4Þ
where RR is the relative risk, OR is the odds ratio, and
ACR is the assumed control risk. The assumed control
risk (ACR) is typically the median control group risk
among the RCTs in a meta-analysis.10
A 95% confidence interval can be calculated for a pre-
dicted RR effect size by using Monte Carlo simulation
to propagate parameter uncertainty around the initial
RMD/SMD effect size through to the final predicted RR
effect size.17,25 Here the RMD/SMD effect size is
assumed to be normally distributed with a mean corre-
sponding with the (raw or standardized) mean difference
and a standard deviation corresponding with the stan-
dard error of that mean difference.14,26
Estimation of the RR per Unit Parameter
The RR per unit (RRpu) associated with a psychiatric rat-
ing scale is a central parameter in equations (1) and (2) of
the RMD/SMD conversion methods. However, no study
has yet calculated RRpu parameters for scales involving
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major depression and eating disorders. Data from studies
examining the diagnostic utility (i.e., sensitivity and speci-
ficity) of a psychiatric rating scale can be used to estimate
the RR of having a mental disorder when scoring above
a cutoff on the scale. In turn, the RRpu parameter can be
estimated by solving 2 simultaneous equations to convert
1) the RR of having a mental disorder when scoring
above a cutoff on the scale, a categorical RR estimate,
into 2) the RR of having a mental disorder per unit score
on the scale (RRpu), a continuous RR estimate. The 2
simultaneous equations are based on comparative risk
assessment methods used in burden of disease studies to
quantify the impact of risk factor exposures on final
health outcomes.23,24,27
Supplemental Text S2 provides a complete description
of the methods used to estimate RRpu parameters for sev-
eral psychiatric rating scales that are commonly
employed by RCTs examining the efficacy of interven-
tions for the prevention of major depression and eating
disorders. In-scope psychiatric rating scales for depres-
sion included the Beck Depression Inventory, first edi-
tion (BDI-I, 21 items); the Beck Depression Inventory,
second edition (BDI-II, 21 items); and the Center for
Epidemiologic Studies Depression scale (CES-D, 20
items). Likewise, in-scope rating scales for eating disor-
ders encompassed the EDDS (22 items) and the Eating
Disorder Diagnostic Interview (EDDI, 31 items). The
main characteristics of each scale are summarized in
Table 1. Briefly, a search was conducted to identify diag-
nostic utility studies for in-scope psychiatric rating scales
that 1) were conducted in population-representative sam-
ples and 2) contained the necessary data to estimate the
RRpu parameter. An estimate of RRpu was calculated for
each study by solving the aforementioned simultaneous
equations. If multiple RRpu estimates were available from
different diagnostic utility studies for the same scale,
then a meta-analysis was performed to calculate a pooled
RRpu for that scale. Meta-analyses were conducted using
the ‘‘inverse variance heterogeneity’’ (IVhet) model,
which calculates an estimator under the fixed-effect
model assumption with a quasi-likelihood-based var-
iance structure.28 The I2 statistic was used to measure the
presence of statistical heterogeneity in pooled estimates,
with heterogeneity classified as low, moderate, or high
based on I2 values of 25%, 50%, and 75%, respec-
tively.10 Meta-analyses were conducted using MetaXL
5.3, an Excel add-in developed by EpiGear International
Pty Ltd (available at http://www.epigear.com/index_
files/metaxl.html).
Validation Analysis of the RMD Conversion
Method
The first step in validating the RMD conversion method
involved compiling data from RCTs examining the effi-
cacy of interventions for the prevention of depression in
youth (aged  17 years) and adults (aged 18
years),13,29–31 as well as the prevention of eating disor-
ders in young women (aged  21 years).12,32 These
RCTs were identified based on a search of previous sys-
tematic reviews. Inclusion criteria comprised RCTs that
simultaneously 1) presented data on the mean and stan-
dard deviation of scores for a given rating scale in both
intervention and control groups and 2) calculated an RR
effect size estimate from dichotomous diagnostic out-
comes identified using Diagnostic and Statistical Manual
of Mental Disorders (DSM)/International Classification
of Diseases (ICD) diagnostic criteria via structured clini-
cal interviews. RCTs conducted in community or pri-
mary care settings were in scope for the baseline
validation analysis, while RCTs involving clinical sam-
ples were excluded.
Data were extracted for each follow-up period that
was reported by in-scope RCTs on the actual RR effect
size reported and the mean/standard deviation of rating
scale scores reported for the intervention and control
Table 1 Selected Psychiatric Rating Scales for Depression and Eating Disorders
Psychiatric Rating Scale (by Disorder)
Year of
Release
Minimum
Score
Maximum
Score
Cutoff
Score Sources
Depression
Beck Depression Inventory, first edition (21 items) 1961 0 63 10 5,87
Beck Depression Inventory, second edition (21 items) 1996 0 63 14 6
Center for Epidemiologic Studies Depression scale (20 items) 1977 0 60 16 88
Eating disorders
Eating Disorder Diagnostic Scale (22 items) 2000 0 122 16.5 7,9
Eating Disorder Diagnostic Interview (31 items) 2000 0 87 NA 89,90
NA, not applicable.
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groups. It follows that a single RCT could contribute
multiple data points if it contained extractable data for
more than 1 follow-up period. In addition, RCTs that
included multiple comparisons (e.g., multiple interven-
tion arms) were treated as independent studies for the
purposes of both data extraction and analysis, with
Cochrane Collaboration methods used to overcome unit-
of-analysis errors.10 Extracted data were used to calcu-
late predicted RR effect sizes using the RMD conversion
method. Ersatz (version 1.31, Sunrise Beach, Australia;
available at http://www.epigear.com/) was used to per-
form Monte Carlo simulations (10,000 iterations) to pro-
duce 95% confidence intervals for each predicted RR
estimate. A scatterplot was generated by plotting pre-
dicted RR estimates on the x-axis and actual RR esti-
mates on the y-axis.33 Pearson’s correlation coefficient
(r) was used to measure the strength of the linear rela-
tionship between both sets of estimates, which was
defined as ‘‘weak’’ if rj j was 0.00 to 0.33, ‘‘moderate’’ if
rj j was 0.34 to 0.66, and ‘‘strong’’ if rj j was 0.67 to 1.00.34
A simple linear regression was also conducted to regress
observed RR values against predicted RR values. The
slope and intercept of the fitted line were compared
against the 1:1 line (a.k.a. the line of equality) by con-
ducting t tests to examine the null hypothesis that
slope=1 and intercept= 0.33 Statistical analyses were
performed in R using the in-built ‘‘stats’’ package.35
The RMD conversion method calculates a predicted
RR effect size based on RRpu parameters for a matching
scale. However, several RCTs used rating scales with no
matching RRpu parameter. When analyzing RCTs involv-
ing depression in adults, this problem was addressed by
using data from studies that employed item response the-
ory (IRT) to calculate crosswalks between different
depression rating scales among adult samples.36,37 These
crosswalks allow scores from different rating scales to be
converted into a common metric. The primary analytic
scenario for the RMD validation of depression in adults
involved using the ‘‘original scale’’ when a matching
RRpu parameter was available and converting scores to
the BDI-I scale using crosswalks when no matching RRpu
parameter was available. In addition, secondary analytic
scenarios were evaluated to examine the impact of using
crosswalks to convert all scores into the BDI-I, BDI-II,
or CES-D scales. Crosswalks were not applied to RCTs
involving depression in youth or eating disorders in
young women due to the absence of available crosswalks
for these particular subgroups. When analyzing RCTs
involving depression in youth, several RCTs were found
to use rating scales with no matching RRpu parameter
(e.g., the Children’s Depression Inventory [CDI]). These
RCTs were excluded from the analysis as it was not pos-
sible to calculate predicted RR effect sizes using the
RMD conversion method. All RCTs involving eating
disorders in young women used rating scales with match-
ing RRpu parameters and were thus included in the RMD
validation.
Validation Analysis of the SMD Conversion
Method
The SMD conversion method was validated using the
same set of intervention RCTs that were used to validate
the RMD method. In this case, however, crosswalks were
not required as the SMD method inherently accounts for
rating scale heterogeneity. Subsequently, RCTs of
depression in youth that were previously excluded from
the RMD validation due to the absence of matching
RRpu parameters were reincluded in the SMD validation.
The validation of the SMD conversion method required
estimates of the pooled within-group standard deviation
(swithin). A swithin parameter was estimated for each psy-
chiatric rating scale with a corresponding RRpu parameter
by 1) obtaining estimates of swithin for a given scale from
the intervention RCTs included in the validation analysis
and 2) calculating the weighted arithmetic mean of these
estimates to produce a pooled swithin parameter. The
RCTs included in the SMD validation analysis did not
contain data by which to calculate swithin parameters for
the BDI-II scale or any of the eating disorders scales. It
follows that swithin parameters were only calculated for
the BDI-I and CES-D scales, with separate parameters
calculated for depression in adults and depression in
youth.
The SMD validation was only conducted for the BDI-
I and CES-D scales using RCTs involving depression in
adults and depression in youth. No SMD validation was
conducted for the BDI-II scale and the 2 eating disorders
scales due to the absence of corresponding swithin para-
meters. As before, predicted RR effect sizes were calcu-
lated (with 95% confidence intervals) and compared to
actual RR estimates using scatterplots, correlation coeffi-
cients, and simple linear regression.
Validation Analysis of the Cochrane Conversion
Method
The Cochrane conversion method was validated using
the same set of RCTs used to validate the RMD conver-
sion method. This comprised all RCTs examining the
prevention of depression in adults, depression in youth
(including those RCTs that were formerly excluded due
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to the absence of matching RRpu parameters), and eating
disorders in young women. Predicted RR effect sizes
were calculated here by assuming that the ACR was the
median of the observed control group risks among the
RCTs included in the validation analysis. Once again,
predicted RR estimates were calculated (with 95% confi-
dence intervals) and compared to actual RR estimates
using scatterplots, correlation coefficients, and simple
linear regression.
Sensitivity Analysis Including RCTs Comprising
Clinical Samples
RCTs comprising clinical samples were excluded from
the baseline validation of the RMD, SMD, and
Cochrane conversion methods. Sensitivity analyses were
subsequently conducted to test the robustness of the
baseline validation results by reanalyzing the data after
including RCTs comprising clinical samples.
Applied Analysis of the 3 Conversion Methods in
a Cost-Effectiveness Model
An analysis was conducted to evaluate the impact of
applying the RMD, SMD, and Cochrane conversion
methods in a cost-effectiveness model. The applied anal-
ysis used a model developed to evaluate the cost-
effectiveness of implementing a community-based inter-
vention to prevent the incidence of major depression
among Australian adults with subthreshold depression
(i.e., depressive symptoms that fall short of the full diag-
nostic threshold for major depression). This model was
adapted from a previous population-based model evalu-
ating the cost-effectiveness of school-based interventions
to prevent depression in youth.38 Briefly, the current
model simulated changes in depression incidence result-
ing from the community-based intervention with respect
to a ‘‘no intervention’’ comparator. Incremental net costs
were equal to the cost of the intervention minus cost off-
sets (i.e., treatment costs averted due to the prevention
of new depression cases). Incremental benefits were cal-
culated as the difference in health outcomes between the
population cohorts in the intervention and comparator
scenarios. Health outcomes were evaluated using the
disability-adjusted life year (DALY), which is a sum-
mary measure of changes in mortality and morbidity.
The resulting incremental cost-effectiveness ratio (ICER)
was measured in 2013 Australian dollars per DALY
averted and was evaluated with respect to an Australian
willingness-to-pay (WTP) threshold of A$50,000 per
DALY averted.39,40 Costs and benefits were discounted
at 3% per annum, and Monte Carlo analysis was used to
calculate 95% uncertainty intervals for all model out-
puts. A manuscript providing a complete description of
the model is available from the authors upon request,
with a summary of the model’s main features provided
in Supplemental Text S3.
Intervention effect sizes were based on a meta-analysis
of RCTs examining the efficacy of community-based
interventions for the prevention of major depression
among adults with subthreshold depression. Intervention
RCTs were identified as part of the same search con-
ducted to identify RCTs for the validation of the 3 con-
version methods (see previous section describing the
RMD validation analysis). Seven in-scope RCTs were
identified. Six RCTs evaluated intervention outcomes
using a continuous score on a depression rating scale
(i.e., the BDI-I and CES-D scales),41–46 while 1 RCT
evaluated dichotomous intervention outcomes using a
cutoff on the BDI-I scale.47 Predicted RR effect sizes
were calculated for the 6 RCTs that measured continu-
ous intervention outcomes by using the RMD, SMD,
and Cochrane conversion methods. The RMD conver-
sion calculated predicted RR effect sizes by using cross-
walks to convert scores from various scales into the BDI-
I scale. The SMD conversion used swithin parameter for
the BDI-I scale to calculate predicted RR effect sizes. No
estimates of control group risk were available from the 6
RCTs measuring continuous intervention outcomes. As
such, the Cochrane conversion method used an ACR of
0.63 obtained from the single RCT that measured dichot-
omous intervention outcomes.47 No conversion was
required for this particular RCT as the actual RR effect
size could be calculated directly. Further details on the
aforementioned RCTs and the predicted RR effect sizes
are presented in Supplemental Text S3.
The meta-analysis of RR effect sizes was performed
using the IVhet model in MetaXL 5.3 (see previous sec-
tion on the estimation of the RRpu parameter). Pooled
RR effect sizes were calculated at postintervention and
1-year follow-up using the RMD, SMD, and Cochrane
conversion methods. Each pooled RR effect size was
multiplied by the annual incidence of major depression
at the corresponding follow-up period in the model time
horizon. The resulting ICERs were analyzed to gauge
the relative impact of using each conversion method to
calculate predicted RR effect size estimates. The cost-
effectiveness model was developed in Microsoft Excel
2013, and Ersatz (version 1.31, Sunrise Beach, Australia;
available at http://www.epigear.com/) was used to per-
form Monte Carlo simulations (3000 iterations) to pro-
duce 95% uncertainty intervals.
6 Medical Decision Making 00(0)
Results
Estimation of the RR per Unit Parameter
RRpu parameter estimates are presented in Table 2. We
found 19 studies examining the diagnostic utility of sev-
eral depression rating scales in population-representative
samples. Of these, 10 studies involved adult samples
comprising the BDI-I (n= 1),48 BDI-II (n= 3),49–51 and
CES-D (n = 6).48,52–56 Conversely, 7 studies involved
youth samples comprising the BDI-I (n = 4)57–60 and
CES-D (n = 3).59,61,62 For eating disorders, we found 1
study that examined the EDDS scale.9 No relevant stud-
ies were identified for the EDDI scale. An imputed RRpu
estimate for the EDDI scale was calculated by perform-
ing a mathematical transformation to convert the RRpu
estimate for the EDDS scale into a corresponding esti-
mate for the EDDI scale. Input data and additional
results are presented in Supplemental Text S2.
Validation Analysis of the RMD Conversion
Method
A total of 11 intervention RCTs met inclusion criteria
for the baseline validation of the RMD conversion
method. Of these, there were 5 studies (d= 5) for depres-
sion in adults,63–67 3 studies (d = 12) for depression in
youth,68–70 and 3 studies (d = 3) for eating disorders in
young women.71–73 Input data and predicted RR effect
sizes are presented in Supplemental Text S4. Scatterplots
showing the relationship between actual and predicted
RR effect sizes are presented in Figure 1 for RCTs
involving depression in adults, Figure 2 for RCTs
involving depression in youth, and Figure 3 for RCTs
involving eating disorders in young women. Data points
have been plotted against the 1:1 line of equality, which
Table 2 Estimates for Included RR per Unit Parameters
Psychiatric Rating Scale (by Disorder) Age Group Total No. of Studies RR per Unit (95% CI) I2 Statistic Sources
Depression
BDI-I, 21 items Adults 1 1.14 (1.08-1.18) NAa 48
BDI-II, 21 items Adults 3 1.12 (1.02-1.22) 95.6 49–51
CES-D, 20 items Adults 6 1.15 (0.95-1.39) 93.8 48,52–56
BDI-I, 21 items Youth 4 1.12 (1.00-1.25) 90.9 57–60
CES-D, 20 items Youth 3 1.18 (1.12-1.25) 63.2 59,61,62
Eating disorders
EDDS, 22 items Young women 1 1.06 (1.04-1.08) NAa 9
EDDI, 31 items Young women Imputed estimateb 1.09 (1.06-1.11) NAa NAb
BDI-I, Beck Depression Inventory, first edition; BDI-II, Beck Depression Inventory, second edition; CES-D, Center for Epidemiologic Studies
Depression scale; CI, confidence interval; EDDI, Eating Disorder Diagnostic Interview; EDDS, Eating Disorder Diagnostic Scale; NA, not
applicable; RR, relative risk.
aAn I2 statistic was not available as the RR per unit estimate was based on the results of a single study (i.e., no meta-analysis was conducted).
bThe RR per unit for the EDDI scale was calculated by performing a mathematical transformation to convert the estimate of the RR per unit
for the EDDS scale into a corresponding estimate for the EDDI scale (see Supplemental Text S2).
Figure 1 Scatterplot of predicted v. actual RR effect sizes
among intervention RCTs for adults with depression (raw
mean difference conversion method). BDI-I, Beck Depression
Inventory, first edition; BDI-II, Beck Depression Inventory,
second version; CES-D, Center for Epidemiologic Studies
Depression scale; RCT, randomized controlled trial; RR,
relative risk.
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denotes when predicted RR effect sizes are equal to
actual RR effect sizes. A crude visual inspection of scat-
terplots revealed a close correspondence between pre-
dicted and actual RR effect sizes among RCTs involving
depression in adults. Conversely, predicted RR effect sizes
were consistently higher than actual RR effect sizes among
RCTs involving depression in youth and, to a lesser extent,
eating disorders in young women. This upward bias led to
predicted RR effect sizes that approached the null (RR =
1.0) and thus underestimated the true RR effect size.
Table 3 presents the results of statistical analyses that
were conducted to validate the predicted RR effect sizes
calculated using the RMD conversion method. A strong
correlation was observed between predicted and actual
RR effect sizes across all analytic scenarios involving
depression in adults (r. 0:85). In addition, there was
insufficient evidence to reject null hypotheses that
slope = 1 and intercept = 0. A moderate correlation
was observed among RCTs involving depression in
youth (r= 0:50) alongside sufficient evidence to reject
the null hypothesis that slope = 1. In the case of eating
disorders, a strong correlation was observed between pre-
dicted and actual RR effect sizes (r= 0:89). However,
the point estimates for the slope and intercept diverged
from the desired outcomes. It is also likely that this anal-
ysis was underpowered to detect meaningful differences
due to the paucity of in-scope RCTs for eating disorders.
Validation Analysis of the SMD Conversion
Method
A total of 16 RCTs met inclusion criteria for the baseline
validation of the SMD conversion method. Of these,
there were 5 studies (d = 5) for depression in adults63–67
and 11 studies (d= 29) for depression in youth.68–70,74–81
Input data, predicted RR effect sizes, and scatterplots
are presented in Supplemental Text S5. Data from RCTs
involving depression in adults produced swithin parameters
of 3.22 for the BDI-I scale and 8.65 for the CES-D scale.
Similarly, data from RCTs involving depression in youth
produced swithin parameters of 9.67 for the BDI-I scale
and 8.95 for the CES-D scale. Table 4 presents the results
of statistical analyses that were conducted to validate the
predicted RR effect sizes calculated using the SMD con-
version method. Moderate correlations were observed
across all analytic scenarios in the SMD validation.
Unlike the RMD scenario, only a moderate correlation
was observed among RCTs involving depression in
adults (r = 0.41–0.67). Even so, there was insufficient
evidence to reject null hypotheses for the slope and inter-
cept parameters across every analytic scenario for adult
depression. A moderate correlation was again observed
Figure 2 Scatter plot of predicted v. actual RR effect sizes
among intervention randomized controlled trials for youth
with depression (raw mean difference conversion method).
RR, relative risk.
Figure 3 Scatterplot of predicted v. actual RR effect sizes
among intervention randomized controlled trials for young
women with eating disorders (raw mean difference conversion
method). RR, relative risk.
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among RCTs involving depression in youth (r = 0.46–
0.47) alongside sufficient evidence to reject the null
hypothesis that slope = 1 for the CES-D scale. Likewise,
predicted RR effect sizes were found to underestimate
the true RR effect size when analyzing RCTs involving
depression in youth.
Validation Analysis of the Cochrane Conversion
Method
The same 16 RCTs that met inclusion criteria for the
baseline validation of the SMD conversion method (i.e.,
5 for depression in adults and 11 for depression in youth)
also met inclusion criteria for the baseline validation of
the Cochrane conversion method. In addition, the 3
studies for eating disorders in young women that were
included in the RMD validation also met inclusion cri-
teria for the baseline validation of the Cochrane conver-
sion method. Input data, predicted RR effect sizes, and
scatterplots are presented in Supplemental Text S6. The
ACR was calculated to be 0.22 among RCTs involving
depression in adults, 0.20 among RCTs involving depres-
sion in youth, and 0.08 among RCTs involving eating dis-
orders in young women. Table 5 presents the results of
statistical analyses conducted to validate the predicted RR
effect sizes that were calculated using the Cochrane con-
version method. A strong correlation was observed
between predicted and actual RR effect sizes for RCTs
involving depression in adults (r= 0:73) and eating disor-
ders in young women (r= 0:96). There was also insuffi-
cient evidence to reject null hypotheses that slope = 1 and
intercept = 0 in both cases. Even so, the point estimates
of the slope and intercept in these 2 groups diverged from
the desired outcomes. By comparison, the slope and inter-
cept in the RMD validation involving depression in adults
better approximated slope = 1 and intercept = 0 (see
Table 3). A moderate correlation was observed among
RCTs involving depression in youth (r= 0:47) alongside
sufficient evidence to reject the null hypothesis that slope
= 1. Once again, predicted RR effect sizes underestimated
the true RR effect size in this age group.
Table 3 Results of the Baseline Validation Analysis for the Raw Mean Difference Conversion Method
Analytic Scenario (by Disorder)
Correlation
Coefficient, r Slope (SE) t Statistic P Value Intercept (SE) t Statistic P Value
Depression in adults (n = 5; d= 5)
Original scale 0.878 0.796 (0.250) 3.181 0.474 0.168 (0.194) 0.866 0.450
BDI-I scale 0.885 1.183 (0.359) 3.294 0.645 –0.192 (0.292) –0.658 0.558
BDI-II scale 0.885 0.993 (0.300) 3.307 0.982 –0.007 (0.237) –0.030 0.978
CES-D scale 0.897 0.817 (0.232) 3.524 0.487 0.187 (0.170) 1.099 0.352
Depression in youth (n = 3, d = 12)
Original scale 0.500 0.391 (0.214) 1.826 0.017* 0.123 (0.163) 0.752 0.469
Eating disorders in young women (n = 3, d = 3)
EDDS/EDDI scales 0.893 8.784 (4.262) 2.061 0.319 –7.494 (3.978) –1.884 0.311
BDI-I, Beck Depression Inventory, first edition; BDI-II, Beck Depression Inventory, second edition; CES-D, Center for Epidemiologic Studies
Depression scale; d, total number of data points; EDDI, Eating Disorder Diagnostic Interview; EDDS, Eating Disorder Diagnostic Scale.
*P\ 0.05.
Table 4 Results of the Baseline Validation Analysis for the Standardized Mean Difference Conversion Method
Analytic Scenario (by Disorder)
Correlation
Coefficient, r
Slope
(SE) t Statistic P Value Intercept (SE) t Statistic P Value
Depression in adults (n = 5; d= 5)
BDI-I scale 0.409 0.282 (0.363) 0.777 0.143 0.552 (0.281) 1.964 0.144
CES-D scale 0.673 0.449 (0.285) 1.577 0.148 0.502 (0.186) 2.695 0.074
Depression in youth (n = 11, d = 29)
BDI-I scale 0.464 0.614 (0.226) 2.722 0.099 0.007 (0.190) 0.036 0.971
CES-D scale 0.456 0.512 (0.192) 2.660 0.017* 0.109 (0.157) 0.695 0.493
BDI-I, Beck Depression Inventory, first edition; CES-D, Center for Epidemiologic Studies Depression scale; d, total number of data points.
*P\ 0.05.
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Sensitivity Analysis Including RCTs Comprising
Clinical Samples
Several RCTs involving depression in adults and depres-
sion in youth were excluded from the baseline validations
of the RMD, SMD, and Cochrane conversion methods
due to clinical samples. In the RMD validation, 1 RCT
comprising adults82 and 2 RCTs comprising youth83,84
were excluded. In the SMD and Cochrane validations, 1
adult RCT82 and 3 youth RCTs83–85 were excluded. No
exclusions were applied among RCTs involving eating
disorders in young women. The input data and results of
the sensitivity analysis are presented in Supplemental
Text S7. Among RCTs involving depression in adults,
the inclusion of RCTs comprising clinical samples led
to lower correlation coefficients relative to the baseline
across the RMD, SMD, and Cochrane conversion
methods. For example, the range of correlation coeffi-
cients across the different analytic scenarios in the
RMD validation decreased from r = 0.88 to 0.90 at
baseline to r = 0.70 to 0.83 in the sensitivity analysis.
Among RCTs involving depression in youth, negligible
changes to baseline correlations were observed across
the 3 conversion methods. For example, the correlation
coefficient in the baseline RMD validation decreased
from r= 0:50 at baseline to r= 0:47 in the sensitivity
analysis.
Applied Analysis of the 3 Conversion Methods in
a Cost-Effectiveness Model
The results of the analysis comparing the RMD, SMD,
and Cochrane conversion methods when applied to a
cost-effectiveness model are presented in Table 6. The
range of RR effect sizes across the different conversion
methods was between 0.68 and 0.70 at postintervention
and 0.84 and 0.85 at 1-year follow-up. It follows that
RR effect sizes, incremental benefits, incremental net
costs, and ICERs were all found to be of a similar
magnitude across each of the 3 conversion methods.
Overall, the applied analysis found that a community-
based intervention to prevent major depression in
Australian adults with subthreshold depression was not
cost-effective relative to a WTP threshold of A$50,000
per DALY averted. This finding was robust to changes
in the conversion method used to calculate predicted RR
effect sizes.
Discussion
Summary and Interpretation of Findings
This study compared the predictive performance of 3
methods to convert continuous scores measured using a
psychiatric rating scale into corresponding RR effect
sizes. To put these methods into context, previous studies
have cited an absolute reduction of 5 points on the
BDI-I scale to be a minimum clinically important differ-
ence.86 The RMD conversion method would translate
this 5-point reduction into a predicted RR of 0.529 (i.e.,
a 47.1% risk reduction). Of the 3 conversion methods,
the RMD and Cochrane conversion methods performed
best in calculating predicted RR effect sizes, particularly
when analyzing intervention RCTs involving depression
in adults and eating disorders in young women. When
analyzing intervention RCTs involving depression in
youth, all 3 conversion methods produced moderate cor-
relations between actual and predicted RR effect sizes.
Furthermore, these predicted RR effect sizes systemati-
cally underestimated the true RR effect size, regardless
of the conversion method used. Potential explanations
for this finding include 1) the depression rating scales
used to measure depressive symptomatology in youth
have poor construct validity, or 2) depressive symptoma-
tology, as measured by a depression rating scale, does
not adequately predict diagnoses of major depression in
younger age groups. Interestingly, the applied analysis of
the 3 conversion methods led to similar cost-effectiveness
Table 5 Results of the Baseline Validation Analysis for the Cochrane Conversion Method
Analytic Scenario (by Disorder)
Correlation
Coefficient, r
Slope
(SE) t Statistic P Value Intercept (SE) t Statistic P Value
Depression in adults (n = 5; d= 5)
Cochrane conversion 0.730 0.486 (0.263) 1.850 0.145 0.506 (0.161) 3.136 0.052
Depression in youth (n = 11, d = 29)
Cochrane conversion 0.471 0.522 (0.188) 2.772 0.017* 0.116 (0.149) 0.780 0.442
Eating disorders in young women (n = 3, d = 3)
Cochrane conversion 0.963 1.881 (0.528) 3.559 0.344 –0.807 (0.424) –1.904 0.308
d, total number of data points.
*P\ 0.05.
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results despite the poorer predictive performance that
was observed for the SMD conversion method relative
to the other conversion methods.
Negligible differences in predictive performance were
observed across all the analytic scenarios in the RMD
validation that used crosswalks to convert scores from
different rating scales into a common metric. These find-
ings suggest that an overlapping construct is being mea-
sured by every depression rating scale included in this
particular analysis. Furthermore, these findings affirm
the validity of previous studies that have used item
response theory to translate heterogeneous depression
rating scales into a common metric among adult sam-
ples.36,37 Even so, the RMD conversion led to less accu-
rate predictions when including a single RCT comprising
a clinical sample of stroke patients. It is unclear whether
this poorer predictive performance was the result of
problems in measuring changes in depressive symptoma-
tology among stroke patients or broader deficiencies in
applying the method across clinical samples.
Implication of Findings
The RMD conversion method performed as well as the
Cochrane conversion method when calculating predicted
RR effect sizes from continuous outcomes data. At first
glance, the Cochrane conversion method would appear
to be easier to implement than the RMD conversion
method, especially in cases when an appropriate RRpu
parameter is not available or when the intervention
RCTs in a meta-analysis use different rating scales that
cannot be converted into a common metric. Nonetheless,
there may be circumstances when the RMD validation
method may be preferable to the Cochrane conversion
method. This would occur when 1) the assumptions
underlying the Cochrane conversion method are violated,
2) an ACR parameter is not able to be calculated from
intervention RCT data, or 3) the ACR parameter derived
from RCT data is biased. The RMD conversion method
may be a viable alternative to the Cochrane conversion
method in these situations, particularly when a greater
number of data sources are available to inform the RMD
conversion method relative to the Cochrane conversion
method. In contrast to the RMD and Cochrane conver-
sion methods, the SMD conversion method performed
relatively poorly. This may be due to difficulties in esti-
mating a valid within-group standard deviation that is
applicable across all RCTs in a meta-analysis. Further
research is required to determine whether the SMD con-
version method can be refined to produce more accurate
predictions of the RR effect size.
Study Limitations
This study has several limitations. First, the RRpu para-
meters may be susceptible to bias as a systematic search
was not conducted to identify all in-scope diagnostic util-
ity studies. Second, validation analyses may have been
underpowered due to the paucity of intervention RCTs
that simultaneously contained data on both continuous
and dichotomous intervention outcomes. Third, the
scope of this study focused on applying the conversion
methods to 2 mental disorders. Additional studies are
required to test the validity of these methods when
Table 6 Results of the Applied Analysis of the 3 Conversion Methods in a Cost-Effectiveness Model
Model Parameter/Output RMD Conversion (BDI-I Scale) SMD Conversion (BDI-I Scale) Cochrane Conversion
Pooled RR effect size (95% CI)
Postintervention (n = 7, d = 8) 0.678 (0.585 to 0.785) 0.703 (0.535 to 0.922) 0.694 (0.480 to 1.003)
1-year follow-up (n = 2, d= 2) 0.847 (0.701 to 1.025) 0.838 (0.684 to 1.026) 0.846 (0.699 to 1.023)
Intervention costs (95% UI)
A$ thousands 47,971 (29,977 to 67,793) 47,986 (30,061 to 67,662) 47,860 (30,017 to 68,394)
Cost offsets (95% UI)
A$ thousands –1952 (–4567 to –564) –1900 (–4522 to –440) –1871 (–4602 to –371)
Incremental net costs (95% UI)
A$ thousands 46,019 (28,669 to 65,104) 46,087 (28,961 to 64,970) 45,989 (28,643 to 66,355)
Incremental benefits (95% UI)
DALYs averted 409 (116 to 960) 399 (93 to 984) 392 (75 to 1,010)
Mean ICER (95% UI)
A$ per DALY averted 112,384 (47,865 to 365,497) 115,516 (46,821 to 460,884) 117,282 (42,895 to 545,269)
A$, Australian dollars; CI, confidence interval; BDI-I, Beck Depression Inventory, first edition; d, total number of data points; DALYs,
disability-adjusted life years; ICER, incremental cost-effectiveness ratio; RMD, raw mean difference; SMD, standardized mean difference; UI,
uncertainty interval.
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applied to different diseases and intervention types.
Further investigation is also warranted to explore
whether covariate adjustments could be incorporated to
increase the accuracy of RR effect size predictions.
Conclusion
This study found that the RMD and Cochrane conver-
sion methods are both valid approaches for converting
continuous scores measured using a psychiatric rating
scale into RR effect sizes. By contrast, the SMD method
performed relatively poorly as a means for estimating
predicted RR effect sizes. These methods will require fur-
ther validation and refinement if they are to be applied
more broadly.
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Discount rate 9 Report the choice of discount rate(s) used for costs and 
outcomes and say why appropriate. 
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Measurement of 
effectiveness 
11a Single study–based estimates: Describe fully the 
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why the single study was a sufficient source of clinical 
effectiveness data. 
Not applicable 
11b Synthesis-based estimates: Describe fully the methods 
used for the identification of included studies and 
synthesis of clinical effectiveness data. 
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valuation of preference-
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12 If applicable, describe the population and methods 
used to elicit preferences for outcomes. 
Not applicable 
Estimating resources 
and costs 
13a Single study–based economic evaluation: Describe 
approaches used to estimate resource use associated 
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Not applicable 
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APPENDIX 12: Supplementary data of publication 4 
Title of publication: The Modelled Cost‐Effectiveness of Family-Based and Adolescent-
Focused Treatment for Anorexia Nervosa. 
 
 
 
 
 
Figure S1: State transition diagram used to estimate health benefit of treatment 
intervention for Anorexia Nervosa. 
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Table S2: Included studies for estimating Recovery/Remission of Family-Based Therapy 
Study 
name 
FBT 
Duration 
(months) 
Follow-
up 
duration 
(months) 
Total time 
at-risk 
(months) 
Total time 
at-risk 
(years) 
Remission 
Cases 
(FBT) 
Total 
(FBT) 
Remission 
probability 
(FBT) 
Remission/recovery defined 
Russell et 
al. 1987 
(Russell 
et al. 
1987) 
12 0 12.0 1.0 6 10 60% Good outcome of the Morgan and 
Russell Scales 
Lock et 
al. 2010 
(Lock et 
al. 2010) 
12 0 12.0 1.0 21 61 34% Combination of a minimum of 95% of 
expected IBW + scores within 1 SD 
from global mean EDE published norms 
Robin 
1999 
(Robin et 
al. 1999) 
15.9 0 15.9 1.3 10 19 53% Achieved 50th percentile BMI 
Agras 
2014 
(Agras et 
al. 2014) 
9 0 9.0 0.8 27 78 35% Achieve a minimum of 95% of expected 
IBW 
Eisler et 
al.2000 
(Eisler et 
al. 2000) 
12.6 0 12.6 1.0 5 19 26% Good outcome of the Morgan and 
Russell Scales 
Rhodes et 
al. 2008 
(Rhodes 
et al. 
2008) 
12 0 12.0 1.0 5 10 50% Combination of a minimum of 95% of 
expected IBW + scores within 1 SD 
from global mean EDE published norms 
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Madden 
2015 
(Madden 
et al. 
2015) 
13 0 13 1.08 10 41 24% Combination of a minimum of 95% of 
expected IBW + scores within 1 SD 
from global mean EDE published norms 
Pooled remission probability at post treatment (equivalent to 12 months). 36%   
Lock et 
al. 2010 
(Lock et 
al. 2010) 
12 12 24.0 2.0 22 61 36% Combination of a minimum of 95% of 
expected IBW + scores within 1 SD 
from global mean EDE published norms 
Robin 
1999 
(Robin et 
al. 1999) 
15.9 12 27.9 2.3 13 19 68% Achieved 50th percentile BMI  
Agras 
2014 
(Agras et 
al. 2014) 
9 12 21.0 1.8 32 78 41% Achieve a minimum of 95% of expected 
IBW 
Madden 
2015 
(Madden 
et al. 
2015) 
13 12 25.0 2.08 12 41 29% Combination of a minimum of 95% of 
expected IBW + scores within 1 SD 
from global mean EDE published norms 
Pooled remission probability at 1 year follow up (equivalent to 24 months) 39%   
Eisler et 
al.1997 
(Eisler et 
al. 1997) 
12 62.4 74.4 6.2 9 10 90% Good outcome of the Morgan and 
Russell Scales 
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Eisler et 
al.2007 
(Eisler et 
al. 2007) 
12.6 62.4 75.0 6.2 13 19 68% Good outcome of the Morgan and 
Russell Scales 
Pooled remission probability at 5-year follow up (equivalent to 72 months) 82%   
IBW: Ideal Body Weight; BMI: Body Mass Index; EDE: Eating Disorder Examination; SD: Standard Deviation. 
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Table S3: Included studies for estimating Recovery/Remission of Treatment As Usual. 
Study Durations 
(months) 
Total time 
at-risk 
(years) 
Remission 
cases 
Total 
cases 
Recovery/ 
Remission 
probability 
Recovery/remission definition Treatment 
Salbach-Andrae 
et al. 2009 
(Salbach-
Andrae et al. 
2009) 
12 1 5 57 9% Good outcome of the Morgan and 
Russell Scales AND (1) eating 
attitudes and weight concerns had 
to be less than one standard 
deviation above the mean of a 
comparison group without AN 
AND (2) absent binge eating or 
purging behaviors. 
Inpatient treatment 
(12 weeks) 
Claussen et al. 
2008 (Clausen 
2008) 
30 2.5 38 78 49% The Psychiatric Status Rating 
Scale <2 
100% Dietary 
counselling, 
individual integrated 
psychotherapy, 20% 
family therapy, 40% 
group therapy 
Herpertz-
Dahlmann et al. 
2001 (Herpertz‐
Dahlmann et al. 
2001) 
36 3 16 39 41% Not meet DSM-IV for AN during 
last 6 month + Good outcome  
Dietary counselling, 
individual integrated 
psychotherapy, 
supplementary family 
therapy 
Pooled recovery remission at 3 year 47%   
Keski-
Rahkonen et al. 
2007 (Keski-
Rahkonen et al. 
2007) 
60 5 37 55 67% Restoration of weight and 
menstruation and the absence of 
bingeing and purging for at least 1 
year prior to assessment 
A combination of 
individual and group 
psychotherapy, 
family therapy, and 
behavioural programs 
for weight restoration 
AN: Anorexia Nervosa; DSM-IV: Diagnostic and Statistical Manual 4th edition. 
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Table S4: Included studies for estimating Relapse of Anorexia Nervosa. 
Study Durations 
(months) 
Total time 
at-risk 
(years) 
Relapse 
cases 
Total 
cases 
Recovery/ 
Remission 
probability 
Relapse criteria Treatment 
Pike, Walsh et 
al. 2003 (Pike et 
al. 2003) 
12 1 8 15 53% The Eating Disorder Examination Nutritional 
counseling 
Carter, 
Blackmore, et 
al. 2004 (Carter 
et al. 2004) 
15.6 1.3 18 51 35% BMI<17.5 for at least 3 
consecutive months 
Some forms of 
specialized treatment 
for their eating 
disorder. 
Carter, Mercer-
Lynn, et al. 2012 
(Carter et al. 
2012) 
12 1 41 100 41% BMI ≤ 17.5 for 3 consecutive 
months or at least one episode of 
binge-purge behaviour per week 
for 3 consecutive months during 
the 1-year follow-up period 
Unclear 
Carter, 
McFarlane, et al. 
2009 (Carter et 
al. 2009a) 
12 1 20 30 66.6% BMI ≤ 17.5 for 3 months or the 
resumption of regular binge eating 
and/or purging behavior for 3 
months. 
Three 90-min group 
therapy sessions 
per week for up to 12 
weeks (if patients 
needed) 
Richard, Bauer 
and Kordy 2005 
(Richard, Bauer 
& Kordy 2005) 
12 1 40 135 30% Returning to full symptomatic 
status at least 1 month. 
Hospitalization. 
Richard, Bauer 
and Kordy 2005 
(Richard, Bauer 
& Kordy 2005) 
24 1 44 135 33% Returning to full symptomatic 
status at least 1 month. 
Hospitalization. 
AN: Anorexia Nervosa; DSM-IV: Diagnostic and Statistical Manual 4th edition. 
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